0000318154-20-000031.txt : 20200501 0000318154-20-000031.hdr.sgml : 20200501 20200430204821 ACCESSION NUMBER: 0000318154-20-000031 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 83 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200501 DATE AS OF CHANGE: 20200430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37702 FILM NUMBER: 20837991 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 10-Q 1 amgn-2020331x10q.htm 10-Q Document
1.011.011.011.011.011.011.011.011.011.011.011.011.011.011.011.011.011.011.011.011.011.011.011.011.011.011.011.011.011.011.011.011.011.011.011.011.01false--12-31Q1202000003181541.601.601.451.600.00010.00012750000000275000000059140000058800000047500000070000000012500000007500000007000000000.05500.05150.05750.05650.053750.04000.04500.04400.04950.0410.04100.046630.01250.06400.06900.063750.038750.03450.031250.036250.036250.03200.02000.021250.02700.02650.0260.02600.02250.02200.00410.0170.0000.0200.0110.0090.0160.0140.0030.0170.0260.0200.0110.0180.0270.0320.018 0000318154 2020-01-01 2020-03-31 0000318154 2019-01-01 2019-12-31 0000318154 2020-04-27 0000318154 exch:XNYS amgn:A1.250SeniorNotesDue2022Member 2020-01-01 2020-03-31 0000318154 exch:XNYS amgn:A2.00SeniorNotesDue2026Member 2020-01-01 2020-03-31 0000318154 exch:XNGS us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000318154 2019-01-01 2019-03-31 0000318154 us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-03-31 0000318154 us-gaap:ProductMember 2019-01-01 2019-03-31 0000318154 us-gaap:ProductAndServiceOtherMember 2019-01-01 2019-03-31 0000318154 us-gaap:ProductMember 2020-01-01 2020-03-31 0000318154 2019-12-31 0000318154 2020-03-31 0000318154 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000318154 us-gaap:CommonStockMember 2019-03-31 0000318154 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2018-12-31 0000318154 us-gaap:CommonStockMember 2018-12-31 0000318154 2018-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-03-31 0000318154 us-gaap:RetainedEarningsMember 2019-03-31 0000318154 2019-03-31 0000318154 us-gaap:RetainedEarningsMember 2018-12-31 0000318154 us-gaap:CommonStockMember 2020-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000318154 us-gaap:RetainedEarningsMember 2020-01-01 0000318154 2020-01-01 0000318154 us-gaap:CommonStockMember 2019-12-31 0000318154 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000318154 us-gaap:RetainedEarningsMember 2019-12-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2020-03-31 0000318154 us-gaap:RetainedEarningsMember 2020-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000318154 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000318154 amgn:NeulastaMember 2020-01-01 2020-03-31 0000318154 amgn:EnbrelMember 2020-01-01 2020-03-31 0000318154 amgn:KyprolisMember 2019-01-01 2019-03-31 0000318154 amgn:RepathaevolocumabMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000318154 amgn:RepathaevolocumabMember 2019-01-01 2019-03-31 0000318154 amgn:AranespMember country:US 2020-01-01 2020-03-31 0000318154 amgn:EnbrelMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000318154 amgn:OtherProductsMember 2019-01-01 2019-03-31 0000318154 amgn:XgevaMember country:US 2020-01-01 2020-03-31 0000318154 amgn:AranespMember 2020-01-01 2020-03-31 0000318154 amgn:RepathaevolocumabMember country:US 2020-01-01 2020-03-31 0000318154 amgn:RepathaevolocumabMember 2020-01-01 2020-03-31 0000318154 amgn:OtezlaMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000318154 amgn:XgevaMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000318154 amgn:KyprolisMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000318154 amgn:NeulastaMember 2019-01-01 2019-03-31 0000318154 us-gaap:ProductMember country:US 2019-01-01 2019-03-31 0000318154 amgn:OtezlaMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000318154 us-gaap:ProductMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000318154 amgn:AranespMember country:US 2019-01-01 2019-03-31 0000318154 amgn:EnbrelMember country:US 2019-01-01 2019-03-31 0000318154 amgn:ProliaMember country:US 2020-01-01 2020-03-31 0000318154 amgn:AranespMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000318154 amgn:ProliaMember country:US 2019-01-01 2019-03-31 0000318154 amgn:KyprolisMember 2020-01-01 2020-03-31 0000318154 amgn:KyprolisMember country:US 2020-01-01 2020-03-31 0000318154 amgn:AranespMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000318154 amgn:XgevaMember 2019-01-01 2019-03-31 0000318154 amgn:EnbrelMember country:US 2020-01-01 2020-03-31 0000318154 amgn:OtherProductsMember country:US 2019-01-01 2019-03-31 0000318154 us-gaap:ProductMember country:US 2020-01-01 2020-03-31 0000318154 amgn:EnbrelMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000318154 amgn:ProliaMember 2019-01-01 2019-03-31 0000318154 amgn:NeulastaMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000318154 amgn:OtherProductsMember 2020-01-01 2020-03-31 0000318154 amgn:ProliaMember 2020-01-01 2020-03-31 0000318154 amgn:XgevaMember country:US 2019-01-01 2019-03-31 0000318154 amgn:ProliaMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000318154 amgn:RepathaevolocumabMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000318154 amgn:OtezlaMember country:US 2020-01-01 2020-03-31 0000318154 amgn:NeulastaMember country:US 2019-01-01 2019-03-31 0000318154 us-gaap:ProductMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000318154 amgn:XgevaMember 2020-01-01 2020-03-31 0000318154 amgn:KyprolisMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000318154 amgn:ProliaMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000318154 amgn:OtherProductsMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000318154 amgn:OtezlaMember country:US 2019-01-01 2019-03-31 0000318154 amgn:OtezlaMember 2020-01-01 2020-03-31 0000318154 amgn:OtezlaMember 2019-01-01 2019-03-31 0000318154 amgn:OtherProductsMember country:US 2020-01-01 2020-03-31 0000318154 amgn:NeulastaMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000318154 amgn:AranespMember 2019-01-01 2019-03-31 0000318154 amgn:EnbrelMember 2019-01-01 2019-03-31 0000318154 amgn:OtherProductsMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000318154 amgn:RepathaevolocumabMember country:US 2019-01-01 2019-03-31 0000318154 amgn:XgevaMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000318154 amgn:KyprolisMember country:US 2019-01-01 2019-03-31 0000318154 amgn:NeulastaMember country:US 2020-01-01 2020-03-31 0000318154 amgn:BeiGeneMember 2020-01-01 2020-03-31 0000318154 amgn:BeiGeneMember 2020-01-02 2020-01-02 0000318154 us-gaap:USTreasurySecuritiesMember 2020-03-31 0000318154 amgn:OtherShortTermInterestBearingSecuritiesMember 2020-03-31 0000318154 us-gaap:USTreasuryBillSecuritiesMember 2020-03-31 0000318154 us-gaap:MoneyMarketFundsMember 2020-03-31 0000318154 amgn:CorporateDebtSecuritiesFinancialMember 2020-03-31 0000318154 us-gaap:ResidentialMortgageBackedSecuritiesMember 2020-03-31 0000318154 amgn:CorporateDebtSecuritiesOtherMember 2020-03-31 0000318154 amgn:CorporateDebtSecuritiesIndustrialMember 2020-03-31 0000318154 srt:MaximumMember amgn:BeiGeneMember 2020-01-01 2020-03-31 0000318154 amgn:BeiGeneMember 2020-03-31 0000318154 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember srt:PartnershipInterestMember 2020-03-31 0000318154 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember srt:PartnershipInterestMember 2019-12-31 0000318154 amgn:BeiGeneMember 2020-01-02 0000318154 srt:MinimumMember amgn:BeiGeneMember 2020-01-01 2020-03-31 0000318154 amgn:CorporateDebtSecuritiesFinancialMember 2019-12-31 0000318154 amgn:OtherShortTermInterestBearingSecuritiesMember 2019-12-31 0000318154 amgn:CorporateDebtSecuritiesOtherMember 2019-12-31 0000318154 us-gaap:ResidentialMortgageBackedSecuritiesMember 2019-12-31 0000318154 us-gaap:USTreasurySecuritiesMember 2019-12-31 0000318154 us-gaap:MoneyMarketFundsMember 2019-12-31 0000318154 us-gaap:USTreasuryBillSecuritiesMember 2019-12-31 0000318154 amgn:CorporateDebtSecuritiesIndustrialMember 2019-12-31 0000318154 amgn:AvailableForSalesInvestmentsMember 2019-12-31 0000318154 amgn:AvailableForSalesInvestmentsMember 2020-03-31 0000318154 us-gaap:LicensingAgreementsMember 2019-12-31 0000318154 us-gaap:DevelopedTechnologyRightsMember 2020-03-31 0000318154 us-gaap:InProcessResearchAndDevelopmentMember 2019-12-31 0000318154 amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember 2019-12-31 0000318154 us-gaap:MarketingRelatedIntangibleAssetsMember 2020-03-31 0000318154 us-gaap:MarketingRelatedIntangibleAssetsMember 2019-12-31 0000318154 us-gaap:InProcessResearchAndDevelopmentMember 2020-03-31 0000318154 us-gaap:LicensingAgreementsMember 2020-03-31 0000318154 us-gaap:DevelopedTechnologyRightsMember 2019-12-31 0000318154 amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember 2020-03-31 0000318154 amgn:ThreePointEightSevenFivePercentNotesDue2021Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:SixPointNineZeroPercentNotesDue2038Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:FourPointOneZeroPercentNotesDue2021Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:ThreePointOneFivePercentNotesDue2040Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:FivePointSixFivePercentNotesDue2042Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:TwoPointSixFiveNotesDue2022Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:TwoPointTwoZeroNotesDue2020Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:OnePointEightFivePercentNotesDueTwoZeroTwoOneMember us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2022Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:FivePointSevenFivePercentNotesDue2040Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:FivePointSixFivePercentNotesDue2042Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:FourPointNineFivePercentNotesDue2041Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:FivePointSevenFivePercentNotesDue2040Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:SixPointThreeSevenFivePercentNotesDue2037Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:FivePointThreeSevenFivePercentNotesDue2043Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:ThreePointTwoZeroNotesDue2027Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:OtherNotesDue2097Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:TwoPointFourFivePercentNotesDue2030Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2024Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2024Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:TwoPointTwoZeroNotesDue2020Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:FourPercentPoundSterlingNotesDue2029Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:SixPointThreeSevenFivePercentNotesDue2037Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:SixPointFourZeroPercentNotesDue2039Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:ThreePointFourFivePercentNotesDue2020Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:FivePointOneFivePercentNotesDue2041Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:SixPointFourZeroPercentNotesDue2039Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:FivePointOneFivePercentNotesDue2041Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:FourPercentPoundSterlingNotesDue2029Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:FourPointNineFivePercentNotesDue2041Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:TwoPointSixFiveNotesDue2022Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:ThreePointThreeSevenFivePercentNotesDue2050Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2022Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:FloatingRateNotesDue2020Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:SixPointNineZeroPercentNotesDue2038Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:OnePointEightFivePercentNotesDueTwoZeroTwoOneMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:FourPointFiveZeroPercentNotesDue2020Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:FloatingRateNotesDue2020Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:FivePointThreeSevenFivePercentNotesDue2043Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:ThreePointTwoZeroNotesDue2027Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:ThreePointEightSevenFivePercentNotesDue2021Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:OtherNotesDue2097Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2022Member us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0000318154 amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember us-gaap:NotesPayableOtherPayablesMember 2020-03-31 0000318154 amgn:ThreePointEightSevenFivePercentNotesDue2021Member us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0000318154 amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0000318154 amgn:ThreePointEightSevenFivePercentNotesDue2021Member us-gaap:NotesPayableOtherPayablesMember 2020-03-31 0000318154 us-gaap:NotesPayableOtherPayablesMember 2020-03-31 0000318154 amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember us-gaap:NotesPayableOtherPayablesMember 2020-03-31 0000318154 amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0000318154 amgn:ThreePointFourFivePercentNotesDue2020Member us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0000318154 amgn:FourPointOneZeroPercentNotesDue2021Member us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2024Member us-gaap:NotesPayableOtherPayablesMember 2020-03-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2024Member us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0000318154 amgn:FourPointOneZeroPercentNotesDue2021Member us-gaap:NotesPayableOtherPayablesMember 2020-03-31 0000318154 amgn:ThreePointFourFivePercentNotesDue2020Member us-gaap:NotesPayableOtherPayablesMember 2020-03-31 0000318154 amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0000318154 amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember us-gaap:NotesPayableOtherPayablesMember 2020-03-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2022Member us-gaap:NotesPayableOtherPayablesMember 2020-03-31 0000318154 us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0000318154 amgn:FourPointOneZeroPercentNotesDue2021Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:InterestRateSwapThreeMember us-gaap:ForwardContractsMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000318154 amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember 2020-01-01 2020-03-31 0000318154 us-gaap:InterestExpenseMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 srt:MinimumMember us-gaap:DebtSecuritiesPayableMember 2020-01-01 2020-03-31 0000318154 amgn:ThreePointFourFivePercentNotesDue2020Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 srt:MaximumMember us-gaap:DebtSecuritiesPayableMember 2020-01-01 2020-03-31 0000318154 amgn:ThreePointEightSevenFivePercentNotesDue2021Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:InterestRateSwapOneMember us-gaap:ForwardContractsMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000318154 amgn:FourPointFiveZeroPercentNotesDue2020Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-03-31 0000318154 us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:InterestRateSwapTwoMember us-gaap:ForwardContractsMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000318154 amgn:FourPointNineFivePercentNotesDue2041Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:FivePointOneFivePercentNotesDue2041Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2024Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:TwoPointTwoZeroNotesDue2020Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:ThreePointOneFivePercentNotesDue2040Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:FloatingRateNotesDue2020Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:FourPointFiveZeroPercentNotesDue2020Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:FivePointSixFivePercentNotesDue2042Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:OnePointEightFivePercentNotesDueTwoZeroTwoOneMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:TwoPointSixFiveNotesDue2022Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2022Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:ThreePointFourFivePercentNotesDue2020Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:ThreePointTwoZeroNotesDue2027Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:FourPercentPoundSterlingNotesDue2029Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:FivePointThreeSevenFivePercentNotesDue2043Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:FivePointSevenFivePercentNotesDue2040Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:SixPointFourZeroPercentNotesDue2039Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:FourPointOneZeroPercentNotesDue2021Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:ThreePointThreeSevenFivePercentNotesDue2050Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:SixPointThreeSevenFivePercentNotesDue2037Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:TwoPointFourFivePercentNotesDue2030Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:SixPointNineZeroPercentNotesDue2038Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-03-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2024Member us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-12-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2022Member us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-03-31 0000318154 amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-03-31 0000318154 amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-12-31 0000318154 amgn:ThreePointEightSevenFivePercentNotesDue2021Member us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-12-31 0000318154 amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-03-31 0000318154 amgn:FourPointOneZeroPercentNotesDue2021Member us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-03-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2024Member us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-03-31 0000318154 amgn:ThreePointEightSevenFivePercentNotesDue2021Member us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-03-31 0000318154 amgn:ThreePointFourFivePercentNotesDue2020Member us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-12-31 0000318154 amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-12-31 0000318154 amgn:ThreePointFourFivePercentNotesDue2020Member us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-03-31 0000318154 amgn:FourPointOneZeroPercentNotesDue2021Member us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-12-31 0000318154 amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-12-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2022Member us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-12-31 0000318154 2020-03-01 2020-03-31 0000318154 2019-12-01 2019-12-31 0000318154 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0000318154 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-03-31 0000318154 amgn:AccumulatedOtherAdjustmentAttributabletoParentMember 2020-03-31 0000318154 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000318154 amgn:AccumulatedOtherAdjustmentAttributabletoParentMember 2020-01-01 2020-03-31 0000318154 amgn:AccumulatedOtherAdjustmentAttributabletoParentMember 2019-12-31 0000318154 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-03-31 0000318154 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-03-31 0000318154 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-31 0000318154 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-03-31 0000318154 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0000318154 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-31 0000318154 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-03-31 0000318154 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0000318154 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0000318154 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-03-31 0000318154 us-gaap:ProductMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0000318154 us-gaap:ProductMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0000318154 srt:ScenarioForecastMember 2020-06-01 2020-06-30 0000318154 us-gaap:FairValueInputsLevel3Member 2020-03-31 0000318154 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member 2020-03-31 0000318154 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2020-03-31 0000318154 us-gaap:FairValueInputsLevel2Member 2020-03-31 0000318154 us-gaap:FairValueInputsLevel1Member amgn:CorporateDebtSecuritiesOtherMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2020-03-31 0000318154 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2020-03-31 0000318154 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member 2020-03-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:FairValueInputsLevel1Member 2020-03-31 0000318154 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel1Member 2020-03-31 0000318154 us-gaap:FairValueInputsLevel1Member amgn:OtherShortTermInterestBearingSecuritiesMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel2Member amgn:CorporateDebtSecuritiesIndustrialMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel3Member amgn:CorporateDebtSecuritiesFinancialMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel1Member amgn:CorporateDebtSecuritiesFinancialMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel2Member amgn:CorporateDebtSecuritiesFinancialMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel3Member amgn:CorporateDebtSecuritiesOtherMember 2020-03-31 0000318154 us-gaap:InterestRateSwapMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel1Member amgn:CorporateDebtSecuritiesIndustrialMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel3Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryBillSecuritiesMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel3Member amgn:CorporateDebtSecuritiesIndustrialMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryBillSecuritiesMember 2020-03-31 0000318154 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member 2020-03-31 0000318154 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member 2020-03-31 0000318154 us-gaap:FairValueInputsLevel2Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2020-03-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:FairValueInputsLevel2Member 2020-03-31 0000318154 amgn:CrossCurrencySwapContractsMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel3Member amgn:OtherShortTermInterestBearingSecuritiesMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel1Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2020-03-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:FairValueInputsLevel3Member 2020-03-31 0000318154 us-gaap:FairValueInputsLevel2Member amgn:OtherShortTermInterestBearingSecuritiesMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel2Member amgn:CorporateDebtSecuritiesOtherMember 2020-03-31 0000318154 us-gaap:ForeignExchangeContractMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBillSecuritiesMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel3Member 2019-12-31 0000318154 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000318154 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000318154 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2019-12-31 0000318154 amgn:CrossCurrencySwapContractsMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel1Member 2019-12-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000318154 us-gaap:FairValueInputsLevel2Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel3Member amgn:CorporateDebtSecuritiesIndustrialMember 2019-12-31 0000318154 us-gaap:ForeignExchangeContractMember 2019-12-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000318154 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000318154 us-gaap:FairValueInputsLevel3Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel1Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel2Member amgn:OtherShortTermInterestBearingSecuritiesMember 2019-12-31 0000318154 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000318154 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel1Member amgn:CorporateDebtSecuritiesFinancialMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel2Member amgn:CorporateDebtSecuritiesIndustrialMember 2019-12-31 0000318154 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000318154 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryBillSecuritiesMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel1Member amgn:OtherShortTermInterestBearingSecuritiesMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryBillSecuritiesMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel2Member 2019-12-31 0000318154 us-gaap:FairValueInputsLevel2Member amgn:CorporateDebtSecuritiesOtherMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBillSecuritiesMember 2019-12-31 0000318154 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000318154 us-gaap:FairValueInputsLevel3Member amgn:OtherShortTermInterestBearingSecuritiesMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel3Member amgn:CorporateDebtSecuritiesOtherMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2019-12-31 0000318154 us-gaap:InterestRateSwapMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel3Member amgn:CorporateDebtSecuritiesFinancialMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel1Member amgn:CorporateDebtSecuritiesOtherMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel1Member amgn:CorporateDebtSecuritiesIndustrialMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel2Member amgn:CorporateDebtSecuritiesFinancialMember 2019-12-31 0000318154 amgn:OtherGovernmentRelatedAndCorporateDebtSecuritiesMember 2020-01-01 2020-03-31 0000318154 amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 currency:USD amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 currency:CHF amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 currency:EUR amgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 currency:USD amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 currency:USD amgn:FourPercentPoundSterlingNotesDue2029Member amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 amgn:FourPercentPoundSterlingNotesDue2029Member amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 currency:EUR amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 currency:GBP amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 currency:USD amgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 currency:GBP amgn:FourPercentPoundSterlingNotesDue2029Member amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 amgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 currency:USD amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 us-gaap:InterestRateSwapMember 2019-01-01 2019-03-31 0000318154 us-gaap:ProductMember us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0000318154 us-gaap:LongTermDebtMember 2019-12-31 0000318154 amgn:LongTermDebtCurrentMaturitiesMember 2019-12-31 0000318154 us-gaap:LongTermDebtMember 2020-03-31 0000318154 amgn:LongTermDebtCurrentMaturitiesMember 2020-03-31 0000318154 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000318154 us-gaap:ForwardContractsMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000318154 amgn:InterestRateSwapAtThenCurrentInterestRatesMember us-gaap:LongTermDebtMember 2020-03-31 0000318154 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember 2020-03-31 0000318154 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember 2019-12-31 0000318154 us-gaap:ForwardContractsMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000318154 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000318154 amgn:ForeignCurrencyAndCrossCurrencySwapsMember 2020-03-31 0000318154 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2020-01-01 2020-03-31 0000318154 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2019-01-01 2019-03-31 0000318154 us-gaap:CashFlowHedgingMember 2019-01-01 2019-03-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-01-01 2020-03-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2019-01-01 2019-03-31 0000318154 us-gaap:CashFlowHedgingMember 2020-01-01 2020-03-31 0000318154 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2020-01-01 2020-03-31 0000318154 us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000318154 amgn:OtherCurrentNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000318154 amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember amgn:CrossCurrencySwapContractsMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000318154 amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000318154 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-12-31 0000318154 amgn:OtherCurrentNoncurrentAssetsMember amgn:CrossCurrencySwapContractsMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000318154 us-gaap:NondesignatedMember 2019-12-31 0000318154 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-12-31 0000318154 amgn:OtherCurrentNoncurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000318154 amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000318154 amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000318154 amgn:OtherCurrentNoncurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000318154 amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember amgn:CrossCurrencySwapContractsMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000318154 us-gaap:NondesignatedMember 2020-03-31 0000318154 amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000318154 us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000318154 amgn:OtherCurrentNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000318154 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2020-03-31 0000318154 amgn:OtherCurrentNoncurrentAssetsMember amgn:CrossCurrencySwapContractsMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000318154 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2020-03-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0000318154 us-gaap:ProductMember us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0000318154 us-gaap:InterestRateSwapMember 2020-01-01 2020-03-31 0000318154 amgn:HospiraMember 2020-03-23 2020-03-23 0000318154 amgn:HospiraMember us-gaap:SubsequentEventMember 2020-04-17 2020-04-17 iso4217:GBP iso4217:USD amgn:segment iso4217:USD xbrli:shares iso4217:CHF xbrli:pure iso4217:EUR xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2020
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 001-37702
Amgen Inc.
(Exact name of registrant as specified in its charter)
Delaware
 
95-3540776
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
 
 
One Amgen Center Drive
 
91320-1799
Thousand Oaks
 
California
 
(Address of principal executive offices)
 
(Zip Code)
(805) 447-1000
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, $0.0001 par value
AMGN
The NASDAQ Global Select Market
1.250% Senior Notes Due 2022
AMGN22
New York Stock Exchange
2.00% Senior Notes Due 2026
AMGN26
New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or Section 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
Emerging growth company
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
No 
As of April 27, 2020, the registrant had 588,247,399 shares of common stock, $0.0001 par value, outstanding.



AMGEN INC.
INDEX

i


PART I — FINANCIAL INFORMATION 
Item 1.
FINANCIAL STATEMENTS
AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(In millions, except per-share data)
(Unaudited)

 
Three months ended
March 31,
 
2020
 
2019
Revenues:
 
 
 
Product sales
$
5,894

 
$
5,286

Other revenues
267

 
271

Total revenues
6,161

 
5,557

 
 
 
 
Operating expenses:
 
 
 
Cost of sales
1,513

 
1,055

Research and development
952

 
879

Selling, general and administrative
1,316

 
1,154

Other
25

 
(3
)
Total operating expenses
3,806

 
3,085

 
 
 
 
Operating income
2,355

 
2,472

 
 
 
 
Interest expense, net
346

 
343

Interest and other income, net
11

 
185

 
 
 
 
Income before income taxes
2,020

 
2,314

 
 
 
 
Provision for income taxes
195

 
322

 
 
 
 
Net income
$
1,825

 
$
1,992

 
 
 
 
Earnings per share:
 
 
 
Basic
$
3.09

 
$
3.20

Diluted
$
3.07

 
$
3.18

 
 
 
 
Shares used in calculation of earnings per share:
 
 
 
Basic
590

 
622

Diluted
594

 
626


See accompanying notes.

1


AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In millions)
(Unaudited)

 
Three months ended
March 31,
 
2020
 
2019
Net income
$
1,825

 
$
1,992

Other comprehensive (loss) income, net of reclassification adjustments and taxes:
 
 
 
Losses on foreign currency translation
(52
)
 
(13
)
(Losses) gains on cash flow hedges
(61
)
 
45

(Losses) gains on available-for-sale securities
(19
)
 
221

Other
(2
)
 

Other comprehensive (loss) income, net of taxes
(134
)
 
253

Comprehensive income
$
1,691

 
$
2,245


See accompanying notes.

2


AMGEN INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In millions, except per-share data)

 
March 31,
2020
 
December 31,
2019
 
(Unaudited)
 
 
ASSETS
Current assets:
 
 
 
Cash and cash equivalents
$
7,687

 
$
6,037

Marketable securities
325

 
2,874

Trade receivables, net
5,009

 
4,057

Inventories
3,682

 
3,584

Other current assets
2,110

 
1,888

Total current assets
18,813

 
18,440

 
 
 
 
Property, plant and equipment, net
4,879

 
4,928

Intangible assets, net
18,653

 
19,413

Goodwill
14,683

 
14,703

Other assets
4,641

 
2,223

Total assets
$
61,669

 
$
59,707

 
 
 
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
 
 
 
Accounts payable
$
1,338

 
$
1,371

Accrued liabilities
8,649

 
8,511

Current portion of long-term debt
1,840

 
2,953

Total current liabilities
11,827

 
12,835

 
 
 
 
Long-term debt
30,008

 
26,950

Long-term deferred tax liabilities
427

 
606

Long-term tax liabilities
8,111

 
8,037

Other noncurrent liabilities
1,811

 
1,606

 
 
 
 
Contingencies and commitments

 

 
 
 
 
Stockholders’ equity:
 
 
 
Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding — 588.0 shares in 2020 and 591.4 shares in 2019
31,525

 
31,531

Accumulated deficit
(21,378
)
 
(21,330
)
Accumulated other comprehensive loss
(662
)
 
(528
)
Total stockholders’ equity
9,485

 
9,673

Total liabilities and stockholders’ equity
$
61,669

 
$
59,707


See accompanying notes.

3


AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In millions, except per-share data)
(Unaudited)

 
Number
of shares
of common
stock
 
Common
stock and
additional
paid-in capital
 
Accumulated
deficit
 
Accumulated
other
comprehensive
loss
 
Total
Balance as of December 31, 2019
591.4

 
$
31,531

 
$
(21,330
)
 
$
(528
)
 
$
9,673

Cumulative effect of changes in accounting principles, net of tax

 

 
(2
)
 

 
(2
)
Net income

 

 
1,825

 

 
1,825

Other comprehensive loss, net of taxes

 

 

 
(134
)
 
(134
)
Dividends declared on common stock ($1.60 per share)

 

 
(938
)
 

 
(938
)
Issuance of common stock in connection with the Company’s equity award programs
0.9

 
10

 

 

 
10

Stock-based compensation expense

 
52

 

 

 
52

Tax impact related to employee stock-based compensation expense

 
(68
)
 

 

 
(68
)
Repurchases of common stock
(4.3
)
 

 
(933
)
 

 
(933
)
Balance as of March 31, 2020
588.0

 
$
31,525

 
$
(21,378
)
 
$
(662
)
 
$
9,485

 
Number
of shares
of common
stock
 
Common
stock and
additional
paid-in capital
 
Accumulated
deficit
 
Accumulated
other
comprehensive
loss
 
Total
Balance as of December 31, 2018
629.6

 
$
31,246

 
$
(17,977
)
 
$
(769
)
 
$
12,500

Net income

 

 
1,992

 

 
1,992

Other comprehensive income, net of taxes

 

 

 
253

 
253

Dividends declared on common stock ($1.45 per share)

 

 
(879
)
 

 
(879
)
Issuance of common stock in connection with the Company’s equity award programs
0.7

 
6

 

 

 
6

Stock-based compensation expense

 
64

 

 

 
64

Tax impact related to employee stock-based compensation expense

 
(73
)
 

 

 
(73
)
Repurchases of common stock
(15.9
)
 

 
(3,031
)
 

 
(3,031
)
Balance as of March 31, 2019
614.4

 
$
31,243

 
$
(19,895
)
 
$
(516
)
 
$
10,832


See accompanying notes.


4


AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
(Unaudited)

 
Three months ended
March 31,
 
2020
 
2019
Cash flows from operating activities:
 
 
 
Net income
$
1,825

 
$
1,992

Depreciation, amortization and other
897

 
495

Deferred income taxes
(84
)
 
(50
)
Other items, net
107

 
24

Changes in operating assets and liabilities, net of acquisition:
 
 
 
Trade receivables, net
(955
)
 
(207
)
Inventories
(113
)
 
(28
)
Other assets
319

 
(249
)
Accounts payable
(25
)
 
(112
)
Accrued income taxes, net
137

 
277

Long-term tax liabilities
74

 
100

Other liabilities
(48
)
 
(397
)
Net cash provided by operating activities
2,134

 
1,845

Cash flows from investing activities:
 
 
 
Purchases of marketable securities
(129
)
 
(6,898
)
Proceeds from sales of marketable securities
2,574

 
125

Proceeds from maturities of marketable securities
113

 
10,455

Purchases of property, plant and equipment
(142
)
 
(116
)
Purchases of equity method investments
(2,645
)
 
(5
)
Other
(1
)
 
(6
)
Net cash (used in) provided by investing activities
(230
)
 
3,555

Cash flows from financing activities:
 
 
 
Net proceeds from issuance of debt
4,963

 

Repayment of debt
(3,250
)
 
(1,000
)
Repurchases of common stock
(961
)
 
(3,032
)
Dividends paid
(945
)
 
(901
)
Other
(61
)
 
(54
)
Net cash used in financing activities
(254
)
 
(4,987
)
Increase in cash and cash equivalents
1,650

 
413

Cash and cash equivalents at beginning of period
6,037

 
6,945

Cash and cash equivalents at end of period
$
7,687

 
$
7,358


See accompanying notes.

5


AMGEN INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2020
(Unaudited)
1. Summary of significant accounting policies
Business
Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.
Basis of presentation
The financial information for the three months ended March 31, 2020 and 2019, is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year.
The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2019.
Principles of consolidation
The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.
Use of estimates
The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
Property, plant and equipment, net
Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization of $8.5 billion and $8.4 billion as of March 31, 2020 and December 31, 2019, respectively.
Equity method investments
The equity method of accounting is used for equity investments that give us the ability to exert significant influence, but not control, over an investee based on such factors as our ownership percentage, voting and other shareholder rights, board of director representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of the investees’ earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Interest and other income, net, in the Condensed Consolidated Statements of Income.
We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors including, but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value.
Recent accounting pronouncements
In June 2016, the Financial Accounting Standards Board (FASB) issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. We adopted this standard as of January 1, 2020, using a modified-retrospective approach. Adoption of the standard did not have a material impact on our condensed consolidated financial statements.

6


In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens of the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity may change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022, as a result of reference rate reform. We are currently evaluating the impact that this new standard will have on our condensed consolidated financial statements.
2. Revenues
We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. Rest-of-world (ROW) revenues relate to products that are sold primarily in Europe.
Revenues were as follows (in millions):
 
 
Three months ended March 31,
 
 
2020
 
2019
 
 
US
 
ROW
 
Total
 
US
 
ROW
 
Total
Enbrel® (etanercept)
 
$
1,117

 
$
36

 
$
1,153

 
$
1,106

 
$
45

 
$
1,151

Prolia® (denosumab)
 
422

 
232

 
654

 
390

 
202

 
592

Neulasta® (pegfilgrastim)
 
534

 
75

 
609

 
893

 
128

 
1,021

XGEVA® (denosumab)
 
355

 
126

 
481

 
356

 
115

 
471

Otezla® (apremilast)
 
377

 
102

 
479

 

 

 

Aranesp® (darbepoetin alfa)
 
175

 
247

 
422

 
182

 
232

 
414

KYPROLIS® (carfilzomib)
 
187

 
93

 
280

 
154

 
91

 
245

Repatha® (evolocumab)
 
124

 
105

 
229

 
83

 
58

 
141

Other products
 
988

 
599

 
1,587

 
827

 
424

 
1,251

Total product sales(1)
 
$
4,279

 
$
1,615

 
5,894

 
$
3,991

 
$
1,295

 
5,286

Other revenues
 
 
 
 
 
267

 
 
 
 
 
271

Total revenues
 
 
 
 
 
$
6,161

 
 
 
 
 
$
5,557

____________ 
(1) 
Hedging gains and losses, which are included in product sales, were not material for the three months ended March 31, 2020 and 2019.
3. Income taxes
The effective tax rates for the three months ended March 31, 2020 and 2019, were 9.7% and 13.9%, respectively.
The decrease in our effective tax rate for the three months ended March 31, 2020, was due primarily to amortization related to the Otezla® acquisition, changes in jurisdictional mix of earnings and certain favorable items in the quarter. The effective tax rates differ from the federal statutory rate primarily as a result of foreign earnings from the Company’s operations conducted in Puerto Rico, a territory of the United States that is treated as a foreign jurisdiction for U.S. tax purposes and are subject to tax incentive grants through 2035. In addition, the Company’s operations conducted in Singapore are subject to a tax incentive grant through 2034. These earnings are also subject to U.S. tax at a reduced rate of 10.5%.
The U.S. territory of Puerto Rico imposes an excise tax on the gross intercompany purchase price of goods and services from our manufacturer in Puerto Rico. The rate of 4% is effective through December 31, 2027. We account for the excise tax as a manufacturing cost that is capitalized in inventory and expensed in cost of sales when the related products are sold. For U.S. income tax purposes, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred.

7


One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes may arise with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. As previously disclosed, we received a Revenue Agent Report (RAR) from the Internal Revenue Service (IRS) for the years 2010, 2011 and 2012. The RAR proposes to make significant adjustments that relate primarily to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. In November 2017, we received a modified RAR that revised the IRS’s calculations but continued to propose substantial adjustments. We disagree with the proposed adjustments and calculations and are pursuing resolution with the IRS administrative appeals office, which currently has jurisdiction over the matter. If we deem necessary, we will vigorously contest the proposed adjustments through the judicial process. In addition, in April, we received draft notice of proposed adjustments (NOPAs) from the IRS for the years 2013, 2014 and 2015, which are similar to the proposed adjustments for the years 2010, 2011 and 2012 that relate primarily to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagree with the proposed adjustments and calculations and intend to contest them. We are also currently under examination by a number of other state and foreign tax jurisdictions.
Final resolution of these complex matters is not likely within the next 12 months and could have a material impact on our condensed consolidated financial statements. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes, the ultimate resolution of any tax matters may result in payments substantially greater or less than amounts accrued. We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009.
During the three months ended March 31, 2020, the gross amounts of our unrecognized tax benefits (UTBs) increased $50 million as a result of tax positions taken during the current year. Substantially all of the UTBs as of March 31, 2020, if recognized, would affect our effective tax rate.
4. Earnings per share
The computation of basic earnings per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which include primarily shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method.
The computations for basic and diluted EPS were as follows (in millions, except per-share data):
 
Three months ended
March 31,
 
2020
 
2019
Income (Numerator):
 
 
 
Net income for basic and diluted EPS
$
1,825

 
$
1,992

 
 
 
 
Shares (Denominator):
 
 
 
Weighted-average shares for basic EPS
590

 
622

Effect of dilutive securities
4

 
4

Weighted-average shares for diluted EPS
594

 
626

 
 
 
 
Basic EPS
$
3.09

 
$
3.20

Diluted EPS
$
3.07

 
$
3.18


For the three months ended March 31, 2020 and 2019, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.

8


5. Collaborations
On January 2, 2020, we closed our strategic collaboration with BeiGene, Ltd. (BeiGene) to expand our oncology presence in China. Under the collaboration, BeiGene will commercialize XGEVA®, KYPROLIS® and BLINCYTO® (blinatumomab) in China, and Amgen will share profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China.
In addition, we will jointly develop a portion of our oncology portfolio with BeiGene sharing in global research and development (R&D) costs by providing cash and development services up to $1.25 billion. Upon regulatory approval, BeiGene will assume commercialization rights in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside of China, Amgen will also pay BeiGene royalties.
For the three months ended March 31, 2020, costs recovered from BeiGene for oncology product candidates were $57 million and were recorded in R&D expense in the Condensed Consolidated Statements of Income. For the three months ended March 31, 2020, no profit share payments or product sales were recorded between Amgen and BeiGene. In connection with this collaboration, we acquired an ownership interest in BeiGene. See Note 6, Investments.
6. Investments
Available-for-sale investments
The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions):
Types of securities as of March 31, 2020
 
Amortized
cost
 
Gross
unrealized
gains
 
Gross
unrealized
losses
 
Fair
values
U.S. Treasury notes
 
$
173

 
$
3

 
$

 
$
176

U.S. Treasury bills
 
900

 

 

 
900

Corporate debt securities:
 
 
 
 
 
 
 
 
Financial
 
12

 

 

 
12

Industrial
 
12

 

 

 
12

Other
 

 

 

 

Residential-mortgage-backed securities
 

 

 

 

Money market mutual funds
 
5,762

 

 

 
5,762

Other short-term interest-bearing securities
 
432

 

 

 
432

Total interest-bearing securities
 
$
7,291

 
$
3

 
$

 
$
7,294

Types of securities as of December 31, 2019
 
Amortized
cost
 
Gross
unrealized
gains
 
Gross
unrealized
losses
 
Fair
values
U.S. Treasury notes
 
$
359

 
$
1

 
$

 
$
360

U.S. Treasury bills
 

 

 

 

Corporate debt securities:
 
 
 
 
 
 
 
 
Financial
 
1,108

 
13

 

 
1,121

Industrial
 
824

 
10

 

 
834

Other
 
195

 
3

 

 
198

Residential-mortgage-backed securities
 
181

 
1

 

 
182

Money market mutual funds
 
5,250

 

 

 
5,250

Other short-term interest-bearing securities
 
289

 

 

 
289

Total interest-bearing securities
 
$
8,206

 
$
28

 
$

 
$
8,234



9


The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions):
Condensed Consolidated Balance Sheets locations
 
March 31,
2020
 
December 31,
2019
Cash and cash equivalents
 
$
6,969

 
$
5,360

Marketable securities
 
325

 
2,874

Total interest-bearing securities
 
$
7,294

 
$
8,234


Cash and cash equivalents in the above table excludes bank account cash of $718 million and $677 million as of March 31, 2020 and December 31, 2019, respectively.
The fair values of interest-bearing securities by contractual maturity, except for residential-mortgage-backed securities that do not have a single maturity date, were as follows (in millions):
Contractual maturities
 
March 31,
2020
 
December 31,
2019
Maturing in one year or less
 
$
7,165

 
$
5,629

Maturing after one year through three years
 
129

 
2,304

Maturing after three years through five years
 

 
119

Residential mortgage-backed securities
 

 
182

Total interest-bearing securities
 
$
7,294

 
$
8,234


For the three months ended March 31, 2020 and 2019, realized gains on interest-bearing securities were $37 million and $1 million, respectively, and realized losses on interest-bearing securities were $4 million and $5 million, respectively. Realized gains and losses on interest-bearing securities are recorded in Interest and other income, net, in the Condensed Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method.
The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.
As of March 31, 2020 and December 31, 2019, aggregated gross unrealized losses of available-for-sale investments were not material, and accordingly, no allowance for credit losses was recorded as of March 31, 2020.
Equity securities
We held investments in equity securities with readily determinable fair values of $220 million and $303 million as of March 31, 2020 and December 31, 2019, respectively, which are included in Other assets in the Condensed Consolidated Balance Sheets. Gains and losses recognized on equity securities with readily determinable fair values, including gains and losses recognized on sales, were not material for the three months ended March 31, 2020 and 2019.
We held investments of $183 million and $176 million in equity securities without readily determinable fair values as of March 31, 2020 and December 31, 2019, respectively, which are included in Other assets in the Condensed Consolidated Balance Sheets. Adjustments to the carrying values of these securities were not material for the three months ended March 31, 2020 and 2019.
Equity method investments
Limited partnerships
We held limited partnership investments of $331 million and $320 million as of March 31, 2020 and December 31, 2019, respectively, which are included in Other assets in the Condensed Consolidated Balance Sheets. These investments, primarily investment funds of early-stage biotechnology companies, are accounted for by using the equity method of accounting and measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of March 31, 2020, unfunded additional commitments to be made for these investments during the next several years were not material. Gains and losses recognized on our limited partnership investments were not material for the three months ended March 31, 2020 and 2019.

10


BeiGene
On January 2, 2020, we acquired a 20.5% ownership interest in BeiGene for $2.8 billion, of which $2.6 billion was attributed to the fair value of equity securities upon closing, with the remainder attributed to prepaid R&D. Our equity investment in BeiGene is included in Other assets in the Condensed Consolidated Balance Sheets. The fair value of equity securities acquired exceeded our proportionate share of the carrying value of the underlying net assets of BeiGene by approximately $2.4 billion. This investment is accounted for by using the equity method of accounting, which requires us to identify and allocate amounts to the items that give rise to the basis difference and to amortize these items over their useful lives. This amortization, along with our share of the results of operations of BeiGene, will be recognized in Interest and other income, net, in our Condensed Consolidated Statements of Income. Recognition will occur one quarter in arrears, beginning in the second quarter of 2020. The basis difference was allocated to finite-lived intangible assets, indefinite-lived intangible assets, equity-method goodwill and related deferred taxes. The finite-lived intangible assets will be amortized over a period ranging from 8 to 15 years.
As of March 31, 2020, the carrying and fair values of our approximately 20.5% ownership interest in BeiGene totaled $2.6 billion and $2.0 billion, respectively. As of March 31, 2020, we believe the carrying value of our equity investment in BeiGene is fully recoverable. See Note 1, Summary of significant accounting policies, for factors considered in determining our conclusion. For information on a collaboration agreement we entered into with BeiGene in connection with this investment, see Note 5, Collaborations.
7. Inventories
Inventories consisted of the following (in millions):
 
March 31,
2020
 
December 31,
2019
Raw materials
$
446

 
$
358

Work in process
2,192

 
2,227

Finished goods
1,044

 
999

Total inventories
$
3,682

 
$
3,584


8. Goodwill and other intangible assets
Goodwill
The change in the carrying amount of goodwill was as follows (in millions):
 
Three months ended
March 31, 2020
Beginning balance
$
14,703

Currency translation adjustment
(20
)
Ending balance
$
14,683



11


Other intangible assets
Other intangible assets consisted of the following (in millions):
 
March 31, 2020
 
December 31, 2019
 
Gross
carrying
amounts
 
Accumulated
amortization
 
Other intangible
assets, net
 
Gross
carrying
amounts
 
Accumulated
amortization
 
Other intangible
assets, net
Finite-lived intangible assets:
 
 
 
 
 
 
 
 
 
 
 
Developed-product-technology rights
$
25,549

 
$
(8,876
)
 
$
16,673

 
$
25,575

 
$
(8,322
)
 
$
17,253

Licensing rights
3,746

 
(2,494
)
 
1,252

 
3,761

 
(2,398
)
 
1,363

Marketing-related rights
1,375

 
(979
)
 
396

 
1,382

 
(965
)
 
417

Research and development technology rights
1,269

 
(967
)
 
302

 
1,273

 
(947
)
 
326

Total finite-lived intangible assets
31,939

 
(13,316
)
 
18,623

 
31,991

 
(12,632
)
 
19,359

Indefinite-lived intangible assets:
 
 
 
 
 
 
 
 
 
 
 
In-process research and development
30

 

 
30

 
54

 

 
54

Total other intangible assets
$
31,969

 
$
(13,316
)
 
$
18,653

 
$
32,045

 
$
(12,632
)
 
$
19,413


Developed-product-technology rights consists of rights related to marketed products. Licensing rights consists primarily of contractual rights to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and up-front payments associated with royalty obligations for marketed products. Marketing-related rights consists primarily of rights related to the sale and distribution of marketed products. R&D technology rights pertains to technologies used in R&D that have alternative future uses.
In-process research and development (IPR&D) consists of R&D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. We review IPR&D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval.
During the three months ended March 31, 2020 and 2019, we recognized amortization associated with our finite-lived intangible assets of $709 million and $315 million, respectively. Amortization of intangible assets is included primarily in Cost of sales in the Condensed Consolidated Statements of Income. The total estimated amortization for our finite-lived intangible assets for the remaining nine months ending December 31, 2020, and the years ending December 31, 2021, 2022, 2023, 2024 and 2025, are $2.1 billion, $2.6 billion, $2.5 billion, $2.4 billion, $2.4 billion and $2.2 billion, respectively.

12


9. Financing arrangements
Our borrowings consisted of the following (in millions):
 
March 31,
2020
 
December 31,
2019
4.50% notes due 2020 (4.50% 2020 Notes)
$

 
$
300

2.125% notes due 2020 (2.125% 2020 Notes)
750

 
750

Floating Rate Notes due 2020
300

 
300

2.20% notes due 2020 (2.20% 2020 Notes)
700

 
700

3.45% notes due 2020 (3.45% 2020 Notes)

 
900

4.10% notes due 2021 (4.10% 2021 Notes)

 
1,000

1.85% notes due 2021 (1.85% 2021 Notes)

 
750

3.875% notes due 2021 (3.875% 2021 Notes)
1,450

 
1,750

1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes)
1,379

 
1,402

2.70% notes due 2022 (2.70% 2022 Notes)
500

 
500

2.65% notes due 2022 (2.65% 2022 Notes)
1,500

 
1,500

3.625% notes due 2022 (3.625% 2022 Notes)
750

 
750

0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)
728

 
725

2.25% notes due 2023 (2.25% 2023 Notes)
750

 
750

3.625% notes due 2024 (3.625% 2024 Notes)
1,400

 
1,400

1.90% notes due 2025 (1.90% 2025 Notes)
500

 

3.125% notes due 2025 (3.125% 2025 Notes)
1,000

 
1,000

2.00% €750 million notes due 2026 (2.00% 2026 euro Notes)
827

 
841

2.60% notes due 2026 (2.60% 2026 Notes)
1,250

 
1,250

5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes)
590

 
630

2.20% notes due 2027 (2.20% 2027 Notes)
750

 

3.20% notes due 2027 (3.20% 2027 Notes)
1,000

 
1,000

4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes)
869

 
928

2.45% notes due 2030 (2.45% 2030 Notes)
1,250

 

6.375% notes due 2037 (6.375% 2037 Notes)
552

 
552

6.90% notes due 2038 (6.90% 2038 Notes)
291

 
291

6.40% notes due 2039 (6.40% 2039 Notes)
466

 
466

3.15% notes due 2040 (3.15% 2040 Notes)
1,250

 

5.75% notes due 2040 (5.75% 2040 Notes)
412

 
412

4.95% notes due 2041 (4.95% 2041 Notes)
600

 
600

5.15% notes due 2041 (5.15% 2041 Notes)
974

 
974

5.65% notes due 2042 (5.65% 2042 Notes)
487

 
487

5.375% notes due 2043 (5.375% 2043 Notes)
261

 
261

4.40% notes due 2045 (4.40% 2045 Notes)
2,250

 
2,250

4.563% notes due 2048 (4.563% 2048 Notes)
1,415

 
1,415

3.375% notes due 2050 (3.375% 2050 Notes)
1,250

 

4.663% notes due 2051 (4.663% 2051 Notes)
3,541

 
3,541

Other notes due 2097
100

 
100

Unamortized bond discounts, premiums and issuance costs, net
(892
)
 
(868
)
Fair value adjustments
648

 
296

Total carrying value of debt
31,848

 
29,903

Less current portion
(1,840
)
 
(2,953
)
Total long-term debt
$
30,008

 
$
26,950


There are no material differences between the effective interest rates and coupon rates of any of our borrowings, except for the 4.563% 2048 Notes and the 4.663% 2051 Notes, which have effective interest rates of 6.3% and 5.6%, respectively.

13


Debt issuances and repayments
During the three months ended March 31, 2020, we issued $5.0 billion of debt, consisting of the 1.90% 2025 Notes, the 2.20% 2027 Notes, the 2.45% 2030 Notes, the 3.15% 2040 Notes and the 3.375% 2050 Notes. In the event of a change-in-control triggering event, as defined in the terms of the notes, we may be required to purchase all or a portion of these notes at a price equal to 101% of the principal amount of the notes plus accrued and unpaid interest. In addition, these notes may be redeemed at any time at our option, in whole or in part, at the principal amount of the notes being redeemed plus accrued and unpaid interest and a “make-whole” amount, which are defined by the terms of the notes. The notes may be redeemed without payment of make-whole amounts if redemption occurs during specified periods of time immediately prior to the maturity of the notes. Such time periods range from one month to six months prior to maturity.
A portion of the proceeds from the issuance of these notes were used to redeem the 3.45% 2020 Notes, the 4.10% 2021 Notes, the 1.85% 2021 Notes and $300 million aggregate principal amount of our 3.875% 2021 Notes. In connection with the redemption of these notes, we paid a total of $50 million in make-whole amounts plus associated accrued and unpaid interest, all of which was recognized in Interest expense, net, in the Condensed Consolidated Statements of Income during the three months ended March 31, 2020. In addition to these redemptions, the 4.50% 2020 Notes matured and were repaid during the three months ended March 31, 2020.
Interest rate swaps
In connection with the redemption of certain of the notes discussed above, associated interest rate swap contracts with an aggregate notional value of $2.2 billion were terminated. Additionally, due to historically low interest rates, during the three months ended March 31, 2020, we terminated interest rate swaps with an aggregate notional amount of $5.2 billion that hedged the 3.625% 2024 Notes, 2.60% 2026 Notes, 4.663% 2051 Notes and portions of our 3.625% 2022 Notes and 3.125% 2025 Notes, which resulted in the receipt of $576 million of cash and reduced counterparty credit risk. Immediately following termination of these contracts, we entered into new interest rate swap agreements at then-current interest rates on the same $5.2 billion principal amount of notes. See Note 12, Derivative instruments.
The effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions):
 
 
March 31, 2020
 
December 31, 2019
Notes
 
Notional amounts
Effective interest rates
 
Notional amounts
Effective interest rates
3.45% 2020 Notes
 
$

LIBOR + 1.1%
 
$
900

LIBOR + 1.1%
4.10% 2021 Notes
 

LIBOR + 1.7%
 
1,000

LIBOR + 1.7%
3.875% 2021 Notes
 
1,450

LIBOR + 2.0%
 
1,750

LIBOR + 2.0%
3.625% 2022 Notes
 
750

LIBOR + 2.7%
 
750

LIBOR + 1.6%
3.625% 2024 Notes
 
1,400

LIBOR + 3.2%
 
1,400

LIBOR + 1.4%
3.125% 2025 Notes
 
1,000

LIBOR + 1.8%
 
1,000

LIBOR + 0.9%
2.60% 2026 Notes
 
1,250

LIBOR + 1.8%
 
1,250

LIBOR + 0.3%
4.663% 2051 Notes(1)
 
1,500

LIBOR + 2.6%
 
1,500

LIBOR + 0.0%
Total notional amounts
 
$
7,350

 
 
$
9,550

 
____________ 
(1)
Excludes an additional 1.5% of interest for the difference between the coupon rate paid to note holders and the fixed rate received under the interest rate swap contracts.

14


10. Stockholders’ equity
Stock repurchase program
Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):
 
2020
 
2019
 
Shares
 
Dollars 
 
Shares
 
Dollars
First quarter
4.3

 
$
933

 
15.9

 
$
3,031


In December 2019, our Board of Directors increased the amount authorized under our stock repurchase program by an additional $4.0 billion. As of March 31, 2020, $5.5 billion of authorization remained available under our stock repurchase program.
Dividends
In March 2020, the Board of Directors declared a quarterly cash dividend of $1.60 per share, which will be paid in June 2020. In December 2019, the Board of Directors declared a quarterly cash dividend of $1.60 per share, which was paid in March 2020.
Accumulated other comprehensive income (loss)
The components of Accumulated other comprehensive income (loss) (AOCI) were as follows (in millions):
 
Foreign
currency
translation
 
Cash flow
hedges
 
Available-for-sale
securities
 
Other
 
AOCI
Balance as of December 31, 2019
$
(718
)
 
$
175

 
$
22

 
$
(7
)
 
$
(528
)
Foreign currency translation adjustments
(52
)
 

 

 

 
(52
)
Unrealized (losses) gains

 
(162
)
 
8

 

 
(154
)
Reclassification adjustments to income

 
84

 
(33
)
 

 
51

Other

 

 

 
(2
)
 
(2
)
Income taxes

 
17

 
6

 

 
23

Balance as of March 31, 2020
$
(770
)
 
$
114

 
$
3

 
$
(9
)
 
$
(662
)

Reclassifications out of AOCI and into earnings were as follows (in millions):
 
 
Three months ended March 31,
 
 
Components of AOCI
 
2020
 
2019
 
Condensed Consolidated
Statements of Income locations
Cash flow hedges:
 
 
 
 
 
 
Foreign currency contract gains
 
$
49

 
$
14

 
Product sales
Cross-currency swap contract losses
 
(133
)
 
(42
)
 
Interest and other income, net
 
 
(84
)
 
(28
)
 
Income before income taxes
 
 
18

 
6

 
Provision for income taxes
 
 
$
(66
)
 
$
(22
)
 
Net income
Available-for-sale securities:
 
 
 
 
 
 
Net realized gains (losses)
 
$
33

 
$
(4
)
 
Interest and other income, net
 
 
(7
)
 

 
Provision for income taxes
 
 
$
26

 
$
(4
)
 
Net income

 
 
Three months ended March 31,
 
 


15


11. Fair value measurement
To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows:
Level 1
Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access
Level 2
Valuations for which all significant inputs are observable either directly or indirectly—other than Level 1 inputs
Level 3
Valuations based on inputs that are unobservable and significant to the overall fair value measurement
The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.
The fair values of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):
 
 
Quoted prices in
active markets for
identical assets
(Level 1)
 
Significant
other observable
inputs
(Level 2)
 
Significant
unobservable
inputs
(Level 3)
 
 
 
 
 
 
 
 
Fair value measurement as of March 31, 2020, using:
 
 
 
 
Total
Assets:
 
 
 
 
 
 
 
 
Available-for-sale securities:
 
 
 
 
 
 
 
 
U.S. Treasury notes
 
$
176

 
$

 
$

 
$
176

U.S. Treasury bills
 
900

 

 

 
900

Corporate debt securities:
 
 
 
 
 
 
 
 
Financial
 

 
12

 

 
12

Industrial
 

 
12

 

 
12

Other
 

 

 

 

Residential-mortgage-backed securities
 

 

 

 

Money market mutual funds
 
5,762

 

 

 
5,762

Other short-term interest-bearing securities
 

 
432

 

 
432

Equity securities
 
220

 

 

 
220

Derivatives:
 
 
 
 
 
 
 
 
Foreign currency contracts
 

 
375

 

 
375

Cross-currency swap contracts
 

 
10

 

 
10

Interest rate swap contracts
 

 
89

 

 
89

Total assets
 
$
7,058

 
$
930

 
$

 
$
7,988

 
 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
 
Derivatives:
 
 
 
 
 
 
 
 
Foreign currency contracts
 
$

 
$
5

 
$

 
$
5

Cross-currency swap contracts
 

 
657

 

 
657

Interest rate swap contracts
 

 
23

 

 
23

Contingent consideration obligations
 

 

 
60

 
60

Total liabilities
 
$

 
$
685

 
$
60

 
$
745



16


 
 
Quoted prices in
active markets for
identical assets
(Level 1)
 
Significant
other observable
inputs
(Level 2)
 
Significant
unobservable
inputs
(Level 3)
 
 
 
 
 
 
 
 
Fair value measurement as of December 31, 2019, using:
 
 
 
 
Total
Assets:
 
 
 
 
 
 
 
 
Available-for-sale securities:
 
 
 
 
 
 
 
 
U.S. Treasury notes
 
$
360

 
$

 
$

 
$
360

U.S. Treasury bills
 

 

 

 

Corporate debt securities:
 
 
 
 
 
 
 
 
Financial
 

 
1,121

 

 
1,121

Industrial
 

 
834

 

 
834

Other
 

 
198

 

 
198

Residential-mortgage-backed securities
 

 
182

 

 
182

Money market mutual funds
 
5,250

 

 

 
5,250

Other short-term interest-bearing securities
 

 
289

 

 
289

Equity securities
 
303

 

 

 
303

Derivatives:
 
 
 
 
 
 
 
 
Foreign currency contracts
 

 
224

 

 
224

Cross-currency swap contracts
 

 
66

 

 
66

Interest rate swap contracts
 

 
259

 

 
259

Total assets
 
$
5,913

 
$
3,173

 
$

 
$
9,086

 
 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
 
Derivatives:
 
 
 
 
 
 
 
 
Foreign currency contracts
 
$

 
$
31

 
$

 
$
31

Cross-currency swap contracts
 

 
315

 

 
315

Interest rate swap contracts
 

 

 

 

Contingent consideration obligations
 

 

 
61

 
61

Total liabilities
 
$

 
$
346

 
$
61

 
$
407


Interest-bearing and equity securities
The fair values of our U.S. Treasury securities, money market mutual funds and equity securities are based on quoted market prices in active markets, with no valuation adjustment.
As of March 31, 2020, our corporate debt securities are investment grade and have maturity dates of three years or less from the balance sheet date. Our corporate debt securities portfolio has weighted-average credit ratings of BBB or equivalent by Standard & Poor’s Financial Services LLC (S&P), BBB+ by Moody’s Investors Service, Inc. (Moody’s) and A– by Fitch Ratings, Inc. (Fitch). We estimate the fair values of these securities by taking into consideration valuations obtained from third-party pricing services. The pricing services use industry-standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable either directly or indirectly to estimate fair value. The inputs include reported trades of and broker-dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs.
We value our other short-term interest-bearing securities at amortized cost, which approximates fair value given their near-term maturity dates.
Derivatives
All of our foreign currency forward derivative contracts have maturities of three years or less, and all are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts include implied volatility measures. These inputs, when applicable, are at commonly quoted intervals. See Note 12, Derivative instruments.

17


Our cross-currency swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency-basis swap spreads. See Note 12, Derivative instruments.
Our interest rate swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by using an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include LIBOR, swap rates and obligor credit default swap rates. See Note 12, Derivative instruments.
During the three months ended March 31, 2020 and 2019, there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis.
Summary of the fair values of other financial instruments
Cash equivalents
The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.
Borrowings
We estimated the fair values of our borrowings by using Level 2 inputs. As of March 31, 2020 and December 31, 2019, the aggregate fair values of our borrowings were $35.8 billion and $33.7 billion, respectively, and the carrying values were $31.8 billion and $29.9 billion, respectively.
12. Derivative instruments
The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, foreign currency option, cross-currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative trading purposes.
Cash flow hedges
We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates associated primarily with our euro-denominated international product sales. Increases and decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are offset partially by corresponding increases and decreases in the cash flows from our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations with regard to our international product sales, we enter into foreign currency forward contracts to hedge a portion of our projected international product sales primarily over a three-year time horizon, with, at any given point in time, a higher percentage of nearer-term projected product sales being hedged than in successive periods.
As of March 31, 2020 and December 31, 2019, we had outstanding foreign currency forward contracts with aggregate notional amounts of $4.9 billion and $5.0 billion, respectively. We have designated these foreign currency forward contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report the unrealized gains and losses on these contracts in AOCI in the Condensed Consolidated Balance Sheets, and we reclassify them to Product sales in the Condensed Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings.
To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros, pounds sterling and Swiss francs and received U.S. dollars for the notional amounts at the inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the lives of the contracts by paying U.S. dollars and receiving euros, pounds sterling and Swiss francs. In addition, we will pay U.S. dollars to and receive euros, pounds sterling and Swiss francs from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros, pounds sterling and Swiss francs to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Condensed Consolidated Balance Sheets and reclassified to Interest and other income, net, in the Condensed Consolidated Statements of Income in the same periods during which the hedged debt affects earnings.

18


The notional amounts and interest rates of our cross-currency swaps as of March 31, 2020, were as follows (notional amounts in millions):
 
 
Foreign currency
 
U.S. dollars
Hedged notes
 
Notional amounts
 
Interest rates
 
Notional amounts
 
Interest rates
1.25% 2022 euro Notes
 
1,250

 
1.3
%
 
$
1,388

 
3.2
%
0.41% 2023 Swiss franc Bonds
 
CHF
700

 
0.4
%
 
$
704

 
3.4
%
2.00% 2026 euro Notes
 
750

 
2.0
%
 
$
833

 
3.9
%
5.50% 2026 pound sterling Notes
 
£
475

 
5.5
%
 
$
747

 
6.0
%
4.00% 2029 pound sterling Notes
 
£
700

 
4.0
%
 
$
1,111

 
4.5
%

In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI in the Condensed Consolidated Balance Sheets and are amortized into Interest expense, net, in the Condensed Consolidated Statements of Income over the lives of the associated debt issuances. Amounts recognized in connection with forward interest rate swaps during the three months ended March 31, 2020, and amounts expected to be recognized during the subsequent 12 months are not material.
The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):
 
 
Three months ended
March 31,
Derivatives in cash flow hedging relationships
 
2020
 
2019
Foreign currency contracts
 
$
239

 
$
85

Cross-currency swap contracts
 
(401
)
 
(55
)
Total unrealized (losses) gains
 
$
(162
)
 
$
30


Fair value hedges
To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate LIBOR-based coupons over the terms of the related hedge contracts. As of March 31, 2020 and December 31, 2019, we had interest rate swap contracts with aggregate notional amounts of $7.4 billion and $9.6 billion, respectively, that hedge certain portions of our long-term debt issuances.
Interest rate swaps with an aggregate notional value of $2.2 billion were terminated during the three months ended March 31, 2020, in connection with the redemption of certain of our notes. The termination of these interest rate swaps resulted in a gain of $17 million recognized in Interest expense, net, in the Condensed Consolidated Statements of Income. Additionally, we terminated $5.2 billion aggregate notional amount of interest rate swaps, which resulted in the receipt of $576 million from the counterparties that was included in Net cash provided by operating activities in the Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2020. This amount will be recognized in Interest expense, net, in the Condensed Consolidated Statements of Income over the remaining life of the underlying notes. Immediately following the termination of these interest rate swap contracts, we entered into new interest rate swap agreements at then-current interest rates on the same $5.2 billion principal amount of notes. See Note 9, Financing arrangements, for information on our interest rate swaps.
For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Condensed Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining life of the previously hedged debt.

19


The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions):
 
 
Carrying amounts of hedged liabilities(1)
 
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities(2)
Condensed Consolidated Balance Sheets locations
 
March 31, 2020
 
December 31, 2019
 
March 31, 2020
 
December 31, 2019
Current portion of long-term debt
 
$
90

 
$
903

 
$
90

 
$
4

Long-term debt
 
$
7,784

 
$
8,814

 
$
558

 
$
292

____________ 
(1)
Current portion of long-term debt includes $90 million of carrying value with discontinued hedging relationships as of March 31, 2020. Long-term debt includes $592 million and $136 million of carrying value with discontinued hedging relationships as of March 31, 2020 and December 31, 2019, respectively.
(2) 
Current portion of long-term debt includes $90 million of hedging adjustments on discontinued hedging relationships as of March 31, 2020. Long-term debt includes $492 million and $36 million of hedging adjustments on discontinued hedging relationships as of March 31, 2020 and December 31, 2019, respectively.

20


Impact of hedging transactions
The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):
 
 
Three months ended March 31, 2020
 
 
Product sales
 
Interest and other income, net
 
Interest (expense), net
Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income
 
$
5,894

 
$
11

 
$
(346
)
The effects of cash flow and fair value hedging:
 
 
 
 
 
 
Gains (losses) on cash flow hedging relationships reclassified out of AOCI:
 
 
 
 
 
 
Foreign currency contracts
 
$
49

 
$

 
$

Cross-currency swap contracts
 
$

 
$
(133
)
 
$

Gains (losses) on fair value hedging relationships—interest rate swap agreements:
 
 
 
 
 
 
Hedged items(1)
 
$

 
$

 
$
210

Derivatives designated as hedging instruments
 
$

 
$

 
$
(190
)
 
 
Three months ended March 31, 2019
 
 
Product sales
 
Interest and other income, net
 
Interest (expense), net
Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income
 
$
5,286

 
$
185

 
$
(343
)
The effects of cash flow and fair value hedging:
 
 
 
 
 
 
Gains (losses) on cash flow hedging relationships reclassified out of AOCI:
 
 
 
 
 
 
Foreign currency contracts
 
$
14

 
$

 
$

Cross-currency swap contracts
 
$

 
$
(42
)
 
$

(Losses) gains on fair value hedging relationships—interest rate swap agreements:
 
 
 
 
 
 
Hedged items(1)
 
$

 
$

 
$
(130
)
Derivatives designated as hedging instruments
 
$

 
$

 
$
133

__________ 
(1) 
Gains (losses) on hedged items do not completely offset gains (losses) on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges where the corresponding hedged item was paid down in the period.
No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of March 31, 2020, we expected to reclassify $162 million of net gains on our foreign currency and cross-currency swap contracts out of AOCI and into earnings during the next 12 months.
Derivatives not designated as hedges
To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of March 31, 2020 and December 31, 2019, the total notional amounts of these foreign currency forward contracts were $0.8 billion and $1.2 billion, respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the three months ended March 31, 2020 and 2019.

21


The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions):
 
 
Derivative assets
 
Derivative liabilities
March 31, 2020
 
Condensed Consolidated
Balance Sheets locations
 
Fair values
 
Condensed Consolidated
Balance Sheets locations
 
Fair values
Derivatives designated as hedging instruments:
 
 
 
 
 
 
 
 
Foreign currency contracts
 
Other current assets/ Other assets
 
$
375

 
Accrued liabilities/ Other noncurrent liabilities
 
$
5

Cross-currency swap contracts
 
Other current assets/ Other assets
 
10

 
Accrued liabilities/ Other noncurrent liabilities
 
657

Interest rate swap contracts
 
Other current assets/ Other assets
 
89

 
Accrued liabilities/ Other noncurrent liabilities
 
23

Total derivatives designated as hedging instruments
 
 
 
474

 
 
 
685

Derivatives not designated as hedging instruments:
 
 
 
 
 
 
 
 
Foreign currency contracts
 
Other current assets
 

 
Accrued liabilities
 

Total derivatives not designated as hedging instruments
 
 
 

 
 
 

Total derivatives
 
 
 
$
474

 
 
 
$
685

 
 
Derivative assets
 
Derivative liabilities
December 31, 2019
 
Condensed Consolidated
Balance Sheets locations
 
Fair values
 
Condensed Consolidated
Balance Sheets locations
 
Fair values
Derivatives designated as hedging instruments:
 
 
 
 
 
 
 
 
Foreign currency contracts
 
Other current assets/ Other assets
 
$
223

 
Accrued liabilities/ Other noncurrent liabilities
 
$
31

Cross-currency swap contracts
 
Other current assets/ Other assets
 
66

 
Accrued liabilities/ Other noncurrent liabilities
 
315

Interest rate swap contracts
 
Other current assets/ Other assets
 
259

 
Accrued liabilities/ Other noncurrent liabilities
 

Total derivatives designated as hedging instruments
 
 
 
548

 
 
 
346

Derivatives not designated as hedging instruments:
 
 
 
 
 
 
 
 
Foreign currency contracts
 
Other current assets
 
1

 
Accrued liabilities
 

Total derivatives not designated as hedging instruments
 
 
 
1

 
 
 

Total derivatives
 
 
 
$
549

 
 
 
$
346


Our derivative contracts that were in liability positions as of March 31, 2020, contain certain credit-risk-related contingent provisions that would be triggered if (i) we were to undergo a change in control and (ii) our or the surviving entity’s creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right but not the obligation to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur.
The cash flow effects of our derivative contracts in the Condensed Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash used in financing activities.

22


13. Contingencies and commitments
Contingencies
In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See our Annual Report on Form 10-K for the year ended December 31, 2019, Part I, Item 1A. Risk Factors—Our business may be affected by litigation and government investigations. We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote.
We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.
Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing, or in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing, or in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.
Certain recent developments concerning our legal proceedings and other matters are discussed below:
Abbreviated New Drug Application (ANDA) Patent Litigation
KYPROLIS® (carfilzomib) ANDA Patent Litigation
Onyx Therapeutics, Inc. v. Cipla Limited, et al.
On March 30, 2020, the U.S. District Court for the District of Delaware (the Delaware District Court) issued an order advising the parties in the litigation that, due to the recent and current challenges, the court does not anticipate issuing its post-trial opinion until approximately on or before May 8, 2020.
Otezla® (apremilast) ANDA Patent Litigation
Amgen Inc. v. Sandoz Inc., et al.
On February 14, 2020, the U.S. District Court for the District of New Jersey (the New Jersey District Court) granted the motion by Amgen and Celgene Corp. (Celgene) and issued an order substituting Amgen for Celgene as plaintiff in the consolidated action and all related actions, terminating Celgene as plaintiff in the consolidated action and all related actions, and amending the case caption in the consolidated action and all related actions to reflect Amgen as the sole plaintiff.
On March 25, 2020, based on a joint request by Amgen and Unichem Laboratories, Ltd. (Unichem), the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Unichem’s apremilast product during the term of the U.S. Patent Nos. 6,962,940 (the ’940 Patent); 7,427,638 (the ’638 Patent); 7,659,302 (the ’302 Patent); 7,893,101 (the ’101 Patent); 8,455,536 (the ’536 Patent); 9,018,243 (the ’243 Patent); 9,724,330 (the ’330 Patent); and 10,092,541 (the ’541 Patent), unless authorized pursuant to a confidential settlement agreement. On April 3, 2020, based on a joint request by Amgen and Annora Pharma Private Ltd. and Hetero USA Inc. (collectively, Hetero), the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Hetero’s apremilast product during the term of the ’940 Patent; U.S. Patent No. 7,208,516; the ’638 Patent; the ’302 Patent; the ’101 Patent; the ’536 Patent; U.S. Patent No. 8,802,717; the ’243 Patent; the ’330 Patent; U.S. Patent No. 9,872,854 and the ’541 Patent, unless authorized pursuant to a confidential settlement agreement. Trial in the consolidated action is scheduled to commence in May 2021.

23


Sensipar® (cinacalcet) ANDA Patent Litigation
Amgen Inc. v. Amneal Pharmaceuticals LLC, et al. (formerly, Amgen Inc. v. Aurobindo Pharma Ltd. et al.) Consolidated Case
On February 13, 2020, Amgen petitioned the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit Court) to rehear Amgen’s appeal of the judgment of noninfringement with respect to Piramal Healthcare UK Limited, and Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York, LLC (collectively, Amneal) petitioned the Federal Circuit Court for panel rehearing of the court’s opinion vacating and remanding the judgment of noninfringement with respect to Amneal. On April 15, 2020, the Federal Circuit Court denied each of Amgen’s and Amneal’s petitions. On April 22, 2020, the Federal Circuit Court issued a mandate returning the case to the Delaware District Court.
ENBREL (etanercept) Patent Litigation
Immunex Corporation, et al. v. Sandoz Inc., et al.
On March 4, 2020, the Federal Circuit Court heard oral argument on the appeal by Sandoz Inc., Sandoz International GmbH and Sandoz GmbH from final judgment upholding the validity of U.S. Patent Nos. 8,063,182 and 8,163,522.
Repatha® (evolocumab) Patent Litigation
Patent Disputes in the International Region
A two-day hearing before the Technical Board of Appeal of the European Patent Office, which was scheduled to begin on March 24, 2020, has been rescheduled to begin on October 28, 2020.
As previously disclosed, we are also involved in and expect future involvement in additional disputes regarding our proprotein convertase subtilisin/kexin type 9 (PCSK9) patents in other jurisdictions and regions, including matters filed against us and that we have filed in the United Kingdom, Germany, France and Japan.
On April 24, 2020, the Supreme Court of Japan declined to hear Sanofi K.K.’s appeals making final the Japanese High Court’s decisions that PRALUENT® infringes Amgen’s valid patent rights in Japan.
NEUPOGEN® (filgrastim)/Neulasta® (pegfilgrastim) Patent Litigation
Apotex PTAB Challenge
On March 24, 2020, the Federal Circuit Court vacated the decision by the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office and remanded the case to the PTAB for proceeding consistent with the Federal Circuit Court’s decision in Arthrex Inc. v. Smith & Nephew, Inc., 941 F.3d 1320 (Fed. Cir. 2019).
Amgen Inc., et al. v. Pfizer Inc. et al.
On February 18, 2020, the Delaware District Court entered an amended scheduling order moving the trial on the infringement of our U.S. Patent No. 9,643,997 to May 17, 2021, to enable Amgen Inc. and its wholly owned subsidiary, Amgen Manufacturing, Limited (collectively Amgen), to seek additional discovery into the defenses of Pfizer Inc. (Pfizer) and Hospira Inc. (Hospira).
On April 24, 2020, Amgen filed a separate lawsuit in the Delaware District Court against Hospira and Pfizer for infringement of U.S. Patent No. 10,577,392 (the ’392 Patent) and seeks, among other remedies, damages and injunctive relief to prohibit Hospira and Pfizer from infringing the ’392 Patent by the manufacture, import and sale of Pfizer’s NIVESTYMTM biosimilar filgrastim product, which was launched in the U.S. in October 2018.
Amgen Inc., et al. v. Hospira Inc. et al.
On March 4, 2020, Hospira and Pfizer filed a motion requesting the Delaware District Court to dismiss the complaint by Amgen Inc. and its wholly owned subsidiary, Amgen Manufacturing, Limited, alleging non-infringement of U.S. Patent No. 8,273,707. The motion has been fully briefed.
Fresenius PTAB Challenge
On March 30, 2020, Amgen filed its preliminary response to a petition to institute inter partes review before the PTAB to challenge the patentability of U.S. Patent No. 9,856,287 filed by Fresenius Kabi USA, LLC and Fresenius Kabi SwissBioSim GmbH, and the PTAB will have 3 months to render a decision on whether to institute trial proceedings.

24


EPOGEN® (epoetin alfa) Patent Litigation
Amgen Inc., et al. v. Hospira, Inc.
The Federal Circuit Court denied petition for rehearing en banc by Hospira and issued the mandate on March 23, 2020 affirming the final judgment of the Delaware District Court that Amgen’s U.S. Patent No. 5,856,298 is valid and infringed by Hospira, that Amgen’s U.S. Patent No. 5,756,349 is not infringed by Hospira, and awarding Amgen $70 million in damages for Hospira’s infringement. On April 17, 2020, Amgen acknowledged satisfaction of judgment upon receipt of $83 million in damages, interest and cost.
Litigation relating to our Biosimilar Products
KANJINTI® (trastuzumab-anns) Patent Litigation
Genentech, Inc. v. Amgen Inc.
On March 6, 2020, the Federal Circuit Court affirmed the District Court’s denial of Genentech Inc.’s (Genentech) motion for a preliminary injunction. On March 9, 2020, the Delaware District Court entered a Markman order construing a term of U.S. Patent No. 8,574,869 (the ’869 Patent). On March 16, 2020, the Delaware District Court signed a joint stipulation and order vacating the April 20, 2020 trial date. On April 17, 2020, the Delaware District Court rescheduled the jury trial to begin on February 22, 2021.
MVASI® (bevacizumab-awwb) Patent Litigation
Genentech, Inc. and City of Hope v. Amgen Inc.
On February 19, 2020, Genentech filed its second amended complaint in the Delaware District Court, adding additional claims for legal and declaratory relief with respect to patents already in suit. On March 4, 2020, Amgen filed its second amended affirmative answer and counterclaims, adding affirmative defenses and counterclaims that the ’869 Patent is unenforceable for inequitable conduct and unclean hands. On March 9, 2020, the Delaware District Court entered a Markman order construing a term of the ’869 Patent.
Genentech, Inc. and City of Hope v. Immunex Rhode Island Corp. and Amgen Inc.
Argument before the Federal Circuit Court on Genentech’s appeal of the Delaware District Court’s denial of Genentech’s motions for injunctive relief has been scheduled for June 3, 2020.
Breach of Contract Action
Cipla Ltd. et al. v. Amgen Inc.
On February 6, 2020, Amgen’s motion was transferred to the U.S. Magistrate Judge for the District of Delaware for a recommendation. A hearing on the motion was held on April 28, 2020.
Novartis Pharma AG v. Amgen Inc.
On February 18, 2020, Novartis Pharma AG filed in the U.S. District Court for the Southern District of New York its answer and affirmative defenses to Amgen’s second amended counterclaims.
Antitrust Class Action
Sensipar® Antitrust Class Actions
On February 6, 2020, the motions in the class action lawsuits against Amgen and various entities affiliated with Teva Pharmaceutical Industries Limited were transferred to the U.S. Magistrate Judge for the District of Delaware for a recommendation. A hearing on the motions was held on April 28, 2020.
The multidistrict litigation panel certified its conditional transfer order on February 6, 2020 transferring the additional class action lawsuit brought in the U.S. District Court for the Southern District of Florida, captioned MSP Recovery Claims v. Amgen Inc., et al., to the Delaware District Court.

25


Item 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is intended to assist the reader in understanding Amgen’s business. MD&A is provided as a supplement to and should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2019. Our results of operations discussed in MD&A are presented in conformity with GAAP. Amgen operates in one business segment: human therapeutics. Therefore, our results of operations are discussed on a consolidated basis.
Forward-looking statements
This report and other documents we file with the Securities and Exchange Commission (SEC) contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, our future performance, our business, our beliefs and our management’s assumptions. In addition, we, or others on our behalf, may make forward-looking statements in press releases, written statements or our communications and discussions with investors and analysts in the normal course of business through meetings, webcasts, phone calls and conference calls. Such words as “expect,” “anticipate,” “outlook,” “could,” “target,” “project,” “intend,” “plan,” “believe,” “seek,” “estimate,” “should,” “may,” “assume” and “continue” as well as variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and they involve certain risks, uncertainties and assumptions that are difficult to predict. We describe our respective risks, uncertainties and assumptions that could affect the outcome or results of operations in Item 1A. Risk Factors in Part II herein and in Part I, Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2019. We have based our forward-looking statements on our management’s beliefs and assumptions based on information available to our management at the time the statements are made. We caution you that actual outcomes and results may differ materially from what is expressed, implied or forecasted by our forward-looking statements. Reference is made in particular to forward-looking statements regarding product sales, regulatory activities, clinical trial results, reimbursement, expenses, EPS, liquidity and capital resources, trends, planned dividends, stock repurchases, collaborations and effects of pandemics. Except as required under the federal securities laws and the rules and regulations of the SEC, we do not have any intention or obligation to update publicly any forward-looking statements after the distribution of this report, whether as a result of new information, future events, changes in assumptions or otherwise.
Overview
Amgen is a biotechnology company committed to unlocking the potential of biology for patients suffering from serious illnesses. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. In 2020, we are celebrating our 40th anniversary, continuing our history of focusing on innovative medicines that have the potential to be first-in-class molecules and that have a large-effect size on serious diseases.
Our principal products—those with the most significant annual commercial sales—are ENBREL, Prolia®, Neulasta®, XGEVA®, Otezla®, Aranesp®, KYPROLIS® and Repatha®. We also market a number of other products, including Nplate® (romiplostim), Vectibix® (panitumumab), Parsabiv®(etelcalcetide), EPOGEN®, Sensipar®/Mimpara®, KANJINTI®, MVASI®, EVENITY®(romosozumab-aqqg), BLINCYTO®, AMGEVITATM (adalimumab), Aimovig® (erenumab-aooe), NEUPOGEN®, IMLYGIC® (talimogene laherparepvec) and Corlanor® (ivabradine).
COVID-19 pandemic
A novel strain of coronavirus (COVID-19) was declared a global pandemic by the World Health Organization on March 11, 2020. We have been carefully monitoring the COVID-19 pandemic and its impact on our global operations. We have taken appropriate steps to minimize the risk to our employees. Our employees have been working remotely with the exception of certain essential staff that continue to report to Amgen locations. The essential staff are primarily at our manufacturing sites, working in accordance with applicable government health and safety protocols and guidance issued in response to the COVID-19 pandemic, and are being paid a labor premium during this period. To date, our remote working arrangements have not significantly impacted our ability to maintain critical business operations. Further, we currently do not expect disruptions or shortages of our supply of medicine.

26



Since the beginning of the COVID-19 pandemic, we have seen changes in demand trends for some of our products, including lower demand for certain products as continuing patient access to those products has been impacted by COVID-19. For example, near the end of March, we began to observe a decline in sales of Prolia®, as elderly patients vulnerable to COVID-19 avoided doctors’ offices. To respond to COVID-19, we are managing our clinical development on a case-by-case basis. Patients who are already enrolled in studies continue to receive study drug, including through direct-to-patient shipments. For those studies that have the potential for significant benefit in a serious or life-threatening condition and where site resources allow new patients to be enrolled safely and monitored closely, we are allowing enrollment to continue. For those clinical trials where there is uncertainty with regard to the trial sites’ ability to ensure subject safety or data integrity at the present time, we have temporarily paused enrollment. We remain focused on supporting our active clinical sites in providing care for these patients and providing investigational drug supply. In addition, our R&D organization is supporting efforts to combat the pandemic in a number of ways including: (i) conducting a population-based study by our subsidiary deCODE Genetics in partnership with the Icelandic government, (ii) entering into a collaboration with Adaptive Biotechnologies to discover and develop antibody therapies for prevention or treatment options and (iii) joining a public-private partnership between leading companies in our industry and U.S. government health agencies to develop a strategy for a coordinated research response to the COVID-19 pandemic. Further, we anticipate that Otezla® will be investigated as a potential immunomodulatory treatment in adult patients with COVID-19 in upcoming platform trials.
We continue to believe that existing funds, cash generated from operations and existing sources of and access to financing are adequate to satisfy our needs for working capital, capital expenditures and debt service requirements as well as to engage in the capital return and other business initiatives that we plan to strategically pursue. To respond to some of the challenges experienced in the healthcare community as a result of the pandemic, we recently extended credit terms with certain customers for a subset of our products globally. For a discussion of the risks presented by the COVID-19 pandemic to our results, see Risk Factors in Part II, Item 1A of this Form 10-Q.
Significant developments
Following is a summary of selected significant developments affecting our business that have occurred since the filing of our Annual Report on Form 10-K for the year ended December 31, 2019. For additional developments or for a more comprehensive discussion of certain developments discussed below, see our Annual Report on Form 10-K for the year ended December 31, 2019.
Establishment of wholly-owned affiliate in Japan
In April 2020, we completed our purchase from Astellas of the remaining shares of Amgen Astellas BioPharma K.K. (AABP), a joint venture between Amgen and Astellas established in 2013. AABP, now a wholly-owned Amgen affiliate in Japan and renamed Amgen K.K., has enabled us to build a strong presence in Japan as we continue to advance treatments for serious illnesses.
Selected financial information
The following is an overview of our results of operations (in millions, except percentages and per-share data):
 
Three months ended
March 31,
 
 
 
2020
 
2019
 
Change
Product sales
 
 
 
 
 
U.S.
$
4,279

 
$
3,991

 
7
 %
ROW
1,615

 
1,295

 
25
 %
Total product sales
5,894

 
5,286

 
12
 %
Other revenues
267

 
271

 
(1
)%
Total revenues
$
6,161

 
$
5,557

 
11
 %
Operating expenses
$
3,806

 
$
3,085

 
23
 %
Operating income
$
2,355

 
$
2,472

 
(5
)%
Net income
$
1,825

 
$
1,992

 
(8
)%
Diluted EPS
$
3.07

 
$
3.18

 
(3
)%
Diluted shares
594

 
626

 
(5
)%

27


In the following discussion of changes in product sales, any reference to unit demand growth or decline refers to changes in the purchases of our products by healthcare providers (such as physicians or their clinics), dialysis centers, hospitals and pharmacies. In addition, any reference to increases or decreases in inventory refers to changes in inventory held by wholesaler customers and end users (such as pharmacies).
Total product sales increased for the three months ended March 31, 2020, driven primarily by sales from Otezla®, acquired in November 2019 and recently launched biosimilar products, offset partially by a decline in net selling price. For the remainder of 2020, we expect net selling price to continue to decline primarily on our legacy products. Further, since the beginning of the COVID-19 pandemic, we have seen changes in demand trends for some of our products, including lower demand for certain products as patient access to those products has been impacted by the pandemic. We expect this trend to continue to some extent through at least the duration of the pandemic. As discussed above, in response to the challenges being experienced by the healthcare community as a result of COVID-19, we have extended credit terms with certain customers for a subset of our products globally. In addition, a number of insurance plans (commercial and governmental) have been required to or have voluntarily covered 90-day prescription fills for a number of medicines including some of our products that are used in chronic conditions. As a result, there is increased uncertainty around the timing and magnitude of our sales during the COVID-19 pandemic.
Other revenues decreased slightly for the three months ended March 31, 2020, driven primarily by lower profit share payments, offset partially by higher royalties.
Operating expenses increased for the three months ended March 31, 2020, driven primarily by acquisition related expenses and the first full quarter of commercial-related support for Otezla®. For the remainder of 2020, we expect to continue to see the effects of our acquisition of Otezla® on our operating expenses, including increases to Cost of sales, R&D and Selling, general and administrative (SG&A) expenses.
Although changes in foreign currency exchange rates result in increases or decreases in our reported international product sales, the benefit or detriment that such movements have on our international product sales is offset partially by corresponding increases or decreases in our international operating expenses and our related foreign currency hedging activities. Our hedging activities seek to offset the impacts, both positive and negative, that foreign currency exchange rate changes may have on our net income by hedging our net foreign currency exposure, primarily with respect to product sales denominated in euros. The net impact from changes in foreign currency exchange rates was not material for the three months ended March 31, 2020 and 2019.
Results of operations
Product sales
Worldwide product sales were as follows (dollar amounts in millions):
 
Three months ended
March 31,
 
 
 
2020
 
2019
 
Change
ENBREL
$
1,153

 
$
1,151

 
 %
Prolia® 
654

 
592

 
10
 %
Neulasta®
609

 
1,021

 
(40
)%
XGEVA® 
481

 
471

 
2
 %
Otezla® 
479

 

 
*

Aranesp®
422

 
414

 
2
 %
KYPROLIS®
280

 
245

 
14
 %
Repatha®
229

 
141

 
62
 %
Other products
1,587

 
1,251

 
27
 %
Total product sales
$
5,894

 
$
5,286

 
12
 %
* Change in excess of 100%.
Future sales of our products will depend in part on the factors discussed below and in the following sections of our Annual Report on Form 10-K for the year ended December 31, 2019: (i) Item 1. Business—Marketing, Distribution and Selected Marketed Products, (ii) Item 1A. Risk Factors and (iii) Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Overview, and Results of Operations—Product Sales, as well as in our Quarterly Report on Form 10-Q for the period ended March 31, 2020, in Part II, Item 1A. Risk Factors.

28


ENBREL
Total ENBREL sales by geographic region were as follows (dollar amounts in millions):
 
Three months ended
March 31,
 
 
 
2020
 
2019
 
Change
ENBREL — U.S.
$
1,117

 
$
1,106

 
1
 %
ENBREL — Canada
36

 
45

 
(20
)%
Total ENBREL
$
1,153

 
$
1,151

 
 %
The slight increase in ENBREL sales for the three months ended March 31, 2020, was driven by favorable changes to estimated sales deductions and inventory, offset by lower unit demand and net selling price. For the remainder of 2020, we expect the trend of lower unit demand to continue.
In April 2019, the U.S. Food and Drug Administration (FDA) approved a second biosimilar version of ENBREL, and we are involved in patent litigations with the two companies seeking to market their FDA-approved biosimilar versions of ENBREL. See Note 13, Contingencies and commitments, to the condensed consolidated financial statements and Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019. Other companies are also developing purposed biosimilar versions of ENBREL. Companies with approved biosimilar versions of ENBREL may seek to enter the U.S. market if we are not successful in our litigations, or even earlier.
Prolia® 
Total Prolia® sales by geographic region were as follows (dollar amounts in millions):
 
Three months ended
March 31,
 
 
 
2020
 
2019
 
Change
Prolia® — U.S.
$
422

 
$
390

 
8
%
Prolia® — ROW
232

 
202

 
15
%
Total Prolia®
$
654

 
$
592

 
10
%
The increase in global Prolia® sales for the three months ended March 31, 2020, was driven by higher unit demand. Prolia®, which has a six-month dosing interval, has exhibited a historical sales pattern with the first and third quarters of a year representing lower sales than the second and fourth quarters of a year. However, disruptions in patient visits as a result of the COVID-19 pandemic have begun to impact near-term demand, which may result in changes to the historical sales pattern.
Neulasta® 
Total Neulasta® sales by geographic region were as follows (dollar amounts in millions):
 
Three months ended
March 31,
 
 
 
2020
 
2019
 
Change
Neulasta®— U.S.
$
534

 
$
893

 
(40
)%
Neulasta®— ROW
75

 
128

 
(41
)%
Total Neulasta®
$
609

 
$
1,021

 
(40
)%
The decrease in global Neulasta® sales for the three months ended March 31, 2020, was driven by the impact of biosimilar competition on unit demand and lower net selling price. Neulasta® sales included a $98 million order from the U.S. government in the first quarter of 2019.
We face increased competition in the United States and Europe as a result of launches of biosimilar versions of Neulasta®, which has had and will continue to have a material adverse impact on sales. We also expect other biosimilar versions to be approved in the near future. For a discussion of ongoing patent litigations related to these and other biosimilars, see Note 13, Contingencies and commitments, to the condensed consolidated financial statements and Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019.

29


XGEVA®  
Total XGEVA® sales by geographic region were as follows (dollar amounts in millions):
 
Three months ended
March 31,
 
 
 
2020
 
2019
 
Change
XGEVA® — U.S.
$
355

 
$
356

 
%
XGEVA® — ROW
126

 
115

 
10
%
Total XGEVA®
$
481

 
$
471

 
2
%
The increase in global XGEVA® sales for the three months ended March 31, 2020, was driven by higher unit demand and net selling price, offset partially by unfavorable changes to estimated sales deductions and inventory.
Otezla®  
Total Otezla® sales by geographic region were as follows (dollar amounts in millions):
 
Three months ended
March 31,
 
 
 
2020
 
2019
 
Change
Otezla® — U.S.
$
377

 
$

 
*
Otezla® — ROW
102

 

 
*
Total XGEVA®
$
479

 
$

 
*
* Change in excess of 100%.
Otezla® was acquired on November 21, 2019 and generated $479 million in sales for the three months ended March 31, 2020.
Aranesp® 
Total Aranesp® sales by geographic region were as follows (dollar amounts in millions):
 
Three months ended
March 31,
 
 
 
2020
 
2019
 
Change
Aranesp® — U.S.
$
175

 
$
182

 
(4
)%
Aranesp® — ROW
247

 
232

 
6
 %
Total Aranesp®
$
422

 
$
414

 
2
 %
The increase in global Aranesp® sales for the three months ended March 31, 2020, was driven by higher unit demand and favorable changes in inventory, offset by a decline in net selling price.
Aranesp® faces competition from a long-acting erythropoiesis-stimulating agent (ESA). Aranesp® also faces competition from a biosimilar version of EPOGEN®. Other biosimilar versions of EPOGEN ® may also receive approval in the future. For the remainder of 2020, we expect sales to decline at a faster rate than in 2019 due to short- and long-acting competition.

30


KYPROLIS® 
Total KYPROLIS® sales by geographic region were as follows (dollar amounts in millions):
 
Three months ended
March 31, 2020
 
 
 
2020
 
2019
 
Change
KYPROLIS® — U.S.
$
187

 
$
154

 
21
%
KYPROLIS® — ROW
93

 
91

 
2
%
Total KYPROLIS®
$
280

 
$
245

 
14
%
The increase in global KYPROLIS® sales for the three months ended March 31, 2020, was driven by higher unit demand and to a lesser extent an increase in net selling price.
We are engaged in litigation with two related companies that are challenging our material patents related to KYPROLIS® and that are seeking to market generic carfilzomib products. Separately, we have entered into confidential settlement agreements with other companies developing generic carfilzomib products, and the court has entered consent judgments enjoining those companies from infringing certain of our patents, subject to terms of the confidential settlement agreements. See Note 13, Contingencies and commitments, to the condensed consolidated financial statements and Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019. The FDA has reported that it has tentatively approved ANDAs filed by two companies for generic carfilzomib products. The date of final approval of those ANDAs is governed by the Hatch-Waxman Act and any applicable settlement agreements between the parties.
Repatha® 
Total Repatha® sales by geographic region were as follows (dollar amounts in millions):
 
Three months ended
March 31, 2020
 
 
 
2020
 
2019
 
Change
Repatha® — U.S.
$
124

 
$
83

 
49
%
Repatha® — ROW
105

 
58

 
81
%
Total Repatha®
$
229

 
$
141

 
62
%
The increase in global Repatha® sales for the three months ended March 31, 2020, was driven primarily by higher unit demand, offset partially by lower net selling price.

31


Other products
Other product sales by geographic region were as follows (dollar amounts in millions):
 
Three months ended
March 31,
 
 
 
2020
 
2019
 
Change
Nplate®— U.S.
$
127

 
$
114

 
11
 %
Nplate®— ROW
91

 
75

 
21
 %
Vectibix®— U.S.
80

 
78

 
3
 %
Vectibix®— ROW
122

 
92

 
33
 %
Parsabiv® — U.S.
146

 
109

 
34
 %
Parsabiv® — ROW
29

 
17

 
71
 %
EPOGEN® — U.S.
155

 
219

 
(29
)%
Sensipar® — U.S.
42

 
135

 
(69
)%
Sensipar®/Mimpara® — ROW
81

 
78

 
4
 %
KANJINTI®— U.S.
96

 

 
*

KANJINTI®— ROW
23

 
24

 
(4
)%
MVASI®— U.S.
108

 

 
*

MVASI®— ROW
7

 

 
*

EVENITY® — U.S.
37

 

 
*

EVENITY®— ROW
63

 
17

 
*

BLINCYTO® — U.S.
57

 
40

 
43
 %
BLINCYTO® — ROW
37

 
29

 
28
 %
AMGEVITATM — ROW
86

 
31

 
*

Aimovig® — U.S.
71

 
59

 
20
 %
NEUPOGEN®— U.S.
45

 
50

 
(10
)%
NEUPOGEN®— ROW
20

 
23

 
(13
)%
Other — U.S.
24

 
23

 
4
 %
Other — ROW
40

 
38

 
5
 %
Total other products
$
1,587

 
$
1,251

 
27
 %
Total U.S. — other products
$
988

 
$
827

 
19
 %
Total ROW — other products
599

 
424

 
41
 %
Total other products
$
1,587

 
$
1,251

 
27
 %
* Change in excess of 100%.

32


Operating expenses
Operating expenses were as follows (dollar amounts in millions):
 
Three months ended
March 31,
 
 
 
2020
 
2019
 
Change
Operating expenses:
 
 
 
 
 
Cost of sales
$
1,513

 
$
1,055

 
43
%
% of product sales
25.7
%
 
20.0
%
 
 
% of total revenues
24.6
%
 
19.0
%
 
 
Research and development
$
952

 
$
879

 
8
%
% of product sales
16.2
%
 
16.6
%
 
 
% of total revenues
15.5
%
 
15.8
%
 
 
Selling, general and administrative
$
1,316

 
$
1,154

 
14
%
% of product sales
22.3
%
 
21.8
%
 
 
% of total revenues
21.4
%
 
20.8
%
 
 
Other
$
25

 
$
(3
)
 
*

* Change in excess of 100%.
Cost of sales
Cost of sales increased to 24.6% of total revenues for the three months ended March 31, 2020, driven primarily by the amortization of intangible assets as a result of our acquisition of Otezla® and an increase in milestone payments, offset partially by lower manufacturing costs.
Research and development
The increase in R&D expenses for the three months ended March 31, 2020, was driven by higher late-stage program support for our oncology programs, primarily AMG 510 (sotorasib), along with Otezla® and higher marketed-product support for Otezla®, offset partially by recoveries from our collaboration with BeiGene that reduced other expenses in late-stage program support and in research and early pipeline.
Selling, general and administrative
The increase in SG&A expenses for the three months ended March 31, 2020, was driven primarily by the first full quarter of Otezla® commercial-related expenses.
Other
Other operating expenses for the three months ended March 31, 2020, consisted of an impairment charge for an early-stage program. Other operating expenses for the three months ended March 31, 2019, included changes in the fair value of contingent consideration and certain net charges related to our restructuring plan.
See the Overview and Selected financial information sections above for discussion of impacts to operating expenses from the COVID-19 pandemic.

33


Nonoperating expense/income and income taxes
Nonoperating expense/income and income taxes were as follows (dollar amounts in millions):
 
Three months ended
March 31,
 
2020
 
2019
Interest expense, net
$
346

 
$
343

Interest and other income, net
$
11

 
$
185

Provision for income taxes
$
195

 
$
322

Effective tax rate
9.7
%
 
13.9
%
Interest expense, net
The increase in Interest expense, net, for the three months ended March 31, 2020, was due primarily to early debt retirement costs, offset partially by realized gains upon the termination of associated interest rate swaps, a reduction in outstanding long-term debt and lower LIBOR rates on floating-rate debt.
Interest and other income, net
The decrease in Interest and other income, net, for the three months ended March 31, 2020 was due primarily to reduced interest income as a result of lower average cash balances and a decline in interest yields.
Income taxes
The decrease in our effective tax rate for the three months ended March 31, 2020, was due primarily to amortization related to the Otezla® acquisition, changes in jurisdictional mix of earnings and certain favorable items in the quarter.
On March 27, 2020, in response to the COVID-19 pandemic, the president of the United States signed the Coronavirus Aid, Relief, and Economic Security (CARES) Act, which provides additional economic stimulus to address the impact of the COVID-19 pandemic. We do not expect there to be any significant benefit to our income tax provision as a result of the CARES Act, and we continue to closely monitor the impact of the COVID-19 pandemic, as well as any effects that may result from the CARES Act or future legislation.
As previously disclosed, we received an RAR from the IRS for the years 2010, 2011 and 2012. The RAR proposes to make significant adjustments that relate primarily to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. In November 2017, we received a modified RAR that revised the IRS’s calculations but continued to propose substantial adjustments. We disagree with the proposed adjustments and calculations and are pursuing resolution with the IRS administrative appeals office, which currently has jurisdiction over the matter. If we deem necessary, we will vigorously contest the proposed adjustments through the judicial process. In addition, in April, we received draft NOPAs from the IRS for the years 2013, 2014 and 2015, which are similar to the proposed adjustments for the years 2010, 2011 and 2012 that relate primarily to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagree with the proposed adjustments and calculations and intend to contest them. Final resolution of these complex matters is not likely within the next 12 months and could have a material impact on our condensed consolidated financial statements. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes, the ultimate resolution of any tax matters may result in payments substantially greater or less than amounts accrued.
See Note 3, Income taxes, to the condensed consolidated financial statements for further discussion.

34


Financial condition, liquidity and capital resources
Selected financial data was as follows (in millions):
 
March 31,
2020
 
December 31,
2019
Cash, cash equivalents and marketable securities
$
8,012

 
$
8,911

Total assets
$
61,669

 
$
59,707

Current portion of long-term debt
$
1,840

 
$
2,953

Long-term debt
$
30,008

 
$
26,950

Stockholders’ equity
$
9,485

 
$
9,673

Cash, cash equivalents and marketable securities
We have global access to our $8.0 billion balance of cash, cash equivalents and marketable securities. The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.
Capital allocation
Consistent with the objective to optimize our capital structure, we deploy our accumulated cash balances in a strategic manner and consider a number of alternatives, including strategic transactions (including those that expand our portfolio of products in areas of therapeutic interest), repayment of debt, payment of dividends and stock repurchases.
We intend to continue to invest in our business while returning capital to stockholders through the payment of cash dividends and stock repurchases, thereby reflecting our confidence in the future cash flows of our business. The timing and amount of future dividends and stock repurchases will vary based on a number of factors, including future capital requirements for strategic transactions, availability of financing on acceptable terms, debt service requirements, our credit rating, changes to applicable tax laws or corporate laws, changes to our business model and periodic determination by our Board of Directors that cash dividends and/or stock repurchases are in the best interests of stockholders and are in compliance with applicable laws and the Company’s agreements. In addition, the timing and amount of stock repurchases may also be affected by our overall level of cash, stock price and blackout periods, during which we are restricted from repurchasing stock. The manner of stock repurchases may include private block purchases, tender offers and market transactions.
In December 2019, the Board of Directors declared a quarterly cash dividend of $1.60 per share of common stock, an increase of 10% from the cash dividend paid in each of the previous four quarters, which was paid on March 6, 2020. In March 2020, the Board of Directors declared a quarterly cash dividend of $1.60 per share of common stock, which will be paid on June 8, 2020.
We have also returned capital to stockholders through our stock repurchase program. During the three months ended March 31, 2020, we executed trades to repurchase $933 million of common stock. As of March 31, 2020, $5.5 billion of authorization remained available under our stock repurchase program.
As a result of stock repurchases and quarterly dividend payments, we have an accumulated deficit as of March 31, 2020 and December 31, 2019. Our accumulated deficit is not expected to affect our future ability to operate, repurchase stock, pay dividends or repay our debt given our continuing profitability and strong financial position.
We believe that existing funds, cash generated from operations and existing sources of and access to financing are adequate to satisfy our needs for working capital, capital expenditure and debt service requirements, our plans to pay dividends and repurchase stock and other business initiatives we plan to strategically pursue, including acquisitions and licensing activities. We anticipate that our liquidity needs can be met through a variety of sources, including cash provided by operating activities, sales of marketable securities, borrowings through commercial paper and/or syndicated credit facilities and access to other domestic and foreign debt markets and equity markets. See our Annual Report on Form 10-K for the year ended December 31, 2019, Part I, Item 1A. Risk Factors—Global economic conditions may negatively affect us and may magnify certain risks that affect our business.
Certain of our financing arrangements contain nonfinancial covenants. In addition, our revolving credit agreement includes a financial covenant, which requires that we maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (Consolidated EBITDA) to (ii) Consolidated Interest Expense, each as defined and described in the credit agreement. We were in compliance with all applicable covenants under these arrangements as of March 31, 2020.

35


Cash flows
Our summarized cash flow activity was as follows (in millions):
 
Three months ended
March 31,
 
2020
 
2019
Net cash provided by operating activities
$
2,134

 
$
1,845

Net cash (used in) provided by investing activities
$
(230
)
 
$
3,555

Net cash used in financing activities
$
(254
)
 
$
(4,987
)
Operating
Cash provided by operating activities is expected to be our primary recurring source of funds. Cash provided by operating activities during the three months ended March 31, 2020, increased compared with the same period in the prior year due primarily to monetization of interest rate swap contracts, a decrease in sales deductions paid to customers and lower corporate partner payments, offset partially due to timing of collections from customers as a result of our recent acquisition of Otezla®.
Investing
Cash used in investing activities during the three months ended March 31, 2020, was due primarily to our $2.6 billion equity investment in BeiGene, offset substantially by net cash inflows related to marketable securities of $2.6 billion. Cash provided by investing activities during the three months ended March 31, 2019, was due primarily to net cash inflows related to marketable securities of $3.7 billion. Capital expenditures for the three months ended March 31, 2020 and 2019, were $142 million and $116 million, respectively. We now estimate reduced 2020 spending on capital projects of approximately $600 million versus our prior projection of $700 million due to a change in timing from the COVID-19 pandemic.
Financing
Cash used in financing activities during the three months ended March 31, 2020, was due primarily to repayment of debt of $3.3 billion, payments to repurchase our common stock of $961 million and payment of dividends of $945 million, offset by net proceeds from the issuance of debt of $5.0 billion. Cash used in financing activities during the three months ended March 31, 2019, was due primarily to payments to repurchase our common stock of $3.0 billion, repayment of debt of $1.0 billion and payment of dividends of $901 million. See Note 9, Financing arrangements, and Note 10, Stockholders’ equity, to the condensed consolidated financial statements for further discussion.
Critical accounting policies
The preparation of our condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes to the financial statements. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions. A summary of our critical accounting policies is presented in Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations, of our Annual Report on Form 10-K for the year ended December 31, 2019.
During the three months ended March 31, 2020, our critical accounting policies were changed to include our assessment of impairment of equity method investments. We review the carrying value of our equity method investments whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time and the extent to which the fair value is below the carrying value, volatility of the security price, the financial condition of the issuer, changes in technology that may impair the earnings potential of the investment and our intent and ability to retain the investment to allow for a recovery in fair value. We believe our judgments used in assessing impairment of equity method investments are based on reasonable assumptions given the facts and circumstances as of the related dates of the assessments.

36


Item 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Information about our market risk is disclosed in Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk, of our Annual Report on Form 10-K for the year ended December 31, 2019, and is incorporated herein by reference. Except as noted below, there have been no material changes during the three months ended March 31, 2020, to the information provided in Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk, of our Annual Report on Form 10-K for the year ended December 31, 2019.
During the three months ended March 31, 2020, we issued $5.0 billion in long-term debt with a weighted-average maturity of approximately 17 years and redeemed/repaid approximately $3.3 billion of debt, all with maturities of less than two years. These changes increased the sensitivity of fluctuations in fair value of our outstanding long-term debt resulting from changes in market interest rates. A hypothetical 100 basis point decrease in interest rates relative to interest rates at March 31, 2020 and December 31, 2019, would have resulted in increases of $3.7 billion and $3.0 billion, respectively, in the aggregate fair values of our outstanding long-term debt on each of these dates. These amounts do not consider the impact that hypothetical changes in interest rates would have on our associated interest rate swap and cross-currency swap contracts.
During the three months ended March 31, 2020, we terminated interest rate swaps with an aggregate notional amount of $5.2 billion with respect to certain of our long-term debt, which resulted in the receipt of $576 million of cash and reduced counterparty credit risk. Immediately following termination of these contracts, we entered into new interest rate swap agreements at then-current interest rates on the same $5.2 billion principal amount of notes. See Note 9, Financing arrangements, and Note 12, Derivative instruments, to the condensed consolidated financial statements for further discussion.
Item 4.
CONTROLS AND PROCEDURES
We maintain “disclosure controls and procedures,” as such term is defined under the Securities Exchange Act Rule 13a-15(e), that are designed to ensure that information required to be disclosed in Amgen’s Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to Amgen’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, Amgen’s management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives and, in reaching a reasonable level of assurance, Amgen’s management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. We have carried out an evaluation under the supervision and with the participation of our management, including Amgen’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of Amgen’s disclosure controls and procedures. Based upon their evaluation and subject to the foregoing, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2020.
Management determined that, as of March 31, 2020, there were no changes in our internal control over financial reporting that occurred during the fiscal quarter then ended that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

37


PART II — OTHER INFORMATION
Item 1.
LEGAL PROCEEDINGS
See Note 13, Contingencies and commitments, to the condensed consolidated financial statements included in our Quarterly Report on Form 10-Q for the period ended March 31, 2020, for discussions that are limited to certain recent developments concerning our legal proceedings. Those discussions should be read in conjunction with Note 19, Contingencies and commitments, to the consolidated financial statements in Part IV of our Annual Report on Form 10-K for the year ended December 31, 2019.
Item 1A.
RISK FACTORS
This report and other documents we file with the SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, our future performance, our business, our beliefs and our management’s assumptions. These statements are not guarantees of future performance, and involve certain risks, uncertainties and assumptions that are difficult to predict. You should carefully consider the risks and uncertainties our business faces. We have described in our Annual Report on Form 10-K for the year ended December 31, 2019, the primary risks related to our business, and we periodically update those risks for material developments. Those risks are not the only ones we face. Our business is also subject to the risks that affect many other companies, such as employment relations, general economic conditions, geopolitical events, international operations and the effects of pandemics. Further, additional risks not currently known to us or that we currently believe are immaterial may in the future materially and adversely affect our business, operations, liquidity and stock price.
Below, we are providing, in supplemental form, the material changes to our risk factors that occurred during the past quarter. Our risk factors disclosed in Part I, Item 1A, of our Annual Report, on Form 10-K for the year ended December 31, 2019, provide additional disclosure for these supplemental risks and are incorporated herein by reference.
The COVID-19 pandemic, and the public and governmental effort to mitigate against the spread of the disease, have had, and are expected to continue to have, an adverse effect, and may have a material adverse effect, on our clinical trials, operations, supply chains, distribution systems, product development, product sales, business and results of operations.
The novel coronavirus identified in late 2019, SARS-CoV-2, which causes the disease known as COVID-19, is an ongoing global pandemic that has resulted in public and governmental efforts to contain or slow the spread of the disease, including widespread shelter-in-place orders, social distancing interventions, quarantines, travel restrictions and various forms of operational shutdowns. The COVID-19 pandemic and the resulting measures implemented in response to the pandemic is adversely affecting, and is expected to continue to adversely affect, a number of our business activities (including our clinical trials, operations, supply chains, distribution systems, product development and sales) as well as our suppliers, customers, third-party payers and patients. Due to these measures and their effects, we have experienced, and expect to continue to experience, unpredictable reductions in demand for certain of our products, and, in some cases, have experienced, and could continue to experience, unpredictable increases in demand for certain of our products.
Our clinical trials have been, and are expected to continue to be, adversely affected by the COVID-19 pandemic. We have clinical work ongoing at investigational sites across around the globe. An increasing number of clinical trial sites have restricted site visits and have imposed restrictions on the initiation of new clinical trials and patient visits, to protect both site staff and patients from possible COVID-19 exposure. In response to the safety concerns related to COVID-19, we have suspended enrollment and screening in clinical trials where sites are unable to perform clinical trial work due to COVID-19 or there is uncertainty around the ability of sites to ensure subject safety or data integrity. Further, the COVID-19 pandemic is expected to adversely affect our ability to continue enrollment of certain required post-marketing studies, including pediatric studies. The disruption caused by the COVID-19 pandemic to our clinical trials and our clinical trial plans and timelines may have a significant adverse effect on our product development and launches, and, in turn, on future product sales, business and results of operations. For example, we reported a pause in enrollment of our AMG 510 (sotorasib) Phase 1 combination study with Keytruda and Phase 3 confirmatory study to ensure patient safety and that such pause may impact the timelines of these studies. Additionally, while we are investing in research and collaborations to potentially develop treatments for COVID-19, such activities may not result in therapeutic candidates, product approvals and/or significant commercial value being derived from potential COVID-19-related medicines.

38


We anticipate that the COVID-19 pandemic may result in regulatory delays, including delays in receiving regulatory advice, reviews of applications, or performance of inspections required for approvals. The pandemic may also result in greater regulatory uncertainty. For example, the FDA and the European Medicines Agency have issued guidance to provide biopharmaceutical manufacturers greater flexibility in certain regulatory areas, including protocol deviations and adverse event reporting. However, such flexibility may result in greater uncertainty regarding the expectations of such health authorities in relation to this guidance. Additionally, there may be delays in ongoing or new patent office or court patent proceedings in the U.S. or internationally that may delay the outcome of such proceedings. Such delays and disruptions may have a significant adverse effect on our product development and launches, product sales, business and results of operations.
In response to COVID-19, we have activated our business continuity plans, including suspending all U.S. in-person meetings and interactions with the healthcare community and professionals, all international business travel and the majority of domestic travel within the U.S. and all U.S. employees who are able to work from home have been doing so since mid-March 2020. Our ability to perform critical functions and maintain operations could be adversely affected as a result of such workforce restrictions, and the COVID-19-related support programs we have put into place for our staff, suppliers and customers are increasing our operating expenses and reducing the efficiency of our operations. Additionally, disruptions in public and private infrastructure, including transportation and supply chains, have further adversely affected the efficiency of our business operations. Also, the transition of the majority of our workforce to a remote work environment in response to COVID-19, as have a number of our third-party service providers, may exacerbate certain risks to our business, including an increased demand for information technology resources, increased risk of social engineering and other cybersecurity attacks, and increased risk of unauthorized dissemination of sensitive personal information or proprietary or confidential information about us or our service providers or other third-parties. For example, in April 2020, a vendor that provides information technology services to us experienced a cybersecurity incident that required us to disconnect our systems from this vendor. While we do not believe this cybersecurity incident has had a significant adverse effect on our operations, an extended service outage, particularly where a vendor is the single source from which we obtain services, or where a cybersecurity incident significantly affects the operation of our systems, could have a material adverse effect on our business. We may experience significant adverse effects on our commercial and clinical manufacturing activities, our operations, and our cybersecurity, and our suppliers and vendors may experience significant disruptions to their manufacturing activities and operations, and cybersecurity, as a result of the COVID-19 pandemic.
Federal, state and local, and international governmental policies and initiatives designed to reduce the transmission of COVID-19 also have resulted in the cancellation of diagnostic, elective, specialty and other procedures and appointments to avoid non-essential patient exposure to medical environments and potential infection with COVID-19 and to focus limited resources and personnel capacity toward the treatment of COVID-19. These measures and challenges will likely continue for the duration of the pandemic, which is uncertain, and have significantly reduced patient access to and administration of certain of our drugs. For example, Prolia® is a product requiring administration by a healthcare provider in doctors’ offices or other healthcare settings that are affected by COVID-19. The U.S. label for Prolia® instructs healthcare professionals who discontinue Prolia® to transition the patient to an alternative antiresorptive, including oral treatments that do not require administration by a healthcare provider. Further, as a result of COVID-19, oncology patients, in consultation with their doctors, may be selecting less immunosuppressive therapies or therapies that do not require administration in a hospital setting, potentially adversely affecting certain of our products. Our general medicine products have benefited from 90-day supply availability for existing patients but new patients are less likely to be diagnosed and/or to start these therapeutics during the pandemic. Once the pandemic subsides, we anticipate there will be a substantial backlog of patients seeking appointments with physicians relating to a variety of medical conditions, and as a result, patients seeking treatment with certain of our products may have to navigate limited provider capacity and this limited provider capacity could have a continued adverse effect on our sales following the end of the pandemic. Further, the effects of the COVID-19 pandemic may result in long-term shifts in preferences among healthcare professionals and patients toward treatments that do not require administration by healthcare professionals or visits to medical facilities.

39


The legislative and regulatory environment governing our businesses is dynamic and changing frequently in response to COVID-19. Several states have taken action to help patients maintain access to prescription drugs during the COVID-19 pandemic including requiring state-regulated commercial plans to cover 90-day fills and emergency fills in certain circumstances. At the federal level, legislation has been proposed seeking to incentivize greater drug manufacturing in the United States with the stated goal of improving supply reliability in the United States. One such legislative proposal would prohibit the U.S. Department of Veterans Affairs from purchasing certain drugs that have active pharmaceutical ingredients manufactured outside the United States. While we perform a substantial majority of our commercial manufacturing activities in the U.S., including in the U.S. territory of Puerto Rico, and a substantial majority of our clinical manufacturing activities at our facility in Thousand Oaks, California, the passage of such legislation could result in foreign governments enacting retaliatory legislation or regulatory actions, which may have an adverse effect on our product sales, business and results of operations internationally. The COVID-19 pandemic has also resulted in increased interest in compulsory licenses, march-in rights or other governmental interventions, both in the U.S. and internationally, related to the procurement of drugs. Pursuant to the declaration of a national emergency in March 2020 under the Stafford Act, state and local governments may request access to discounted pricing for certain items related to the COVID-19 response. The CARES Act implements initiatives to provide advanced payments from Medicare to healthcare providers, clinics and physicians and to require Medicare plans to provide up to a 90-day supply of Part D drugs. However, despite such initiatives and government support, there may be adverse effects on the timing and collectability of our customer receivables as a result of the COVID-19 pandemic. The COVID-19 pandemic has also resulted in a significant increase in unemployment in the United States which may continue after the pandemic. Such a significant increase in unemployment is expected to lead to a substantial reduction in disposable income and access to health insurance which could adversely affect our product sales. Further, the substantial pressures placed on governmental and payor budgets as a result of the COVID-19 pandemic and the projected governmental budget shortfalls caused by significantly reduced economic activity during and potentially after the COVID-19 pandemic may result in greater and continued downward price pressure on biopharmaceutical products and increased intensity of stakeholder negotiations across the biopharmaceutical value chain.
In recent weeks, the continued global spread of COVID-19 has also led to disruption and volatility in the global capital markets. We have certain assets, including equity investments, that are exposed to market fluctuations that could, in a sustained market disruption, result in impairments. Further, the economic downturn resulting from this global pandemic may be of an extended duration and precipitate a global recession.
If the pandemic continues and conditions worsen, we expect to experience additional adverse effects on our operational and commercial activities, customer purchases and our collections of accounts receivable, which adverse effects may be material, and it remains uncertain the degree to which these adverse effects would impact our future operational and commercial activities, customer purchases and our collections even if conditions begin to improve. In addition to existing travel restrictions, jurisdictions may continue to close borders, impose prolonged quarantines and further restrict travel and business activity, which could significantly affect our ability to support our operations and customers and the ability of our employees to get to their workplaces to discover, study, develop and produce our product candidates and products, and disrupt the movement of our products through the supply chain. Further, in connection with the global outbreak and spread of COVID-19 and in an effort to increase the wider availability of needed medical products, we or our suppliers may elect to, or governments may require us, or our suppliers to, allocate manufacturing capacity (for example pursuant to the U.S. Defense Production Act) in a way that adversely affects our regular operations, customer relationships, and financial results. In addition, unpredictable increases in demand for certain of our products could exceed our capacity to meet such demand, which could adversely affect our financial results and customer relationships.
The rapid development and fluidity of this situation precludes any prediction as to the ultimate effect on us of COVID-19. The duration of the measures being taken by the authorities to mitigate against the spread of COVID-19, and the extent to which such measures are effective, if at all, remain highly uncertain. We believe the magnitude and degree of COVID-19’s adverse effect on our product development, product sales, businesses, operating results, cash flows and financial condition will be driven by the severity and duration of the pandemic, the pandemic’s effect on the U.S. and global economies and the timing, scope and effectiveness of federal, state, local and international governmental responses to the pandemic. However, if the spread continues on at or near, its current trajectory or mitigation continues to require similar levels of shelter-in-place and shut-down orders, such effect will grow and our product development, product sales, business, results of operations, cash flows and financial position could be materially adversely affected.

40


Item 2.
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
During the three months ended March 31, 2020, we had one outstanding stock repurchase program, under which the repurchase activity was as follows:
Period
 
Total number
of shares
purchased
 
Average
price paid
per share (1)
 
Total number
of shares purchased
as part of publicly announced program
 
Maximum dollar
value that may
yet be purchased
under the program(2)
January 1 - 31
 
1,362,200

 
$
233.67

 
1,362,200

 
$
6,155,729,344

February 1 - 29
 
1,707,100

 
$
220.32

 
1,707,100

 
$
5,779,612,845

March 1 - 31
 
1,184,327

 
$
201.66

 
1,184,327

 
$
5,540,776,983

Total
 
4,253,627

 
$
219.40

 
4,253,627

 
 
___________ 
(1) 
Average price paid per share includes related expenses.
(2) 
In December 2019, our Board of Directors increased the amount authorized under our stock repurchase program by an additional $4.0 billion.
Item 6. 
EXHIBITS
Reference is made to the Index to Exhibits included herein.

41


INDEX TO EXHIBITS
Exhibit No.
 
Description
2.1
 
Asset Purchase Agreement, dated August 25, 2019, by and between Amgen Inc. and Celgene Corporation. (Filed as an exhibit to Form 8-K on August 26, 2019 and incorporated herein by reference.)
 
 
 
2.2
 
Amendment No. 1 to the Asset Purchase Agreement, dated October 17, 2019, by and between Amgen Inc. and Celgene Corporation. (Filed as an exhibit to Form 8-K on October 17, 2019 and incorporated herein by reference.)
 
 
 
2.3
 
Amendment No. 2 to the Asset Purchase Agreement, dated October 17, 2019, by and between Amgen Inc. and Celgene Corporation. (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)
 
 
 
2.4
 
Letter Agreement, dated November 21, 2019, by and between Amgen Inc. and the parties named therein re: Treatment of Certain Product Inventory in connection with Amgen’s acquisition of Otezla®. (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)
 
 
 
2.5
 
Irrevocable Guarantee, dated August 25, 2019, by and between Amgen Inc. and Bristol-Myers Squibb Company. (Filed as an exhibit to Form 8-K on August 26, 2019 and incorporated herein by reference.)
 
 
 
3.1
 
Restated Certificate of Incorporation of Amgen Inc. (As Restated March 6, 2013.) (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2013 on May 3, 2013 and incorporated herein by reference.)
 
 
 
3.2
 
Amended and Restated Bylaws of Amgen Inc. (As Amended and Restated February 15, 2016.) (Filed as an exhibit to Form 8-K on February 17, 2016 and incorporated herein by reference.)
 
 
 
4.1
 
Form of stock certificate for the common stock, par value $.0001 of the Company. (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 1997 on May 14, 1997 and incorporated herein by reference.)
 
 
 
4.2
 
Form of Indenture, dated January 1, 1992. (Filed as an exhibit to Form S-3 Registration Statement filed on December 19, 1991 and incorporated herein by reference.)
 
 
 
4.3
 
Agreement of Resignation, Appointment and Acceptance dated February 15, 2008. (Filed as an exhibit to Form 10-K for the year ended December 31, 2007 on February 28, 2008 and incorporated herein by reference.)
 
 
 
4.4
 
First Supplemental Indenture, dated February 26, 1997. (Filed as an exhibit to Form 8-K on March 14, 1997 and incorporated herein by reference.)
 
 
 
4.5
 
8-1/8% Debentures due April 1, 2097. (Filed as an exhibit to Form 8-K on April 8, 1997 and incorporated herein by reference.)
 
 
 
4.6
 
 
 
 
4.7
 
Indenture, dated August 4, 2003. (Filed as an exhibit to Form S-3 Registration Statement on August 4, 2003 and incorporated herein by reference.)
 
 
 
4.8
 
Corporate Commercial Paper - Master Note between and among Amgen Inc., as Issuer, Cede & Co., as Nominee of The Depository Trust Company, and Citibank, N.A., as Paying Agent. (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 1998 on May 13, 1998 and incorporated herein by reference.)
 
 
 
4.9
 
Officers’ Certificate of Amgen Inc., dated May 30, 2007, including form of the Company’s 6.375% Senior Notes due 2037. (Filed as an exhibit to Form 8-K on May 30, 2007 and incorporated herein by reference.)
 
 
 
4.10
 
Officers’ Certificate of Amgen Inc., dated May 23, 2008, including form of the Company’s 6.90% Senior Notes due 2038. (Filed as exhibit to Form 8-K on May 23, 2008 and incorporated herein by reference.)
 
 
 
4.11
 
Officers’ Certificate of Amgen Inc., dated January 16, 2009, including form of the Company’s 6.40% Senior Notes due 2039. (Filed as exhibit to Form 8-K on January 16, 2009 and incorporated herein by reference.)
 
 
 
4.12
 
Officers’ Certificate of Amgen Inc., dated March 12, 2010, including form of the Company’s 5.75% Senior Notes due 2040. (Filed as exhibit to Form 8-K on March 12, 2010 and incorporated herein by reference.)
 
 
 
4.13
 
Officers’ Certificate of Amgen Inc., dated September 16, 2010, including form of the Company’s 4.95% Senior Notes due 2041. (Filed as an exhibit to Form 8-K on September 17, 2010 and incorporated herein by reference.)
 
 
 

42


4.14
 
Officers’ Certificate of Amgen Inc., dated June 30, 2011, including form of the Company’s 5.65% Senior Notes due 2042. (Filed as an exhibit to Form 8-K on June 30, 2011 and incorporated herein by reference.)
 
 
 
4.15
 
 
 
 
4.16
 
Officers’ Certificate of Amgen Inc., dated December 5, 2011, including form of the Company’s 5.50% Senior Notes due 2026. (Filed as an exhibit to Form 8-K on December 5, 2011 and incorporated herein by reference.)
 
 
 
4.17
 
 
 
 
4.18
 
Officers’ Certificate of Amgen Inc., dated September 13, 2012, including form of the Company’s 4.000% Senior Notes due 2029. (Filed as an exhibit to Form 8-K on September 13, 2012 and incorporated herein by reference.)
 
 
 
4.19
 
Indenture, dated May 22, 2014, between Amgen Inc. and The Bank of New York Mellon Trust Company, N.A., as Trustee. (Filed as an exhibit to Form 8-K on May 22, 2014 and incorporated herein by reference.)
 
 
 
4.20
 
Officers’ Certificate of Amgen Inc., dated May 22, 2014, including form of the Company’s 3.625% Senior Notes due 2024. (Filed as an exhibit to Form 8-K on May 22, 2014 and incorporated herein by reference.)
 
 
 
4.21
 
 
 
 
4.22
 
 
 
 
4.23
 
Form of Permanent Global Certificate for the Company’s 0.410% bonds due 2023. (Filed as an exhibit on Form 8-K on March 8, 2016 and incorporated herein by reference.)
 
 
 
4.24
 
Terms of the Bonds for the Company’s 0.410% bonds due 2023. (Filed as an exhibit on Form 8-K on March 8, 2016 and incorporated herein by reference.)
 
 
 
4.25
 
 
 
 
4.26
 
 
 
 
4.27
 
 
 
 
4.28
 
Officer’s Certificate of Amgen Inc., dated as of November 2, 2017, including in the form of the Company’s 3.200% Senior Notes due 2027. (Filed as an exhibit to Form 8-K on November 2, 2017 and incorporated herein by reference.)
 
 
 
4.29
 
 
 
 
10.1+
 
Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (Filed as Appendix C to the Definitive Proxy Statement on Schedule 14A on April 8, 2013 and incorporated herein by reference.)
 
 
 
10.2+
 
First Amendment to Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, effective March 4, 2015. (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2015 on April 27, 2015 and incorporated herein by reference.)
 
 
 
10.3+
 
Second Amendment to Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, effective March 2, 2016. (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2016 on May 2, 2016 and incorporated herein by reference.)
 
 
 

43


10.4+
 
Form of Grant of Stock Option Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended on December 10, 2019.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)
 
 
 
10.5+
 
Form of Restricted Stock Unit Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended on December 10, 2019.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)
 
 
 
10.6+
 
Amgen Inc. 2009 Performance Award Program. (As Amended on December 12, 2017.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2017 on February 13, 2018 and incorporated herein by reference.)
 
 
 
10.7+
 
Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award Program. (As Amended on December 10, 2019.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)
 
 
 
10.8+
 
Amgen Inc. 2009 Director Equity Incentive Program. (As Amended on December 11, 2019.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)
 
 
 
10.9+
 
Form of Grant of Non-Qualified Stock Option Agreement for the Amgen Inc. 2009 Director Equity Incentive Program. (Filed as an exhibit to Form 8-K on May 8, 2009 and incorporated herein by reference.)
 
 
 
10.10+
 
Form of Restricted Stock Unit Agreement for the Amgen Inc. 2009 Director Equity Incentive Program. (As Amended on December 11, 2019.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)
 
 
 
10.11+
 
Form of Cash-Settled Restricted Stock Unit Agreement for the Amgen 2009 Director Equity Incentive Program. (As Amended on December 11, 2019.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)
 
 
 
10.12+
 
Amgen Inc. Supplemental Retirement Plan. (As Amended and Restated effective October 16, 2013.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2013 on February 24, 2014 and incorporated herein by reference.)
 
 
 
10.13+
 
First Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 14, 2016. (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2016 on October 28, 2016 and incorporated herein by reference.)
 
 
 
10.14+
 
Second Amendment to the Amgen Inc. Supplemental Retirement Plan (As Amended and Restated effective October 23, 2019.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)
 
 
 
10.15+
 
Amended and Restated Amgen Change of Control Severance Plan. (As Amended and Restated effective December 9, 2010 and subsequently amended effective March 2, 2011.) (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2011 on May 10, 2011 and incorporated herein by reference.)
 
 
 
10.16+
 
Amgen Inc. Executive Incentive Plan. (As Amended and Restated effective January 1, 2009.) (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2008 on November 7, 2008 and incorporated herein by reference.)
 
 
 
10.17+
 
First Amendment to the Amgen Inc. Executive Incentive Plan, effective December 13, 2012. (Filed as an exhibit to Form 10-K for the year ended December 31, 2012 on February 27, 2013 and incorporated herein by reference.)
 
 
 
10.18+
 
Second Amendment to the Amgen Inc. Executive Incentive Plan, effective January 1, 2017. (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2017 on April 27, 2017 and incorporated herein by reference.)
 
 
 
10.19+
 
Amgen Nonqualified Deferred Compensation Plan. (As Amended and Restated effective October 16, 2013.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2013 on February 24, 2014 and incorporated herein by reference.)
 
 
 
10.20+
 
First Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective October 14, 2016. (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2016 on October 28, 2016 and incorporated herein by reference.)
 
 
 
10.21+
 
Second Amendment to the Amgen Nonqualified Deferred Compensation Plan (As Amended and Restated effective January 1, 2020.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)
 
 
 
10.22+
 
Agreement between Amgen Inc. and David W. Meline, effective July 21, 2014. (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2014 on October 29, 2014 and incorporated herein by reference.)
 
 
 

44


10.23+
 
Agreement between Amgen Inc. and Jonathan Graham, dated May 11, 2015. (Filed as an exhibit to Form 10-Q/A for the quarter ended June 30, 2015 on August 6, 2015 and incorporated herein by reference.)
 
 
 
10.24+
 
Agreement between Amgen Inc. and Murdo Gordon, dated July 25, 2018. (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2018 on October 31, 2018 and incorporated herein by reference.)
 
 
 
10.25+*†
 
 
 
 
10.26
 
 
 
 
10.27
 
Collaboration and License Agreement between Amgen Inc. and Celltech R&D Limited dated May 10, 2002 (portions of the exhibit have been omitted pursuant to a request for confidential treatment) and Amendment No. 1, effective June 9, 2003, to Collaboration and License Agreement between Amgen Inc. and Celltech R&D Limited (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-K/A for the year ended December 31, 2012 on July 31, 2013 and incorporated herein by reference.)
 
 
 
10.28
 
Amendment No. 2 to Collaboration and License Agreement, effective November 14, 2016, between Amgen Inc. and Celltech R&D Limited (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-K for the year ended December 31, 2016 on February 14, 2017 and incorporated herein by reference.)
 
 
 
10.29
 
Letter Agreement, dated June 25, 2019, by and between Amgen Inc. and UCB Celltech (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2019 on July 31, 2019 and incorporated herein by reference.)
 
 
 
10.30
 
Collaboration Agreement, dated April 22, 1994, by and between Bayer Corporation (formerly Miles, Inc.) and Onyx Pharmaceuticals, Inc. (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2011 by Onyx Pharmaceuticals, Inc. on May 10, 2011 and incorporated herein by reference.)
 
 
 
10.31
 
Amendment to Collaboration Agreement, dated April 24, 1996, by and between Bayer Corporation and Onyx Pharmaceuticals, Inc. (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2006 by Onyx Pharmaceuticals, Inc. on May 10, 2006 and incorporated herein by reference.)
 
 
 
10.32
 
Amendment to Collaboration Agreement, dated February 1, 1999, by and between Bayer Corporation and Onyx Pharmaceuticals, Inc. (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2006 by Onyx Pharmaceuticals, Inc. on May 10, 2006 and incorporated herein by reference.)
 
 
 
10.33
 
Settlement Agreement and Release, dated October 11, 2011, by and between Bayer Corporation, Bayer AG, Bayer HealthCare LLC and Bayer Pharma AG and Onyx Pharmaceuticals, Inc. (Filed as an exhibit to Form 10-K for the year ended December 31, 2011 by Onyx Pharmaceuticals, Inc. on February 27, 2012 and incorporated herein by reference.)
 
 
 
10.34
 
Fourth Amendment to Collaboration Agreement, dated October 11, 2011, by and between Bayer Corporation and Onyx Pharmaceuticals, Inc. (Filed as an exhibit to Form 10-K for the year ended December 31, 2011 by Onyx Pharmaceuticals, Inc. on February 27, 2012 and incorporated herein by reference.)
 
 
 
10.35
 
Side Letter Regarding Collaboration Agreement, dated May 29, 2015, by and between Bayer HealthCare LLC and Onyx Pharmaceuticals, Inc. (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2015 on August 5, 2015 and incorporated herein by reference.)
 
 
 
10.36*
 
 
 
 
10.37
 
Sourcing and Supply Agreement, dated January 6, 2017, by and between Amgen USA Inc., a wholly owned subsidiary of Amgen Inc., and DaVita Inc. (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2017 on April 27, 2017 and incorporated herein by reference.)
 
 
 
10.38
 
Exclusive License and Collaboration Agreement, dated August 28, 2015, by and between Amgen Inc. and Novartis Pharma AG (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2017 on July 26, 2017 and incorporated herein by reference.)
 
 
 

45


10.39
 
Amendment No. 1 to the Exclusive License and Collaboration Agreement, dated April 21, 2017, by and between Amgen Inc. and Novartis Pharma AG (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2017 on July 26, 2017 and incorporated herein by reference.)
 
 
 
10.40
 
Amendment No. 2 to the Exclusive License and Collaboration Agreement, dated April 21, 2017, by and between Amgen Inc. and Novartis Pharma AG (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2017 on July 26, 2017 and incorporated herein by reference.)
 
 
 
10.41
 
Collaboration Agreement, dated April 21, 2017, by and between Amgen Inc. and Novartis Pharma AG (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2017 on July 26, 2017 and incorporated herein by reference.)
 
 
 
10.42
 
Amendment No. 1 to the Collaboration Agreement, dated March 20, 2018, by and between Novartis Pharma AG and Amgen Inc. (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2018 on April 25, 2018 and incorporated herein by reference.)
 
 
 
10.43
 
Collaboration Agreement, dated October 31, 2019, by and between Amgen Inc. and BeiGene Switzerland GmbH, a wholly-owned subsidiary of BeiGene, Ltd. (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)
 
 
 
10.44
 
Guarantee, dated as of October 31, 2019, made by and among BeiGene, Ltd. and Amgen Inc. (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)
 
 
 
10.45
 
Share Purchase Agreement, dated October 31, 2019, by and between Amgen Inc. and BeiGene, Ltd. (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Schedule 13D on January 8, 2020 and incorporated herein by reference.)
 
 
 
10.46
 
Amendment No. 1 to Share Purchase Agreement, dated December 6, 2019, by and among BeiGene, Ltd. and Amgen Inc. (Filed as an exhibit to Schedule 13D on January 8, 2020 and incorporated herein by reference.)
 
 
 
10.47*
 
 
 
 
31*
 
 
 
 
32**
 
 
 
 
101.INS
 
XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.
 
 
 
101.SCH*
 
XBRL Taxonomy Extension Schema Document.
 
 
 
101.CAL*
 
XBRL Taxonomy Extension Calculation Linkbase Document.
 
 
 
101.DEF*
 
XBRL Taxonomy Extension Definition Linkbase Document.
 
 
 
101.LAB*
 
XBRL Taxonomy Extension Label Linkbase Document.
 
 
 
101.PRE*
 
XBRL Taxonomy Extension Presentation Linkbase Document.
 
 
 
104
 
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
____________________________
(* = filed herewith)
(** = furnished herewith and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended)
(+ = management contract or compensatory plan or arrangement)
(† = Peter Griffith became Executive Vice President and Chief Financial Officer of Amgen Inc. on January 1, 2020)


46


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
Amgen Inc.
 
 
(Registrant)
 
 
 
 
Date:
April 30, 2020
By:
 
/S/    PETER H. GRIFFITH
 
 
 
 
Peter H. Griffith
 
 
 
 
Executive Vice President and Chief Financial Officer
 
 
 
 
(Principal Financial and Accounting Officer)


47
EX-10.25 2 petergriffith-signedof.htm AGREEMENT BETWEEN AMGEN INC. AND MR. PETER GRIFFITH Exhibit

petergriffithsignedof_image1.jpg








October 18, 2019


Mr. Peter Griffith
XXXXXXXX
XXXXXXXX

Dear Peter:

Congratulations! You have made an excellent impression on Amgen and I am excited to present you with the attached offer package. As an organization dedicated to improving the lives of patients around the world, Amgen welcomes you to join the environment of diverse, ethical, committed and highly accomplished people who respect each other while competing intensely to win. Together, we live the Amgen values as we continue advancing science to serve patients.

On behalf of Amgen, I am pleased to offer you the position of Executive Vice President Finance Level 11, reporting to Robert A. Bradway. This offer and the compensation listed are subject to your appointment by our Board of Directors (the Board) and the Compensation and Management Development Committee (the Compensation Committee) providing final approval of the compensation listed in this letter.

Your annual salary will be $970,000.20 paid out bi-weekly and over 26 pay periods in one year.

This position is located in Thousand Oaks, CA.

Provided that you sign a “Sign-On/Retention Bonus Agreement for New Hire Staff Members” in the form provided by Amgen, you will be eligible to earn a bonus of $500,000.00, less federal and state tax deductions and other applicable deductions and withholdings, subject to the terms of that Agreement. Please review that Agreement for information regarding timing and other payment details.

Subject to the approval of the Compensation and Management Development Committee of the Board of Directors or the Equity Award Committee of Amgen Inc. (the “Committee”), and subject to the vesting rules, you will be granted restricted stock units (RSU) with a USD value of $4,000,000. The actual number of RSUs to be awarded shall be determined by dividing the grant value by the Amgen common stock closing price on the applicable grant date. Upon each applicable vesting date, you will receive a number of shares of Amgen common stock equal to the number of restricted stock units that vest, less any shares that are withheld to satisfy applicable taxes. This grant will vest beginning with the second anniversary of the grant date through the fourth




anniversary at a rate of 33%, 33% and 34% each year, respectively, contingent upon your being actively employed with Amgen through each vesting date.

Restricted stock units will be subject to the terms and conditions set forth in the applicable grant agreement.

As an Amgen executive you are required to hold Amgen common stock in accordance with the Amgen Stock Ownership Guidelines. Your holding requirement is based on your Amgen GCF level and as a Executive Vice President Finance you are required to hold Amgen common stock in the amount equal to 3x base salary. You must meet your holding requirement by December 31st of the fifth calendar year following the date on which you became an Officer of Amgen. To help you meet your holding requirement, the Amgen Stock Ownership Guidelines prohibit you from selling stock that you receive as part of your Amgen LTI awards (including shares that you receive as a result of option exercise, special, promotional, and annual grants) until you have met your required stock ownership level.

Providing your start date is in 2019, you will be eligible for additional grants as part of Amgen’s Long Term Incentive (LTI) program. Your projected 2020 annual grant value is $4,000,000 and will be allocated between performance units, stock options and restricted stock units consistent with other senior executive grants. Grants under the LTI program are discretionary as approved by the Committee.

You will be eligible to participate in Amgen’s Global Management Incentive Plan (the “GMIP”) pursuant to the terms of the GMIP. Your annual target incentive opportunity will be 100% of your base salary earnings during the plan year. Awards under the GMIP are discretionary. Your actual GMIP bonus may be more or less than this target amount, and may vary based on Company performance, any other criteria selected by the Company, and management’s assessment of your individual performance and contribution. You must be actively employed through the last regularly scheduled Amgen business day of the plan year to be eligible for that year’s GMIP bonus.

You are also eligible to participate in the Amgen Nonqualified Deferred Compensation Plan (the “DCP”) to voluntarily defer, on a pre-tax basis, a portion of your annual earnings, including base salary, sales incentive plan, and/or Executive Incentive Plan/Global Management Incentive Plan (GMIP) bonus. Shortly after commencing your employment at Amgen, you will receive an enrollment notice via e-mail regarding the Amgen’s DCP plan. A Q&A regarding the DCP is enclosed.

In addition, your position makes you eligible to participate in the Amgen Inc. Change of Control Severance Plan, as amended from time to time (the “COC”). COC eligibility and benefit levels are determined immediately prior to a “Change of Control” as defined in the COC. If, upon your termination, you are eligible to receive severance benefits under the COC and you are also eligible to receive severance benefits from another plan agreement or other source, you will be paid the greater of the amount from that plan or the amount provided in the COC, but not both amounts. A copy of the COC is enclosed.

If, within the first three (3) years of your employment with Amgen, Amgen terminates your employment without “Cause,” as defined below, you will be entitled to the benefits described in this paragraph (the “Termination Paragraph), provided that you sign a general release in the form furnished to you by Amgen and do not timely revoke it. The following are such benefits: two (2) years of your annual base salary, then in effect, and target cash incentive opportunity (i.e., GMIP or successor bonus plan target, which is currently 100%), then in effect, paid in a lump sum as soon as administratively practicable, but in no event later than March 15 of the year following the year in which Amgen terminates your employment and (2) if you elect continuation coverage under the Amgen group medical and dental plans for yourself and your qualified beneficiaries under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”), Amgen will pay the cost of such coverage until the earlier to occur of the following: (A) eighteen (18) months following your termination of employment or (B) the date on which you are no longer eligible for such COBRA coverage. Please note that this Termination Paragraph does not alter the at-will nature of your employment at Amgen.





For purposes of the Termination Paragraph, “Cause” means (i) unfitness for service, inattention to or neglect of duties, or incompetence; (ii) dishonesty; (iii) disregard or violation of the policies or procedures of Amgen; (iv) refusal or failure to follow lawful directions of the Company; (v) illegal, unethical or immoral conduct; or (vi) breach of the attached Amgen Proprietary Information and Inventions Agreement.

As an executive at Amgen, you will be eligible for the following: an annual physical examination provided by Amgen; and, reimbursement for up to $15,000.00, tax assisted, per year for financial counseling, tax preparation and related services.

You will also have the opportunity to participate in our comprehensive benefits program. Amgen’s excellent health care plan currently includes medical, dental, and vision coverage for you and your eligible dependents. Amgen covers the majority of the health care plan’s cost while staff members contribute towards the balance through payroll deductions. Please be advised that in order for you and your dependents to be eligible for Amgen’s benefits program you must:

1.
Report to work at Amgen or another location to which you are required to travel and perform the regular duties of your employment.
2.
Contact the Amgen Benefits Center at 1-800-97AMGEN, to enroll within 31 days of your hire date.
3.
Meet all other eligibility requirements under the plan.

The Amgen Retirement and Savings Plan, our 401(k) plan, provides an opportunity for you to save a percentage of your pay on a tax-deferred basis, within Internal Revenue Service limits. Amgen will also contribute to your 401(k) account to help you save for your future financial goals. These benefits, services, and programs are summarized in the enclosed brochure called “A Guide to Total Rewards at Amgen.”

Amgen is a Military Friendly Employer and proudly offers a generous military leave policy for Military Active Duty and Reservists.

This offer of employment is contingent upon confirmation by Amgen of information listed on your employment application, and the receipt by Amgen of satisfactory results from a background verification and pre-employment drug test.

You will be eligible for a merit increase in March 2020, under Amgen’s regular and customary performance and merit review cycle.

Enclosed and included as part of this offer (Attachment 1) is information regarding Amgen's Proprietary Information and Inventions Agreement, and a packet of materials entitled "Arbitration of Disputes" which includes a Mutual Agreement to Arbitrate Claims. Also enclosed and included as part of this offer in Attachment 1 is information regarding Amgen's New Staff Member Letter and Certification. This offer is contingent upon you truthfully and accurately completing the Certification, and returning it to the Company before your first day of employment.

This offer of employment is also contingent upon your completing the items described in Attachment 1, and upon your ability to perform for Amgen all of the duties of your position without restriction from, or violation of, any enforceable contractual obligations owed to any former employer or entity for whom you worked or provided service(s).

By signing this letter, you understand and agree that your employment with Amgen is at-will. This means that your employment can terminate, with or without cause, and with or without notice, at any time, at your option or Amgen's option, and Amgen can terminate or change all other terms and conditions of your employment, with or without cause, and with or without notice, at any time. This at-will relationship will remain in effect




throughout your employment with either Amgen Inc. or any of its subsidiaries or affiliates. This letter, and its enclosures, constitutes the entire agreement, arrangement and understanding between you and Amgen on the nature and terms of your employment with Amgen, including, but not limited to, the kind, character, and existence of your proposed job duties, the length of time your employment will last, and the compensation you will receive. This letter, its enclosures, supersedes any prior or contemporaneous agreement, arrangement, or understanding on this subject matter. By executing this letter as provided below, you expressly acknowledge the termination of any such prior agreement, arrangement, or understanding, except as referenced in this letter and/or its enclosures. Also, by your execution of this letter, you affirm that no one has made any written or oral statement that contradicts the provisions of this letter or its enclosures. The at-will nature of your employment, as set forth in this paragraph, can be modified only by a written agreement signed by both Amgen's Senior Vice President of Human Resources and you which expressly alters it. This at-will relationship may not be modified by any oral or implied agreement or by any Company policies, practices, or patterns of conduct.

The complete terms of the plans, programs, and policies referenced in this letter are set forth in their respective documents, which are maintained by the Company. The Company reserves the right to amend or terminate any of these plans, programs, or policies at any time, in its sole discretion. In the event of any difference between this offer letter and the provisions of the respective plan, program, or policy document, the respective document will govern.

You have made an excellent impression on the staff at Amgen. We are enthusiastic about the contribution you can make, and we believe that Amgen can provide you with attractive opportunities for personal achievement and growth. I look forward to your favorable reply by October 28, 2019. If you accept our offer, please sign and date the copy of the letter and return it to our Talent Acquisition Department along with the completed and signed Proprietary Information and Inventions Agreement and the Mutual Agreement to Arbitrate Claims. Please retain the original offer letter for your records. If you have any questions regarding this offer, please contact Greg Comeaux at (805) 447-8035.








Sincerely,


/s/ Robert A. Bradway

Robert A. Bradway
Chairman of the Board, President & Chief Executive Officer


JD:tb
Enclosures

/s/ Peter H. Griffith
10-19-2019
Signature of Acceptance

Date


XXXX
Last 4 Digits of Social Security Number (For Identification Purposes)
Last 4 Digits of Government ID (If No Social Security Number)

October 23, 2019
Anticipated Start Date










ATTACHMENT 1

In order to accept our offer you will be required to:

A)
Complete, date and sign the Amgen New Staff Member Letter and Certification and return it with your signed offer letter.

B)
Complete, date and sign the Amgen Proprietary Information and Inventions Agreement and return it with your signed offer letter.

C)
Date and sign the enclosed Mutual Agreement to Arbitrate Claims and return it with your signed offer letter.

D)
You will be required to provide Amgen with proof of your identity and eligibility for employment per requirements of the Immigration Reform and Control Act of 1986 within 3 (three) days of hire.

E)
For California non-exempt staff only, sign and date the Notice To Employee, Labor Code 2810.5





NEW STAFF MEMBER LETTER AND CERTIFICATION

Welcome to Amgen (the “Company”). The Company has no need to learn and does not want any proprietary, confidential or trade secret information or other property that belongs to any prior employers, entities or other persons you have worked for (collectively, “Prior Employers”). Please review and comply with the following instructions and policies, and execute the Certification below.

Carefully read the Company’s Proprietary Information and Inventions Agreement (“PIIA”) that you have executed, and make sure that you understand your obligations under the terms of the PIIA. If you have any questions, please contact Amgen Human Resources.

You may not bring any material to the Company from third parties in hard copy, in electronic format or in any other form. Nor should you use any such material in your work for the Company.

Prior to commencing any work for the Company, conduct a search of your personal computer(s), email accounts, and any other electronic storage devices you possess, as well as any files you maintain in hard copy, for information or materials belonging to your Prior Employers. You are instructed to make appropriate arrangements to return any such information or materials belonging to your Prior Employers, consistent with any obligations you have to the Prior Employers.

Do not disclose to or provide the Company with any customer lists you obtained from or during your employment with your Prior Employers. When interacting with doctors or other members of the healthcare industry with whom you may have had contact while working for your Prior Employers, clearly indicate to such persons that you are an Amgen staff member, and focus on the Company’s products rather than using or discussing information related to your prior employment.

If you have any doubts regarding whether you may take, disclose, upload, access, or use any information in your possession, you must err on the side of not taking, disclosing, uploading, accessing or using the information.

Do not begin any work for the Company before your employment with your Prior Employers has officially ended.

After commencing work for the Company, do not request that any employee of your Prior Employers provide you with, or take any other steps to obtain, any information or property of your Prior Employers.

Under no circumstances are you permitted to connect to a Company computer any electronic storage device containing information or property relating to your Prior Employers. Likewise, in performing work for the Company, you are not permitted to use, disclose, access or upload any such information or property. If you discover that any confidential, proprietary, or trade secret information or property of your Prior Employers has been uploaded to any Company computer or email system(s), immediately inform Amgen Human Resources.

The Company may monitor and/or conduct an audit of your use of Company computer systems, and you should not have any expectation of privacy in data sent, stored or received on any Company systems. See the Company’s Use of Company Systems and Internet Conduct Policy for further details.

Disclose and identify below all agreements relating to your Prior Employers that may affect your eligibility to become employed by and/or to perform work for the Company, including any non-competition agreement(s), agreements relating to the solicitation of employees or customers, or other restrictive agreements (collectively, “Restrictive Agreements”), regardless of whether you believe these agreements are enforceable, apply to your potential employment with the Company, or have expired, and provide a copy to Amgen Human Resources. If “none,” please so indicate. Do not leave blank.

If your position at the Company will involve manufacturing or process development; chemical, biologic, pharmaceutical, medical device, or diagnostic research; or development of therapeutic molecules, medical devices, or diagnostic assays or agents, please review your agreements with Prior Employers to determine whether you are required to assign intellectual property rights to any Prior Employer even after that employment has ended. If you do find such an agreement or if you are unsure, please send such agreement to Amgen Human Resources. If “none,” please so indicate. Do not leave blank.

 




 Name of Agreement
Employer
Date Signed
 
 
 
 None
EY
 
 None
Sherwood Canyon Group, LLC
 

(Attach additional sheets, if necessary)
 
 
If you are subject to an agreement not to solicit employees of your Prior Employers, you should refrain from doing so. You should specifically inform Human Resources if you are subject to such an agreement. If you are subject to such an agreement and a former colleague contacts you about employment opportunities with the Company, please contact Human Resources for assistance.

Do not use any email account (including Company email accounts), text messages, Instant Messaging, or any other method of written communication to store or discuss any proprietary, confidential or trade secret information or other property belonging to your Prior Employers.

Immediately inform Human Resources if you are contacted in any manner by any former employer regarding your work for Amgen and/or any non-competition agreements, agreements that relate to the solicitation of employees or customers, or any other restrictive agreements you entered into in connection with any Prior Employers.

CERTIFICATION

I understand that the above list is only a summary and does not purport to include all of my continuing obligations to the Company. By signing below I certify that I have and will continue to comply with the above instructions and policies.

I hereby agree that the Company may, at its sole option and discretion contact my Prior Employer(s) to determine whether any Restrictive Agreements exist and, if so, their applicable terms. I acknowledge that the Company may revoke its offer or terminate my employment if it determines in its reasonable business judgment that I have failed to disclose or am otherwise subject to an enforceable Restrictive Agreement or my failure to abide by the certifications contained herein.

Nothing in this Letter and Certification is intended to alter, or shall have any impact on, my status as an at-will employee of the Company. In addition to its right to terminate my employment, the Company shall have the right to suspend me from work without pay during its investigation into (1) the existence and/or enforceability of any restrictions on my ability to perform work for the Company should I fail to disclose a Restrictive Agreement, or (2) the failure to abide by the certifications contained herein.

I agree:
/s/ Peter H. Griffith
Signature of Staff Member

Peter H. Griffith
Print Name of Staff Member
 


XXXX
Last 4 Digits of Social Security Number (For Identification Purposes)
Last 4 Digits of Government ID (If No Social Security Number)

October 19, 2019
Date









AMGEN SIGN-ON/RETENTION BONUS AGREEMENT
FOR NEW HIRE STAFF MEMBERS




I,     Peter H. Griffith , agree to accept my sign-on/retention bonus payment (“Bonus”) from Amgen on the following terms.

1.
The amount of the Bonus is described in the offer letter (as may be amended) that was provided separately to me.

2.
The Bonus will generally be paid to me as an advance after thirty (30) days following my start date with Amgen, and will be earned only after I complete two years of employment with Amgen. The Bonus is intended to facilitate my acceptance of employment with Amgen and my continued employment with Amgen for a period of at least two years. Amgen is providing me the Bonus with the expectation that I will not resign my employment during this two-year period.

3.
I understand and agree that I am an at-will employee and that I am free to resign at any time and Amgen is free to terminate my employment, with or without cause, at any time. Nevertheless, I understand that if I resign my employment with Amgen or are terminated for cause before I complete two years of employment, I have not earned any portion of the Bonus amount. Therefore, I agree to repay Amgen for the gross amount of my Bonus if I resign my employment for any reason or are terminated for cause within 24 months from my hire date at Amgen. I also agree that in the event of such a resignation, the amount to be reimbursed shall be due in full and payable by me immediately in cash (i.e., by check, wire transfer, or similar immediate payment) without further notice or demand by Amgen.

4.
Generally, a sign-on/retention bonus is considered ordinary wage income to the recipient. I understand that Amgen will report to appropriate federal and state taxing authorities all income that Amgen considers to be subject to taxation and will withhold appropriate taxes in accordance with federal and state regulations. I understand that it is my obligation to declare all income and pay all taxes owed on such income, if any.

5.
I understand that this agreement shall be governed by the law of the State of California.

6.
Nothing in this Agreement will be construed as an employment contract or to guarantee me employment at Amgen for any fixed term. I understand that my employment at Amgen is at will.

7.
The provisions of this agreement are severable. If any part is found to be unenforceable, all other provisions shall remain fully valid and enforceable.
 
I agree:
 
Amgen Inc.:
 
 
 
/s/ Peter H. Griffith
 
/s/ NHMiller
Signature of Staff Member
 
Signature of Authorized Representative
 
 
 
Peter H. Griffith
 
Global Head, Talent Acquisition
Print Name of Staff Member
 
Title of Representative

XXXX
10/18/2019
Last 4 Digits of Social Security Number (For Identification Purposes)
Last 4 Digits of Government ID (If No Social Security Number)
Date

October 19, 2019
Date






EX-10.36 3 sideletterregardingcol.htm SIDE LETTER TO COLLABORATION AGREEMENT Exhibit

Execution Copy
February 13, 2020


Bayer Healthcare LLC
100 Bayer Boulevard
PO Box 915
Whippany, NJ 07981
Attention: Global Head of Oncology


Re:    Side Letter Regarding Collaboration Agreement and Stivarga Agreement

Dear Sir or Madam:

Reference is hereby made to the Collaboration Agreement, dated April 22, 1994, as amended on April 24, 1996 (the “First Amendment”), on February 1, 1999 (the “Second Amendment”), on March 6, 2006 (the “Co-Promotion Agreement”), on January 1, 2009 (the “Co-Development Costs Side Letter”),on October 11, 2011 (the “Fourth Amendment”), and on May 29, 2015 (the “2015 Side Letter Regarding Collaboration Agreement”) (such agreement as amended by the First Amendment, Second Amendment, the Co-Promotion Agreement, the Co-Development Costs Side Letter, Fourth Amendment and 2015 Side Letter Regarding Collaboration Agreement being referred to herein as the “Collaboration Agreement”) by and between Onyx Pharmaceuticals, Inc., a Delaware corporation having its principal place of business in South San Francisco, California (“Onyx”), and Bayer HealthCare LLC, a Delaware company having its principal place of business in Whippany, New Jersey and the successor-in-interest to Bayer Corporation (“Bayer” and, together with Onyx, the “Parties”). Capitalized terms used but not otherwise defined in this letter shall have the meanings assigned to such terms in the Collaboration Agreement.

Reference is hereby also made to (i) the Agreement Regarding Regorafenib dated October 11, 2011 by and between Onyx and Bayer (the “Stivarga Agreement”), (ii)  the Combination Development Agreement dated October 11, 2011, as amended on March 21, 2014 (as amended, the “Combination Development Agreement”), and (iii) the Letter of Agreement Regarding Pharmacovigilance Between Bayer HealthCare LLC and Amgen, Inc. Concerning Nexavar Worldwide” dated November 30, 2017 (the “Pharmacovigilance Agreement”).

Pursuant to Section 17.2 of the Collaboration Agreement and Section 4.7 of the Stivarga Agreement, Onyx retained KPMG LLP (“KPMG”) to review records related to the correctness of reports or payments made pursuant to the Collaboration Agreement and the Stivarga Agreement for the period January 1, 2013 through December 31, 2015 and, in connection therewith, KPMG prepared a draft report dated April 2018 pursuant to which KPMG made certain observations regarding the calculation of Marketing Profit or Loss made pursuant to the Collaboration Agreement for such period (the “KPMG Observations”) with which the Parties reasonably disagree.

The Parties have agreed to resolve their differences with respect to the KPMG Observations and to convert the financial arrangement set forth in the Collaboration Agreement with respect to the Ex-U.S. Territory (as hereafter defined) to a royalty arrangement.
In furtherance of the foregoing, and in order to operationalize the collaboration more efficiently, the Parties desire to modify certain terms of the Collaboration Agreement and the Stivarga Agreement as set forth in this letter.
In consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:
1.Resolution of KPMG Review.
a.
In consideration of and effective upon receipt of the payment made by Bayer to Onyx pursuant to paragraph 1.b below, the sufficiency of which is acknowledged by Onyx, Onyx agrees on behalf of itself and its Affiliates that (a) no payment, repayment or refund shall be due from Bayer to Onyx as a result of the KPMG Observations and Onyx agrees not to make any additional Claims against Bayer with respect to (i) the correctness of any report or payment made under the Collaboration Agreement with respect to Marketing Profit or Loss or Co-Development Costs through December 31, 2015 or (ii) the correctness of any report or payment made under the Stivarga Agreement through December 31, 2015 and (b) it waives its rights pursuant to (i) Section 17.2 of the Collaboration Agreement to examine those records as may be necessary or reasonably useful to determine, with respect to the period from January 1, 2016 through December 31, 2019, the correctness of any report or payment made under the Collaboration Agreement with respect to Marketing Profit or Loss or Co-Development Costs for the period from January 1, 2016 through December 31, 2019 and (ii) Section 4.7 of the Stivarga Agreement to examine those records as may be necessary or reasonably useful to determine, with respect to the period from January 1, 2016 through December 31, 2019, accuracy of all reports and payments made pursuant to the Stivarga Agreement for the period from January 1, 2016 through December 31, 2019. Notwithstanding the foregoing, the Parties acknowledge that, pursuant to a letter dated October 1, 2018 (the “Stivarga Royalty Letter”), Onyx disputes the royalty reports and payments delivered by Bayer to Onyx under the Stivarga Agreement and demands revised royalty reports that cover “Net Sales” of all “Products” (as such terms are defined in the Stivarga Agreement) worldwide, and Onyx expressly reserves all of its rights with respect to such dispute, and the Parties agree that nothing herein shall be construed to waive, limit or adversely affect such rights, including (i) the right to make additional Claims against Bayer with respect to the correctness of any report or payment made under the Stivarga Agreement dating to the third fiscal quarter of 2018 and (ii) the right to examine those records as may be necessary or reasonably useful to determine the accuracy of all reports and payments made pursuant to the Stivarga Agreement dating to the third fiscal quarter of 2018.
b.
Provided Onyx has submitted an invoice to the address set forth in paragraph 2.f., Bayer agrees to make to Onyx a non-refundable, non-creditable payment in the amount of six million U.S. dollars (US$6,000,000.00).
c.
The Parties hereby agree that, notwithstanding anything to the contrary in the Collaboration Agreement, during the Ex-U.S. Royalty Term (as defined below), Bayer shall have exclusive authority and control over the development of Collaboration Products in all countries of the world and commercialization of the Collaboration Products in the Ex-U.S. Territory (including control over when and how to discontinue commercialization of the Collaboration Products in the Ex-U.S. Territory). In exercising such authority and control, Bayer shall use the level of efforts and resources (including the promptness with which such efforts and resources would be applied) commonly used in the pharmaceutical industry with respect to a product of commercial potential similar to the Collaboration Products at a similar stage in its development or product life, taking into consideration its safety and efficacy, its cost to develop, the competitiveness of alternative products of Third Parties, the patent and other proprietary position of such product, its profitability and all other relevant factors.
d.
Additionally and in furtherance of Bayer’s exclusive authority and control set forth in Paragraph 1.c above, from and after January 1, 2020 and continuing throughout the Ex- U.S. Royalty Term, Bayer shall control, and be solely responsible for all costs and expenses relating to, development and commercialization of the Collaboration Products in all countries of the world, including, without limitation: (i) marketing and promotion, (ii) pricing and access and (iii) medical affairs.
e.
The Parties hereby agree that, for purposes of the Parties’ prospective arrangements set forth in this letter, the “Ex-U.S. Territory” shall refer to all countries of the world except (i) as has been the agreed-upon practice of the Parties under the Collaboration Agreement, the fifty (50) states of the United States of America and the District of Columbia (but shall include territories and possessions thereof) and (ii) Japan. For clarity, the Ex-U.S. Territory includes the United States territories and possessions other than the fifty (50) states and the District of Columbia.
2.Ex-U.S. Royalties. The Parties hereby agree that, notwithstanding anything in the Collaboration Agreement to the contrary, the allocation of Marketing Profits or Losses set forth in Section 16.1 of the Collaboration Agreement (including, without limitation, the allocation and/or reimbursement of Allowable Expenses) shall not apply with respect to the sale of Collaboration Products in the Ex-U.S. Territory during the Ex-U.S. Royalty Term. The Parties hereby agree that, during the Ex- U.S. Royalty Term, the exclusive compensation for sales of Collaboration Products in the Ex-U.S. Territory shall be as follows:
a.
Royalty. Bayer shall pay to Onyx non-refundable, non-creditable royalties equal to thirty- two percent (32%) of Net Sales of all Collaboration Products in the Ex-U.S. Territory during the Ex- U.S. Royalty Term. Any sales of Collaboration Products in the Ex-U.S. Territory by or on behalf of Bayer, its Affiliates, licensees and/or sublicensees shall be treated hereunder as if such sales were made by Bayer. If Bayer grants licenses to its Affiliates or Third Parties to make or sell Collaboration Products in any country, possession or territory of the Ex-U.S. Territory, it shall include an obligation for such parties to account for and report Net Sales of Collaboration Products on the same basis as if such sales were made by Bayer, and Bayer shall pay royalties to Onyx under this letter as if the Net Sales of such Collaboration Products by such Affiliates and Third Parties were Net Sales of Bayer. For the purposes of applying the definition of “Net Sales” to Net Sales from a country in the Ex-U.S. Territory, a licensee or sublicensee of Bayer or its Affiliates or any of their licensees or sublicensees who is granted such license or sublicense as a result of a settlement by Bayer of any action taken in a court or Governmental or Regulatory Authority, a compulsory license granted pursuant to Applicable Law or any action taken by a court or Governmental or Regulatory Authority shall not be considered a licensee or sublicensee of Bayer or its Affiliates or any of their licensees or sublicensees and, accordingly, gross receipts received by such licensee or sublicensees on account of sales of Collaboration Products shall not be taken into account for determining Net Sales. For clarity, however, amounts received by Bayer from such licensees or sublicensees in the form of license fees or royalties shall be treated as Net Sales, and Bayer shall pay royalties to Onyx under this letter as , amounts received by Bayer from such licensees or sublicensees in the form of license fees or royalties were Net Sales of Bayer. Notwithstanding the foregoing, on a country-by-country basis, if during the Ex-U.S. Royalty Term, a Third Party receives marketing authorization for and commences commercial sale of a Generic Product (as defined below) in a country, possession, or territory of the Ex-U.S. Territory set forth on Appendix A hereto (such countries, possessions or territories, the “Tier One Ex-U.S. Countries”), then royalties payable to Onyx with respect to Net Sales of the applicable Collaboration Product in such country, possession or territory shall be reduced to sixteen percent (16%) beginning on the first day of the first full calendar quarter following the date of first sale of the Generic Product in which Net Sales of the applicable Collaboration Product in such country, possession or territory in such calendar quarter decrease by more than fifty percent (50%) from the Net Sales of such Collaboration Product in such country, possession or territory in the calendar quarter immediately preceding the first sale of such Generic Product in such country, possession or territory. For the purposes of this provision, a “Generic Product” shall mean, with respect to a Collaboration Product, any pharmaceutical product in such Tier One Ex-U.S. Country that: (i) contains the same active pharmaceutical ingredient (irrespective of its solvate, hydrate, salt, pro-drug or polymorphic form) as the Collaboration Product; (ii) is approved by the applicable Governmental or Regulatory Authority in such jurisdiction in reliance, in whole or in part, on the prior Drug Approval of such Collaboration Product; (iii) is bioequivalent to such Collaboration Product; and (iv) is sold in such jurisdiction by a Third Party that (a) is not a licensee or sublicensee of Bayer or its Affiliates or any of their licensees or sublicensees, (b) has not obtained such product from a chain of distribution including Bayer, its Affiliates or any of their licensees or sublicensees, and (c) is not otherwise authorized by Bayer or any of its Affiliates, licensees, sublicensees or distributors to sell such product (provided that a licensee or sublicensee of Bayer or its Affiliates or any of their licensees or sublicensees who is granted such license or sublicense as a result of a settlement by Bayer of any action taken in a court or Governmental or Regulatory Authority, a compulsory license granted pursuant to Applicable Law or any action taken by a court or Governmental or Regulatory Authority shall not be considered as having been authorized by Bayer or any of its Affiliates, licensees, sublicensees or distributors to sell such product for the purposes of this Paragraph 2.a.). Notwithstanding the foregoing, on a country-by country basis, from and after the calendar quarter in which Loss of Exclusivity (as defined below) occurs in any country, possession or territory of the Ex-U.S. Territory other than the Tier One Ex-U.S. Countries, then royalties payable to Onyx with respect to Net Sales of the applicable Collaboration Product in such country, possession or territory of the Ex-U.S. Territory shall be reduced to sixteen percent (16%).

For the purposes of this provision, “Loss of Exclusivity” shall mean, on a country-by-country basis, the expiration of the last-to-expire Bayer Patent that includes a Valid Claim that covers a Collaboration Product sold in such country, possession or territory and, additionally, shall be deemed to have occurred (a) as of the Effective Date on a country-by-country basis in such countries where no Bayer Patent that includes a Valid Claim that covers the Collaboration Product sold in such country exists or (b) in the event a Third Party is granted (i) a license or sublicense as a result of a settlement by Bayer of any action taken in a court or Governmental or Regulatory Authority, or (ii) a compulsory license granted pursuant to Applicable Law or any action taken by a court or Governmental or Regulatory Authority; and “Valid Claim” shall mean a claim of a pending patent application or an issued and unexpired patent, which has not been held invalid or unenforceable by a patent office, court or other governmental agency of competent jurisdiction, which holding is unappealable. For purposes of this Agreement, “Loss of Exclusivity” shall be deemed to have occurred as of the date on a country-by-country basis in such countries where no Bayer Patent that includes a Valid Claim that covers the Collaboration Product sold in such country, possession or territory exists. “Bayer Patent” means the patents listed in Appendix B hereto.
b.
Ex- U.S. Royalty Term. Royalties shall be paid under this Paragraph 2 on a country-by-country basis during the period from January 1, 2020 until the date of the termination or expiration, as the case may be, of the Collaboration Agreement in accordance with its terms (such period, the “Ex- U.S. Royalty Term”).
c.
Royalty Reports and Payments. Within thirty (30) days following the end of each calendar quarter during the Ex- U.S. Royalty Term, Bayer shall provide Onyx with a report containing the following information for such calendar quarter on a country-by-country basis: (i) the amount of gross sales of Collaboration Products in such country (in Euros), (ii) Net Sales in such country (in Euros), (iii) the conversion of such Net Sales from Euros into Dollars, and (iv) the calculation of the royalty payment due on such sales pursuant to Paragraph 2.a hereof. Bayer shall pay to Onyx all amounts due to Onyx pursuant to this Paragraph 2 following the receipt of an invoice pursuant to Paragraph 2.f.
d.
Books and Records. During the Ex- U.S. Royalty Term, Bayer shall, and shall cause its Affiliates, licensees and sublicensees to, keep complete and accurate books and records that disclose, on a country-by-country basis, the total Ex-U.S. Territory sales and Net Sales of Collaboration Products in such country in the Ex-U.S. Territory, the number of units of Collaboration Products sold in such country in the Ex-U.S. Territory, and all matters relating to those sales that are relevant for the purposes of determining the royalties due to Onyx hereunder. During the Ex- U.S. Royalty Term, Bayer shall, and shall cause its Affiliates to, (i) maintain such books and records in sufficient detail to calculate all amounts payable hereunder and to verify compliance with Bayer’s obligations under this letter, and (ii) retain such books and records until five (5) years after the end of the period to which such books and records pertain.
e.
Other Royalty Terms. The Parties hereby acknowledge and agree that the terms of Sections 4.4 (Mode of Payment), 4.5 (Taxes), 4.6 (Interest on Late Payments), 4.7 (Audit), 4.8 (Audit Dispute) and 4.9 (Confidentiality) of the Stivarga Agreement, are incorporated into the Collaboration Agreement mutatis mutantis such that these provisions apply to sales of Collaboration Products in the Ex-U.S. Territory during the Ex- U.S. Royalty Term and the royalties payable to Onyx under this Paragraph 2 in connection therewith.
f.
Invoices. Payments due to Onyx under paragraph 1.b. and 2.c. shall be made thirty (30) days after receipt of invoice which shall be sent to by electronic mail to invoice.bhc.usa@bayer.com.
3.Taxes. The “Tax Partnership,” as defined in Section 23.1 of the Collaboration Agreement, shall, effective January 1, 2020, be considered terminated and liquidated pursuant to Section 23.9 of the Collaboration Agreement. Article 23 of the Collaboration Agreement shall continue to govern any tax matters arising out of the Tax Partnership which relate to an event or transaction occurring before January 1, 2020. Without limiting the generality of the foregoing, royalties paid under Paragraph 2.a hereof shall not be deemed to be distributive shares of income from the Tax Partnership referred to in Section 23 of the Collaboration Agreement.
4.Collaboration Agreement.
a.
Governance. Article 3 of the Collaboration Agreement, from and after January 1, 2020 shall no longer have force or effect. Accordingly, any decision to be made by a committee to be constituted by Article 3 of the Collaboration is from and after January 1, 2020, reserved for Bayer in its sole discretion consistent with the terms of the Collaboration Agreement. No less than twice each calendar year (no later than July 1 and December 1 of each calendar year), Bayer shall provide the following information to the Amgen Alliance Manager: (a)for the Tier One Ex-U.S. Countries: (i) sales forecast for the following calendar year, (ii) any product-specific marketing programs anticipated to be implemented during the following calendar year (to the extent such information is available as of July 1 and December 1) and (iii) any known or anticipated entry of a Generic Product and (b) for the Ex-U.S. Territory, the total sales forecast for the following calendar year. Within sixty (60) days of the receipt of such information, the Amgen Alliance Manger may request a meeting (which can occur by means of telephone conference, videoconference or other means of communications) with knowledgeable representatives of Bayer to address any reasonable questions Amgen may have with respect to such information.

b.
Disputes and Escalation. Each Party shall nominate (or maintain) a representative to act as its alliance manager (the “Alliance Manager”). The Alliance Managers shall, inter alia, serve as the key contact point between the Parties, facilitate interactions between the Parties and facilitate the escalation process described in Section 25.1 of the Collaboration Agreement. A Party may replace its Alliance Manager at any time by providing written notice to the other Party. Notwithstanding Section 25.1 of the Collaboration Agreement, any disputes among the Parties that cannot be resolved by good faith negotiation shall be referred to the Parties’ respective Alliance Managers. Any disputes which cannot be resolved by the Alliance Managers that cannot be resolved by good faith negotiations shall be referred to the Executive Officers, who shall meet as soon as possible, and not less than sixty (60) days after a dispute is referred to the Executive Officers. In the event that the Executive Officers are not able to resolve such dispute during such sixty (60) day period, either party may submit such dispute to arbitration in accordance with the terms of Section 25.1, which shall apply mutatis mutandis to disputes which are not resolved by the Executive Officers. “Executive Officers” means the Head of the Oncology Strategic Business Unit of Bayer and the Global Marketing Oncology Headof Amgen, or to such other senior officer of similar authority and standing as each Party may from time to time designate.

c.
Global Development. Except as expressly set forth in this letter, nothing in this letter is intended to modify or otherwise alter the provisions of the Collaboration Agreement with respect to ongoing and / or future global clinical development of the Collaboration Compounds.

d.
Effect on Other Agreements. This letter agreement shall have no effect on the Pharmacovigilance Agreement or the Stivarga Agreement (except that paragraph 1.a shall serve as a waiver of Onyx’s rights under the Stivarga Agreement as described, and only to the extent described, therein) which each shall continue in full force and effect according to their respective terms.
c.
Notice. The addresses to which notices to Bayer pursuant to Section 28.7 of the Collaboration Agreement shall be addressed shall be:
If to Bayer, addressed to:
Bayer HealthCare LLC
100 Bayer Boulevard
Whippany, New Jersey 09781
Attention: Global Head of Oncology
With a copy to:
Bayer HealthCare LLC
100 Bayer Boulevard
Whippany, New Jersey 09781
Attention: Head, Law, Patents and Compliance (Pharmaceuticals)

If to Onyx, addressed to:

Onyx Pharmaceuticals, Inc.
c/o Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320
Attention: General Counsel
Facsimile: (805) 499-4531
5.2015 Side Letter Regarding Collaboration Agreement.

a.
The proviso set forth in the first sentence of Paragraph 1.a. of the 2015 Side Letter Regarding Collaboration Agreement is hereby amended (new language is underlined).

provided, however, that, if Bayer elects to discontinue commercialization of the Collaboration Products in the United States prior to later of (a) the expiration of the last-to-expire Bayer Patent that includes a Valid Claim that covers Collaboration Products sold in the United States, or (b) the expiration of regulatory exclusivity of the Collaboration Products in the United States, Onyx shall have the right to assume exclusive authority and control over the commercialization of the Collaboration Products in the United States and, in such event, the Parties would promptly agree upon a transition plan and agreement which addresses, inter alia, indemnification of Bayer for actions and activities undertaken by Onyx (and its Affiliates), a royalty payable to Bayer in recognition of its contributions to the Collaboration Product commensurate with the royalty payable hereunder and such other terms as the Parties may agree upon.”

b.
The last sentence of Paragraph 2 of the 2015 Side Letter Regarding Collaboration Agreement is hereby amended as follows (new language is underlined):

“Notwithstanding the foregoing, the Parties hereby acknowledge and agree that each and every product that Bayer commercializes in the United States as of the date hereof (including, without limitation, Stivarga® (regorafenib)), and combinations with such products, shall not be considered a Competing Product for the purposes hereof.”
    
c.
Paragraph 3.a. of the 2015 Side Letter Regarding Collaboration Agreement is hereby amended to include the following sentence:

“Notwithstanding the foregoing, a licensee or sublicensee of Bayer or its Affiliates or any of their licensees or sublicensees who is granted such license or sublicense as a result of a settlement by Bayer of any action taken in a court or Governmental or Regulatory Authority or any action taken by a court or Governmental or Regulatory Authority shall not be considered a licensee or sublicensee of Bayer or its Affiliates or any of their licensees or sublicensees. Gross receipts received by such licensee or sublicensees on account of sales of Collaboration Products shall not be taken into account for determining Net Sales. For clarity, however, amounts received by Bayer from such licensees or sublicensees in the form of license fees or royalties shall be treated as Net Sales, and Bayer shall pay royalties to Onyx under this letter as , amounts received by Bayer from such licensees or sublicensees in the form of license fees or royalties were Net Sales of Bayer.”

6.Combination Development Agreement. The Parties hereby acknowledge and agree that effective immediately, the Combination Development Agreement shall be terminated and shall have no further force or effect.
7.Full Force and Effect. Except as expressly set forth in this letter, the Collaboration Agreement remains in full force and effect.
8.Miscellaneous. Each Party shall bear its own costs and expenses required to implement the terms of this letter agreement and any such costs and expenses shall not be shared by the Parties. This letter, together with the Collaboration Agreement, as modified hereby, contains all of the terms agreed to by the Parties regarding the subject matter of this letter and supersedes any prior oral or written agreements, understandings or arrangements between the Parties as to the subject matter hereof. This letter may not be amended, modified, altered or supplemented except by means of a written agreement or other instrument executed by both Parties. This letter may be executed in one or more counterparts, each of which shall be deemed an original, but both of which together shall constitute one and the same instrument. Each Party may execute this letter by facsimile transmission or in PDF format sent by electronic mail. Facsimile or PDF signatures of authorized signatories of the Parties will be deemed to be original signatures, will be valid and binding upon the Parties and, upon delivery, will constitute due execution of this letter. This letter shall be deemed to have been entered into and shall be construed and enforced in accordance with the laws of the State of California without giving effect to any choice or conflict of laws provision.


[signature page follows]


Please confirm that the foregoing is in accordance with your understanding of our agreement by signing and returning to us a copy of this letter.


Sincerely,


ONYX PHARMACEUTICALS, INC.



/s/ David A. Piacquad_____________
Name: David A. Piacquad
Title: Senior Vice President, Business Development









ACKNOWLEDGED AND AGREED:
BAYER HEALTHCARE LLC
/s/ Robert LaCaze        
Name: Robert LaCaze
Title: EVP and Head of the Oncology Business Unit



Cc:    
Bayer HealthCare Pharmaceuticals Inc.
100 Bayer Boulevard
PO Box 915
Whippany, NJ 07981-0915
Attention: Head, Law Patents and Compliance
Facsimile: 862-404-3053

Appendix Omitted from Side Letter

Pursuant to Regulation S-K, Item 601(a)(5), the appendices to the Side Letter, as listed below, have not been filed. The Registrant agrees to furnish supplementally a copy of any omitted appendices to the Securities and Exchange Commission upon request; provided, however, that the Registrant may request confidential treatment of omitted items.

Appendix

Appendix A     Tier One Ex-U.S. Countries
Appendix B     Bayer Patents


EX-10.47 4 amendmentno2tosharepur.htm AMENDMENT NO. 2 TO BEIGENE SHARE PURCHASE AGREEMENT Exhibit
Execution Version

BEIGENE, LTD.
AMENDMENT NO. 2 TO SHARE PURCHASE AGREEMENT
THIS AMENDMENT NO. 2 (this “Amendment”) to the SHARE PURCHASE AGREEMENT, dated as of October 31, 2019, as amended on December 6, 2019 (the “Agreement”), is made and entered into as of March 17, 2020, by and among BeiGene, Ltd., an exempted company incorporated in the Cayman Islands (the “Company”), and Amgen Inc., a Delaware corporation (the “Investor”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement.
RECITALS
WHEREAS, pursuant to the Agreement, the Investor purchased and subscribed for Two Hundred Six Million Six Hundred Thirty-Five Thousand Thirteen (206,635,013) Ordinary Shares in the form of Fifteen Million Eight Hundred Ninety-Five Thousand One (15,895,001) American Depositary Shares of the Company at a purchase price of $13.45 per share, or $174.85 per American Depositary Share, at the Closing, which represented approximately twenty point five percent (20.5%) of the Company’s outstanding share capital as of that date;
WHEREAS, in order to account for periodic dilution from the issuance of the Company’s shares under its equity incentive plans, the Company and the Investor would like to provide for the option to purchase by the Investor of such supplemental amount of Ordinary Shares in the form of American Depositary Shares on a monthly basis such that the Investor will hold approximately twenty point six percent (20.6%) of the Company’s outstanding share capital immediately following each such purchase in order to maintain the Investor’s equity method accounting treatment for its investment in the Company;
WHEREAS, pursuant to Section 8.9 of the Agreement, no provision in the Agreement may be supplemented, deleted or amended except in a writing executed by an authorized representative of each of the Investor and the Company; and
WHEREAS, the Company will seek all approvals of the Company’s shareholders required for the Company to (i) enter into this Amendment and (ii) issue the Monthly Firm Shares (as defined below), in each case in accordance with the HK Listing Rules.
NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:
1.    Addition of Section 2.4. The following shall be inserted as a new Section 2.4 of the Agreement:
2.4 Monthly Sale of Additional Shares.
(a)    Subject to the Subsequent Shareholder Approval, purchases and sales under this Section 2.4 shall commence on the first (1st) day of the month following the Subsequent

1


Execution Version

Shareholder Approval (or if the Company’s American Depositary Shares are not trading on NASDAQ on such day, the next trading day) (the “Commencement Date”) and shall continue until the earliest of (i) the date on which the Investor and its Affiliates collectively own less than twenty percent (20%) of the outstanding share capital of the Company as a result of the Investor’s sale of Shares, (ii) written notice from either the Investor or the Company that such party wishes to terminate such monthly purchases and sales, which notice shall be provided at least sixty (60) days in advance of the termination of such monthly purchases and sales or such longer period as reasonably required, upon advice of Investor’s counsel, to permit the Investor to commence market purchases under a trading plan in accordance with Rule 10b5-1 under the Exchange Act, and (iii) the third anniversary of the Commencement Date (the “Monthly Sale Period”). Upon mutual agreement by the parties and subject to approval by the Company’s shareholders if required by the HK Listing Rules, this Amendment shall be extended for additional three-year terms upon expiration of the then current term.
(b)    During the Monthly Sale Period, on the first (1st) day of each month (or if the Company’s American Depositary Shares are not trading on NASDAQ on such day, the next trading day), the Company shall send or cause to be sent via e-mail to the Investor the following information (such notice, the “Monthly Firm Shares Notice”): (i) the number of ADSs Outstanding as of the applicable Reference Date, (ii) the Amgen Percentage as of such Reference Date based on the latest information provided by the Investor (which shall be confirmed by the Investor and revised if inaccurate), (iii) the volume weighted average price of one Company American Depositary Share on NASDAQ for the ninety (90) calendar days preceding such Reference Date, as reported by Bloomberg (each, a “Monthly Firm Shares Purchase Price”) and (iv) an updated Company Disclosure Schedule as of the applicable Reference Date in accordance with Section 2.4(d), if any. If the Amgen Percentage is less than the Trigger Percentage as of such Reference Date, then, upon the Investor’s written request (the “Investor Request”) delivered within two (2) Business Days following Investor’s receipt of the Monthly Firm Shares Notice, the Company hereby agrees to sell to the Investor and the Investor agrees to subscribe for such additional number of Ordinary Shares in the form of American Depositary Shares (the “Monthly Firm Shares”) equal to: (x) the number of ADSs Outstanding multiplied by (y) a percentage equal to the Target Percentage minus the Amgen Percentage, based on the Monthly Firm Shares Notice, at a purchase price per Monthly Firm Share equal to the Monthly Firm Shares Purchase Price; provided, however, that in no event shall the aggregate number of Monthly Firm Shares issued during the Monthly Sale Period, exceed Seventy-Five Million (75,000,000) Ordinary Shares (subject to appropriate adjustment in the event of any share dividend, share split, combination or other similar recapitalization with respect to the Ordinary Shares). If the Amgen Percentage in any such Monthly Firm Shares Notice is equal to or greater than the Trigger Percentage, then the Company shall not issue, and the Investor shall not have the option to subscribe for, any Monthly Firm Shares for such month. The Monthly Firm Shares shall be in the form of American Depositary Shares, unless the Investor requests in writing that the Monthly Firm Shares be delivered in the form of Ordinary Shares, in which case the number of shares and purchase price shall be adjusted accordingly based on the ADS to Ordinary Share ratio. Any Monthly Firm Shares purchased hereunder shall be “Shares” or “Deposit Shares” as the context shall so require for purposes of Article 1, Article 3, Article 4, Article 5 and Article 8 of the Agreement. Until such time as the Investor elects to cease equity method accounting for its investment in the Company, the Investor and Company acknowledge and agree that the Investor’s direct purchase of

2


Execution Version

Ordinary Shares in the form of American Depositary Shares from the Company on a monthly basis hereunder shall be the primary means for the Investor to purchase shares in order to maintain such equity method accounting treatment.
(c)    Subject to the terms and conditions hereof, the closing of the purchase and sale of Monthly Firm Shares, if any, shall take place each month within seven (7) Business Days following the Reference Date, or at such other time as mutually agreed by the Company and the Investor (the “Monthly Closing”). At each Monthly Closing, the Company will instruct the Transfer Agent to deliver to the Investor, via book entry to the applicable balance account registered in the name of the Investor, the Monthly Firm Shares for such month, against payment of the aggregate Monthly Firm Share Purchase Price for such Monthly Firm Shares in U.S. dollars by wire transfer of immediately available funds to the order of the Company.
(d)    For purposes of Article 3 and Article 4 of the Agreement, the representations and warranties contained therein shall be deemed made as of the date of the applicable Monthly Closing, as supplemented by, in the case of Article 3, (i) the Company’s most recent Form 10-K (including any information incorporated by reference therein from the Company’s definitive proxy statement on Schedule 14A) and any subsequent Form 10-Q and Form 8-K filed with or furnished to the SEC and made publicly available prior to the date of delivery of the Monthly Firm Shares Notice (other than (x) any information that is contained in the “Risk Factors” or “Note Regarding Forward-Looking Statements” or similar sections of such Company SEC Documents and (y) any forward-looking statements, or other statements that are similarly predictive or forward-looking in nature, contained in such Company SEC Documents), and (ii) any update to the Company Disclosure Schedule as of the applicable Reference Date provided by the Company to Investor in accordance with Section 2.4(b); provided that the Company shall not be required to provide any updates to (x) Section 3.2 (Subsidiaries) to list any newly formed subsidiaries since the most recent disclosures in the Form 10-K or any Form 10-Q, or (y) Section 3.3 (Capitalization) other than the updated number of outstanding shares included in the Monthly Firm Shares Notice, which shall constitute a representation and warranty of the Company under the Agreement; and provided, further, that if there are any material updates to the Company Disclosure Schedule following delivery of the Investor Request, the Investor Request may be revoked prior to the issuance of the shares in the Investor’s sole discretion.
(e)    For purposes of this Section 2.4:
(i)    “ADSs Outstanding” means the total number of the Company’s Ordinary Shares outstanding prior to NASDAQ market opening on the Reference Date, expressed in terms of American Depositary Shares.
(ii)    “Amgen Percentage” means the percentage of the ADSs Outstanding held by the Investor as of the latest Reference Date.
(iii)    “Reference Date” means the day on which the Company’s ADSs are trading on NASDAQ immediately preceding the first (1st) day of each calendar month during the Monthly Sale Period.

3


Execution Version

(iv)    “Subsequent Shareholder Approval” means all approvals of the Company’s shareholders required for the Company to (i) enter into Amendment No. 2 to the Share Purchase Agreement and (ii) issue the Monthly Firm Shares, in each case in accordance with the HK Listing Rules.
(v)    “Target Percentage” means 20.6% of the Company’s outstanding share capital after giving effect to the issuance of the Monthly Firm Shares hereunder.”
(vi)    “Trigger Percentage” means 20.4% of the Company’s outstanding share capital.
2.    Amendment to Section 5.16(a). The first sentence of Section 5.16(a) is deleted in its entirety and replaced with:
“If the Company proposes to offer or sell any Ordinary Shares, American Depositary Shares or Ordinary Share Equivalents after the Closing Date, other than pursuant to the Plans (“New Securities”), and at the time immediately prior to such offer or sale the Investor holds no more than twenty one percent (21.0%) of the Company’s outstanding share capital, the Company shall use reasonable best efforts to provide the Investor with an opportunity to participate in such offering or sale and purchase upon the same terms and conditions as other purchasers in the offering or sale of the New Securities, up to that portion of such New Securities as is necessary to allow the Investor to hold approximately twenty point six percent (20.6%) of the Company’s share capital after the sale of New Securities, so long as the Investor’s ownership percentage prior to such sale has not decreased as a result of the Investor’s sale of Shares or the Investor’s failure to participate in future offerings or sales of New Securities in which Investor is given the opportunity to participate pursuant to this Section 5.16(a), subject to applicable Law, HK Listing Rules and any waiver therefrom granted by the HK Stock Exchange.”
3.    Addition of Section 5.21. The following shall be inserted as a new Section 5.21 of the Agreement:
“5.21 Preparation of Proxy; Shareholders Meeting; Board Recommendation.

(a)     As promptly as reasonably practicable after the execution of this Amendment, the Company shall prepare and cause to be filed with the SEC and the HK Stock Exchange a proxy circular relating to the Subsequent Shareholder Approval (such proxy circular, and any amendments or supplements thereto, the “Supplemental Proxy Statement”). The Investor shall assist and cooperate with the Company in the preparation of the Supplemental Proxy Statement and the resolution of any comments to the Supplemental Proxy Statement received from the SEC or HK Stock Exchange. The Company shall promptly correct any information in the Supplemental Proxy Statement if and to the extent such information becomes false or misleading in any material respect. The Company shall notify the Investor upon the receipt of any comments from the SEC or HK Stock Exchange, as applicable, and of any request by the SEC or HK Stock Exchange, as applicable, for amendments or supplements to the Supplemental Proxy Statement. The Company shall use its reasonable best efforts to (i) respond as promptly as reasonably practicable to any comments received from the SEC or HK Stock Exchange, as applicable, concerning the Supplemental Proxy Statement

4


Execution Version

and to resolve such comments with the SEC or HK Stock Exchange, as applicable, and (ii) to cause the Supplemental Proxy Statement to be disseminated to its shareholders as promptly as reasonably practicable after the resolution of any such comments.

(b)     The Company shall take all necessary actions in accordance with applicable Law, the governing documents of the Company and the rules of NASDAQ and the HK Stock Exchange, as applicable, to duly call, give notice of, convene and hold a special shareholders meeting (the “Supplemental Meeting”) for the purpose of obtaining the Subsequent Shareholder Approval, as soon as reasonably practicable after the SEC or HK Stock Exchange, as applicable, confirms that it has no further comments on the Supplemental Proxy Statement. Notwithstanding any provision of this Agreement to the contrary, the Company may adjourn, recess or postpone the Supplemental Meeting (i) to the extent necessary to ensure that any required supplement or amendment to the Supplemental Proxy Statement is provided to the shareholders of the Company within a reasonable amount of time in advance of the Supplemental Meeting, (ii) if as of the time for which the Supplemental Meeting is originally scheduled (as set forth in the Supplemental Proxy Statement) there are insufficient shares of capital stock of the Company represented (either in person or by proxy) to constitute a quorum necessary to conduct the business of the Supplemental Meeting or (iii) as may be required by applicable Law.”

4.    General
A.    Except as expressly modified by this Amendment, the terms and provisions of the Agreement shall remain unchanged and in full force and effect in accordance with its terms.
B.    Each of the parties hereto shall bear its respective costs, including legal fees, and expenses incurred in connection with the preparation of this Amendment and the activities incurred in connection therewith.
C.    This Amendment may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which shall constitute one and the same agreement.
D.    This Amendment shall be governed by and construed in accordance with the Laws of the State of New York, without regard to the conflict of laws principles thereof that would require the application of the Law of any other jurisdiction.
E.    The Agreement and this Amendment constitute the full and entire understanding and agreement between the Company and the Investor with regard to the subject matter hereof and neither the Company nor the Investor shall be liable or bound to any other in any manner by any representations, warranties, covenants and agreements except as specifically set forth herein and therein.
F.    This Amendment shall become effective immediately upon execution by the Company and the Investor.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

5


Execution Version



IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first written above.
THE COMPANY:
BEIGENE, LTD.
By: /s/ Scott A. Samuels    
Name:    Scott A. Samuels
Title:    Senior Vice President, General Counsel



6


Execution Version

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first written above.
INVESTOR:
AMGEN INC.
By: /s/ Robert A. Bradway    
Name:    Robert A. Bradway
Title:    Chairman of the Board, President & CEO


7

EX-31 5 amgn-ex312020331xq1.htm RULE 13A-14(A) CERTIFICATIONS Exhibit
Exhibit 31

CERTIFICATIONS
I, Robert A. Bradway, Chairman of the Board, Chief Executive Officer and President of Amgen Inc., certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Amgen Inc.;
2.
Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3.
Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and
(d)
Disclosed in this quarterly report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: April 30, 2020
/s/ ROBERT A. BRADWAY
 
Robert A. Bradway
 
Chairman of the Board,
 
Chief Executive Officer and President

1


CERTIFICATIONS
I, Peter H. Griffith, Executive Vice President and Chief Financial Officer of Amgen Inc., certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Amgen Inc.;
2.
Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3.
Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and
(d)
Disclosed in this quarterly report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: April 30, 2020
/s/ PETER H. GRIFFITH
 
Peter H. Griffith
 
Executive Vice President and Chief Financial Officer

2
EX-32 6 amgn-ex322020331xq1.htm SECTION 1350 CERTIFICATIONS Exhibit
Exhibit 32

Certification of Chief Executive Officer
Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Amgen Inc. (the “Company”) hereby certifies that:
(i)
the accompanying Quarterly Report on Form 10-Q of the Company for the period ended March 31, 2020 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(ii)
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: April 30, 2020
/s/ ROBERT A. BRADWAY
 
Robert A. Bradway
 
Chairman of the Board,
 
Chief Executive Officer and President
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 (“Section 906”), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Amgen Inc. and will be retained by Amgen Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

1


Certification of Chief Financial Officer
Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Amgen Inc. (the “Company”) hereby certifies that:
(i)
the accompanying Quarterly Report on Form 10-Q of the Company for the period ended March 31, 2020 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(ii)
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: April 30, 2020
/s/ PETER H. GRIFFITH
 
Peter H. Griffith
 
Executive Vice President and Chief Financial Officer
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 (“Section 906”), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Amgen Inc. and will be retained by Amgen Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

2
EX-101.SCH 7 amgn-20200331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2107100 - Disclosure - Collaborations link:presentationLink link:calculationLink link:definitionLink 2407401 - Disclosure - Collaborations (Details) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Statements of Income link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Contingencies and commitments link:presentationLink link:calculationLink link:definitionLink 2416401 - Disclosure - Contingencies and commitments (Details) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Derivative instruments link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Derivative instruments (Cross-currency Swaps) (Details) link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Derivative instruments (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2415404 - Disclosure - Derivative instruments (Effective Portion of Unrealized Gain (Loss)) (Details) link:presentationLink link:calculationLink link:definitionLink 2415407 - Disclosure - Derivative instruments (Fair Value of Derivatives) (Details) link:presentationLink link:calculationLink link:definitionLink 2415405 - Disclosure - Derivative instruments (Hedged Liabilities and Cumulative Amount) (Details) link:presentationLink link:calculationLink link:definitionLink 2415406 - Disclosure - Derivative instruments (Summary of Income and Expense Line Items) (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Derivative instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Earnings per share link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Earnings per share (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Earnings per share (Tables) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Fair value measurement link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Fair value measurement (Details) link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - Fair value measurement (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Fair value measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Financing arrangements link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Financing arrangements (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - Financing arrangements (Interest Rate Swaps Textual) (Details) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details) link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - Financing arrangements (Schedule Interest Rate Swaps) (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Financing arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Goodwill and other intangible assets link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Goodwill and other intangible assets (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Goodwill and other intangible assets (Goodwill Roll Forward) (Details) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Goodwill and other intangible assets (Identifiable Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Goodwill and other intangible assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - Investments (Available-for-sale Investments) (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2408407 - Disclosure - Investments (Equity Securities) (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Investments (Fair Values by Classification) (Details) link:presentationLink link:calculationLink link:definitionLink 2408405 - Disclosure - Investments (Fair Values by Contractual Maturity) (Details) link:presentationLink link:calculationLink link:definitionLink 2408408 - Disclosure - Investments Investments (Limited Partnership Investments) (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Revenues link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Revenues (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Stockholders' equity link:presentationLink link:calculationLink link:definitionLink 2413404 - Disclosure - Stockholders' equity (Components of AOCI) (Details) link:presentationLink link:calculationLink link:definitionLink 2413403 - Disclosure - Stockholders' equity (Details Textual) (Details) link:presentationLink link:calculationLink link:definitionLink 2413405 - Disclosure - Stockholders' equity (Reclassifications out of AOCI) (Details) link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Stockholders' equity (Share Repurchase Program) (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Stockholders' equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Summary of significant accounting policies link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Summary of significant accounting policies (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Summary of significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 amgn-20200331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 amgn-20200331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 amgn-20200331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Revenue from Contract with Customer [Abstract] Number of operating segments Number of Operating Segments Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Product sales [Member] Product [Member] Enbrel® (etanercept) [Member] ENBREL [Member] ENBREL. Prolia® (denosumab) [Member] Prolia [Member] Prolia. Neulasta® (pegfilgrastim) [Member] Neulasta [Member] Neulasta. XGEVA® (denosumab) [Member] XGEVA [Member] XGEVA. Otezla (apremilast) [Member] Otezla [Member] Otezla [Member] Aranesp® (darbepoetin alfa) [Member] Aranesp [Member] Aranesp. KYPROLIS® (carfilzomib) [Member] Kyprolis [Member] Kyprolis [Member] Repatha (evolocumab) [Member] Repatha (evolocumab) [Member] Repatha (evolocumab) [Member] Other products [Member] Other Products [Member] Other Products [Member] Other revenues [Member] Product and Service, Other [Member] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] US [Member] UNITED STATES ROW [Member] Non-US [Member] Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Total product sales Revenue from Contract with Customer, Including Assessed Tax Total revenues Revenues Income Statement [Abstract] Statement [Table] Statement [Table] Statement [Line Items] Statement [Line Items] Revenues: Revenues [Abstract] Product sales Operating expenses: Costs and Expenses [Abstract] Cost of sales Cost of Goods and Services Sold Research and development Research and Development Expense (Excluding Acquired in Process Cost) Selling, general and administrative Selling, General and Administrative Expense Other Other General Expense Total operating expenses Costs and Expenses Operating income Operating Income (Loss) Interest expense, net Interest Expense, Debt Interest and other income, net Nonoperating Income (Expense) Income before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Provision for income taxes Income Tax Expense (Benefit) Net income Net Income (Loss) Attributable to Parent Earnings per share: Earnings Per Share [Abstract] Basic (in usd per share) Earnings Per Share, Basic Diluted (in usd per share) Earnings Per Share, Diluted Shares used in calculation of earnings per share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Accounting Policies [Abstract] Business Nature Of Operations [Policy Text Block] Describes the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Disclosures about the nature of operations need not be quantified; relative importance could be conveyed by use of terms such as "predominately", "about equally", or "major and other". This element is also referred to as "Business Description". Basis of presentation Basis Of Presentation [Policy Text Block] Shows the basis of presentation of financial information for interim periods. Principles of consolidation Consolidation, Policy [Policy Text Block] Use of estimates Use of Estimates, Policy [Policy Text Block] Property, plant and equipment, net Property, Plant and Equipment, Policy [Policy Text Block] Equity method investments Equity Method Investments [Policy Text Block] Other recent accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Notes [Member] Notes Payable to Banks [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] 4.50% notes due 2020 (4.50% 2020 Notes) [Member] Four Point Five Zero Percent Notes Due 2020 [Member] Four Point Five Zero Percent Notes Due 2020 [Member] 2.125% notes due 2020 (2.125% 2020 Notes) [Member] Two Point One Two Five Percent Notes Due Two Zero Two Zero [Member] Two Point One Two Five Percent Notes Due Two Zero Two Zero [Member] Floating Rate Notes Due 2020 [Member] Floating Rate Notes Due 2020 [Member] Floating Rate Notes Due 2020 [Member] 2.20% notes due 2020 (2.20% 2020 Notes) [Member] Two Point Two Zero Notes Due 2020 [Member] Two Point Two Zero Notes Due 2020 [Member] 3.45% notes due 2020 (3.45% 2020 Notes) [Member] Three Point Four Five Percent Notes Due 2020 [Member] Three Point Four Five Percent Notes Due 2020 [Member] 4.10% notes due 2021 (4.10% 2021 Notes) [Member] Four Point One Zero Percent Notes Due 2021 [Member] Four Point One Zero Percent Notes Due 2021 [Member] 1.85% notes due 2021 (1.85% 2021 Notes) [Member] One Point Eight Five Percent Notes Due Two Zero Two One [Member] One Point Eight Five Percent Notes Due Two Zero Two One [Member] 3.875% notes due 2021 (3.875% 2021 Notes) [Member] Three Point Eight Seven Five Percent Notes Due 2021 [Member] Three Point Eight Seven Five Percent Notes Due 2021 [Member] 1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes) [Member] One Point Two Five Percent Euro Notes due Two Zero Two Two [Member] One Point Two Five Percent Euro Notes due Two Zero Two Two [Member] 2.70% notes due 2022 (2.70% 2022 Notes) [Member] Two Point Seven Zero Percent Notes Due Two Zero Two Two [Member] Two Point Seven Zero Percent Notes Due Two Zero Two Two [Member] 2.65% notes due 2022 (2.65% 2022 Notes) [Member] Two Point Six Five Notes Due 2022 [Member] Two Point Six Five Notes Due 2022 [Member] 3.625% notes due 2022 (3.625% 2022 Notes) [Member] Three Point Six Two Five Percent Notes Due 2022 [Member] Three Point Six Two Five Percent Notes Due 2022 [Member] 0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) [Member] Zero Point Forty One Percent Swiss Franc Bonds Due Two Thousand Twenty Three [Member] Zero Point Forty One Percent Swiss Franc Bonds Due Two Thousand Twenty Three [Member] 2.25% notes due 2023 (2.25% 2023 Notes) [Member] Two Point Two Five Percent Notes Due Two Zero Two Three [Member] Two Point Two Five Percent Notes Due Two Zero Two Three [Member] 3.625% notes due 2024 (3.625% 2024 Notes) [Member] Three Point Six Two Five Percent Notes Due 2024 [Member] Three Point Six Two Five Percent Notes Due 2024 [Member] 1.90% notes due 2025 (1.90% 2025 Notes) [Member] One Point Nine Zero Percent Notes Due Two Zero Two Five [Member] One Point Nine Zero Percent Notes Due Two Zero Two Five [Member] 3.125% notes due 2025 (3.125% 2025 Notes) [Member] Three Point One Two Five Percent Notes Due Two Zero Two Five [Member] Three Point One Two Five Percent Notes Due Two Zero Two Five [Member] 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) [Member] Two Percent Euro Notes Due Two Thousand Twenty Six [Member] Two Percent Euro Notes Due Two Thousand Twenty Six [Member] 2.60% notes due 2026 (2.60% 2026 notes) [Member] Two Point Six Zero Notes Due Two Zero Two Six [Member] Two Point Six Zero Notes Due Two Zero Two Six [Member] 5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) [Member] Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member] Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member] 2.20% notes due 2027 (2.20% 2027 Notes) [Member] Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member] Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member] 3.20% notes due 2027 (3.20% 2027 Notes) [Member] Three Point Two Zero Notes Due 2027 [Member] Three Point Two Zero Notes Due 2027 [Member] 4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) [Member] Four Percent Pound Sterling Notes Due 2029 [Member] Four Percent Pound Sterling Notes Due 2029 [Member] 2.45% notes due 2030 (2.45% 2030 Notes) [Member] Two Point Four Five Percent Notes Due 2030 [Member] Two Point Four Five Percent Notes Due 2030 [Member] 6.375% notes due 2037 (6.375% 2037 Notes) [Member] Six Point Three Seven Five Percent Notes Due 2037 [Member] Six Point Three Seven Five Percent Notes Due 2037 [Member] 6.90% notes due 2038 (6.90% 2038 Notes) [Member] Six Point Nine Zero Percent Notes Due 2038 [Member] Six Point Nine Zero Percent Notes Due 2038 [Member] 6.40% notes due 2039 (6.40% 2039 Notes) [Member] Six Point Four Zero Percent Notes Due 2039 [Member] Six Point Four Zero Percent Notes Due 2039 [Member] 3.15% notes due 2040 (3.15% 2040 Notes) [Member] Three Point One Five Percent Notes Due 2040 [Member] Three Point One Five Percent Notes Due 2040 [Member] 5.75% notes due 2040 (5.75% 2040 Notes) [Member] Five Point Seven Five Percent Notes Due 2040 [Member] Five Point Seven Five Percent Notes Due 2040 [Member] 4.95% notes due 2041 (4.95% 2041 Notes) [Member] Four Point Nine Five Percent Notes Due 2041 [Member] Four Point Nine Five Percent Notes Due 2041 [Member] 5.15% notes due 2041 (5.15% 2041 Notes) [Member] Five Point One Five Percent Notes Due 2041 [Member] Five Point One Five Percent Notes Due 2041 [Member] 5.65% notes due 2042 (5.65% 2042 Notes) [Member] Five Point Six Five Percent Notes Due 2042 [Member] Five Point Six Five Percent Notes Due 2042 [Member] 5.375% notes due 2043 (5.375% 2043 Notes) [Member] Five Point Three Seven Five Percent Notes Due 2043 [Member] Five Point Three Seven Five Percent Notes Due 2043 [Member] 4.40% notes due 2045 (4.40% 2045 Notes) [Member] Four Point Four Zero Percent Notes Due Two Zero Four Five [Member] Four Point Four Zero Percent Notes Due Two Zero Four Five [Member] 4.563% notes due 2048 (4.563% 2048 Notes) [Member] Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member] Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member] 3.375% notes due 2050 (3.375% 2050 Notes) [Member] Three Point Three Seven Five Percent Notes Due 2050 [Member] Three Point Three Seven Five Percent Notes Due 2050 [Member] 4.663% notes due 2051 (4.663% 2051 Notes) [Member] Four Point Six Six Three Percent Notes Due Two Zero Five One [Member] Four Point Six Six Three Percent Notes Due Two Zero Five One [Member] Other notes due 2097 [Member] Other Notes Due 2097 [Member] Other Notes Due 2097 [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Long-term debt, gross Long-term Debt, Gross Unamortized bond discounts, premiums and issuance costs, net Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Fair value adjustments Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) Total carrying value of debt Long-term Debt Less current portion Long-term Debt, Current Maturities Total long-term debt Long-term Debt, Excluding Current Maturities Face amount Debt Instrument, Face Amount Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event Earnings per share Earnings Per Share [Text Block] Investments, Debt and Equity Securities [Abstract] Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Available-for-sale investments [Member] Available For Sales Investments [Member] Available for sales investments. Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets Fair Values Of Available For Sale Investments By Classification In Consolidated Balance Sheets [Abstract] Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets. Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Marketable securities Debt Securities, Available-for-sale, Current Total interest-bearing securities Debt Securities, Available-for-sale Schedule of borrowings Schedule of Long-term Debt Instruments [Table Text Block] Schedule of interest rate swaps Schedule of Interest Rate Derivatives [Table Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] In-process Research and Development [Member] In Process Research and Development [Member] Indefinite-lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] Indefinite-lived intangible assets Indefinite-lived Intangible Assets (Excluding Goodwill) Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Developed-Product-Technology Rights [Member] Developed Technology Rights [Member] Licensing Rights [Member] Licensing Agreements [Member] Marketing-Related Rights [Member] Marketing-Related Intangible Assets [Member] Research and Development Technology Rights [Member] Acquired Research And Development Technology Rights [Member] Acquired research and development technology rights. Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Gross carrying amounts Finite-Lived Intangible Assets, Gross Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Other intangible assets, net Finite-Lived Intangible Assets, Net Gross carrying amount Identifiable Intangible Assets Gross Identifiable intangible assets gross. Accumulated amortization Identifiable Intangible Assets Accumulated Amortization Identifiable intangible assets accumulated amortization. Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Commitments and Contingencies Disclosure [Abstract] Loss Contingencies [Table] Loss Contingencies [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event [Member] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Patent Trial and Appeal Board Patent Challenges [Member] Patent Trial And Appeal Board Patent Challenges [Member] Patent Trial And Appeal Board Patent Challenges [Member] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Hospira, Inc. [Member] Hospira [Member] Hospira [Member] KANJINTI Patent Litigation [Member] KANJINTI Patent Litigation [Member] KANJINTI Patent Litigation [Member] Humira Biosimilar Antitrust Class Actions [Member] Humira Biosimilar Antitrust Class Actions [Member] Humira Biosimilar Antitrust Class Actions [Member] Sensipar Antitrust Class Actions [Member] Sensipar Antitrust Class Actions [Member] Sensipar Antitrust Class Actions [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Amount awarded from settlement Litigation Settlement, Damages Sought, Value Litigation Settlement, Damages Sought, Value Amount received from settlement Litigation Settlement, Amount Awarded from Other Party Number of patents allegedly infringed upon Loss Contingency, Patents Allegedly Infringed, Number Number of lawsuits Loss Contingency, Number Of Lawsuits Loss Contingency, Number Of Lawsuits Number of plaintiffs Loss Contingency, Number of Plaintiffs Schedule of goodwill Schedule of Goodwill [Table Text Block] Schedule of identifiable intangible assets Schedule Of Intangible Assets [Table Text Block] Tabular disclosure of finite-lived and indefinite-lived identifiable intangible assets. Income Tax Disclosure [Abstract] Income taxes Income Tax Disclosure [Text Block] Goodwill and other intangible assets Goodwill and Intangible Assets Disclosure [Text Block] Maturing in one year or less Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value Maturing after one year through three years Available-For Sale Securities, Debt Maturities, After One Through Three Years, Fair Value Available-For Sale Securities, Debt Maturities, After One Through Three Years, Fair Value Maturing after three years through five years Available-For-Sale Securities, Debt Maturities, After Three Through Five Years, Fair Value Available-For-Sale Securities, Debt Maturities, After Three Through Five Years, Fair Value Maturing after five years through ten years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Fair Value Residential mortgage-backed securities Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security Debt Securities, Available-for-sale [Table Text Block] Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets Fair Values of Available for Sale Investments By Classification In Consolidated Balance Sheets [Table Text Block] Tabular disclosure of fair values of available-for-sale investments by classification in the consolidated balance sheets. Fair values of available-for-sale interest-bearing security investments by contractual maturity Investments Classified by Contractual Maturity Date [Table Text Block] Inventory Disclosure [Abstract] Inventories Schedule of Inventory, Current [Table Text Block] Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Trade receivables, net Accounts Receivable, after Allowance for Credit Loss, Current Inventories Inventory, Net Other current assets Other Assets, Current Total current assets Assets, Current Property, plant and equipment, net Property, Plant and Equipment, Net Intangible assets, net Goodwill Goodwill Other assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued liabilities Accrued Liabilities, Current Current portion of long-term debt Total current liabilities Liabilities, Current Long-term debt Long-term deferred tax liabilities Deferred Income Tax Liabilities, Net Long-term tax liabilities Liability for Uncertainty in Income Taxes, Noncurrent Other noncurrent liabilities Other Liabilities, Noncurrent Contingencies and commitments Commitments and Contingencies Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding — 588.0 shares in 2020 and 591.4 shares in 2019 Common Stocks, Including Additional Paid in Capital Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Total stockholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders’ equity Liabilities and Equity Raw materials Inventory, Raw Materials, Net of Reserves Work in process Inventory, Work in Process, Net of Reserves Finished goods Inventory, Finished Goods, Net of Reserves Total inventories Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative [Table] Derivative [Table] Liability Class [Axis] Liability Class [Axis] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Current portion of long-term debt [Member] Long-Term Debt, Current Maturities [Member] Long-Term Debt, Current Maturities [Member] Long-term debt [Member] Long-term Debt [Member] Derivative [Line Items] Derivative [Line Items] Hedged Liability, Fair Value Hedge Hedged Liability, Fair Value Hedge Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities Carrying value with discontinued hedging relationships Hedged Liability, Discontinued Fair Value Hedge Hedged Liability, Discontinued Fair Value Hedge Hedging adjustments on discontinued hedging relationships Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease) Organization, Consolidation and Presentation of Financial Statements [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative arrangement with BeiGene, Ltd. [Member] BeiGene [Member] BeiGene [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Global research and development costs (up to) Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross Research and development expense Research and Development Expense Equity [Abstract] Stockholders' equity Stockholders' Equity Note Disclosure [Text Block] Cash and cash equivalents Cash Total realized gains Debt Securities, Available-for-sale, Realized Gain Total realized losses Debt Securities, Available-for-sale, Realized Loss Cover [Abstract] Entities [Table] Entities [Table] Entity Listings, Exchange [Axis] Entity Listings, Exchange [Axis] Exchange [Domain] Exchange [Domain] The NASDAQ Global Select Market [Member] NASDAQ/NGS (GLOBAL SELECT MARKET) [Member] New York Stock Exchange [Member] NEW YORK STOCK EXCHANGE, INC. [Member] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock [Member] Common Stock [Member] 1.250% Senior Notes Due 2022 [Member] 1.250% Senior Notes Due 2022 [Member] 1.250% Senior Notes Due 2022 [Member] 2.00% Senior Notes Due 2026 [Member] 2.00% Senior Notes Due 2026 [Member] 2.00% Senior Notes Due 2026 [Member] Entity Information [Line Items] Entity Information [Line Items] Document Type Document Type Document Quarterly Report Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Current Fiscal Year End Date Current Fiscal Year End Date Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Statement of Stockholders' Equity [Abstract] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Number of shares of common stock [Member] Common stock and additional paid-in capital [Member] Common Stock Including Additional Paid in Capital [Member] Accumulated deficit [Member] Retained Earnings [Member] Accumulated other comprehensive loss [Member] AOCI Attributable to Parent [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning Balance, Shares Common Stock, Shares, Outstanding Balance as of beginning of period Cumulative effect of changes in accounting principles, net of taxes Cumulative Effect of New Accounting Principle in Period of Adoption Net income for basic and diluted EPS Other comprehensive income (loss), net of taxes Other Comprehensive Income (Loss), Net of Tax Dividends declared on common stock Dividends, Common Stock, Cash Issuance of common stock in connection with the Company’s equity award programs, Shares Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Issuance of common stock in connection with the Company’s equity award programs Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Stock-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Tax impact related to employee stock-based compensation expense Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net Repurchases of common stock, Shares Stock Repurchased and Retired During Period, Shares Repurchases of common stock Stock Repurchased and Retired During Period, Value Other Stockholders' Equity, Other Ending Balance, Shares Balance as of end of period Notes Payable, Other Payables [Member] Notes Payable, Other Payables [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] London Interbank Offered Rate (LIBOR) [Member] London Interbank Offered Rate (LIBOR) [Member] Rate difference in an interest rate swap relationship Rate difference in an interest rate swap relationship Rate difference in an interest rate swap relationship Notional amounts Derivative, Notional Amount Derivative, Basis Spread on Variable Rate Derivative, Basis Spread on Variable Rate Interest Rate Swap [Axis] Interest Rate Swap [Axis] Interest Rate Swap [Axis] Interest Rate Swap [Domain] Interest Rate Swap [Domain] [Domain] for Interest Rate Swap [Axis] $2.2 Billion Notional Value Interest Rate Swap [Member] Interest Rate Swap, One [Member] Interest Rate Swap, One [Member] $5.2 Billion Notional Value Interest Rate Swap, Original [Member] Interest Rate Swap, Two [Member] Interest Rate Swap, Two [Member] $5.2 Billion Notional Value Interest Rate Swap [Member] Interest Rate Swap, Three [Member] Interest Rate Swap, Three [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Forward Contracts [Member] Forward Contracts [Member] Interest Rate Swap [Member] Interest Rate Swap [Member] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Designated as Hedging Instrument [Member] Designated as Hedging Instrument [Member] Value of derivative contracts terminated Derivative, Notional Amount, Amount Terminated Derivative, Notional Amount, Amount Terminated Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Repayments of Long-term Debt Repayments of Long-term Debt Derivative instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Scenario [Axis] Scenario [Axis] Scenario [Domain] Scenario [Domain] Forecast [Member] Forecast [Member] Class of Stock [Line Items] Class of Stock [Line Items] Stock repurchase program, additional authorized amount Stock Repurchase Program, Authorized Amount Amount available for stock repurchases under a board approved stock repurchase plan Stock Repurchase Program, Remaining Authorized Repurchase Amount Dividends declared per share (in usd per share) Common Stock, Dividends, Per Share, Declared Dividends paid per share (in usd per share) Common Stock, Dividends, Per Share, Cash Paid Fair Value Disclosures [Abstract] Fair value measurement Fair Value Disclosures [Text Block] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Other Government-related and Corporate Debt Securities [Member] Other Government-related and Corporate Debt Securities [Member] Other Government-related and Corporate Debt Securities [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Investment maturity period Investment Maturity Period Investment Maturity Period Length of time hedged in foreign currency contracts (or less) Maximum Length of Time, Foreign Currency Cash Flow Hedge Long-term debt, fair value Notes Payable, Fair Value Disclosure Carrying value of debt Contingencies and commitments Commitments and Contingencies Disclosure [Text Block] Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net income Depreciation, amortization and other Depreciation, Depletion and Amortization Deferred income taxes Deferred Income Taxes and Tax Credits Other items, net Other Noncash Income (Expense) Changes in operating assets and liabilities, net of acquisition: Increase (Decrease) in Operating Capital [Abstract] Trade receivables, net Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Other assets Increase (Decrease) in Other Operating Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued income taxes, net Increase (Decrease) in Income Taxes Payable Long-term tax liabilities Increase (Decrease) In Noncurrent Tax Liability Increase (Decrease) In Noncurrent Tax Liability Other liabilities Increase (Decrease) in Other Operating Liabilities Net cash provided by operating activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of marketable securities Payments to Acquire Marketable Securities Proceeds from sales of marketable securities Proceeds from Sale of Debt Securities, Available-for-sale Proceeds from maturities of marketable securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Purchases of equity method investments Payments to Acquire Equity Method Investments Other Payments for (Proceeds from) Other Investing Activities Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from Issuance of Long-term Debt Proceeds from Issuance of Long-term Debt Repayment of debt Repurchases of common stock Payments for Repurchase of Common Stock Dividends paid Payments of Ordinary Dividends, Common Stock Other Proceeds from (Payments for) Other Financing Activities Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash and cash equivalents at beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents at end of period Computation of basic and diluted earnings per share Basic And Diluted Earning Per Share [Abstract] Basic and diluted earning per share. Income (Numerator): Net Income (Loss) Attributable to Parent [Abstract] Shares (Denominator): Weighted-average shares for basic EPS (in shares) Effect of dilutive securities (in shares) Weighted Average Number Diluted Shares Outstanding Adjustment Weighted-average shares for diluted EPS (in shares) Basic EPS (in usd per share) Diluted EPS (in usd per share) Investment Income [Table] Investment Income [Table] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] BeiGene [Member] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Limited Partnership [Member] Partnership Interest [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Fair Value Measured at Net Asset Value Per Share [Member] Fair Value Measured at Net Asset Value Per Share [Member] Net Investment Income [Line Items] Net Investment Income [Line Items] Carrying value of equity method investment Equity Method Investments Equity Method Investment, Aggregate Cost Equity Method Investment, Aggregate Cost Investments Alternative Investment Ownership percentage Equity Method Investment, Ownership Percentage Equity Method Investments,Quoted Market Price Equity Method Investment, Quoted Market Value Equity Method Investment, Difference Between Carrying Amount and Underlying Equity Equity Method Investment, Difference Between Carrying Amount and Underlying Equity Finite-Lived Intangible Asset, Useful Life Finite-Lived Intangible Asset, Useful Life Equity Method Investments, Fair Value Disclosure Equity Method Investments, Fair Value Disclosure Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Cash flow hedge [Member] Cash Flow Hedging [Member] Foreign currency contracts [Member] Foreign Exchange Contract [Member] Cross-currency swap contracts [Member] Cross Currency Swap Contracts [Member] Cross currency swap contracts. Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Total unrealized (losses) gains Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Member] Reclassification out of Accumulated Other Comprehensive Income [Member] Cash flow hedges [Member] Foreign currency contract [Member] Cross-currency swap contract [Member] Cash flow hedges [Member] Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Available-for-sale securities [Member] AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Reclassification out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Income before income taxes Provision for income taxes Net income Revenues Revenue from Contract with Customer [Text Block] Goodwill [Roll Forward] Goodwill [Roll Forward] Beginning balance Currency translation adjustment Goodwill, Foreign Currency Translation Gain (Loss) Ending balance Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Increase in unrecognized tax benefits resulting from tax positions taken during the current period Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Amortization charges associated with finite-lived intangible assets Amortization of Intangible Assets Total estimated amortization of finite-lived intangible assets for the six months ending December 31, 2019 Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Total estimated amortization of finite-lived intangible assets for 2020 Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months Total estimated amortization of finite-lived intangible assets for 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Two Total estimated amortization of finite-lived intangible assets for 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Three Total estimated amortization of finite-lived intangible assets for 2023 Finite-Lived Intangible Assets, Amortization Expense, Year Four Total estimated amortization of finite-lived intangible assets for 2024 Finite-Lived Intangible Assets, Amortization Expense, Year Five Debt Securities Payable [Member] Debt Securities Payable [Member] 4.563% notes due 2048 (4.563% 2048 Notes) [Member] Interest Expense [Member] Interest Expense [Member] Debt Instrument, Redemption Period without Payment of Make Whole Amount Debt Instrument, Redemption Period without Payment of Make Whole Amount Debt Instrument, Redemption Period without Payment of Make Whole Amount MakeWholePayments MakeWholePayments MakeWholePayments Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Equity securities Equity Securities, FV-NI Equity securities without readily determinable fair value Equity Securities without Readily Determinable Fair Value, Amount Common stock and additional paid-in capital, par value (in usd per share) Common Stock, Par or Stated Value Per Share Common stock and additional paid-in capital, shares authorized Common Stock, Shares Authorized Common stock and additional paid-in capital, shares outstanding Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Foreign currency translation [Member] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Other [Member] Accumulated Other Adjustment Attributable to Parent [Member] Accumulated Other Adjustment Attributable to Parent [Member] AOCI [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Increase (Decrease) in AOCI [Roll Forward] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Unrealized (losses) gains OCI, before Reclassifications, before Tax, Attributable to Parent Reclassification adjustments to income Reclassification from AOCI, Current Period, before Tax, Attributable to Parent Other Other Comprehensive Income (Loss), Other Adjustment, before Tax Other Comprehensive Income (Loss), Other Adjustment, before Tax Income taxes Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] U.S. Treasury notes [Member] US Treasury Securities [Member] U.S. Treasury bills [Member] US Treasury Bill Securities [Member] Other government-related debt securities - U.S. [Member] US Government Agencies Debt Securities [Member] Other government-related debt securities - Foreign and other [Member] Debt Security, Government, Non-US [Member] Corporate debt securities - Financial [Member] Corporate Debt Securities Financial [Member] Corporate debt securities financial Member. Corporate debt securities - Industrial [Member] Corporate Debt Securities Industrial [Member] Corporate debt securities industrial Member. Corporate debt securities - Other [Member] Corporate Debt Securities Other [Member] Corporate debt securities other. Residential mortgage-backed securities [Member] Residential Mortgage Backed Securities [Member] Other mortgage- and asset-backed securities [Member] Asset-backed Securities [Member] Money market mutual funds [Member] Money Market Funds [Member] Other short-term interest-bearing securities [Member] Other Short Term Interest Bearing Securities [Member] Other short-term interest bearing securities. Quoted prices in active markets for identical assets (Level 1) [Member] Fair Value, Inputs, Level 1 [Member] Significant other observable inputs (Level 2) [Member] Fair Value, Inputs, Level 2 [Member] Significant unobservable inputs (Level 3) [Member] Fair Value, Inputs, Level 3 [Member] Cross-currency swap contracts [Member] Interest rate swap contracts [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Assets: Assets, Fair Value Disclosure [Abstract] Interest-bearing securities Derivatives: Derivative Assets Fair Value Disclosure [Abstract] Derivative assets. Foreign currency and cross-currency swap contracts Foreign Currency Contract, Asset, Fair Value Disclosure Interest rate swap contracts Interest Rate Fair Value Hedge Asset at Fair Value Total assets Assets, Fair Value Disclosure Liabilities: Liabilities, Fair Value Disclosure [Abstract] Derivatives: Derivative Financial Instruments Liabilities Fair Value Disclosure [Abstract] Derivative financial instruments liabilities fair value disclosure. Foreign currency and cross-currency swap contracts Foreign Currency Contracts, Liability, Fair Value Disclosure Interest rate swap contracts Interest Rate Fair Value Hedge Liability at Fair Value Contingent consideration obligations Business Combination, Contingent Consideration, Liability Total liabilities Financial and Nonfinancial Liabilities, Fair Value Disclosure Computation for basic and diluted earnings per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Statement of Comprehensive Income [Abstract] Other comprehensive (loss) income, net of reclassification adjustments and taxes: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Losses on foreign currency translation (Losses) gains on cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent (Losses) gains on available-for-sale securities Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Other Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent Other comprehensive (loss) income, net of taxes Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Financing arrangements Debt Disclosure [Text Block] Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Currency [Axis] Currency [Axis] All Currencies [Domain] All Currencies [Domain] Euro Member Countries, Euro Euro Member Countries, Euro Switzerland, Francs Switzerland, Francs United Kingdom, Pounds United Kingdom, Pounds United States of America, Dollars United States of America, Dollars 2.125% 2019 euro Notes [Member] Two Point One Two Five Percent Euro Notes Due 2019 [Member] Two Point One Two Five Percent Euro Notes Due 2019 [Member] 1.25% 2022 euro Notes [Member] One Point Twenty Five Percent Euro Notes Due Two Thousand Twenty Two [Member] One Point Twenty Five Percent Euro Notes Due Two Thousand Twenty Two [Member] 0.41% 2023 Swiss franc Bonds [Member] 2.00% 2026 euro Notes [Member] 5.50% 2026 pound sterling Notes [Member] 4.00% 2029 pound sterling Notes [Member] Interest rates Derivative, Fixed Interest Rate Interest rate swap agreements [Member] Interest expense, net Gains (losses) on fair value hedging relationships, Hedged items Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Collaborations Collaborative Arrangement Disclosure [Text Block] Fair Values Derivatives Balance Sheet Location By Derivative Contract Type By Hedging Designation [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Derivatives designated as hedging instrument [Member] Derivatives not designated as hedging instrument [Member] Not Designated as Hedging Instrument [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other current assets/Other assets [Member] Other Current Noncurrent Assets [Member] Other current assets/other non-current assets. Accrued liabilities/Other noncurrent liabilities [Member] Accrued Liabilities Other Non Current Liabilities [Member] Accrued liabilities/other non-current liabilities. Other current assets [Member] Other Current Assets [Member] Accrued liabilities [Member] Accrued Liabilities [Member] Derivatives Fair Value [Line Items] Derivatives, Fair Value [Line Items] Fair values of both derivatives designated as hedging instruments and not designated as hedging instruments included in Condensed Consolidated Balance Sheets Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets [Abstract] Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets. Assets Derivative Asset, Fair Value, Amount Not Offset Against Collateral [Abstract] Total derivative assets, fair value Derivative Asset, Fair Value, Gross Asset Liabilities Derivative Liability, Fair Value, Amount Not Offset Against Collateral [Abstract] Total derivative liabilities, fair value Derivative Liability, Fair Value, Gross Liability Accumulated depreciation and amortization on property, plant and equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Interest Expense, Net [Member] Foreign currency forward contracts [Member] Foreign currency option contracts [Member] Options Held [Member] Foreign currency and cross currency swap contracts [Member] Foreign Currency and Cross Currency Swaps [Member] Foreign currency and cross currency swaps. Interest Rate Swap, At-Then Current Interest Rates [Member] Interest Rate Swap, At-Then Current Interest Rates [Member] Interest Rate Swap, At-Then Current Interest Rates [Member] Derivative, notional amount Value of derivative contracts terminated resulting in net cash provided by operating activities Derivative, Notional Amount, Amount Terminated Resulting In Net Cash Provided By Operating Activities Derivative, Notional Amount, Amount Terminated Resulting In Net Cash Provided By Operating Activities Gain recognized from termination of contracts Derivative, Gain on Derivative Amounts expected to be reclassified from AOCI into earnings over the next 12 months, foreign currency and cross-currency swaps Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Common stock, dividends declared per share (in usd per share) Amortized cost Debt Securities, Available-for-sale, Amortized Cost Gross unrealized gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Gross unrealized losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Fair values Inventories Inventory Disclosure [Text Block] Disaggregation of revenue by product and by geographic area Disaggregation of Revenue [Table Text Block] Summary of significant accounting policies Significant Accounting Policies [Text Block] Stock repurchased, Shares Stock Repurchased During Period, Shares Stock repurchased Stock Repurchased During Period, Value Schedule of notional amounts and interest rates for cross-currency swaps Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps [Table Text Block] Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps Unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Derivatives in fair value hedging relationships Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block] Summary of amounts of income and expense line items Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Fair values of derivatives included in the Condensed Consolidated Balance Sheets Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Summary of activity under our stock repurchase program Stock Repurchase Program [Table Text Block] Stock Repurchase Program [Table Text Block] Components of accumulated other comprehensive income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Reclassifications out of accumulated other comprehensive income Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] EX-101.PRE 11 amgn-20200331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 petergriffithsignedof_image1.jpg begin 644 petergriffithsignedof_image1.jpg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end XML 13 R27.htm IDEA: XBRL DOCUMENT v3.20.1
Goodwill and other intangible assets (Tables)
3 Months Ended
Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of goodwill
The change in the carrying amount of goodwill was as follows (in millions):
 
Three months ended
March 31, 2020
Beginning balance
$
14,703

Currency translation adjustment
(20
)
Ending balance
$
14,683


Schedule of identifiable intangible assets
Other intangible assets consisted of the following (in millions):
 
March 31, 2020
 
December 31, 2019
 
Gross
carrying
amounts
 
Accumulated
amortization
 
Other intangible
assets, net
 
Gross
carrying
amounts
 
Accumulated
amortization
 
Other intangible
assets, net
Finite-lived intangible assets:
 
 
 
 
 
 
 
 
 
 
 
Developed-product-technology rights
$
25,549

 
$
(8,876
)
 
$
16,673

 
$
25,575

 
$
(8,322
)
 
$
17,253

Licensing rights
3,746

 
(2,494
)
 
1,252

 
3,761

 
(2,398
)
 
1,363

Marketing-related rights
1,375

 
(979
)
 
396

 
1,382

 
(965
)
 
417

Research and development technology rights
1,269

 
(967
)
 
302

 
1,273

 
(947
)
 
326

Total finite-lived intangible assets
31,939

 
(13,316
)
 
18,623

 
31,991

 
(12,632
)
 
19,359

Indefinite-lived intangible assets:
 
 
 
 
 
 
 
 
 
 
 
In-process research and development
30

 

 
30

 
54

 

 
54

Total other intangible assets
$
31,969

 
$
(13,316
)
 
$
18,653

 
$
32,045

 
$
(12,632
)
 
$
19,413


XML 14 R23.htm IDEA: XBRL DOCUMENT v3.20.1
Revenues (Tables)
3 Months Ended
Mar. 31, 2020
Revenue from Contract with Customer [Abstract]  
Disaggregation of revenue by product and by geographic area
Revenues were as follows (in millions):
 
 
Three months ended March 31,
 
 
2020
 
2019
 
 
US
 
ROW
 
Total
 
US
 
ROW
 
Total
Enbrel® (etanercept)
 
$
1,117

 
$
36

 
$
1,153

 
$
1,106

 
$
45

 
$
1,151

Prolia® (denosumab)
 
422

 
232

 
654

 
390

 
202

 
592

Neulasta® (pegfilgrastim)
 
534

 
75

 
609

 
893

 
128

 
1,021

XGEVA® (denosumab)
 
355

 
126

 
481

 
356

 
115

 
471

Otezla® (apremilast)
 
377

 
102

 
479

 

 

 

Aranesp® (darbepoetin alfa)
 
175

 
247

 
422

 
182

 
232

 
414

KYPROLIS® (carfilzomib)
 
187

 
93

 
280

 
154

 
91

 
245

Repatha® (evolocumab)
 
124

 
105

 
229

 
83

 
58

 
141

Other products
 
988

 
599

 
1,587

 
827

 
424

 
1,251

Total product sales(1)
 
$
4,279

 
$
1,615

 
5,894

 
$
3,991

 
$
1,295

 
5,286

Other revenues
 
 
 
 
 
267

 
 
 
 
 
271

Total revenues
 
 
 
 
 
$
6,161

 
 
 
 
 
$
5,557

____________ 
(1) 
Hedging gains and losses, which are included in product sales, were not material for the three months ended March 31, 2020 and 2019.
JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "amgn-2020331x10q.htm": { "axisCustom": 1, "axisStandard": 27, "contextCount": 450, "dts": { "calculationLink": { "local": [ "amgn-20200331_cal.xml" ] }, "definitionLink": { "local": [ "amgn-20200331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "amgn-2020331x10q.htm" ] }, "labelLink": { "local": [ "amgn-20200331_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "amgn-20200331_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml" ] }, "schema": { "local": [ "amgn-20200331.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 517, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 62, "http://www.amgen.com/20200331": 37, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 104 }, "keyCustom": 22, "keyStandard": 291, "memberCustom": 69, "memberStandard": 49, "nsprefix": "amgn", "nsuri": "http://www.amgen.com/20200331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://www.amgen.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - Revenues", "role": "http://www.amgen.com/role/Revenues", "shortName": "Revenues", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - Income taxes", "role": "http://www.amgen.com/role/IncomeTaxes", "shortName": "Income taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Earnings per share", "role": "http://www.amgen.com/role/EarningsPerShare", "shortName": "Earnings per share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - Collaborations", "role": "http://www.amgen.com/role/Collaborations", "shortName": "Collaborations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Investments", "role": "http://www.amgen.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - Inventories", "role": "http://www.amgen.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - Goodwill and other intangible assets", "role": "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssets", "shortName": "Goodwill and other intangible assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - Financing arrangements", "role": "http://www.amgen.com/role/FinancingArrangements", "shortName": "Financing arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - Stockholders' equity", "role": "http://www.amgen.com/role/StockholdersEquity", "shortName": "Stockholders' equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - Fair value measurement", "role": "http://www.amgen.com/role/FairValueMeasurement", "shortName": "Fair value measurement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Condensed Consolidated Statements of Comprehensive Income", "role": "http://www.amgen.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "shortName": "Condensed Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - Derivative instruments", "role": "http://www.amgen.com/role/DerivativeInstruments", "shortName": "Derivative instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - Contingencies and commitments", "role": "http://www.amgen.com/role/ContingenciesAndCommitments", "shortName": "Contingencies and commitments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "amgn:NatureOfOperationsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - Summary of significant accounting policies (Policies)", "role": "http://www.amgen.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of significant accounting policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "amgn:NatureOfOperationsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Revenues (Tables)", "role": "http://www.amgen.com/role/RevenuesTables", "shortName": "Revenues (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Earnings per share (Tables)", "role": "http://www.amgen.com/role/EarningsPerShareTables", "shortName": "Earnings per share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - Investments (Tables)", "role": "http://www.amgen.com/role/InvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - Inventories (Tables)", "role": "http://www.amgen.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - Goodwill and other intangible assets (Tables)", "role": "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsTables", "shortName": "Goodwill and other intangible assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312301 - Disclosure - Financing arrangements (Tables)", "role": "http://www.amgen.com/role/FinancingArrangementsTables", "shortName": "Financing arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "amgn:StockRepurchaseProgramTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313301 - Disclosure - Stockholders' equity (Tables)", "role": "http://www.amgen.com/role/StockholdersEquityTables", "shortName": "Stockholders' equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "amgn:StockRepurchaseProgramTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Condensed Consolidated Statements of Income", "role": "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome", "shortName": "Condensed Consolidated Statements of Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314301 - Disclosure - Fair value measurement (Tables)", "role": "http://www.amgen.com/role/FairValueMeasurementTables", "shortName": "Fair value measurement (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315301 - Disclosure - Derivative instruments (Tables)", "role": "http://www.amgen.com/role/DerivativeInstrumentsTables", "shortName": "Derivative instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "div", "amgn:NatureOfOperationsPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401402 - Disclosure - Summary of significant accounting policies (Details)", "role": "http://www.amgen.com/role/SummaryOfSignificantAccountingPoliciesDetails", "shortName": "Summary of significant accounting policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1", "decimals": "-8", "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "div", "amgn:NatureOfOperationsPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - Revenues (Details)", "role": "http://www.amgen.com/role/RevenuesDetails", "shortName": "Revenues (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US", "decimals": "-6", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405401 - Disclosure - Income taxes (Details)", "role": "http://www.amgen.com/role/IncomeTaxesDetails", "shortName": "Income taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Earnings per share (Details)", "role": "http://www.amgen.com/role/EarningsPerShareDetails", "shortName": "Earnings per share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "D2020Q1Jan02-02_us-gaap_TypeOfArrangementAxis_amgn_BeiGeneMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407401 - Disclosure - Collaborations (Details)", "role": "http://www.amgen.com/role/CollaborationsDetails", "shortName": "Collaborations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "D2020Q1Jan02-02_us-gaap_TypeOfArrangementAxis_amgn_BeiGeneMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - Investments (Details)", "role": "http://www.amgen.com/role/InvestmentsDetails", "shortName": "Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Investments (Fair Values by Classification) (Details)", "role": "http://www.amgen.com/role/InvestmentsFairValuesByClassificationDetails", "shortName": "Investments (Fair Values by Classification) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "amgn:FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1_us-gaap_FinancialInstrumentAxis_amgn_AvailableForSalesInvestmentsMember", "decimals": "-6", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408404 - Disclosure - Investments (Available-for-sale Investments) (Details Textual)", "role": "http://www.amgen.com/role/InvestmentsAvailableForSaleInvestmentsDetailsTextual", "shortName": "Investments (Available-for-sale Investments) (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408405 - Disclosure - Investments (Fair Values by Contractual Maturity) (Details)", "role": "http://www.amgen.com/role/InvestmentsFairValuesByContractualMaturityDetails", "shortName": "Investments (Fair Values by Contractual Maturity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNi", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408407 - Disclosure - Investments (Equity Securities) (Details Textual)", "role": "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual", "shortName": "Investments (Equity Securities) (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "lang": null, "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_us-gaap_InvestmentTypeAxis_srt_PartnershipInterestMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AlternativeInvestment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408408 - Disclosure - Investments Investments (Limited Partnership Investments) (Details)", "role": "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails", "shortName": "Investments Investments (Limited Partnership Investments) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_us-gaap_InvestmentTypeAxis_srt_PartnershipInterestMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AlternativeInvestment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - Inventories (Details)", "role": "http://www.amgen.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - Goodwill and other intangible assets (Goodwill Roll Forward) (Details)", "role": "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsGoodwillRollForwardDetails", "shortName": "Goodwill and other intangible assets (Goodwill Roll Forward) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "amgn:ScheduleOfIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410403 - Disclosure - Goodwill and other intangible assets (Identifiable Intangible Assets) (Details)", "role": "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails", "shortName": "Goodwill and other intangible assets (Identifiable Intangible Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "amgn:ScheduleOfIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Goodwill and other intangible assets (Details Textual)", "role": "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsDetailsTextual", "shortName": "Goodwill and other intangible assets (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412402 - Disclosure - Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details)", "role": "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails", "shortName": "Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfLongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412403 - Disclosure - Financing arrangements (Details Textual)", "role": "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "shortName": "Financing arrangements (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1_us-gaap_DebtInstrumentAxis_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember", "decimals": "3", "lang": null, "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD_us-gaap_DebtInstrumentAxis_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember", "decimals": "3", "first": true, "lang": null, "name": "amgn:Ratedifferenceinaninterestrateswaprelationship", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412404 - Disclosure - Financing arrangements (Schedule Interest Rate Swaps) (Details)", "role": "http://www.amgen.com/role/FinancingArrangementsScheduleInterestRateSwapsDetails", "shortName": "Financing arrangements (Schedule Interest Rate Swaps) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember", "decimals": "-6", "lang": null, "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1002501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.amgen.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412405 - Disclosure - Financing arrangements (Interest Rate Swaps Textual) (Details)", "role": "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails", "shortName": "Financing arrangements (Interest Rate Swaps Textual) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1_amgn_InterestRateSwapAxis_amgn_InterestRateSwapOneMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForwardContractsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-8", "lang": null, "name": "amgn:DerivativeNotionalAmountAmountTerminated", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "amgn:StockRepurchaseProgramTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockRepurchasedDuringPeriodShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413402 - Disclosure - Stockholders' equity (Share Repurchase Program) (Details)", "role": "http://www.amgen.com/role/StockholdersEquityShareRepurchaseProgramDetails", "shortName": "Stockholders' equity (Share Repurchase Program) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "amgn:StockRepurchaseProgramTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockRepurchasedDuringPeriodShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2019Q4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413403 - Disclosure - Stockholders' equity (Details Textual) (Details)", "role": "http://www.amgen.com/role/StockholdersEquityDetailsTextualDetails", "shortName": "Stockholders' equity (Details Textual) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2019Q4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413404 - Disclosure - Stockholders' equity (Components of AOCI) (Details)", "role": "http://www.amgen.com/role/StockholdersEquityComponentsOfAociDetails", "shortName": "Stockholders' equity (Components of AOCI) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember", "decimals": "-6", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NonoperatingIncomeExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413405 - Disclosure - Stockholders' equity (Reclassifications out of AOCI) (Details)", "role": "http://www.amgen.com/role/StockholdersEquityReclassificationsOutOfAociDetails", "shortName": "Stockholders' equity (Reclassifications out of AOCI) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember", "decimals": "-6", "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414402 - Disclosure - Fair value measurement (Details)", "role": "http://www.amgen.com/role/FairValueMeasurementDetails", "shortName": "Fair value measurement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414403 - Disclosure - Fair value measurement (Details Textual)", "role": "http://www.amgen.com/role/FairValueMeasurementDetailsTextual", "shortName": "Fair value measurement (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415402 - Disclosure - Derivative instruments (Details Textual)", "role": "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual", "shortName": "Derivative instruments (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_amgn_ForeignCurrencyAndCrossCurrencySwapsMember", "decimals": "-6", "lang": null, "name": "us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1_us-gaap_DebtInstrumentAxis_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_us-gaap_DerivativeInstrumentRiskAxis_amgn_CrossCurrencySwapContractsMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415403 - Disclosure - Derivative instruments (Cross-currency Swaps) (Details)", "role": "http://www.amgen.com/role/DerivativeInstrumentsCrossCurrencySwapsDetails", "shortName": "Derivative instruments (Cross-currency Swaps) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1_us-gaap_DebtInstrumentAxis_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_us-gaap_DerivativeInstrumentRiskAxis_amgn_CrossCurrencySwapContractsMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415404 - Disclosure - Derivative instruments (Effective Portion of Unrealized Gain (Loss)) (Details)", "role": "http://www.amgen.com/role/DerivativeInstrumentsEffectivePortionOfUnrealizedGainLossDetails", "shortName": "Derivative instruments (Effective Portion of Unrealized Gain (Loss)) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "role": "http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415405 - Disclosure - Derivative instruments (Hedged Liabilities and Cumulative Amount) (Details)", "role": "http://www.amgen.com/role/DerivativeInstrumentsHedgedLiabilitiesAndCumulativeAmountDetails", "shortName": "Derivative instruments (Hedged Liabilities and Cumulative Amount) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1_us-gaap_FairValueByLiabilityClassAxis_amgn_LongTermDebtCurrentMaturitiesMember", "decimals": "-6", "lang": null, "name": "us-gaap:HedgedLiabilityFairValueHedge", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NonoperatingIncomeExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415406 - Disclosure - Derivative instruments (Summary of Income and Expense Line Items) (Details)", "role": "http://www.amgen.com/role/DerivativeInstrumentsSummaryOfIncomeAndExpenseLineItemsDetails", "shortName": "Derivative instruments (Summary of Income and Expense Line Items) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember", "decimals": "-6", "lang": null, "name": "us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415407 - Disclosure - Derivative instruments (Fair Value of Derivatives) (Details)", "role": "http://www.amgen.com/role/DerivativeInstrumentsFairValueOfDerivativesDetails", "shortName": "Derivative instruments (Fair Value of Derivatives) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "D2020Q1Mar23-23_srt_LitigationCaseAxis_amgn_HospiraMember", "decimals": "-6", "first": true, "lang": null, "name": "amgn:LitigationSettlementDamagesSoughtValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416401 - Disclosure - Contingencies and commitments (Details)", "role": "http://www.amgen.com/role/ContingenciesAndCommitmentsDetails", "shortName": "Contingencies and commitments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "D2020Q1Mar23-23_srt_LitigationCaseAxis_amgn_HospiraMember", "decimals": "-6", "first": true, "lang": null, "name": "amgn:LitigationSettlementDamagesSoughtValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "D2020Q2SD", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003501 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)", "role": "http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquityParenthetical", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Summary of significant accounting policies", "role": "http://www.amgen.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of significant accounting policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "amgn-2020331x10q.htm", "contextRef": "I2020Q1jan1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - amgn-2020331x10q.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - amgn-2020331x10q.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 121, "tag": { "amgn_A1.250SeniorNotesDue2022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.250% Senior Notes Due 2022 [Member]", "label": "1.250% Senior Notes Due 2022 [Member]", "terseLabel": "1.250% Senior Notes Due 2022 [Member]" } } }, "localname": "A1.250SeniorNotesDue2022Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "amgn_A2.00SeniorNotesDue2026Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2.00% Senior Notes Due 2026 [Member]", "label": "2.00% Senior Notes Due 2026 [Member]", "terseLabel": "2.00% Senior Notes Due 2026 [Member]" } } }, "localname": "A2.00SeniorNotesDue2026Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accrued liabilities/other non-current liabilities.", "label": "Accrued Liabilities Other Non Current Liabilities [Member]", "verboseLabel": "Accrued liabilities/Other noncurrent liabilities [Member]" } } }, "localname": "AccruedLiabilitiesOtherNonCurrentLiabilitiesMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsFairValueOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "amgn_AccumulatedOtherAdjustmentAttributabletoParentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accumulated Other Adjustment Attributable to Parent [Member]", "label": "Accumulated Other Adjustment Attributable to Parent [Member]", "terseLabel": "Other [Member]" } } }, "localname": "AccumulatedOtherAdjustmentAttributabletoParentMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/StockholdersEquityComponentsOfAociDetails" ], "xbrltype": "domainItemType" }, "amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Acquired research and development technology rights.", "label": "Acquired Research And Development Technology Rights [Member]", "terseLabel": "Research and Development Technology Rights [Member]" } } }, "localname": "AcquiredResearchAndDevelopmentTechnologyRightsMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "amgn_AranespMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Aranesp.", "label": "Aranesp [Member]", "terseLabel": "Aranesp\u00ae (darbepoetin alfa) [Member]" } } }, "localname": "AranespMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue": { "auth_ref": [], "calculation": { "http://www.amgen.com/role/InvestmentsFairValuesByContractualMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Available-For Sale Securities, Debt Maturities, After One Through Three Years, Fair Value", "label": "Available-For Sale Securities, Debt Maturities, After One Through Three Years, Fair Value", "terseLabel": "Maturing after one year through three years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/InvestmentsFairValuesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue": { "auth_ref": [], "calculation": { "http://www.amgen.com/role/InvestmentsFairValuesByContractualMaturityDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Available-For-Sale Securities, Debt Maturities, After Three Through Five Years, Fair Value", "label": "Available-For-Sale Securities, Debt Maturities, After Three Through Five Years, Fair Value", "terseLabel": "Maturing after three years through five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/InvestmentsFairValuesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "amgn_AvailableForSalesInvestmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Available for sales investments.", "label": "Available For Sales Investments [Member]", "verboseLabel": "Available-for-sale investments [Member]" } } }, "localname": "AvailableForSalesInvestmentsMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/InvestmentsFairValuesByClassificationDetails" ], "xbrltype": "domainItemType" }, "amgn_BasicAndDilutedEarningPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Basic and diluted earning per share.", "label": "Basic And Diluted Earning Per Share [Abstract]", "verboseLabel": "Computation of basic and diluted earnings per share" } } }, "localname": "BasicAndDilutedEarningPerShareAbstract", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "amgn_BasisOfPresentationPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shows the basis of presentation of financial information for interim periods.", "label": "Basis Of Presentation [Policy Text Block]", "verboseLabel": "Basis of presentation" } } }, "localname": "BasisOfPresentationPolicyTextBlock", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "amgn_BeiGeneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "BeiGene [Member]", "label": "BeiGene [Member]", "terseLabel": "Collaborative arrangement with BeiGene, Ltd. [Member]", "verboseLabel": "BeiGene [Member]" } } }, "localname": "BeiGeneMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/CollaborationsDetails", "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "domainItemType" }, "amgn_CorporateDebtSecuritiesFinancialMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Corporate debt securities financial Member.", "label": "Corporate Debt Securities Financial [Member]", "terseLabel": "Corporate debt securities - Financial [Member]" } } }, "localname": "CorporateDebtSecuritiesFinancialMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails", "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "amgn_CorporateDebtSecuritiesIndustrialMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Corporate debt securities industrial Member.", "label": "Corporate Debt Securities Industrial [Member]", "terseLabel": "Corporate debt securities - Industrial [Member]" } } }, "localname": "CorporateDebtSecuritiesIndustrialMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails", "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "amgn_CorporateDebtSecuritiesOtherMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Corporate debt securities other.", "label": "Corporate Debt Securities Other [Member]", "terseLabel": "Corporate debt securities - Other [Member]" } } }, "localname": "CorporateDebtSecuritiesOtherMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails", "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "amgn_CrossCurrencySwapContractsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cross currency swap contracts.", "label": "Cross Currency Swap Contracts [Member]", "netLabel": "Cross-currency swap contract [Member]", "terseLabel": "Cross-currency swap contracts [Member]", "verboseLabel": "Cross-currency swap contracts [Member]" } } }, "localname": "CrossCurrencySwapContractsMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsCrossCurrencySwapsDetails", "http://www.amgen.com/role/DerivativeInstrumentsEffectivePortionOfUnrealizedGainLossDetails", "http://www.amgen.com/role/DerivativeInstrumentsFairValueOfDerivativesDetails", "http://www.amgen.com/role/DerivativeInstrumentsSummaryOfIncomeAndExpenseLineItemsDetails", "http://www.amgen.com/role/FairValueMeasurementDetails", "http://www.amgen.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "domainItemType" }, "amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Redemption Period without Payment of Make Whole Amount", "label": "Debt Instrument, Redemption Period without Payment of Make Whole Amount", "terseLabel": "Debt Instrument, Redemption Period without Payment of Make Whole Amount" } } }, "localname": "DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual" ], "xbrltype": "durationItemType" }, "amgn_DerivativeAssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Derivative assets.", "label": "Derivative Assets Fair Value Disclosure [Abstract]", "verboseLabel": "Derivatives:" } } }, "localname": "DerivativeAssetsFairValueDisclosureAbstract", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Derivative financial instruments liabilities fair value disclosure.", "label": "Derivative Financial Instruments Liabilities Fair Value Disclosure [Abstract]", "verboseLabel": "Derivatives:" } } }, "localname": "DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "amgn_DerivativeNotionalAmountAmountTerminated": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Derivative, Notional Amount, Amount Terminated", "label": "Derivative, Notional Amount, Amount Terminated", "terseLabel": "Value of derivative contracts terminated" } } }, "localname": "DerivativeNotionalAmountAmountTerminated", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails" ], "xbrltype": "monetaryItemType" }, "amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Derivative, Notional Amount, Amount Terminated Resulting In Net Cash Provided By Operating Activities", "label": "Derivative, Notional Amount, Amount Terminated Resulting In Net Cash Provided By Operating Activities", "terseLabel": "Value of derivative contracts terminated resulting in net cash provided by operating activities" } } }, "localname": "DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "amgn_EnbrelMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ENBREL.", "label": "ENBREL [Member]", "terseLabel": "Enbrel\u00ae (etanercept) [Member]" } } }, "localname": "EnbrelMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets.", "label": "Fair Values Of Available For Sale Investments By Classification In Consolidated Balance Sheets [Abstract]", "verboseLabel": "Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets" } } }, "localname": "FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/InvestmentsFairValuesByClassificationDetails" ], "xbrltype": "stringItemType" }, "amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of fair values of available-for-sale investments by classification in the consolidated balance sheets.", "label": "Fair Values of Available for Sale Investments By Classification In Consolidated Balance Sheets [Table Text Block]", "verboseLabel": "Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets" } } }, "localname": "FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets.", "label": "Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets [Abstract]", "verboseLabel": "Fair values of both derivatives designated as hedging instruments and not designated as hedging instruments included in Condensed Consolidated Balance Sheets" } } }, "localname": "FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsFairValueOfDerivativesDetails" ], "xbrltype": "stringItemType" }, "amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member]", "label": "Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member]", "terseLabel": "5.50% \u00a3475 million notes due 2026 (5.50% 2026 pound sterling Notes) [Member]", "verboseLabel": "5.50% 2026 pound sterling Notes [Member]" } } }, "localname": "FivePointFiveZeroPercentPoundSterlingNotesDue2026Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsCrossCurrencySwapsDetails", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_FivePointOneFivePercentNotesDue2041Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Five Point One Five Percent Notes Due 2041 [Member]", "label": "Five Point One Five Percent Notes Due 2041 [Member]", "terseLabel": "5.15% notes due 2041 (5.15% 2041 Notes) [Member]" } } }, "localname": "FivePointOneFivePercentNotesDue2041Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_FivePointSevenFivePercentNotesDue2040Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Five Point Seven Five Percent Notes Due 2040 [Member]", "label": "Five Point Seven Five Percent Notes Due 2040 [Member]", "terseLabel": "5.75% notes due 2040 (5.75% 2040 Notes) [Member]" } } }, "localname": "FivePointSevenFivePercentNotesDue2040Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_FivePointSixFivePercentNotesDue2042Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Five Point Six Five Percent Notes Due 2042 [Member]", "label": "Five Point Six Five Percent Notes Due 2042 [Member]", "terseLabel": "5.65% notes due 2042 (5.65% 2042 Notes) [Member]" } } }, "localname": "FivePointSixFivePercentNotesDue2042Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_FivePointThreeSevenFivePercentNotesDue2043Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Five Point Three Seven Five Percent Notes Due 2043 [Member]", "label": "Five Point Three Seven Five Percent Notes Due 2043 [Member]", "terseLabel": "5.375% notes due 2043 (5.375% 2043 Notes) [Member]" } } }, "localname": "FivePointThreeSevenFivePercentNotesDue2043Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_FloatingRateNotesDue2020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Floating Rate Notes Due 2020 [Member]", "label": "Floating Rate Notes Due 2020 [Member]", "terseLabel": "Floating Rate Notes Due 2020 [Member]" } } }, "localname": "FloatingRateNotesDue2020Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_ForeignCurrencyAndCrossCurrencySwapsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign currency and cross currency swaps.", "label": "Foreign Currency and Cross Currency Swaps [Member]", "terseLabel": "Foreign currency and cross currency swap contracts [Member]" } } }, "localname": "ForeignCurrencyAndCrossCurrencySwapsMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual" ], "xbrltype": "domainItemType" }, "amgn_FourPercentPoundSterlingNotesDue2029Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Four Percent Pound Sterling Notes Due 2029 [Member]", "label": "Four Percent Pound Sterling Notes Due 2029 [Member]", "terseLabel": "4.00% \u00a3700 million notes due 2029 (4.00% 2029 pound sterling Notes) [Member]", "verboseLabel": "4.00% 2029 pound sterling Notes [Member]" } } }, "localname": "FourPercentPoundSterlingNotesDue2029Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsCrossCurrencySwapsDetails", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member]", "label": "Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member]", "terseLabel": "4.563% notes due 2048 (4.563% 2048 Notes) [Member]", "verboseLabel": "4.563% notes due 2048 (4.563% 2048 Notes) [Member]" } } }, "localname": "FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_FourPointFiveZeroPercentNotesDue2020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Four Point Five Zero Percent Notes Due 2020 [Member]", "label": "Four Point Five Zero Percent Notes Due 2020 [Member]", "terseLabel": "4.50% notes due 2020 (4.50% 2020 Notes) [Member]" } } }, "localname": "FourPointFiveZeroPercentNotesDue2020Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Four Point Four Zero Percent Notes Due Two Zero Four Five [Member]", "label": "Four Point Four Zero Percent Notes Due Two Zero Four Five [Member]", "terseLabel": "4.40% notes due 2045 (4.40% 2045 Notes) [Member]" } } }, "localname": "FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_FourPointNineFivePercentNotesDue2041Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Four Point Nine Five Percent Notes Due 2041 [Member]", "label": "Four Point Nine Five Percent Notes Due 2041 [Member]", "terseLabel": "4.95% notes due 2041 (4.95% 2041 Notes) [Member]" } } }, "localname": "FourPointNineFivePercentNotesDue2041Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_FourPointOneZeroPercentNotesDue2021Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Four Point One Zero Percent Notes Due 2021 [Member]", "label": "Four Point One Zero Percent Notes Due 2021 [Member]", "terseLabel": "4.10% notes due 2021 (4.10% 2021 Notes) [Member]" } } }, "localname": "FourPointOneZeroPercentNotesDue2021Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails", "http://www.amgen.com/role/FinancingArrangementsScheduleInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Four Point Six Six Three Percent Notes Due Two Zero Five One [Member]", "label": "Four Point Six Six Three Percent Notes Due Two Zero Five One [Member]", "terseLabel": "4.663% notes due 2051 (4.663% 2051 Notes) [Member]" } } }, "localname": "FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails", "http://www.amgen.com/role/FinancingArrangementsScheduleInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "amgn_HedgedLiabilityDiscontinuedFairValueHedge": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Hedged Liability, Discontinued Fair Value Hedge", "label": "Hedged Liability, Discontinued Fair Value Hedge", "terseLabel": "Carrying value with discontinued hedging relationships" } } }, "localname": "HedgedLiabilityDiscontinuedFairValueHedge", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsHedgedLiabilitiesAndCumulativeAmountDetails" ], "xbrltype": "monetaryItemType" }, "amgn_HospiraMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Hospira [Member]", "label": "Hospira [Member]", "terseLabel": "Hospira, Inc. [Member]" } } }, "localname": "HospiraMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/ContingenciesAndCommitmentsDetails" ], "xbrltype": "domainItemType" }, "amgn_HumiraBiosimilarAntitrustClassActionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Humira Biosimilar Antitrust Class Actions [Member]", "label": "Humira Biosimilar Antitrust Class Actions [Member]", "terseLabel": "Humira Biosimilar Antitrust Class Actions [Member]" } } }, "localname": "HumiraBiosimilarAntitrustClassActionsMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/ContingenciesAndCommitmentsDetails" ], "xbrltype": "domainItemType" }, "amgn_IdentifiableIntangibleAssetsAccumulatedAmortization": { "auth_ref": [], "calculation": { "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Identifiable intangible assets accumulated amortization.", "label": "Identifiable Intangible Assets Accumulated Amortization", "negatedLabel": "Accumulated amortization" } } }, "localname": "IdentifiableIntangibleAssetsAccumulatedAmortization", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "amgn_IdentifiableIntangibleAssetsGross": { "auth_ref": [], "calculation": { "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Identifiable intangible assets gross.", "label": "Identifiable Intangible Assets Gross", "terseLabel": "Gross carrying amount" } } }, "localname": "IdentifiableIntangibleAssetsGross", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "amgn_IncreaseDecreaseInNoncurrentTaxLiability": { "auth_ref": [], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) In Noncurrent Tax Liability", "label": "Increase (Decrease) In Noncurrent Tax Liability", "terseLabel": "Long-term tax liabilities" } } }, "localname": "IncreaseDecreaseInNoncurrentTaxLiability", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "amgn_InterestRateSwapAtThenCurrentInterestRatesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Rate Swap, At-Then Current Interest Rates [Member]", "label": "Interest Rate Swap, At-Then Current Interest Rates [Member]", "terseLabel": "Interest Rate Swap, At-Then Current Interest Rates [Member]" } } }, "localname": "InterestRateSwapAtThenCurrentInterestRatesMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual" ], "xbrltype": "domainItemType" }, "amgn_InterestRateSwapAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Rate Swap [Axis]", "label": "Interest Rate Swap [Axis]", "terseLabel": "Interest Rate Swap [Axis]" } } }, "localname": "InterestRateSwapAxis", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails" ], "xbrltype": "stringItemType" }, "amgn_InterestRateSwapDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Interest Rate Swap [Axis]", "label": "Interest Rate Swap [Domain]", "terseLabel": "Interest Rate Swap [Domain]" } } }, "localname": "InterestRateSwapDomain", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails" ], "xbrltype": "domainItemType" }, "amgn_InterestRateSwapOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Rate Swap, One [Member]", "label": "Interest Rate Swap, One [Member]", "terseLabel": "$2.2 Billion Notional Value Interest Rate Swap [Member]" } } }, "localname": "InterestRateSwapOneMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails" ], "xbrltype": "domainItemType" }, "amgn_InterestRateSwapThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Rate Swap, Three [Member]", "label": "Interest Rate Swap, Three [Member]", "terseLabel": "$5.2 Billion Notional Value Interest Rate Swap [Member]" } } }, "localname": "InterestRateSwapThreeMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails" ], "xbrltype": "domainItemType" }, "amgn_InterestRateSwapTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Rate Swap, Two [Member]", "label": "Interest Rate Swap, Two [Member]", "terseLabel": "$5.2 Billion Notional Value Interest Rate Swap, Original [Member]" } } }, "localname": "InterestRateSwapTwoMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails" ], "xbrltype": "domainItemType" }, "amgn_InvestmentMaturityPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Investment Maturity Period", "label": "Investment Maturity Period", "terseLabel": "Investment maturity period" } } }, "localname": "InvestmentMaturityPeriod", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetailsTextual" ], "xbrltype": "durationItemType" }, "amgn_KANJINTIPatentLitigationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "KANJINTI Patent Litigation [Member]", "label": "KANJINTI Patent Litigation [Member]", "terseLabel": "KANJINTI Patent Litigation [Member]" } } }, "localname": "KANJINTIPatentLitigationMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/ContingenciesAndCommitmentsDetails" ], "xbrltype": "domainItemType" }, "amgn_KyprolisMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Kyprolis [Member]", "label": "Kyprolis [Member]", "terseLabel": "KYPROLIS\u00ae (carfilzomib) [Member]" } } }, "localname": "KyprolisMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "amgn_LitigationSettlementDamagesSoughtValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Litigation Settlement, Damages Sought, Value", "label": "Litigation Settlement, Damages Sought, Value", "terseLabel": "Amount awarded from settlement" } } }, "localname": "LitigationSettlementDamagesSoughtValue", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/ContingenciesAndCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "amgn_LongTermDebtCurrentMaturitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-Term Debt, Current Maturities [Member]", "label": "Long-Term Debt, Current Maturities [Member]", "terseLabel": "Current portion of long-term debt [Member]" } } }, "localname": "LongTermDebtCurrentMaturitiesMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsHedgedLiabilitiesAndCumulativeAmountDetails" ], "xbrltype": "domainItemType" }, "amgn_LossContingencyNumberOfLawsuits": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Number Of Lawsuits", "label": "Loss Contingency, Number Of Lawsuits", "terseLabel": "Number of lawsuits" } } }, "localname": "LossContingencyNumberOfLawsuits", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/ContingenciesAndCommitmentsDetails" ], "xbrltype": "integerItemType" }, "amgn_MakeWholePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "MakeWholePayments", "label": "MakeWholePayments", "terseLabel": "MakeWholePayments" } } }, "localname": "MakeWholePayments", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "amgn_NatureOfOperationsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Describes the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Disclosures about the nature of operations need not be quantified; relative importance could be conveyed by use of terms such as \"predominately\", \"about equally\", or \"major and other\". This element is also referred to as \"Business Description\".", "label": "Nature Of Operations [Policy Text Block]", "verboseLabel": "Business" } } }, "localname": "NatureOfOperationsPolicyTextBlock", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "amgn_NeulastaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Neulasta.", "label": "Neulasta [Member]", "terseLabel": "Neulasta\u00ae (pegfilgrastim) [Member]" } } }, "localname": "NeulastaMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "One Point Eight Five Percent Notes Due Two Zero Two One [Member]", "label": "One Point Eight Five Percent Notes Due Two Zero Two One [Member]", "terseLabel": "1.85% notes due 2021 (1.85% 2021 Notes) [Member]" } } }, "localname": "OnePointEightFivePercentNotesDueTwoZeroTwoOneMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "One Point Nine Zero Percent Notes Due Two Zero Two Five [Member]", "label": "One Point Nine Zero Percent Notes Due Two Zero Two Five [Member]", "terseLabel": "1.90% notes due 2025 (1.90% 2025 Notes) [Member]" } } }, "localname": "OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "One Point Twenty Five Percent Euro Notes Due Two Thousand Twenty Two [Member]", "label": "One Point Twenty Five Percent Euro Notes Due Two Thousand Twenty Two [Member]", "verboseLabel": "1.25% 2022 euro Notes [Member]" } } }, "localname": "OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsCrossCurrencySwapsDetails" ], "xbrltype": "domainItemType" }, "amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "One Point Two Five Percent Euro Notes due Two Zero Two Two [Member]", "label": "One Point Two Five Percent Euro Notes due Two Zero Two Two [Member]", "terseLabel": "1.25% \u20ac1,250 million notes due 2022 (1.25% 2022 euro Notes) [Member]" } } }, "localname": "OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_OtezlaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Otezla [Member]", "label": "Otezla [Member]", "terseLabel": "Otezla (apremilast) [Member]" } } }, "localname": "OtezlaMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Other Comprehensive Income (Loss), Other Adjustment, before Tax", "label": "Other Comprehensive Income (Loss), Other Adjustment, before Tax", "terseLabel": "Other" } } }, "localname": "OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/StockholdersEquityComponentsOfAociDetails" ], "xbrltype": "monetaryItemType" }, "amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent": { "auth_ref": [], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent", "label": "Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other" } } }, "localname": "OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "amgn_OtherCurrentNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other current assets/other non-current assets.", "label": "Other Current Noncurrent Assets [Member]", "verboseLabel": "Other current assets/Other assets [Member]" } } }, "localname": "OtherCurrentNoncurrentAssetsMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsFairValueOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "amgn_OtherGovernmentRelatedAndCorporateDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Government-related and Corporate Debt Securities [Member]", "label": "Other Government-related and Corporate Debt Securities [Member]", "terseLabel": "Other Government-related and Corporate Debt Securities [Member]" } } }, "localname": "OtherGovernmentRelatedAndCorporateDebtSecuritiesMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetailsTextual" ], "xbrltype": "domainItemType" }, "amgn_OtherNotesDue2097Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Notes Due 2097 [Member]", "label": "Other Notes Due 2097 [Member]", "terseLabel": "Other notes due 2097 [Member]" } } }, "localname": "OtherNotesDue2097Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_OtherProductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Products [Member]", "label": "Other Products [Member]", "terseLabel": "Other products [Member]" } } }, "localname": "OtherProductsMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "amgn_OtherShortTermInterestBearingSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other short-term interest bearing securities.", "label": "Other Short Term Interest Bearing Securities [Member]", "verboseLabel": "Other short-term interest-bearing securities [Member]" } } }, "localname": "OtherShortTermInterestBearingSecuritiesMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails", "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "amgn_PatentTrialAndAppealBoardPatentChallengesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Patent Trial And Appeal Board Patent Challenges [Member]", "label": "Patent Trial And Appeal Board Patent Challenges [Member]", "terseLabel": "Patent Trial and Appeal Board Patent Challenges [Member]" } } }, "localname": "PatentTrialAndAppealBoardPatentChallengesMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/ContingenciesAndCommitmentsDetails" ], "xbrltype": "domainItemType" }, "amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event", "label": "Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event", "terseLabel": "Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event" } } }, "localname": "PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "percentItemType" }, "amgn_ProliaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Prolia.", "label": "Prolia [Member]", "terseLabel": "Prolia\u00ae (denosumab) [Member]" } } }, "localname": "ProliaMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "amgn_Ratedifferenceinaninterestrateswaprelationship": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Rate difference in an interest rate swap relationship", "label": "Rate difference in an interest rate swap relationship", "terseLabel": "Rate difference in an interest rate swap relationship" } } }, "localname": "Ratedifferenceinaninterestrateswaprelationship", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails", "http://www.amgen.com/role/FinancingArrangementsScheduleInterestRateSwapsDetails" ], "xbrltype": "percentItemType" }, "amgn_RepathaevolocumabMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Repatha (evolocumab) [Member]", "label": "Repatha (evolocumab) [Member]", "terseLabel": "Repatha (evolocumab) [Member]" } } }, "localname": "RepathaevolocumabMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "amgn_ScheduleOfIntangibleAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of finite-lived and indefinite-lived identifiable intangible assets.", "label": "Schedule Of Intangible Assets [Table Text Block]", "terseLabel": "Schedule of identifiable intangible assets" } } }, "localname": "ScheduleOfIntangibleAssetsTableTextBlock", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps", "label": "Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps [Table Text Block]", "terseLabel": "Schedule of notional amounts and interest rates for cross-currency swaps" } } }, "localname": "ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "amgn_SensiparAntitrustClassActionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sensipar Antitrust Class Actions [Member]", "label": "Sensipar Antitrust Class Actions [Member]", "terseLabel": "Sensipar Antitrust Class Actions [Member]" } } }, "localname": "SensiparAntitrustClassActionsMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/ContingenciesAndCommitmentsDetails" ], "xbrltype": "domainItemType" }, "amgn_SixPointFourZeroPercentNotesDue2039Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Six Point Four Zero Percent Notes Due 2039 [Member]", "label": "Six Point Four Zero Percent Notes Due 2039 [Member]", "terseLabel": "6.40% notes due 2039 (6.40% 2039 Notes) [Member]" } } }, "localname": "SixPointFourZeroPercentNotesDue2039Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_SixPointNineZeroPercentNotesDue2038Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Six Point Nine Zero Percent Notes Due 2038 [Member]", "label": "Six Point Nine Zero Percent Notes Due 2038 [Member]", "terseLabel": "6.90% notes due 2038 (6.90% 2038 Notes) [Member]" } } }, "localname": "SixPointNineZeroPercentNotesDue2038Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_SixPointThreeSevenFivePercentNotesDue2037Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Six Point Three Seven Five Percent Notes Due 2037 [Member]", "label": "Six Point Three Seven Five Percent Notes Due 2037 [Member]", "terseLabel": "6.375% notes due 2037 (6.375% 2037 Notes) [Member]" } } }, "localname": "SixPointThreeSevenFivePercentNotesDue2037Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_StockRepurchaseProgramTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Repurchase Program [Table Text Block]", "label": "Stock Repurchase Program [Table Text Block]", "terseLabel": "Summary of activity under our stock repurchase program" } } }, "localname": "StockRepurchaseProgramTableTextBlock", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "amgn_ThreePointEightSevenFivePercentNotesDue2021Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Three Point Eight Seven Five Percent Notes Due 2021 [Member]", "label": "Three Point Eight Seven Five Percent Notes Due 2021 [Member]", "terseLabel": "3.875% notes due 2021 (3.875% 2021 Notes) [Member]" } } }, "localname": "ThreePointEightSevenFivePercentNotesDue2021Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails", "http://www.amgen.com/role/FinancingArrangementsScheduleInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "amgn_ThreePointFourFivePercentNotesDue2020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Three Point Four Five Percent Notes Due 2020 [Member]", "label": "Three Point Four Five Percent Notes Due 2020 [Member]", "terseLabel": "3.45% notes due 2020 (3.45% 2020 Notes) [Member]" } } }, "localname": "ThreePointFourFivePercentNotesDue2020Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails", "http://www.amgen.com/role/FinancingArrangementsScheduleInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "amgn_ThreePointOneFivePercentNotesDue2040Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Three Point One Five Percent Notes Due 2040 [Member]", "label": "Three Point One Five Percent Notes Due 2040 [Member]", "terseLabel": "3.15% notes due 2040 (3.15% 2040 Notes) [Member]" } } }, "localname": "ThreePointOneFivePercentNotesDue2040Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Three Point One Two Five Percent Notes Due Two Zero Two Five [Member]", "label": "Three Point One Two Five Percent Notes Due Two Zero Two Five [Member]", "terseLabel": "3.125% notes due 2025 (3.125% 2025 Notes) [Member]" } } }, "localname": "ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails", "http://www.amgen.com/role/FinancingArrangementsScheduleInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "amgn_ThreePointSixTwoFivePercentNotesDue2022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Three Point Six Two Five Percent Notes Due 2022 [Member]", "label": "Three Point Six Two Five Percent Notes Due 2022 [Member]", "terseLabel": "3.625% notes due 2022 (3.625% 2022 Notes) [Member]" } } }, "localname": "ThreePointSixTwoFivePercentNotesDue2022Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails", "http://www.amgen.com/role/FinancingArrangementsScheduleInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "amgn_ThreePointSixTwoFivePercentNotesDue2024Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Three Point Six Two Five Percent Notes Due 2024 [Member]", "label": "Three Point Six Two Five Percent Notes Due 2024 [Member]", "terseLabel": "3.625% notes due 2024 (3.625% 2024 Notes) [Member]" } } }, "localname": "ThreePointSixTwoFivePercentNotesDue2024Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails", "http://www.amgen.com/role/FinancingArrangementsScheduleInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "amgn_ThreePointThreeSevenFivePercentNotesDue2050Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Three Point Three Seven Five Percent Notes Due 2050 [Member]", "label": "Three Point Three Seven Five Percent Notes Due 2050 [Member]", "terseLabel": "3.375% notes due 2050 (3.375% 2050 Notes) [Member]" } } }, "localname": "ThreePointThreeSevenFivePercentNotesDue2050Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_ThreePointTwoZeroNotesDue2027Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Three Point Two Zero Notes Due 2027 [Member]", "label": "Three Point Two Zero Notes Due 2027 [Member]", "terseLabel": "3.20% notes due 2027 (3.20% 2027 Notes) [Member]" } } }, "localname": "ThreePointTwoZeroNotesDue2027Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Percent Euro Notes Due Two Thousand Twenty Six [Member]", "label": "Two Percent Euro Notes Due Two Thousand Twenty Six [Member]", "terseLabel": "2.00% \u20ac750 million notes due 2026 (2.00% 2026 euro Notes) [Member]", "verboseLabel": "2.00% 2026 euro Notes [Member]" } } }, "localname": "TwoPercentEuroNotesDueTwoThousandTwentySixMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsCrossCurrencySwapsDetails", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_TwoPointFourFivePercentNotesDue2030Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Point Four Five Percent Notes Due 2030 [Member]", "label": "Two Point Four Five Percent Notes Due 2030 [Member]", "terseLabel": "2.45% notes due 2030 (2.45% 2030 Notes) [Member]" } } }, "localname": "TwoPointFourFivePercentNotesDue2030Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Point One Two Five Percent Euro Notes Due 2019 [Member]", "label": "Two Point One Two Five Percent Euro Notes Due 2019 [Member]", "verboseLabel": "2.125% 2019 euro Notes [Member]" } } }, "localname": "TwoPointOneTwoFivePercentEuroNotesDue2019Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsCrossCurrencySwapsDetails" ], "xbrltype": "domainItemType" }, "amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Point One Two Five Percent Notes Due Two Zero Two Zero [Member]", "label": "Two Point One Two Five Percent Notes Due Two Zero Two Zero [Member]", "terseLabel": "2.125% notes due 2020 (2.125% 2020 Notes) [Member]" } } }, "localname": "TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Point Seven Zero Percent Notes Due Two Zero Two Two [Member]", "label": "Two Point Seven Zero Percent Notes Due Two Zero Two Two [Member]", "terseLabel": "2.70% notes due 2022 (2.70% 2022 Notes) [Member]" } } }, "localname": "TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_TwoPointSixFiveNotesDue2022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Point Six Five Notes Due 2022 [Member]", "label": "Two Point Six Five Notes Due 2022 [Member]", "terseLabel": "2.65% notes due 2022 (2.65% 2022 Notes) [Member]" } } }, "localname": "TwoPointSixFiveNotesDue2022Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Point Six Zero Notes Due Two Zero Two Six [Member]", "label": "Two Point Six Zero Notes Due Two Zero Two Six [Member]", "terseLabel": "2.60% notes due 2026 (2.60% 2026 notes) [Member]" } } }, "localname": "TwoPointSixZeroNotesDueTwoZeroTwoSixMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails", "http://www.amgen.com/role/FinancingArrangementsScheduleInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Point Two Five Percent Notes Due Two Zero Two Three [Member]", "label": "Two Point Two Five Percent Notes Due Two Zero Two Three [Member]", "terseLabel": "2.25% notes due 2023 (2.25% 2023 Notes) [Member]" } } }, "localname": "TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_TwoPointTwoZeroNotesDue2020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Point Two Zero Notes Due 2020 [Member]", "label": "Two Point Two Zero Notes Due 2020 [Member]", "terseLabel": "2.20% notes due 2020 (2.20% 2020 Notes) [Member]" } } }, "localname": "TwoPointTwoZeroNotesDue2020Member", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member]", "label": "Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member]", "terseLabel": "2.20% notes due 2027 (2.20% 2027 Notes) [Member]" } } }, "localname": "TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_XgevaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "XGEVA.", "label": "XGEVA [Member]", "terseLabel": "XGEVA\u00ae (denosumab) [Member]" } } }, "localname": "XgevaMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Zero Point Forty One Percent Swiss Franc Bonds Due Two Thousand Twenty Three [Member]", "label": "Zero Point Forty One Percent Swiss Franc Bonds Due Two Thousand Twenty Three [Member]", "terseLabel": "0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) [Member]", "verboseLabel": "0.41% 2023 Swiss franc Bonds [Member]" } } }, "localname": "ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember", "nsuri": "http://www.amgen.com/20200331", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsCrossCurrencySwapsDetails", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "US [Member]" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsCrossCurrencySwapsDetails" ], "xbrltype": "domainItemType" }, "currency_CHF": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Switzerland, Francs", "terseLabel": "Switzerland, Francs" } } }, "localname": "CHF", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsCrossCurrencySwapsDetails" ], "xbrltype": "domainItemType" }, "currency_EUR": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Euro Member Countries, Euro", "terseLabel": "Euro Member Countries, Euro" } } }, "localname": "EUR", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsCrossCurrencySwapsDetails" ], "xbrltype": "domainItemType" }, "currency_GBP": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "United Kingdom, Pounds", "terseLabel": "United Kingdom, Pounds" } } }, "localname": "GBP", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsCrossCurrencySwapsDetails" ], "xbrltype": "domainItemType" }, "currency_USD": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "United States of America, Dollars", "terseLabel": "United States of America, Dollars" } } }, "localname": "USD", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsCrossCurrencySwapsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r373" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r374" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingsExchangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Listings, Exchange [Axis]", "terseLabel": "Entity Listings, Exchange [Axis]" } } }, "localname": "EntityListingsExchangeAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_ExchangeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.", "label": "Exchange [Domain]", "terseLabel": "Exchange [Domain]" } } }, "localname": "ExchangeDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r371" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r372" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "exch_XNGS": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]", "terseLabel": "The NASDAQ Global Select Market [Member]" } } }, "localname": "XNGS", "nsuri": "http://xbrl.sec.gov/exch/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "exch_XNYS": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "NEW YORK STOCK EXCHANGE, INC. [Member]", "terseLabel": "New York Stock Exchange [Member]" } } }, "localname": "XNYS", "nsuri": "http://xbrl.sec.gov/exch/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Currency [Axis]", "terseLabel": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsCrossCurrencySwapsDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amgen.com/role/ContingenciesAndCommitmentsDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amgen.com/role/ContingenciesAndCommitmentsDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "domainItemType" }, "srt_PartnershipInterestMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Partnership Interest [Member]", "terseLabel": "Limited Partnership [Member]" } } }, "localname": "PartnershipInterestMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r127", "r226", "r228", "r357", "r358" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome", "http://www.amgen.com/role/DerivativeInstrumentsSummaryOfIncomeAndExpenseLineItemsDetails", "http://www.amgen.com/role/RevenuesDetails", "http://www.amgen.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome", "http://www.amgen.com/role/DerivativeInstrumentsSummaryOfIncomeAndExpenseLineItemsDetails", "http://www.amgen.com/role/RevenuesDetails", "http://www.amgen.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amgen.com/role/StockholdersEquityDetailsTextualDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amgen.com/role/StockholdersEquityDetailsTextualDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r128", "r226", "r229", "r359", "r368", "r369" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r197", "r323" ], "lang": { "en-US": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amgen.com/role/StockholdersEquityDetailsTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r2", "r14", "r129", "r130", "r227" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "verboseLabel": "Trade receivables, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "verboseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesMember": { "auth_ref": [ "r34" ], "lang": { "en-US": { "role": { "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.", "label": "Accrued Liabilities [Member]", "terseLabel": "Accrued liabilities [Member]" } } }, "localname": "AccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsFairValueOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r29", "r192" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "verboseLabel": "Accumulated depreciation and amortization on property, plant and equipment" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r55", "r63", "r265" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "verboseLabel": "Cash flow hedges [Member]" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsSummaryOfIncomeAndExpenseLineItemsDetails", "http://www.amgen.com/role/StockholdersEquityComponentsOfAociDetails", "http://www.amgen.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r49", "r50", "r51", "r55", "r56" ], "lang": { "en-US": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]", "verboseLabel": "Available-for-sale securities [Member]" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/StockholdersEquityComponentsOfAociDetails", "http://www.amgen.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/StockholdersEquityComponentsOfAociDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r53", "r54", "r55" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/StockholdersEquityComponentsOfAociDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r52", "r55", "r56", "r266" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive loss [Member]", "verboseLabel": "AOCI [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://www.amgen.com/role/StockholdersEquityComponentsOfAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r47", "r55", "r56", "r266" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign currency translation [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/StockholdersEquityComponentsOfAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from a tax benefit (deficiency) associated with an share-based compensation plan other than an employee stock ownership plan (ESOP).", "label": "Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net", "terseLabel": "Tax impact related to employee stock-based compensation expense" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r234", "r235", "r238", "r239" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AlternativeInvestment": { "auth_ref": [ "r306", "r313" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund.", "label": "Alternative Investment", "terseLabel": "Investments" } } }, "localname": "AlternativeInvestment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r90", "r179", "r186" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization charges associated with finite-lived intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CollaborationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r145", "r231" ], "lang": { "en-US": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-backed Securities [Member]", "terseLabel": "Other mortgage- and asset-backed securities [Member]" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails", "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r124", "r332", "r348" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r3", "r4", "r44" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r307" ], "calculation": { "http://www.amgen.com/role/FairValueMeasurementDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "verboseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r138" ], "calculation": { "http://www.amgen.com/role/InvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross unrealized gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r139" ], "calculation": { "http://www.amgen.com/role/InvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Gross unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r136", "r164" ], "calculation": { "http://www.amgen.com/role/InvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortized cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "auth_ref": [ "r140", "r143", "r343" ], "calculation": { "http://www.amgen.com/role/InvestmentsFairValuesByContractualMaturityDetails": { "order": 4.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Fair Value", "terseLabel": "Maturing after five years through ten years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsFairValuesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r140", "r142", "r342" ], "calculation": { "http://www.amgen.com/role/InvestmentsFairValuesByContractualMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value", "terseLabel": "Maturing in one year or less" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsFairValuesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue": { "auth_ref": [ "r144" ], "calculation": { "http://www.amgen.com/role/InvestmentsFairValuesByContractualMaturityDetails": { "order": 5.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.", "label": "Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value", "terseLabel": "Residential mortgage-backed securities" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsFairValuesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r132", "r137", "r164" ], "calculation": { "http://www.amgen.com/role/FairValueMeasurementDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.amgen.com/role/InvestmentsDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 }, "http://www.amgen.com/role/InvestmentsFairValuesByClassificationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amgen.com/role/InvestmentsFairValuesByContractualMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Fair values", "totalLabel": "Total interest-bearing securities", "verboseLabel": "Interest-bearing securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails", "http://www.amgen.com/role/InvestmentsDetails", "http://www.amgen.com/role/InvestmentsFairValuesByClassificationDetails", "http://www.amgen.com/role/InvestmentsFairValuesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r134", "r164" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.amgen.com/role/InvestmentsFairValuesByClassificationDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-sale, Current", "verboseLabel": "Marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets", "http://www.amgen.com/role/InvestmentsFairValuesByClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsFairValueOfDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r277", "r283" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsFairValueOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r250", "r251" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetailsTextual" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r255", "r256", "r257" ], "calculation": { "http://www.amgen.com/role/FairValueMeasurementDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "verboseLabel": "Contingent consideration obligations" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r26", "r361", "r362" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsAvailableForSaleInvestmentsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r0", "r26", "r92" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.amgen.com/role/InvestmentsFairValuesByClassificationDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets", "http://www.amgen.com/role/InvestmentsFairValuesByClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r87", "r92", "r93" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r87", "r317" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r274" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash flow hedge [Member]", "verboseLabel": "Cash flow hedges [Member]" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsCrossCurrencySwapsDetails", "http://www.amgen.com/role/DerivativeInstrumentsEffectivePortionOfUnrealizedGainLossDetails", "http://www.amgen.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "auth_ref": [ "r300" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "terseLabel": "Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments" } } }, "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsSummaryOfIncomeAndExpenseLineItemsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": { "auth_ref": [ "r300" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge", "terseLabel": "Gains (losses) on fair value hedging relationships, Hedged items" } } }, "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsSummaryOfIncomeAndExpenseLineItemsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/StockholdersEquityDetailsTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r258", "r259", "r261" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaborations" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/Collaborations" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CollaborationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r39", "r196", "r337", "r353" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "verboseLabel": "Contingencies and commitments" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r195", "r203" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Contingencies and commitments" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/ContingenciesAndCommitments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Dividends paid per share (in usd per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/StockholdersEquityDetailsTextualDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Common stock, dividends declared per share (in usd per share)", "verboseLabel": "Dividends declared per share (in usd per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquityParenthetical", "http://www.amgen.com/role/StockholdersEquityDetailsTextualDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common stock held by shareholders with par value plus amounts in excess of par value or issuance value (in cases of no-par value stock).", "label": "Common Stock Including Additional Paid in Capital [Member]", "terseLabel": "Common stock and additional paid-in capital [Member]" } } }, "localname": "CommonStockIncludingAdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]", "verboseLabel": "Number of shares of common stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://www.amgen.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common stock and additional paid-in capital, par value (in usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock and additional paid-in capital, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r13", "r216" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending Balance, Shares", "periodStartLabel": "Beginning Balance, Shares", "verboseLabel": "Common stock and additional paid-in capital, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStocksIncludingAdditionalPaidInCapital": { "auth_ref": [ "r13", "r15", "r223" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of par value plus amounts in excess of par value or issuance value for common stock issued.", "label": "Common Stocks, Including Additional Paid in Capital", "verboseLabel": "Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding \u2014 588.0 shares in 2020 and 591.4 shares in 2019" } } }, "localname": "CommonStocksIncludingAdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r59", "r61", "r62" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r94", "r264", "r267", "r268" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "verboseLabel": "Principles of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r68" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r67" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Costs and Expenses [Abstract]", "verboseLabel": "Operating expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "terseLabel": "Cumulative effect of changes in accounting principles, net of taxes" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r212" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "Financing arrangements" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FinancingArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r8", "r9", "r10", "r333", "r334", "r347" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsCrossCurrencySwapsDetails", "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails", "http://www.amgen.com/role/FinancingArrangementsScheduleInterestRateSwapsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r10", "r207", "r334", "r347" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Long-term debt, gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r319", "r321" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r36", "r210", "r319" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r36" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate, stated percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails", "http://www.amgen.com/role/FinancingArrangementsScheduleInterestRateSwapsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails", "http://www.amgen.com/role/FinancingArrangementsScheduleInterestRateSwapsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r37" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsCrossCurrencySwapsDetails", "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails", "http://www.amgen.com/role/FinancingArrangementsScheduleInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r37", "r97", "r217", "r220", "r221", "r222", "r318", "r319", "r321", "r346" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails", "http://www.amgen.com/role/FinancingArrangementsScheduleInterestRateSwapsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r208", "r320" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "negatedLabel": "Unamortized bond discounts, premiums and issuance costs, net" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": { "auth_ref": [ "r149" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Realized Gain", "verboseLabel": "Total realized gains" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsAvailableForSaleInvestmentsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": { "auth_ref": [ "r149" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Realized Loss", "verboseLabel": "Total realized losses" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsAvailableForSaleInvestmentsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r151" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "terseLabel": "Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesPayableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial obligations in a security form.", "label": "Debt Securities Payable [Member]", "terseLabel": "Debt Securities Payable [Member]" } } }, "localname": "DebtSecuritiesPayableMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r243", "r247" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Long-term deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r91" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r90", "r122" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "verboseLabel": "Depreciation, amortization and other" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetFairValueNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Asset, Fair Value, Amount Not Offset Against Collateral [Abstract]", "verboseLabel": "Assets" } } }, "localname": "DerivativeAssetFairValueNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsFairValueOfDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeBasisSpreadOnVariableRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The percentage points added to the reference rate to compute the variable rate on the interest rate derivative.", "label": "Derivative, Basis Spread on Variable Rate", "terseLabel": "Derivative, Basis Spread on Variable Rate" } } }, "localname": "DerivativeBasisSpreadOnVariableRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsScheduleInterestRateSwapsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsCrossCurrencySwapsDetails", "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual", "http://www.amgen.com/role/DerivativeInstrumentsEffectivePortionOfUnrealizedGainLossDetails", "http://www.amgen.com/role/DerivativeInstrumentsFairValueOfDerivativesDetails", "http://www.amgen.com/role/DerivativeInstrumentsSummaryOfIncomeAndExpenseLineItemsDetails", "http://www.amgen.com/role/FairValueMeasurementDetails", "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails", "http://www.amgen.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r45", "r46", "r281", "r328" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Total derivative assets, fair value" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsFairValueOfDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r45", "r46", "r281", "r328" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "terseLabel": "Total derivative liabilities, fair value" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsFairValueOfDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative, Fixed Interest Rate", "verboseLabel": "Interest rates" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsCrossCurrencySwapsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeGainOnDerivative": { "auth_ref": [ "r279" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain on Derivative", "terseLabel": "Gain recognized from termination of contracts" } } }, "localname": "DerivativeGainOnDerivative", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r278", "r282", "r287", "r292" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsCrossCurrencySwapsDetails", "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual", "http://www.amgen.com/role/DerivativeInstrumentsEffectivePortionOfUnrealizedGainLossDetails", "http://www.amgen.com/role/DerivativeInstrumentsFairValueOfDerivativesDetails", "http://www.amgen.com/role/DerivativeInstrumentsSummaryOfIncomeAndExpenseLineItemsDetails", "http://www.amgen.com/role/FairValueMeasurementDetails", "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails", "http://www.amgen.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r305" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "verboseLabel": "Derivative instruments" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r275", "r278", "r287" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsCrossCurrencySwapsDetails", "http://www.amgen.com/role/DerivativeInstrumentsEffectivePortionOfUnrealizedGainLossDetails", "http://www.amgen.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r275", "r278", "r287", "r292", "r293", "r299", "r301" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual", "http://www.amgen.com/role/DerivativeInstrumentsEffectivePortionOfUnrealizedGainLossDetails", "http://www.amgen.com/role/DerivativeInstrumentsSummaryOfIncomeAndExpenseLineItemsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual", "http://www.amgen.com/role/DerivativeInstrumentsEffectivePortionOfUnrealizedGainLossDetails", "http://www.amgen.com/role/DerivativeInstrumentsSummaryOfIncomeAndExpenseLineItemsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilityFairValueNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Liability, Fair Value, Amount Not Offset Against Collateral [Abstract]", "verboseLabel": "Liabilities" } } }, "localname": "DerivativeLiabilityFairValueNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsFairValueOfDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsCrossCurrencySwapsDetails", "http://www.amgen.com/role/DerivativeInstrumentsHedgedLiabilitiesAndCumulativeAmountDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r271", "r273" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amounts", "verboseLabel": "Derivative, notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsCrossCurrencySwapsDetails", "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails", "http://www.amgen.com/role/FinancingArrangementsScheduleInterestRateSwapsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r100", "r270", "r272", "r273", "r275", "r276", "r284", "r287", "r297", "r298", "r301" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsCrossCurrencySwapsDetails", "http://www.amgen.com/role/DerivativeInstrumentsHedgedLiabilitiesAndCumulativeAmountDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsFairValueOfDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r275" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument [Member]", "verboseLabel": "Derivatives designated as hedging instrument [Member]" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual", "http://www.amgen.com/role/DerivativeInstrumentsFairValueOfDerivativesDetails", "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r254" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "verboseLabel": "Developed-Product-Technology Rights [Member]" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r226" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of revenue by product and by geographic area" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/RevenuesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r223" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedTerseLabel": "Dividends declared on common stock" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "verboseLabel": "Earnings per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r66", "r103", "r106", "r107", "r108", "r109", "r111", "r340", "r355" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic EPS (in usd per share)", "verboseLabel": "Basic (in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome", "http://www.amgen.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r66", "r103", "r106", "r107", "r108", "r109", "r111", "r340", "r355" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted EPS (in usd per share)", "verboseLabel": "Diluted (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome", "http://www.amgen.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Earnings per share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r99", "r244", "r245" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]", "terseLabel": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r216" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://www.amgen.com/role/DerivativeInstrumentsSummaryOfIncomeAndExpenseLineItemsDetails", "http://www.amgen.com/role/StockholdersEquityComponentsOfAociDetails", "http://www.amgen.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentAggregateCost": { "auth_ref": [ "r27" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.", "label": "Equity Method Investment, Aggregate Cost", "terseLabel": "Equity Method Investment, Aggregate Cost" } } }, "localname": "EquityMethodInvestmentAggregateCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": { "auth_ref": [ "r157" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.", "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity", "terseLabel": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity" } } }, "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r155" ], "lang": { "en-US": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestmentQuotedMarketValue": { "auth_ref": [ "r158" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.", "label": "Equity Method Investment, Quoted Market Value", "terseLabel": "Equity Method Investments,Quoted Market Price" } } }, "localname": "EquityMethodInvestmentQuotedMarketValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r27", "r125", "r154" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Carrying value of equity method investment" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsFairValueDisclosure": { "auth_ref": [ "r153" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of investments accounted under the equity method.", "label": "Equity Method Investments, Fair Value Disclosure", "terseLabel": "Equity Method Investments, Fair Value Disclosure" } } }, "localname": "EquityMethodInvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r27", "r86", "r94", "r156", "r316" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity Method Investments [Policy Text Block]", "terseLabel": "Equity method investments" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r315" ], "calculation": { "http://www.amgen.com/role/FairValueMeasurementDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI", "terseLabel": "Equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails", "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r152" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Equity securities without readily determinable fair value" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r307", "r308", "r309", "r312" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r231", "r232", "r233", "r308", "r324" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails", "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r311", "r312" ], "lang": { "en-US": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual", "http://www.amgen.com/role/DerivativeInstrumentsHedgedLiabilitiesAndCumulativeAmountDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r311" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Fair value measurement" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurement" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r231", "r232", "r233", "r308", "r325" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "verboseLabel": "Quoted prices in active markets for identical assets (Level 1) [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r231", "r232", "r233", "r308", "r326" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "verboseLabel": "Significant other observable inputs (Level 2) [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r231", "r232", "r233", "r308", "r327" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "verboseLabel": "Significant unobservable inputs (Level 3) [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r310" ], "lang": { "en-US": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual", "http://www.amgen.com/role/DerivativeInstrumentsHedgedLiabilitiesAndCumulativeAmountDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": { "auth_ref": [ "r232", "r306", "r314" ], "lang": { "en-US": { "role": { "documentation": "Fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Measured at Net Asset Value Per Share [Member]", "terseLabel": "Fair Value Measured at Net Asset Value Per Share [Member]" } } }, "localname": "FairValueMeasuredAtNetAssetValuePerShareMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails", "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r277", "r284", "r299" ], "lang": { "en-US": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "terseLabel": "Fair Values Derivatives Balance Sheet Location By Derivative Contract Type By Hedging Designation [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsFairValueOfDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r159", "r160", "r161", "r162", "r163", "r165", "r166", "r167", "r168" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails", "http://www.amgen.com/role/FairValueMeasurementDetailsTextual", "http://www.amgen.com/role/InvestmentsDetails", "http://www.amgen.com/role/InvestmentsFairValuesByClassificationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Finite-Lived Intangible Asset, Useful Life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r185" ], "calculation": { "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r187" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2020" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year", "terseLabel": "Total estimated amortization of finite-lived intangible assets for the six months ending December 31, 2019" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r187" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r187" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r187" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r187" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r180", "r182", "r185", "r189", "r330" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r185", "r330" ], "calculation": { "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross carrying amounts" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r180", "r184" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r185" ], "calculation": { "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Other intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": { "auth_ref": [ "r303" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.", "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months", "terseLabel": "Amounts expected to be reclassified from AOCI into earnings over the next 12 months, foreign currency and cross-currency swaps" } } }, "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.amgen.com/role/FairValueMeasurementDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "verboseLabel": "Foreign currency and cross-currency swap contracts" } } }, "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.amgen.com/role/FairValueMeasurementDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "verboseLabel": "Foreign currency and cross-currency swap contracts" } } }, "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r231", "r290" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign currency contract [Member]", "verboseLabel": "Foreign currency contracts [Member]" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsEffectivePortionOfUnrealizedGainLossDetails", "http://www.amgen.com/role/DerivativeInstrumentsFairValueOfDerivativesDetails", "http://www.amgen.com/role/DerivativeInstrumentsSummaryOfIncomeAndExpenseLineItemsDetails", "http://www.amgen.com/role/FairValueMeasurementDetails", "http://www.amgen.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignGovernmentDebtSecuritiesMember": { "auth_ref": [ "r231", "r360" ], "lang": { "en-US": { "role": { "documentation": "Debt security issued by government not domiciled in United States of America (US).", "label": "Debt Security, Government, Non-US [Member]", "terseLabel": "Other government-related debt securities - Foreign and other [Member]" } } }, "localname": "ForeignGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails", "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForwardContractsMember": { "auth_ref": [ "r288" ], "lang": { "en-US": { "role": { "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.", "label": "Forward Contracts [Member]", "terseLabel": "Forward Contracts [Member]", "verboseLabel": "Foreign currency forward contracts [Member]" } } }, "localname": "ForwardContractsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r173", "r174" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets", "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsGoodwillRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r191" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and other intangible assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r175" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Currency translation adjustment" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsGoodwillRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsGoodwillRollForwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease": { "auth_ref": [ "r296" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk, remaining after discontinued hedge.", "label": "Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)", "terseLabel": "Hedging adjustments on discontinued hedging relationships" } } }, "localname": "HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsHedgedLiabilitiesAndCumulativeAmountDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgedLiabilityFairValueHedge": { "auth_ref": [ "r294" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability hedged in fair value hedging relationship.", "label": "Hedged Liability, Fair Value Hedge", "terseLabel": "Hedged Liability, Fair Value Hedge" } } }, "localname": "HedgedLiabilityFairValueHedge", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual", "http://www.amgen.com/role/DerivativeInstrumentsHedgedLiabilitiesAndCumulativeAmountDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": { "auth_ref": [ "r295" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.", "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)", "terseLabel": "Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities", "verboseLabel": "Fair value adjustments" } } }, "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsHedgedLiabilitiesAndCumulativeAmountDetails", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r275", "r293" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual", "http://www.amgen.com/role/DerivativeInstrumentsFairValueOfDerivativesDetails", "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r275" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual", "http://www.amgen.com/role/DerivativeInstrumentsFairValueOfDerivativesDetails", "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r275" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsCrossCurrencySwapsDetails", "http://www.amgen.com/role/DerivativeInstrumentsEffectivePortionOfUnrealizedGainLossDetails", "http://www.amgen.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In-process Research and Development [Member]" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r98" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "terseLabel": "Income before income taxes", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome", "http://www.amgen.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r194" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r249" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "Income taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r95", "r123", "r248" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Provision for income taxes", "verboseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome", "http://www.amgen.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r89" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r89" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Trade receivables, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r89" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "verboseLabel": "Accrued income taxes, net" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r89" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities, net of acquisition:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r89" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r89" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "verboseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "verboseLabel": "Increase (Decrease) in AOCI [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://www.amgen.com/role/StockholdersEquityComponentsOfAociDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r181", "r188" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-lived Intangible Assets [Line Items]", "terseLabel": "Indefinite-lived Intangible Assets [Line Items]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r188" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived intangible assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r181", "r188" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r178", "r183" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "totalLabel": "Intangible assets, net", "verboseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets", "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r73", "r211" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "negatedTerseLabel": "Interest expense, net", "terseLabel": "Interest expense, net" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome", "http://www.amgen.com/role/DerivativeInstrumentsSummaryOfIncomeAndExpenseLineItemsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r291" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest Expense [Member]", "verboseLabel": "Interest Expense, Net [Member]" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsDetailsTextual" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateFairValueHedgeAssetAtFairValue": { "auth_ref": [ "r282" ], "calculation": { "http://www.amgen.com/role/FairValueMeasurementDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value as of the balance sheet date of all derivative assets designated as interest rate fair value hedging instruments.", "label": "Interest Rate Fair Value Hedge Asset at Fair Value", "terseLabel": "Interest rate swap contracts" } } }, "localname": "InterestRateFairValueHedgeAssetAtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue": { "auth_ref": [ "r282" ], "calculation": { "http://www.amgen.com/role/FairValueMeasurementDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value as of the balance sheet date of all derivative liabilities designated as interest rate fair value hedging instruments.", "label": "Interest Rate Fair Value Hedge Liability at Fair Value", "terseLabel": "Interest rate swap contracts" } } }, "localname": "InterestRateFairValueHedgeLiabilityAtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r289" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "netLabel": "Interest rate swap agreements [Member]", "terseLabel": "Interest Rate Swap [Member]", "verboseLabel": "Interest rate swap contracts [Member]" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual", "http://www.amgen.com/role/DerivativeInstrumentsFairValueOfDerivativesDetails", "http://www.amgen.com/role/DerivativeInstrumentsSummaryOfIncomeAndExpenseLineItemsDetails", "http://www.amgen.com/role/FairValueMeasurementDetails", "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "verboseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r20", "r171" ], "calculation": { "http://www.amgen.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "verboseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r1", "r42", "r170" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.amgen.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Total inventories", "verboseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets", "http://www.amgen.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r22", "r171" ], "calculation": { "http://www.amgen.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "verboseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r21", "r171" ], "calculation": { "http://www.amgen.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "verboseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r363", "r364", "r365", "r366" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r363", "r364", "r365", "r366" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "verboseLabel": "Fair values of available-for-sale interest-bearing security investments by contractual maturity" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r151", "r331", "r345", "r367" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "verboseLabel": "Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r19", "r335", "r351" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r307" ], "calculation": { "http://www.amgen.com/role/FairValueMeasurementDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "verboseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent.", "label": "Liability for Uncertainty in Income Taxes, Noncurrent", "terseLabel": "Long-term tax liabilities" } } }, "localname": "LiabilityForUncertainTaxPositionsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r253" ], "lang": { "en-US": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Licensing Rights [Member]" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount awarded from other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded from Other Party", "terseLabel": "Amount received from settlement" } } }, "localname": "LitigationSettlementAmountAwardedFromOtherParty", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/ContingenciesAndCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR) [Member]" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsScheduleInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r10", "r209", "r334", "r349" ], "calculation": { "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Carrying value of debt", "totalLabel": "Total carrying value of debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "negatedLabel": "Less current portion", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.", "label": "Long-term Debt [Member]", "terseLabel": "Long-term debt [Member]" } } }, "localname": "LongTermDebtMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual", "http://www.amgen.com/role/DerivativeInstrumentsHedgedLiabilitiesAndCumulativeAmountDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Total long-term debt", "verboseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r37" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails", "http://www.amgen.com/role/FinancingArrangementsScheduleInterestRateSwapsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r37", "r206" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails", "http://www.amgen.com/role/FinancingArrangementsScheduleInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r204", "r205" ], "lang": { "en-US": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/ContingenciesAndCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/ContingenciesAndCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r204", "r205" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/ContingenciesAndCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r204", "r205" ], "lang": { "en-US": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/ContingenciesAndCommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyNumberOfPlaintiffs": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.", "label": "Loss Contingency, Number of Plaintiffs", "terseLabel": "Number of plaintiffs" } } }, "localname": "LossContingencyNumberOfPlaintiffs", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/ContingenciesAndCommitmentsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyPatentsAllegedlyInfringedNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of another entity's patents that the entity has allegedly infringed.", "label": "Loss Contingency, Patents Allegedly Infringed, Number", "terseLabel": "Number of patents allegedly infringed upon" } } }, "localname": "LossContingencyPatentsAllegedlyInfringedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/ContingenciesAndCommitmentsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MarketingRelatedIntangibleAssetsMember": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "Marketing-related asset, including, but not limited to, internet domain name, newspaper mast head, and trademark.", "label": "Marketing-Related Intangible Assets [Member]", "terseLabel": "Marketing-Related Rights [Member]" } } }, "localname": "MarketingRelatedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge": { "auth_ref": [ "r304" ], "lang": { "en-US": { "role": { "documentation": "Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.", "label": "Maximum Length of Time, Foreign Currency Cash Flow Hedge", "terseLabel": "Length of time hedged in foreign currency contracts (or less)" } } }, "localname": "MaximumLengthOfTimeForeignCurrencyCashFlowHedge", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetailsTextual" ], "xbrltype": "durationItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r231" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "verboseLabel": "Money market mutual funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails", "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r87" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r87" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r87", "r88", "r91" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "terseLabel": "Net cash provided by operating activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r57", "r60", "r65", "r91", "r110", "r339", "r354" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.amgen.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "netLabel": "Net income", "terseLabel": "Net income for basic and diluted EPS", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.amgen.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome", "http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://www.amgen.com/role/EarningsPerShareDetails", "http://www.amgen.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "verboseLabel": "Income (Numerator):" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Other recent accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "ROW [Member]" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r275" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Derivatives not designated as hedging instrument [Member]" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual", "http://www.amgen.com/role/DerivativeInstrumentsFairValueOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r72" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Interest and other income, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome", "http://www.amgen.com/role/DerivativeInstrumentsSummaryOfIncomeAndExpenseLineItemsDetails", "http://www.amgen.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableFairValueDisclosure": { "auth_ref": [ "r33" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of notes payable.", "label": "Notes Payable, Fair Value Disclosure", "terseLabel": "Long-term debt, fair value" } } }, "localname": "NotesPayableFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Notes Payable, Other Payables [Member]", "terseLabel": "Notes Payable, Other Payables [Member]" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsScheduleInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NotesPayableToBanksMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A written promise to pay a note to a bank.", "label": "Notes Payable to Banks [Member]", "terseLabel": "Notes [Member]" } } }, "localname": "NotesPayableToBanksMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails", "http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/RevenuesDetails", "http://www.amgen.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": { "auth_ref": [ "r55" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "OCI, before Reclassifications, before Tax, Attributable to Parent", "terseLabel": "Unrealized (losses) gains" } } }, "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/StockholdersEquityComponentsOfAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OptionMember": { "auth_ref": [ "r269" ], "lang": { "en-US": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received).", "label": "Options Held [Member]", "verboseLabel": "Foreign currency option contracts [Member]" } } }, "localname": "OptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "verboseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "verboseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r262", "r263", "r265" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "(Losses) gains on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r262", "r263", "r265" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Losses on foreign currency translation", "verboseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "http://www.amgen.com/role/StockholdersEquityComponentsOfAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r53" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "terseLabel": "(Losses) gains on cash flow hedges" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r58", "r61", "r63", "r216" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income (loss), net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r58", "r61", "r262", "r263", "r265" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Other comprehensive (loss) income, net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive (loss) income, net of reclassification adjustments and taxes:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": { "auth_ref": [ "r262", "r263", "r265" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent", "negatedTerseLabel": "Income taxes" } } }, "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/StockholdersEquityComponentsOfAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax": { "auth_ref": [ "r48", "r53", "r302" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax", "verboseLabel": "Total unrealized (losses) gains" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsEffectivePortionOfUnrealizedGainLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r277", "r299" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other current assets [Member]" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsFairValueOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherGeneralExpense": { "auth_ref": [ "r70" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of general expenses not normally included in Other Operating Costs and Expenses.", "label": "Other General Expense", "verboseLabel": "Other" } } }, "localname": "OtherGeneralExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "verboseLabel": "Other noncurrent liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r91" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other items, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r77", "r80", "r101" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r83" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r83" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "auth_ref": [ "r78" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Payments to Acquire Equity Method Investments", "negatedTerseLabel": "Purchases of equity method investments" } } }, "localname": "PaymentsToAcquireEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r133" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r79" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r81" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Proceeds from Issuance of Long-term Debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r75", "r76", "r133" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale", "verboseLabel": "Proceeds from maturities of marketable securities" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r82", "r85", "r101" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "verboseLabel": "Other" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r75", "r76", "r133" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale of Debt Securities, Available-for-sale", "verboseLabel": "Proceeds from sales of marketable securities" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductAndServiceOtherMember": { "auth_ref": [ "r228" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.", "label": "Product and Service, Other [Member]", "terseLabel": "Other revenues [Member]" } } }, "localname": "ProductAndServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome", "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r228" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product sales [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome", "http://www.amgen.com/role/DerivativeInstrumentsSummaryOfIncomeAndExpenseLineItemsDetails", "http://www.amgen.com/role/RevenuesDetails", "http://www.amgen.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r6", "r7", "r193", "r352" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "verboseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r28", "r94", "r193" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Line Items]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": { "auth_ref": [ "r55" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent", "terseLabel": "Reclassification adjustments to income" } } }, "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/StockholdersEquityComponentsOfAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsSummaryOfIncomeAndExpenseLineItemsDetails", "http://www.amgen.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsSummaryOfIncomeAndExpenseLineItemsDetails", "http://www.amgen.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Member]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsSummaryOfIncomeAndExpenseLineItemsDetails", "http://www.amgen.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Reclassifications out of accumulated other comprehensive income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r84" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Repayment of debt", "terseLabel": "Repayments of Long-term Debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.amgen.com/role/FinancingArrangementsDetailsTextual", "http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross": { "auth_ref": [ "r241", "r242" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross", "terseLabel": "Global research and development costs (up to)" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CollaborationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r240", "r370" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CollaborationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r240" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "verboseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResidentialMortgageBackedSecuritiesMember": { "auth_ref": [ "r135", "r231" ], "lang": { "en-US": { "role": { "documentation": "Securities collateralized by residential real estate mortgage loans.", "label": "Residential Mortgage Backed Securities [Member]", "terseLabel": "Residential mortgage-backed securities [Member]" } } }, "localname": "ResidentialMortgageBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails", "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r16", "r223", "r350" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r225", "r226" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Product sales", "verboseLabel": "Total product sales" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome", "http://www.amgen.com/role/DerivativeInstrumentsSummaryOfIncomeAndExpenseLineItemsDetails", "http://www.amgen.com/role/RevenuesDetails", "http://www.amgen.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r230" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/Revenues" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r64", "r120", "r121", "r126" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome", "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "verboseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r55" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Components of accumulated other comprehensive income" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsDetails", "http://www.amgen.com/role/InvestmentsFairValuesByClassificationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r141", "r144", "r146", "r147", "r148", "r150", "r341", "r344" ], "lang": { "en-US": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-sale Securities [Table]", "terseLabel": "Schedule of Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsDetails", "http://www.amgen.com/role/InvestmentsFairValuesByClassificationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r250", "r251" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetailsTextual" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "verboseLabel": "Unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges" } } }, "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r260" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CollaborationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r37", "r97", "r217", "r220", "r221", "r222", "r318", "r319", "r321", "r346" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "verboseLabel": "Schedule of borrowings" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "verboseLabel": "Fair values of derivatives included in the Condensed Consolidated Balance Sheets" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r280" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.", "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]", "terseLabel": "Summary of amounts of income and expense line items" } } }, "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r110" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "verboseLabel": "Computation for basic and diluted earnings per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "auth_ref": [ "r127" ], "lang": { "en-US": { "role": { "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table]", "terseLabel": "Revenue from External Customers by Products and Services [Table]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r307", "r308" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r285" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.", "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]", "terseLabel": "Derivatives in fair value hedging relationships" } } }, "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/DerivativeInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r180", "r184" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r176", "r177" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r188", "r190" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.", "label": "Schedule of Interest Rate Derivatives [Table Text Block]", "terseLabel": "Schedule of interest rate swaps" } } }, "localname": "ScheduleOfInterestRateDerivativesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r5", "r23", "r24", "r25" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "verboseLabel": "Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Net Investment Income [Line Items]", "terseLabel": "Net Investment Income [Line Items]" } } }, "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": { "auth_ref": [ "r71", "r73", "r74", "r356" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.", "label": "Investment Income [Table]", "terseLabel": "Investment Income [Table]" } } }, "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r40", "r96", "r213", "r214", "r215", "r217", "r218", "r219", "r220", "r221", "r222", "r223" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/StockholdersEquityDetailsTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r69", "r169" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "verboseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r102" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Summary of significant accounting policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r11", "r12", "r13", "r216" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r41", "r216" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://www.amgen.com/role/DerivativeInstrumentsSummaryOfIncomeAndExpenseLineItemsDetails", "http://www.amgen.com/role/StockholdersEquityComponentsOfAociDetails", "http://www.amgen.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome", "http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome", "http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r12", "r13", "r216", "r223" ], "lang": { "en-US": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "verboseLabel": "Issuance of common stock in connection with the Company\u2019s equity award programs, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r12", "r13", "r223", "r236", "r237" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock in connection with the Company\u2019s equity award programs" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock repurchase program, additional authorized amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/StockholdersEquityDetailsTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "verboseLabel": "Amount available for stock repurchases under a board approved stock repurchase plan" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/StockholdersEquityDetailsTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "auth_ref": [ "r12", "r13", "r216", "r223" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased and retired during the period.", "label": "Stock Repurchased and Retired During Period, Shares", "negatedTerseLabel": "Repurchases of common stock, Shares" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "auth_ref": [ "r12", "r13", "r216", "r223" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).", "label": "Stock Repurchased and Retired During Period, Value", "negatedTerseLabel": "Repurchases of common stock" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r12", "r13", "r216", "r223" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "terseLabel": "Stock repurchased, Shares" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/StockholdersEquityShareRepurchaseProgramDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r12", "r13", "r216", "r223" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "terseLabel": "Stock repurchased" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/StockholdersEquityShareRepurchaseProgramDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r13", "r17", "r18", "r131" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance as of end of period", "periodStartLabel": "Balance as of beginning of period", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets", "http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://www.amgen.com/role/StockholdersEquityComponentsOfAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r224" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Stockholders' equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "terseLabel": "Other" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/ContingenciesAndCommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r322" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/ContingenciesAndCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r322" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/ContingenciesAndCommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r329" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails", "http://www.amgen.com/role/FairValueMeasurementDetailsTextual", "http://www.amgen.com/role/InvestmentsDetails", "http://www.amgen.com/role/InvestmentsFairValuesByClassificationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r260" ], "lang": { "en-US": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CollaborationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r231", "r336" ], "lang": { "en-US": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "Other government-related debt securities - U.S. [Member]" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails", "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryBillSecuritiesMember": { "auth_ref": [ "r338" ], "lang": { "en-US": { "role": { "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.", "label": "US Treasury Bill Securities [Member]", "terseLabel": "U.S. Treasury bills [Member]" } } }, "localname": "USTreasuryBillSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails", "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r231", "r233", "r336" ], "lang": { "en-US": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasury notes [Member]" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FairValueMeasurementDetails", "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r246" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Increase in unrecognized tax benefits resulting from tax positions taken during the current period" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r113", "r114", "r115", "r116", "r117", "r118", "r119" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "verboseLabel": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsScheduleInterestRateSwapsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/FinancingArrangementsScheduleInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r109" ], "calculation": { "http://www.amgen.com/role/EarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "verboseLabel": "Effect of dilutive securities (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r105", "r109" ], "calculation": { "http://www.amgen.com/role/EarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted-average shares for diluted EPS (in shares)", "verboseLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome", "http://www.amgen.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Shares (Denominator):", "verboseLabel": "Shares used in calculation of earnings per share:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome", "http://www.amgen.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r104", "r109" ], "calculation": { "http://www.amgen.com/role/EarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares for basic EPS (in shares)", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome", "http://www.amgen.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r102": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r112": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=SL6283291-111563" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27340-111563" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563" }, "r151": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117539-209714" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=117311354&loc=d3e32014-111567" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r172": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r191": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r195": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349" }, "r203": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r212": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r249": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5227-128473" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5419-128473" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r261": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "83", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=117415099&loc=d3e34841-113949" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4EE", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109999712-113959" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "4EE", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109999712-113959" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4EE", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109999712-113959" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109978405&loc=d3e80720-113993" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994" }, "r305": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "54B", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117332851&loc=SL7495116-110257" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20,22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r331": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6)(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.6(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r345": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(2)(i))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C(1)(a))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r367": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r371": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r372": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r373": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r374": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r375": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r376": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.6)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=SL94080555-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d),(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" } }, "version": "2.1" } XML 16 R61.htm IDEA: XBRL DOCUMENT v3.20.1
Derivative instruments (Summary of Income and Expense Line Items) (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]    
Interest and other income, net $ 11 $ 185
Interest expense, net (346) (343)
Interest rate swap agreements [Member]    
Derivative Instruments, Gain (Loss) [Line Items]    
Gains (losses) on fair value hedging relationships, Hedged items 210 (130)
Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments (190) 133
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member] | Cross-currency swap contracts [Member]    
Derivative Instruments, Gain (Loss) [Line Items]    
Interest and other income, net (133) (42)
Product sales [Member]    
Derivative Instruments, Gain (Loss) [Line Items]    
Product sales 5,894 5,286
Product sales [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member] | Foreign currency contracts [Member]    
Derivative Instruments, Gain (Loss) [Line Items]    
Product sales $ 49 $ 14
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares
1 Months Ended 3 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Mar. 31, 2020
Mar. 31, 2019
Statement of Stockholders' Equity [Abstract]        
Common stock, dividends declared per share (in usd per share) $ 1.60 $ 1.60 $ 1.60 $ 1.45
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Income - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Revenues:    
Total revenues $ 6,161 $ 5,557
Operating expenses:    
Cost of sales 1,513 1,055
Research and development 952 879
Selling, general and administrative 1,316 1,154
Other 25 (3)
Total operating expenses 3,806 3,085
Operating income 2,355 2,472
Interest expense, net 346 343
Interest and other income, net 11 185
Income before income taxes 2,020 2,314
Provision for income taxes 195 322
Net income $ 1,825 $ 1,992
Earnings per share:    
Basic (in usd per share) $ 3.09 $ 3.20
Diluted (in usd per share) $ 3.07 $ 3.18
Shares used in calculation of earnings per share:    
Basic (in shares) 590 622
Diluted (in shares) 594 626
Product sales [Member]    
Revenues:    
Product sales $ 5,894 $ 5,286
Other revenues [Member]    
Revenues:    
Total revenues $ 267 $ 271
XML 19 R42.htm IDEA: XBRL DOCUMENT v3.20.1
Investments Investments (Limited Partnership Investments) (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2020
Jan. 02, 2020
Dec. 31, 2019
Limited Partnership [Member] | Fair Value Measured at Net Asset Value Per Share [Member]      
Net Investment Income [Line Items]      
Investments $ 331   $ 320
BeiGene [Member]      
Net Investment Income [Line Items]      
Carrying value of equity method investment $ 2,600    
Equity Method Investment, Aggregate Cost   $ 2,800  
Ownership percentage 20.50% 20.50%  
Equity Method Investments,Quoted Market Price   $ 2,600  
Equity Method Investment, Difference Between Carrying Amount and Underlying Equity   $ 2,400  
Equity Method Investments, Fair Value Disclosure $ 2,000    
Minimum [Member] | BeiGene [Member]      
Net Investment Income [Line Items]      
Finite-Lived Intangible Asset, Useful Life 8 years    
Maximum [Member] | BeiGene [Member]      
Net Investment Income [Line Items]      
Finite-Lived Intangible Asset, Useful Life 15 years    
XML 20 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 21 R46.htm IDEA: XBRL DOCUMENT v3.20.1
Goodwill and other intangible assets (Details Textual) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]    
Amortization charges associated with finite-lived intangible assets $ 709 $ 315
Total estimated amortization of finite-lived intangible assets for the six months ending December 31, 2019 2,100  
Total estimated amortization of finite-lived intangible assets for 2020 2,600  
Total estimated amortization of finite-lived intangible assets for 2021 2,500  
Total estimated amortization of finite-lived intangible assets for 2022 2,400  
Total estimated amortization of finite-lived intangible assets for 2023 2,400  
Total estimated amortization of finite-lived intangible assets for 2024 $ 2,200  
XML 24 R57.htm IDEA: XBRL DOCUMENT v3.20.1
Derivative instruments (Details Textual) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]      
Net cash provided by operating activities $ 2,134 $ 1,845  
Foreign currency and cross currency swap contracts [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Amounts expected to be reclassified from AOCI into earnings over the next 12 months, foreign currency and cross-currency swaps (162)    
Derivatives designated as hedging instrument [Member] | Foreign currency forward contracts [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative, notional amount 4,900   $ 5,000
Derivatives designated as hedging instrument [Member] | Interest Rate Swap [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative, notional amount 7,400   9,600
Value of derivative contracts terminated 2,200    
Value of derivative contracts terminated resulting in net cash provided by operating activities 5,200    
Net cash provided by operating activities 576    
Derivatives not designated as hedging instrument [Member] | Foreign currency forward contracts [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative, notional amount 800   1,200
Interest Expense, Net [Member] | Interest Rate Swap [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Gain recognized from termination of contracts 17    
Long-term debt [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Hedged Liability, Fair Value Hedge 7,784   $ 8,814
Long-term debt [Member] | Interest Rate Swap, At-Then Current Interest Rates [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Hedged Liability, Fair Value Hedge $ 5,200    
XML 25 R53.htm IDEA: XBRL DOCUMENT v3.20.1
Stockholders' equity (Components of AOCI) (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Increase (Decrease) in AOCI [Roll Forward]    
Balance as of beginning of period $ 9,673 $ 12,500
Foreign currency translation adjustments (52) (13)
Balance as of end of period 9,485 10,832
Foreign currency translation [Member]    
Increase (Decrease) in AOCI [Roll Forward]    
Balance as of beginning of period (718)  
Foreign currency translation adjustments (52)  
Income taxes 0  
Balance as of end of period (770)  
Cash flow hedges [Member]    
Increase (Decrease) in AOCI [Roll Forward]    
Balance as of beginning of period 175  
Unrealized (losses) gains (162)  
Reclassification adjustments to income 84  
Income taxes (17)  
Balance as of end of period 114  
Available-for-sale securities [Member]    
Increase (Decrease) in AOCI [Roll Forward]    
Balance as of beginning of period 22  
Unrealized (losses) gains 8  
Reclassification adjustments to income (33)  
Income taxes (6)  
Balance as of end of period 3  
Other [Member]    
Increase (Decrease) in AOCI [Roll Forward]    
Balance as of beginning of period (7)  
Unrealized (losses) gains 0  
Other (2)  
Balance as of end of period (9)  
AOCI [Member]    
Increase (Decrease) in AOCI [Roll Forward]    
Balance as of beginning of period (528) (769)
Foreign currency translation adjustments (52)  
Unrealized (losses) gains (154)  
Reclassification adjustments to income 51  
Other (2)  
Income taxes 23  
Balance as of end of period $ (662) $ (516)
XML 26 R9999.htm IDEA: XBRL DOCUMENT v3.20.1
Label Element Value
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ (2,000,000)
Retained Earnings [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ (2,000,000)
XML 27 R32.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of significant accounting policies (Details)
$ in Billions
3 Months Ended
Mar. 31, 2020
USD ($)
segment
Dec. 31, 2019
USD ($)
Accounting Policies [Abstract]    
Number of operating segments | segment 1  
Accumulated depreciation and amortization on property, plant and equipment | $ $ 8.5 $ 8.4
XML 28 R36.htm IDEA: XBRL DOCUMENT v3.20.1
Collaborations (Details) - Collaborative arrangement with BeiGene, Ltd. [Member] - USD ($)
3 Months Ended
Jan. 02, 2020
Mar. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Global research and development costs (up to) $ 1,250,000,000  
Research and development expense   $ 57,000,000
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.20.1
Inventories
3 Months Ended
Mar. 31, 2020
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories consisted of the following (in millions):
 
March 31,
2020
 
December 31,
2019
Raw materials
$
446

 
$
358

Work in process
2,192

 
2,227

Finished goods
1,044

 
999

Total inventories
$
3,682

 
$
3,584


XML 30 R11.htm IDEA: XBRL DOCUMENT v3.20.1
Income taxes
3 Months Ended
Mar. 31, 2020
Income Tax Disclosure [Abstract]  
Income taxes Income taxes
The effective tax rates for the three months ended March 31, 2020 and 2019, were 9.7% and 13.9%, respectively.
The decrease in our effective tax rate for the three months ended March 31, 2020, was due primarily to amortization related to the Otezla® acquisition, changes in jurisdictional mix of earnings and certain favorable items in the quarter. The effective tax rates differ from the federal statutory rate primarily as a result of foreign earnings from the Company’s operations conducted in Puerto Rico, a territory of the United States that is treated as a foreign jurisdiction for U.S. tax purposes and are subject to tax incentive grants through 2035. In addition, the Company’s operations conducted in Singapore are subject to a tax incentive grant through 2034. These earnings are also subject to U.S. tax at a reduced rate of 10.5%.
The U.S. territory of Puerto Rico imposes an excise tax on the gross intercompany purchase price of goods and services from our manufacturer in Puerto Rico. The rate of 4% is effective through December 31, 2027. We account for the excise tax as a manufacturing cost that is capitalized in inventory and expensed in cost of sales when the related products are sold. For U.S. income tax purposes, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred.
One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes may arise with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. As previously disclosed, we received a Revenue Agent Report (RAR) from the Internal Revenue Service (IRS) for the years 2010, 2011 and 2012. The RAR proposes to make significant adjustments that relate primarily to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. In November 2017, we received a modified RAR that revised the IRS’s calculations but continued to propose substantial adjustments. We disagree with the proposed adjustments and calculations and are pursuing resolution with the IRS administrative appeals office, which currently has jurisdiction over the matter. If we deem necessary, we will vigorously contest the proposed adjustments through the judicial process. In addition, in April, we received draft notice of proposed adjustments (NOPAs) from the IRS for the years 2013, 2014 and 2015, which are similar to the proposed adjustments for the years 2010, 2011 and 2012 that relate primarily to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagree with the proposed adjustments and calculations and intend to contest them. We are also currently under examination by a number of other state and foreign tax jurisdictions.
Final resolution of these complex matters is not likely within the next 12 months and could have a material impact on our condensed consolidated financial statements. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes, the ultimate resolution of any tax matters may result in payments substantially greater or less than amounts accrued. We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009.
During the three months ended March 31, 2020, the gross amounts of our unrecognized tax benefits (UTBs) increased $50 million as a result of tax positions taken during the current year. Substantially all of the UTBs as of March 31, 2020, if recognized, would affect our effective tax rate.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.20.1
Fair value measurement
3 Months Ended
Mar. 31, 2020
Fair Value Disclosures [Abstract]  
Fair value measurement Fair value measurement
To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows:
Level 1
Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access
Level 2
Valuations for which all significant inputs are observable either directly or indirectly—other than Level 1 inputs
Level 3
Valuations based on inputs that are unobservable and significant to the overall fair value measurement
The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.
The fair values of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):
 
 
Quoted prices in
active markets for
identical assets
(Level 1)
 
Significant
other observable
inputs
(Level 2)
 
Significant
unobservable
inputs
(Level 3)
 
 
 
 
 
 
 
 
Fair value measurement as of March 31, 2020, using:
 
 
 
 
Total
Assets:
 
 
 
 
 
 
 
 
Available-for-sale securities:
 
 
 
 
 
 
 
 
U.S. Treasury notes
 
$
176

 
$

 
$

 
$
176

U.S. Treasury bills
 
900

 

 

 
900

Corporate debt securities:
 
 
 
 
 
 
 
 
Financial
 

 
12

 

 
12

Industrial
 

 
12

 

 
12

Other
 

 

 

 

Residential-mortgage-backed securities
 

 

 

 

Money market mutual funds
 
5,762

 

 

 
5,762

Other short-term interest-bearing securities
 

 
432

 

 
432

Equity securities
 
220

 

 

 
220

Derivatives:
 
 
 
 
 
 
 
 
Foreign currency contracts
 

 
375

 

 
375

Cross-currency swap contracts
 

 
10

 

 
10

Interest rate swap contracts
 

 
89

 

 
89

Total assets
 
$
7,058

 
$
930

 
$

 
$
7,988

 
 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
 
Derivatives:
 
 
 
 
 
 
 
 
Foreign currency contracts
 
$

 
$
5

 
$

 
$
5

Cross-currency swap contracts
 

 
657

 

 
657

Interest rate swap contracts
 

 
23

 

 
23

Contingent consideration obligations
 

 

 
60

 
60

Total liabilities
 
$

 
$
685

 
$
60

 
$
745


 
 
Quoted prices in
active markets for
identical assets
(Level 1)
 
Significant
other observable
inputs
(Level 2)
 
Significant
unobservable
inputs
(Level 3)
 
 
 
 
 
 
 
 
Fair value measurement as of December 31, 2019, using:
 
 
 
 
Total
Assets:
 
 
 
 
 
 
 
 
Available-for-sale securities:
 
 
 
 
 
 
 
 
U.S. Treasury notes
 
$
360

 
$

 
$

 
$
360

U.S. Treasury bills
 

 

 

 

Corporate debt securities:
 
 
 
 
 
 
 
 
Financial
 

 
1,121

 

 
1,121

Industrial
 

 
834

 

 
834

Other
 

 
198

 

 
198

Residential-mortgage-backed securities
 

 
182

 

 
182

Money market mutual funds
 
5,250

 

 

 
5,250

Other short-term interest-bearing securities
 

 
289

 

 
289

Equity securities
 
303

 

 

 
303

Derivatives:
 
 
 
 
 
 
 
 
Foreign currency contracts
 

 
224

 

 
224

Cross-currency swap contracts
 

 
66

 

 
66

Interest rate swap contracts
 

 
259

 

 
259

Total assets
 
$
5,913

 
$
3,173

 
$

 
$
9,086

 
 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
 
Derivatives:
 
 
 
 
 
 
 
 
Foreign currency contracts
 
$

 
$
31

 
$

 
$
31

Cross-currency swap contracts
 

 
315

 

 
315

Interest rate swap contracts
 

 

 

 

Contingent consideration obligations
 

 

 
61

 
61

Total liabilities
 
$

 
$
346

 
$
61

 
$
407


Interest-bearing and equity securities
The fair values of our U.S. Treasury securities, money market mutual funds and equity securities are based on quoted market prices in active markets, with no valuation adjustment.
As of March 31, 2020, our corporate debt securities are investment grade and have maturity dates of three years or less from the balance sheet date. Our corporate debt securities portfolio has weighted-average credit ratings of BBB or equivalent by Standard & Poor’s Financial Services LLC (S&P), BBB+ by Moody’s Investors Service, Inc. (Moody’s) and A– by Fitch Ratings, Inc. (Fitch). We estimate the fair values of these securities by taking into consideration valuations obtained from third-party pricing services. The pricing services use industry-standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable either directly or indirectly to estimate fair value. The inputs include reported trades of and broker-dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs.
We value our other short-term interest-bearing securities at amortized cost, which approximates fair value given their near-term maturity dates.
Derivatives
All of our foreign currency forward derivative contracts have maturities of three years or less, and all are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts include implied volatility measures. These inputs, when applicable, are at commonly quoted intervals. See Note 12, Derivative instruments.
Our cross-currency swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency-basis swap spreads. See Note 12, Derivative instruments.
Our interest rate swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by using an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include LIBOR, swap rates and obligor credit default swap rates. See Note 12, Derivative instruments.
During the three months ended March 31, 2020 and 2019, there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis.
Summary of the fair values of other financial instruments
Cash equivalents
The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.
Borrowings
We estimated the fair values of our borrowings by using Level 2 inputs. As of March 31, 2020 and December 31, 2019, the aggregate fair values of our borrowings were $35.8 billion and $33.7 billion, respectively, and the carrying values were $31.8 billion and $29.9 billion, respectively.
XML 32 R56.htm IDEA: XBRL DOCUMENT v3.20.1
Fair value measurement (Details Textual) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Business Acquisition [Line Items]    
Length of time hedged in foreign currency contracts (or less) 3 years  
Long-term debt, fair value $ 35,800 $ 33,700
Carrying value of debt $ 31,848 $ 29,903
Other Government-related and Corporate Debt Securities [Member]    
Business Acquisition [Line Items]    
Investment maturity period 3 years  
XML 33 R52.htm IDEA: XBRL DOCUMENT v3.20.1
Stockholders' equity (Details Textual) (Details) - USD ($)
1 Months Ended 3 Months Ended
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Mar. 31, 2020
Mar. 31, 2019
Class of Stock [Line Items]          
Stock repurchase program, additional authorized amount     $ 4,000,000,000.0    
Amount available for stock repurchases under a board approved stock repurchase plan   $ 5,500,000,000   $ 5,500,000,000  
Dividends declared per share (in usd per share)   $ 1.60 $ 1.60 $ 1.60 $ 1.45
Dividends paid per share (in usd per share)   $ 1.60      
Forecast [Member]          
Class of Stock [Line Items]          
Dividends paid per share (in usd per share) $ 1.60        
XML 34 R33.htm IDEA: XBRL DOCUMENT v3.20.1
Revenues (Details)
$ in Millions
3 Months Ended
Mar. 31, 2020
USD ($)
segment
Mar. 31, 2019
USD ($)
Revenue from Contract with Customer [Abstract]    
Number of operating segments | segment 1  
Revenue from External Customer [Line Items]    
Total revenues $ 6,161 $ 5,557
Product sales [Member]    
Revenue from External Customer [Line Items]    
Total product sales 5,894 5,286
Product sales [Member] | US [Member]    
Revenue from External Customer [Line Items]    
Total product sales 4,279 3,991
Product sales [Member] | ROW [Member]    
Revenue from External Customer [Line Items]    
Total product sales 1,615 1,295
Enbrel® (etanercept) [Member]    
Revenue from External Customer [Line Items]    
Total product sales 1,153 1,151
Enbrel® (etanercept) [Member] | US [Member]    
Revenue from External Customer [Line Items]    
Total product sales 1,117 1,106
Enbrel® (etanercept) [Member] | ROW [Member]    
Revenue from External Customer [Line Items]    
Total product sales 36 45
Prolia® (denosumab) [Member]    
Revenue from External Customer [Line Items]    
Total product sales 654 592
Prolia® (denosumab) [Member] | US [Member]    
Revenue from External Customer [Line Items]    
Total product sales 422 390
Prolia® (denosumab) [Member] | ROW [Member]    
Revenue from External Customer [Line Items]    
Total product sales 232 202
Neulasta® (pegfilgrastim) [Member]    
Revenue from External Customer [Line Items]    
Total product sales 609 1,021
Neulasta® (pegfilgrastim) [Member] | US [Member]    
Revenue from External Customer [Line Items]    
Total product sales 534 893
Neulasta® (pegfilgrastim) [Member] | ROW [Member]    
Revenue from External Customer [Line Items]    
Total product sales 75 128
XGEVA® (denosumab) [Member]    
Revenue from External Customer [Line Items]    
Total product sales 481 471
XGEVA® (denosumab) [Member] | US [Member]    
Revenue from External Customer [Line Items]    
Total product sales 355 356
XGEVA® (denosumab) [Member] | ROW [Member]    
Revenue from External Customer [Line Items]    
Total product sales 126 115
Otezla (apremilast) [Member]    
Revenue from External Customer [Line Items]    
Total product sales 479 0
Otezla (apremilast) [Member] | US [Member]    
Revenue from External Customer [Line Items]    
Total product sales 377 0
Otezla (apremilast) [Member] | ROW [Member]    
Revenue from External Customer [Line Items]    
Total product sales 102 0
Aranesp® (darbepoetin alfa) [Member]    
Revenue from External Customer [Line Items]    
Total product sales 422 414
Aranesp® (darbepoetin alfa) [Member] | US [Member]    
Revenue from External Customer [Line Items]    
Total product sales 175 182
Aranesp® (darbepoetin alfa) [Member] | ROW [Member]    
Revenue from External Customer [Line Items]    
Total product sales 247 232
KYPROLIS® (carfilzomib) [Member]    
Revenue from External Customer [Line Items]    
Total product sales 280 245
KYPROLIS® (carfilzomib) [Member] | US [Member]    
Revenue from External Customer [Line Items]    
Total product sales 187 154
KYPROLIS® (carfilzomib) [Member] | ROW [Member]    
Revenue from External Customer [Line Items]    
Total product sales 93 91
Repatha (evolocumab) [Member]    
Revenue from External Customer [Line Items]    
Total product sales 229 141
Repatha (evolocumab) [Member] | US [Member]    
Revenue from External Customer [Line Items]    
Total product sales 124 83
Repatha (evolocumab) [Member] | ROW [Member]    
Revenue from External Customer [Line Items]    
Total product sales 105 58
Other products [Member]    
Revenue from External Customer [Line Items]    
Total product sales 1,587 1,251
Other products [Member] | US [Member]    
Revenue from External Customer [Line Items]    
Total product sales 988 827
Other products [Member] | ROW [Member]    
Revenue from External Customer [Line Items]    
Total product sales 599 424
Other revenues [Member]    
Revenue from External Customer [Line Items]    
Total revenues $ 267 $ 271
XML 35 R37.htm IDEA: XBRL DOCUMENT v3.20.1
Investments (Details) - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Debt Securities, Available-for-sale [Line Items]    
Amortized cost $ 7,291,000,000 $ 8,206,000,000
Gross unrealized gains 3,000,000 28,000,000
Gross unrealized losses 0 0
Fair values 7,294,000,000 8,234,000,000
U.S. Treasury notes [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized cost 173,000,000 359,000,000
Gross unrealized gains 3,000,000 1,000,000
Gross unrealized losses 0 0
Fair values 176,000,000 360,000,000
U.S. Treasury bills [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized cost 900,000,000 0
Gross unrealized gains 0 0
Gross unrealized losses 0 0
Fair values 900,000,000 0
Corporate debt securities - Financial [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized cost 12,000,000 1,108,000,000
Gross unrealized gains 0 13,000,000
Gross unrealized losses 0 0
Fair values 12,000,000 1,121,000,000
Corporate debt securities - Industrial [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized cost 12,000,000 824,000,000
Gross unrealized gains 0 10,000,000
Gross unrealized losses 0 0
Fair values 12,000,000 834,000,000
Corporate debt securities - Other [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized cost 0 195,000,000
Gross unrealized gains 0 3,000,000
Gross unrealized losses 0 0
Fair values 0 198,000,000
Residential mortgage-backed securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized cost 0 181,000,000
Gross unrealized gains 0 1,000,000
Gross unrealized losses 0 0
Fair values 0 182,000,000
Money market mutual funds [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized cost 5,762,000,000 5,250,000,000
Gross unrealized gains 0 0
Gross unrealized losses 0 0
Fair values 5,762,000,000 5,250,000,000
Other short-term interest-bearing securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized cost 432,000,000 289,000,000
Gross unrealized gains 0 0
Gross unrealized losses 0 0
Fair values $ 432,000,000 $ 289,000,000
XML 36 R18.htm IDEA: XBRL DOCUMENT v3.20.1
Stockholders' equity
3 Months Ended
Mar. 31, 2020
Equity [Abstract]  
Stockholders' equity Stockholders’ equity
Stock repurchase program
Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):
 
2020
 
2019
 
Shares
 
Dollars 
 
Shares
 
Dollars
First quarter
4.3

 
$
933

 
15.9

 
$
3,031


In December 2019, our Board of Directors increased the amount authorized under our stock repurchase program by an additional $4.0 billion. As of March 31, 2020, $5.5 billion of authorization remained available under our stock repurchase program.
Dividends
In March 2020, the Board of Directors declared a quarterly cash dividend of $1.60 per share, which will be paid in June 2020. In December 2019, the Board of Directors declared a quarterly cash dividend of $1.60 per share, which was paid in March 2020.
Accumulated other comprehensive income (loss)
The components of Accumulated other comprehensive income (loss) (AOCI) were as follows (in millions):
 
Foreign
currency
translation
 
Cash flow
hedges
 
Available-for-sale
securities
 
Other
 
AOCI
Balance as of December 31, 2019
$
(718
)
 
$
175

 
$
22

 
$
(7
)
 
$
(528
)
Foreign currency translation adjustments
(52
)
 

 

 

 
(52
)
Unrealized (losses) gains

 
(162
)
 
8

 

 
(154
)
Reclassification adjustments to income

 
84

 
(33
)
 

 
51

Other

 

 

 
(2
)
 
(2
)
Income taxes

 
17

 
6

 

 
23

Balance as of March 31, 2020
$
(770
)
 
$
114

 
$
3

 
$
(9
)
 
$
(662
)

Reclassifications out of AOCI and into earnings were as follows (in millions):
 
 
Three months ended March 31,
 
 
Components of AOCI
 
2020
 
2019
 
Condensed Consolidated
Statements of Income locations
Cash flow hedges:
 
 
 
 
 
 
Foreign currency contract gains
 
$
49

 
$
14

 
Product sales
Cross-currency swap contract losses
 
(133
)
 
(42
)
 
Interest and other income, net
 
 
(84
)
 
(28
)
 
Income before income taxes
 
 
18

 
6

 
Provision for income taxes
 
 
$
(66
)
 
$
(22
)
 
Net income
Available-for-sale securities:
 
 
 
 
 
 
Net realized gains (losses)
 
$
33

 
$
(4
)
 
Interest and other income, net
 
 
(7
)
 

 
Provision for income taxes
 
 
$
26

 
$
(4
)
 
Net income

 
 
Three months ended March 31,
 
 

XML 37 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 38 R14.htm IDEA: XBRL DOCUMENT v3.20.1
Investments
3 Months Ended
Mar. 31, 2020
Investments, Debt and Equity Securities [Abstract]  
Investments Investments
Available-for-sale investments
The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions):
Types of securities as of March 31, 2020
 
Amortized
cost
 
Gross
unrealized
gains
 
Gross
unrealized
losses
 
Fair
values
U.S. Treasury notes
 
$
173

 
$
3

 
$

 
$
176

U.S. Treasury bills
 
900

 

 

 
900

Corporate debt securities:
 
 
 
 
 
 
 
 
Financial
 
12

 

 

 
12

Industrial
 
12

 

 

 
12

Other
 

 

 

 

Residential-mortgage-backed securities
 

 

 

 

Money market mutual funds
 
5,762

 

 

 
5,762

Other short-term interest-bearing securities
 
432

 

 

 
432

Total interest-bearing securities
 
$
7,291

 
$
3

 
$

 
$
7,294

Types of securities as of December 31, 2019
 
Amortized
cost
 
Gross
unrealized
gains
 
Gross
unrealized
losses
 
Fair
values
U.S. Treasury notes
 
$
359

 
$
1

 
$

 
$
360

U.S. Treasury bills
 

 

 

 

Corporate debt securities:
 
 
 
 
 
 
 
 
Financial
 
1,108

 
13

 

 
1,121

Industrial
 
824

 
10

 

 
834

Other
 
195

 
3

 

 
198

Residential-mortgage-backed securities
 
181

 
1

 

 
182

Money market mutual funds
 
5,250

 

 

 
5,250

Other short-term interest-bearing securities
 
289

 

 

 
289

Total interest-bearing securities
 
$
8,206

 
$
28

 
$

 
$
8,234


The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions):
Condensed Consolidated Balance Sheets locations
 
March 31,
2020
 
December 31,
2019
Cash and cash equivalents
 
$
6,969

 
$
5,360

Marketable securities
 
325

 
2,874

Total interest-bearing securities
 
$
7,294

 
$
8,234


Cash and cash equivalents in the above table excludes bank account cash of $718 million and $677 million as of March 31, 2020 and December 31, 2019, respectively.
The fair values of interest-bearing securities by contractual maturity, except for residential-mortgage-backed securities that do not have a single maturity date, were as follows (in millions):
Contractual maturities
 
March 31,
2020
 
December 31,
2019
Maturing in one year or less
 
$
7,165

 
$
5,629

Maturing after one year through three years
 
129

 
2,304

Maturing after three years through five years
 

 
119

Residential mortgage-backed securities
 

 
182

Total interest-bearing securities
 
$
7,294

 
$
8,234


For the three months ended March 31, 2020 and 2019, realized gains on interest-bearing securities were $37 million and $1 million, respectively, and realized losses on interest-bearing securities were $4 million and $5 million, respectively. Realized gains and losses on interest-bearing securities are recorded in Interest and other income, net, in the Condensed Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method.
The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.
As of March 31, 2020 and December 31, 2019, aggregated gross unrealized losses of available-for-sale investments were not material, and accordingly, no allowance for credit losses was recorded as of March 31, 2020.
Equity securities
We held investments in equity securities with readily determinable fair values of $220 million and $303 million as of March 31, 2020 and December 31, 2019, respectively, which are included in Other assets in the Condensed Consolidated Balance Sheets. Gains and losses recognized on equity securities with readily determinable fair values, including gains and losses recognized on sales, were not material for the three months ended March 31, 2020 and 2019.
We held investments of $183 million and $176 million in equity securities without readily determinable fair values as of March 31, 2020 and December 31, 2019, respectively, which are included in Other assets in the Condensed Consolidated Balance Sheets. Adjustments to the carrying values of these securities were not material for the three months ended March 31, 2020 and 2019.
Equity method investments
Limited partnerships
We held limited partnership investments of $331 million and $320 million as of March 31, 2020 and December 31, 2019, respectively, which are included in Other assets in the Condensed Consolidated Balance Sheets. These investments, primarily investment funds of early-stage biotechnology companies, are accounted for by using the equity method of accounting and measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of March 31, 2020, unfunded additional commitments to be made for these investments during the next several years were not material. Gains and losses recognized on our limited partnership investments were not material for the three months ended March 31, 2020 and 2019.
BeiGene
On January 2, 2020, we acquired a 20.5% ownership interest in BeiGene for $2.8 billion, of which $2.6 billion was attributed to the fair value of equity securities upon closing, with the remainder attributed to prepaid R&D. Our equity investment in BeiGene is included in Other assets in the Condensed Consolidated Balance Sheets. The fair value of equity securities acquired exceeded our proportionate share of the carrying value of the underlying net assets of BeiGene by approximately $2.4 billion. This investment is accounted for by using the equity method of accounting, which requires us to identify and allocate amounts to the items that give rise to the basis difference and to amortize these items over their useful lives. This amortization, along with our share of the results of operations of BeiGene, will be recognized in Interest and other income, net, in our Condensed Consolidated Statements of Income. Recognition will occur one quarter in arrears, beginning in the second quarter of 2020. The basis difference was allocated to finite-lived intangible assets, indefinite-lived intangible assets, equity-method goodwill and related deferred taxes. The finite-lived intangible assets will be amortized over a period ranging from 8 to 15 years.
As of March 31, 2020, the carrying and fair values of our approximately 20.5% ownership interest in BeiGene totaled $2.6 billion and $2.0 billion, respectively. As of March 31, 2020, we believe the carrying value of our equity investment in BeiGene is fully recoverable. See Note 1, Summary of significant accounting policies, for factors considered in determining our conclusion. For information on a collaboration agreement we entered into with BeiGene in connection with this investment, see Note 5, Collaborations.
XML 39 R10.htm IDEA: XBRL DOCUMENT v3.20.1
Revenues
3 Months Ended
Mar. 31, 2020
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. Rest-of-world (ROW) revenues relate to products that are sold primarily in Europe.
Revenues were as follows (in millions):
 
 
Three months ended March 31,
 
 
2020
 
2019
 
 
US
 
ROW
 
Total
 
US
 
ROW
 
Total
Enbrel® (etanercept)
 
$
1,117

 
$
36

 
$
1,153

 
$
1,106

 
$
45

 
$
1,151

Prolia® (denosumab)
 
422

 
232

 
654

 
390

 
202

 
592

Neulasta® (pegfilgrastim)
 
534

 
75

 
609

 
893

 
128

 
1,021

XGEVA® (denosumab)
 
355

 
126

 
481

 
356

 
115

 
471

Otezla® (apremilast)
 
377

 
102

 
479

 

 

 

Aranesp® (darbepoetin alfa)
 
175

 
247

 
422

 
182

 
232

 
414

KYPROLIS® (carfilzomib)
 
187

 
93

 
280

 
154

 
91

 
245

Repatha® (evolocumab)
 
124

 
105

 
229

 
83

 
58

 
141

Other products
 
988

 
599

 
1,587

 
827

 
424

 
1,251

Total product sales(1)
 
$
4,279

 
$
1,615

 
5,894

 
$
3,991

 
$
1,295

 
5,286

Other revenues
 
 
 
 
 
267

 
 
 
 
 
271

Total revenues
 
 
 
 
 
$
6,161

 
 
 
 
 
$
5,557

____________ 
(1) 
Hedging gains and losses, which are included in product sales, were not material for the three months ended March 31, 2020 and 2019.
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.20.1
Inventories (Tables)
3 Months Ended
Mar. 31, 2020
Inventory Disclosure [Abstract]  
Inventories
Inventories consisted of the following (in millions):
 
March 31,
2020
 
December 31,
2019
Raw materials
$
446

 
$
358

Work in process
2,192

 
2,227

Finished goods
1,044

 
999

Total inventories
$
3,682

 
$
3,584


XML 41 R22.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of significant accounting policies (Policies)
3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Business
Business
Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.
Basis of presentation
Basis of presentation
The financial information for the three months ended March 31, 2020 and 2019, is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year.
The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2019.
Principles of consolidation
Principles of consolidation
The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.
Use of estimates
Use of estimates
The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
Property, plant and equipment, net
Property, plant and equipment, net
Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization of $8.5 billion and $8.4 billion as of March 31, 2020 and December 31, 2019, respectively.
Equity method investments
Equity method investments
The equity method of accounting is used for equity investments that give us the ability to exert significant influence, but not control, over an investee based on such factors as our ownership percentage, voting and other shareholder rights, board of director representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of the investees’ earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Interest and other income, net, in the Condensed Consolidated Statements of Income.
We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors including, but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value.
Other recent accounting pronouncements
Recent accounting pronouncements
In June 2016, the Financial Accounting Standards Board (FASB) issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. We adopted this standard as of January 1, 2020, using a modified-retrospective approach. Adoption of the standard did not have a material impact on our condensed consolidated financial statements.
XML 42 R6.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
shares in Millions, $ in Millions
Total
Number of shares of common stock [Member]
Common stock and additional paid-in capital [Member]
Accumulated deficit [Member]
Accumulated other comprehensive loss [Member]
Beginning Balance, Shares at Dec. 31, 2018   629.6      
Balance as of beginning of period at Dec. 31, 2018 $ 12,500   $ 31,246 $ (17,977) $ (769)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income for basic and diluted EPS 1,992     1,992  
Other comprehensive income (loss), net of taxes 253       253
Dividends declared on common stock (879)     (879)  
Issuance of common stock in connection with the Company’s equity award programs, Shares   0.7      
Issuance of common stock in connection with the Company’s equity award programs 6   6    
Stock-based compensation expense 64   64    
Tax impact related to employee stock-based compensation expense (73)   (73)    
Repurchases of common stock, Shares   (15.9)      
Repurchases of common stock (3,031)     (3,031)  
Ending Balance, Shares at Mar. 31, 2019   614.4      
Balance as of end of period at Mar. 31, 2019 $ 10,832   31,243 (19,895) (516)
Beginning Balance, Shares at Dec. 31, 2019 591.4 591.4      
Balance as of beginning of period at Dec. 31, 2019 $ 9,673   31,531 (21,330) (528)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income for basic and diluted EPS 1,825     1,825  
Other comprehensive income (loss), net of taxes (134)       (134)
Dividends declared on common stock (938)     (938)  
Issuance of common stock in connection with the Company’s equity award programs, Shares   0.9      
Issuance of common stock in connection with the Company’s equity award programs 10   10    
Stock-based compensation expense 52   52    
Tax impact related to employee stock-based compensation expense (68)   (68)    
Repurchases of common stock, Shares   (4.3)      
Repurchases of common stock $ (933)     (933)  
Ending Balance, Shares at Mar. 31, 2020 588.0 588.0      
Balance as of end of period at Mar. 31, 2020 $ 9,485   $ 31,525 $ (21,378) $ (662)
XML 43 R2.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Statement of Comprehensive Income [Abstract]    
Net income $ 1,825 $ 1,992
Other comprehensive (loss) income, net of reclassification adjustments and taxes:    
Losses on foreign currency translation (52) (13)
(Losses) gains on cash flow hedges (61) 45
(Losses) gains on available-for-sale securities (19) 221
Other (2) 0
Other comprehensive (loss) income, net of taxes (134) 253
Comprehensive income $ 1,691 $ 2,245
XML 44 R60.htm IDEA: XBRL DOCUMENT v3.20.1
Derivative instruments (Hedged Liabilities and Cumulative Amount) (Details) - USD ($)
$ in Millions
Mar. 31, 2020
Dec. 31, 2019
Derivative [Line Items]    
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities $ 648 $ 296
Current portion of long-term debt [Member]    
Derivative [Line Items]    
Hedged Liability, Fair Value Hedge 90 903
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities 90 4
Carrying value with discontinued hedging relationships 90  
Hedging adjustments on discontinued hedging relationships 90  
Long-term debt [Member]    
Derivative [Line Items]    
Hedged Liability, Fair Value Hedge 7,784 8,814
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities 558 292
Carrying value with discontinued hedging relationships 592 136
Hedging adjustments on discontinued hedging relationships $ 492 $ 36
XML 45 R43.htm IDEA: XBRL DOCUMENT v3.20.1
Inventories (Details) - USD ($)
$ in Millions
Mar. 31, 2020
Dec. 31, 2019
Inventory Disclosure [Abstract]    
Raw materials $ 446 $ 358
Work in process 2,192 2,227
Finished goods 1,044 999
Total inventories $ 3,682 $ 3,584
XML 46 R47.htm IDEA: XBRL DOCUMENT v3.20.1
Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details)
$ in Millions
3 Months Ended
Mar. 31, 2020
GBP (£)
Mar. 31, 2020
USD ($)
Mar. 31, 2020
CHF (SFr)
Mar. 31, 2020
EUR (€)
Dec. 31, 2019
USD ($)
Debt Instrument [Line Items]          
Unamortized bond discounts, premiums and issuance costs, net   $ (892)     $ (868)
Fair value adjustments   648     296
Total carrying value of debt   31,848     29,903
Less current portion   (1,840)     (2,953)
Total long-term debt   30,008     26,950
Notes [Member]          
Debt Instrument [Line Items]          
Face amount   $ 5,000      
Notes [Member] | 4.50% notes due 2020 (4.50% 2020 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 4.50% 4.50% 4.50% 4.50%  
Long-term debt, gross         300
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 2.125% notes due 2020 (2.125% 2020 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 2.125% 2.125% 2.125% 2.125%  
Long-term debt, gross   $ 750     750
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | Floating Rate Notes Due 2020 [Member]          
Debt Instrument [Line Items]          
Long-term debt, gross   $ 300     300
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 2.20% notes due 2020 (2.20% 2020 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 2.20% 2.20% 2.20% 2.20%  
Long-term debt, gross   $ 700     700
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 3.45% notes due 2020 (3.45% 2020 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 3.45% 3.45% 3.45% 3.45%  
Long-term debt, gross         900
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 4.10% notes due 2021 (4.10% 2021 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 4.10% 4.10% 4.10% 4.10%  
Long-term debt, gross         1,000
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 1.85% notes due 2021 (1.85% 2021 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 1.85% 1.85% 1.85% 1.85%  
Long-term debt, gross   $ 0     750
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 3.875% notes due 2021 (3.875% 2021 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 3.875% 3.875% 3.875% 3.875%  
Long-term debt, gross   $ 1,450     1,750
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 1.25% 1.25% 1.25% 1.25%  
Long-term debt, gross   $ 1,379     1,402
Face amount | €       € 1,250,000,000  
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 2.70% notes due 2022 (2.70% 2022 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 2.70% 2.70% 2.70% 2.70%  
Long-term debt, gross   $ 500     500
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 2.65% notes due 2022 (2.65% 2022 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 2.65% 2.65% 2.65% 2.65%  
Long-term debt, gross   $ 1,500     1,500
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 3.625% notes due 2022 (3.625% 2022 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 3.625% 3.625% 3.625% 3.625%  
Long-term debt, gross   $ 750     750
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 0.41% 0.41% 0.41% 0.41%  
Long-term debt, gross   $ 728     725
Face amount | SFr     SFr 700,000,000    
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 2.25% notes due 2023 (2.25% 2023 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 2.25% 2.25% 2.25% 2.25%  
Long-term debt, gross   $ 750     750
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 3.625% notes due 2024 (3.625% 2024 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 3.625% 3.625% 3.625% 3.625%  
Long-term debt, gross   $ 1,400     1,400
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 1.90% notes due 2025 (1.90% 2025 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 1.90% 1.90% 1.90% 1.90%  
Long-term debt, gross   $ 500      
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 3.125% notes due 2025 (3.125% 2025 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 3.125% 3.125% 3.125% 3.125%  
Long-term debt, gross   $ 1,000     1,000
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 2.00% 2.00% 2.00% 2.00%  
Long-term debt, gross   $ 827     841
Face amount | €       € 750,000,000  
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 2.60% notes due 2026 (2.60% 2026 notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 2.60% 2.60% 2.60% 2.60%  
Long-term debt, gross   $ 1,250     1,250
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 5.50% 5.50% 5.50% 5.50%  
Long-term debt, gross   $ 590     630
Face amount | £ £ 475,000,000        
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 2.20% notes due 2027 (2.20% 2027 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 2.20% 2.20% 2.20% 2.20%  
Long-term debt, gross   $ 750      
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 3.20% notes due 2027 (3.20% 2027 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 3.20% 3.20% 3.20% 3.20%  
Long-term debt, gross   $ 1,000     1,000
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 4.00% 4.00% 4.00% 4.00%  
Long-term debt, gross   $ 869     928
Face amount | £ £ 700,000,000        
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 2.45% notes due 2030 (2.45% 2030 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 2.45% 2.45% 2.45% 2.45%  
Long-term debt, gross   $ 1,250      
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 6.375% notes due 2037 (6.375% 2037 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 6.375% 6.375% 6.375% 6.375%  
Long-term debt, gross   $ 552     552
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 6.90% notes due 2038 (6.90% 2038 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 6.90% 6.90% 6.90% 6.90%  
Long-term debt, gross   $ 291     291
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 6.40% notes due 2039 (6.40% 2039 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 6.40% 6.40% 6.40% 6.40%  
Long-term debt, gross   $ 466     466
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 3.15% notes due 2040 (3.15% 2040 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 3.15% 3.15% 3.15% 3.15%  
Long-term debt, gross   $ 1,250      
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 5.75% notes due 2040 (5.75% 2040 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 5.75% 5.75% 5.75% 5.75%  
Long-term debt, gross   $ 412     412
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 4.95% notes due 2041 (4.95% 2041 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 4.95% 4.95% 4.95% 4.95%  
Long-term debt, gross   $ 600     600
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 5.15% notes due 2041 (5.15% 2041 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 5.15% 5.15% 5.15% 5.15%  
Long-term debt, gross   $ 974     974
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 5.65% notes due 2042 (5.65% 2042 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 5.65% 5.65% 5.65% 5.65%  
Long-term debt, gross   $ 487     487
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 5.375% notes due 2043 (5.375% 2043 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 5.375% 5.375% 5.375% 5.375%  
Long-term debt, gross   $ 261     261
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 4.40% notes due 2045 (4.40% 2045 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 4.40% 4.40% 4.40% 4.40%  
Long-term debt, gross   $ 2,250     2,250
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 4.563% notes due 2048 (4.563% 2048 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 4.563% 4.563% 4.563% 4.563%  
Long-term debt, gross   $ 1,415     1,415
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 3.375% notes due 2050 (3.375% 2050 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 3.375% 3.375% 3.375% 3.375%  
Long-term debt, gross   $ 1,250      
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | 4.663% notes due 2051 (4.663% 2051 Notes) [Member]          
Debt Instrument [Line Items]          
Interest rate, stated percentage 4.663% 4.663% 4.663% 4.663%  
Long-term debt, gross   $ 3,541     3,541
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 101.00%        
Notes [Member] | Other notes due 2097 [Member]          
Debt Instrument [Line Items]          
Long-term debt, gross   $ 100     $ 100
XML 47 R54.htm IDEA: XBRL DOCUMENT v3.20.1
Stockholders' equity (Reclassifications out of AOCI) (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Reclassification out of Accumulated Other Comprehensive Income [Line Items]    
Interest and other income, net $ 11 $ 185
Income before income taxes 2,020 2,314
Provision for income taxes (195) (322)
Net income 1,825 1,992
Product sales [Member]    
Reclassification out of Accumulated Other Comprehensive Income [Line Items]    
Product sales 5,894 5,286
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member]    
Reclassification out of Accumulated Other Comprehensive Income [Line Items]    
Income before income taxes (84) (28)
Provision for income taxes 18 6
Net income (66) (22)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Available-for-sale securities [Member]    
Reclassification out of Accumulated Other Comprehensive Income [Line Items]    
Interest and other income, net 33 (4)
Provision for income taxes (7) 0
Net income 26 (4)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Foreign currency contract [Member] | Cash flow hedges [Member] | Product sales [Member]    
Reclassification out of Accumulated Other Comprehensive Income [Line Items]    
Product sales 49 14
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cross-currency swap contract [Member] | Cash flow hedges [Member]    
Reclassification out of Accumulated Other Comprehensive Income [Line Items]    
Interest and other income, net (133) (42)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member] | Foreign currency contract [Member] | Cash flow hedges [Member] | Product sales [Member]    
Reclassification out of Accumulated Other Comprehensive Income [Line Items]    
Product sales 49 14
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member] | Cross-currency swap contract [Member] | Cash flow hedges [Member]    
Reclassification out of Accumulated Other Comprehensive Income [Line Items]    
Interest and other income, net $ (133) $ (42)
XML 48 R50.htm IDEA: XBRL DOCUMENT v3.20.1
Financing arrangements (Interest Rate Swaps Textual) (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Debt Instrument [Line Items]      
Net cash provided by operating activities $ 2,134 $ 1,845  
Repayments of Long-term Debt $ 3,250 $ 1,000  
4.663% notes due 2051 (4.663% 2051 Notes) [Member]      
Debt Instrument [Line Items]      
Rate difference in an interest rate swap relationship 1.50%    
Notes [Member]      
Debt Instrument [Line Items]      
Face amount $ 5,000    
Notes [Member] | 3.625% notes due 2024 (3.625% 2024 Notes) [Member]      
Debt Instrument [Line Items]      
Interest rate, stated percentage 3.625%    
Notes [Member] | 2.60% notes due 2026 (2.60% 2026 notes) [Member]      
Debt Instrument [Line Items]      
Interest rate, stated percentage 2.60%    
Notes [Member] | 4.663% notes due 2051 (4.663% 2051 Notes) [Member]      
Debt Instrument [Line Items]      
Interest rate, stated percentage 4.663%    
Notes [Member] | 3.625% notes due 2022 (3.625% 2022 Notes) [Member]      
Debt Instrument [Line Items]      
Interest rate, stated percentage 3.625%    
Notes [Member] | 3.125% notes due 2025 (3.125% 2025 Notes) [Member]      
Debt Instrument [Line Items]      
Interest rate, stated percentage 3.125%    
Forward Contracts [Member] | Designated as Hedging Instrument [Member]      
Debt Instrument [Line Items]      
Notional amounts $ 4,900   $ 5,000
Interest Rate Swap [Member] | Designated as Hedging Instrument [Member]      
Debt Instrument [Line Items]      
Notional amounts 7,400   $ 9,600
Value of derivative contracts terminated 2,200    
Net cash provided by operating activities 576    
$2.2 Billion Notional Value Interest Rate Swap [Member] | Forward Contracts [Member] | Designated as Hedging Instrument [Member]      
Debt Instrument [Line Items]      
Value of derivative contracts terminated 2,200    
$5.2 Billion Notional Value Interest Rate Swap, Original [Member] | Forward Contracts [Member] | Designated as Hedging Instrument [Member]      
Debt Instrument [Line Items]      
Value of derivative contracts terminated 5,200    
$5.2 Billion Notional Value Interest Rate Swap [Member] | Forward Contracts [Member] | Designated as Hedging Instrument [Member]      
Debt Instrument [Line Items]      
Notional amounts $ 5,200    
XML 49 R58.htm IDEA: XBRL DOCUMENT v3.20.1
Derivative instruments (Cross-currency Swaps) (Details) - Cash flow hedge [Member] - Cross-currency swap contracts [Member]
€ in Millions, £ in Millions, SFr in Millions, $ in Millions
Mar. 31, 2020
GBP (£)
Mar. 31, 2020
USD ($)
Mar. 31, 2020
CHF (SFr)
Mar. 31, 2020
EUR (€)
1.25% 2022 euro Notes [Member]        
Derivative [Line Items]        
Notional amounts   $ 1,388   € 1,250
0.41% 2023 Swiss franc Bonds [Member]        
Derivative [Line Items]        
Notional amounts   704 SFr 700  
2.00% 2026 euro Notes [Member]        
Derivative [Line Items]        
Notional amounts   833   € 750
5.50% 2026 pound sterling Notes [Member]        
Derivative [Line Items]        
Notional amounts £ 475 747    
4.00% 2029 pound sterling Notes [Member]        
Derivative [Line Items]        
Notional amounts £ 700 $ 1,111    
Euro Member Countries, Euro | 1.25% 2022 euro Notes [Member]        
Derivative [Line Items]        
Interest rates 1.30% 1.30% 1.30% 1.30%
Euro Member Countries, Euro | 2.00% 2026 euro Notes [Member]        
Derivative [Line Items]        
Interest rates 2.00% 2.00% 2.00% 2.00%
Switzerland, Francs | 0.41% 2023 Swiss franc Bonds [Member]        
Derivative [Line Items]        
Interest rates 0.40% 0.40% 0.40% 0.40%
United Kingdom, Pounds | 5.50% 2026 pound sterling Notes [Member]        
Derivative [Line Items]        
Interest rates 5.50% 5.50% 5.50% 5.50%
United Kingdom, Pounds | 4.00% 2029 pound sterling Notes [Member]        
Derivative [Line Items]        
Interest rates 4.00% 4.00% 4.00% 4.00%
United States of America, Dollars | 1.25% 2022 euro Notes [Member]        
Derivative [Line Items]        
Interest rates 3.20% 3.20% 3.20% 3.20%
United States of America, Dollars | 0.41% 2023 Swiss franc Bonds [Member]        
Derivative [Line Items]        
Interest rates 3.40% 3.40% 3.40% 3.40%
United States of America, Dollars | 2.00% 2026 euro Notes [Member]        
Derivative [Line Items]        
Interest rates 3.90% 3.90% 3.90% 3.90%
United States of America, Dollars | 5.50% 2026 pound sterling Notes [Member]        
Derivative [Line Items]        
Interest rates 6.00% 6.00% 6.00% 6.00%
United States of America, Dollars | 4.00% 2029 pound sterling Notes [Member]        
Derivative [Line Items]        
Interest rates 4.50% 4.50% 4.50% 4.50%
XML 50 amgn-2020331x10q_htm.xml IDEA: XBRL DOCUMENT 0000318154 2020-01-01 2020-03-31 0000318154 2019-01-01 2019-12-31 0000318154 2020-04-27 0000318154 amgn:A1.250SeniorNotesDue2022Member exch:XNYS 2020-01-01 2020-03-31 0000318154 amgn:A2.00SeniorNotesDue2026Member exch:XNYS 2020-01-01 2020-03-31 0000318154 us-gaap:CommonStockMember exch:XNGS 2020-01-01 2020-03-31 0000318154 2019-01-01 2019-03-31 0000318154 us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-03-31 0000318154 us-gaap:ProductMember 2019-01-01 2019-03-31 0000318154 us-gaap:ProductAndServiceOtherMember 2019-01-01 2019-03-31 0000318154 us-gaap:ProductMember 2020-01-01 2020-03-31 0000318154 2019-12-31 0000318154 2020-03-31 0000318154 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000318154 us-gaap:CommonStockMember 2019-03-31 0000318154 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2018-12-31 0000318154 us-gaap:CommonStockMember 2018-12-31 0000318154 2018-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-03-31 0000318154 us-gaap:RetainedEarningsMember 2019-03-31 0000318154 2019-03-31 0000318154 us-gaap:RetainedEarningsMember 2018-12-31 0000318154 us-gaap:CommonStockMember 2020-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000318154 us-gaap:RetainedEarningsMember 2020-01-01 0000318154 2020-01-01 0000318154 us-gaap:CommonStockMember 2019-12-31 0000318154 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000318154 us-gaap:RetainedEarningsMember 2019-12-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2020-03-31 0000318154 us-gaap:RetainedEarningsMember 2020-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000318154 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000318154 amgn:NeulastaMember 2020-01-01 2020-03-31 0000318154 amgn:EnbrelMember 2020-01-01 2020-03-31 0000318154 amgn:KyprolisMember 2019-01-01 2019-03-31 0000318154 amgn:RepathaevolocumabMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000318154 amgn:RepathaevolocumabMember 2019-01-01 2019-03-31 0000318154 amgn:AranespMember country:US 2020-01-01 2020-03-31 0000318154 amgn:EnbrelMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000318154 amgn:OtherProductsMember 2019-01-01 2019-03-31 0000318154 amgn:XgevaMember country:US 2020-01-01 2020-03-31 0000318154 amgn:AranespMember 2020-01-01 2020-03-31 0000318154 amgn:RepathaevolocumabMember country:US 2020-01-01 2020-03-31 0000318154 amgn:RepathaevolocumabMember 2020-01-01 2020-03-31 0000318154 amgn:OtezlaMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000318154 amgn:XgevaMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000318154 amgn:KyprolisMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000318154 amgn:NeulastaMember 2019-01-01 2019-03-31 0000318154 us-gaap:ProductMember country:US 2019-01-01 2019-03-31 0000318154 amgn:OtezlaMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000318154 us-gaap:ProductMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000318154 amgn:AranespMember country:US 2019-01-01 2019-03-31 0000318154 amgn:EnbrelMember country:US 2019-01-01 2019-03-31 0000318154 amgn:ProliaMember country:US 2020-01-01 2020-03-31 0000318154 amgn:AranespMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000318154 amgn:ProliaMember country:US 2019-01-01 2019-03-31 0000318154 amgn:KyprolisMember 2020-01-01 2020-03-31 0000318154 amgn:KyprolisMember country:US 2020-01-01 2020-03-31 0000318154 amgn:AranespMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000318154 amgn:XgevaMember 2019-01-01 2019-03-31 0000318154 amgn:EnbrelMember country:US 2020-01-01 2020-03-31 0000318154 amgn:OtherProductsMember country:US 2019-01-01 2019-03-31 0000318154 us-gaap:ProductMember country:US 2020-01-01 2020-03-31 0000318154 amgn:EnbrelMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000318154 amgn:ProliaMember 2019-01-01 2019-03-31 0000318154 amgn:NeulastaMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000318154 amgn:OtherProductsMember 2020-01-01 2020-03-31 0000318154 amgn:ProliaMember 2020-01-01 2020-03-31 0000318154 amgn:XgevaMember country:US 2019-01-01 2019-03-31 0000318154 amgn:ProliaMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000318154 amgn:RepathaevolocumabMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000318154 amgn:OtezlaMember country:US 2020-01-01 2020-03-31 0000318154 amgn:NeulastaMember country:US 2019-01-01 2019-03-31 0000318154 us-gaap:ProductMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000318154 amgn:XgevaMember 2020-01-01 2020-03-31 0000318154 amgn:KyprolisMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000318154 amgn:ProliaMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000318154 amgn:OtherProductsMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000318154 amgn:OtezlaMember country:US 2019-01-01 2019-03-31 0000318154 amgn:OtezlaMember 2020-01-01 2020-03-31 0000318154 amgn:OtezlaMember 2019-01-01 2019-03-31 0000318154 amgn:OtherProductsMember country:US 2020-01-01 2020-03-31 0000318154 amgn:NeulastaMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000318154 amgn:AranespMember 2019-01-01 2019-03-31 0000318154 amgn:EnbrelMember 2019-01-01 2019-03-31 0000318154 amgn:OtherProductsMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000318154 amgn:RepathaevolocumabMember country:US 2019-01-01 2019-03-31 0000318154 amgn:XgevaMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000318154 amgn:KyprolisMember country:US 2019-01-01 2019-03-31 0000318154 amgn:NeulastaMember country:US 2020-01-01 2020-03-31 0000318154 amgn:BeiGeneMember 2020-01-01 2020-03-31 0000318154 amgn:BeiGeneMember 2020-01-02 2020-01-02 0000318154 us-gaap:USTreasurySecuritiesMember 2020-03-31 0000318154 amgn:OtherShortTermInterestBearingSecuritiesMember 2020-03-31 0000318154 us-gaap:USTreasuryBillSecuritiesMember 2020-03-31 0000318154 us-gaap:MoneyMarketFundsMember 2020-03-31 0000318154 amgn:CorporateDebtSecuritiesFinancialMember 2020-03-31 0000318154 us-gaap:ResidentialMortgageBackedSecuritiesMember 2020-03-31 0000318154 amgn:CorporateDebtSecuritiesOtherMember 2020-03-31 0000318154 amgn:CorporateDebtSecuritiesIndustrialMember 2020-03-31 0000318154 srt:MaximumMember amgn:BeiGeneMember 2020-01-01 2020-03-31 0000318154 amgn:BeiGeneMember 2020-03-31 0000318154 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember srt:PartnershipInterestMember 2020-03-31 0000318154 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember srt:PartnershipInterestMember 2019-12-31 0000318154 amgn:BeiGeneMember 2020-01-02 0000318154 srt:MinimumMember amgn:BeiGeneMember 2020-01-01 2020-03-31 0000318154 amgn:CorporateDebtSecuritiesFinancialMember 2019-12-31 0000318154 amgn:OtherShortTermInterestBearingSecuritiesMember 2019-12-31 0000318154 amgn:CorporateDebtSecuritiesOtherMember 2019-12-31 0000318154 us-gaap:ResidentialMortgageBackedSecuritiesMember 2019-12-31 0000318154 us-gaap:USTreasurySecuritiesMember 2019-12-31 0000318154 us-gaap:MoneyMarketFundsMember 2019-12-31 0000318154 us-gaap:USTreasuryBillSecuritiesMember 2019-12-31 0000318154 amgn:CorporateDebtSecuritiesIndustrialMember 2019-12-31 0000318154 amgn:AvailableForSalesInvestmentsMember 2019-12-31 0000318154 amgn:AvailableForSalesInvestmentsMember 2020-03-31 0000318154 us-gaap:LicensingAgreementsMember 2019-12-31 0000318154 us-gaap:DevelopedTechnologyRightsMember 2020-03-31 0000318154 us-gaap:InProcessResearchAndDevelopmentMember 2019-12-31 0000318154 amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember 2019-12-31 0000318154 us-gaap:MarketingRelatedIntangibleAssetsMember 2020-03-31 0000318154 us-gaap:MarketingRelatedIntangibleAssetsMember 2019-12-31 0000318154 us-gaap:InProcessResearchAndDevelopmentMember 2020-03-31 0000318154 us-gaap:LicensingAgreementsMember 2020-03-31 0000318154 us-gaap:DevelopedTechnologyRightsMember 2019-12-31 0000318154 amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember 2020-03-31 0000318154 amgn:ThreePointEightSevenFivePercentNotesDue2021Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:SixPointNineZeroPercentNotesDue2038Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:FourPointOneZeroPercentNotesDue2021Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:ThreePointOneFivePercentNotesDue2040Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:FivePointSixFivePercentNotesDue2042Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:TwoPointSixFiveNotesDue2022Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:TwoPointTwoZeroNotesDue2020Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:OnePointEightFivePercentNotesDueTwoZeroTwoOneMember us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2022Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:FivePointSevenFivePercentNotesDue2040Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:FivePointSixFivePercentNotesDue2042Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:FourPointNineFivePercentNotesDue2041Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:FivePointSevenFivePercentNotesDue2040Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:SixPointThreeSevenFivePercentNotesDue2037Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:FivePointThreeSevenFivePercentNotesDue2043Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:ThreePointTwoZeroNotesDue2027Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:OtherNotesDue2097Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:TwoPointFourFivePercentNotesDue2030Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2024Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2024Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:TwoPointTwoZeroNotesDue2020Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:FourPercentPoundSterlingNotesDue2029Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:SixPointThreeSevenFivePercentNotesDue2037Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:SixPointFourZeroPercentNotesDue2039Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:ThreePointFourFivePercentNotesDue2020Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:FivePointOneFivePercentNotesDue2041Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:SixPointFourZeroPercentNotesDue2039Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:FivePointOneFivePercentNotesDue2041Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:FourPercentPoundSterlingNotesDue2029Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:FourPointNineFivePercentNotesDue2041Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:TwoPointSixFiveNotesDue2022Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:ThreePointThreeSevenFivePercentNotesDue2050Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2022Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:FloatingRateNotesDue2020Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:SixPointNineZeroPercentNotesDue2038Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:OnePointEightFivePercentNotesDueTwoZeroTwoOneMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:FourPointFiveZeroPercentNotesDue2020Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:FloatingRateNotesDue2020Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:FivePointThreeSevenFivePercentNotesDue2043Member us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:ThreePointTwoZeroNotesDue2027Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:ThreePointEightSevenFivePercentNotesDue2021Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember us-gaap:NotesPayableToBanksMember 2019-12-31 0000318154 amgn:OtherNotesDue2097Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2022Member us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0000318154 amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember us-gaap:NotesPayableOtherPayablesMember 2020-03-31 0000318154 amgn:ThreePointEightSevenFivePercentNotesDue2021Member us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0000318154 amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0000318154 amgn:ThreePointEightSevenFivePercentNotesDue2021Member us-gaap:NotesPayableOtherPayablesMember 2020-03-31 0000318154 us-gaap:NotesPayableOtherPayablesMember 2020-03-31 0000318154 amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember us-gaap:NotesPayableOtherPayablesMember 2020-03-31 0000318154 amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0000318154 amgn:ThreePointFourFivePercentNotesDue2020Member us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0000318154 amgn:FourPointOneZeroPercentNotesDue2021Member us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2024Member us-gaap:NotesPayableOtherPayablesMember 2020-03-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2024Member us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0000318154 amgn:FourPointOneZeroPercentNotesDue2021Member us-gaap:NotesPayableOtherPayablesMember 2020-03-31 0000318154 amgn:ThreePointFourFivePercentNotesDue2020Member us-gaap:NotesPayableOtherPayablesMember 2020-03-31 0000318154 amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0000318154 amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember us-gaap:NotesPayableOtherPayablesMember 2020-03-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2022Member us-gaap:NotesPayableOtherPayablesMember 2020-03-31 0000318154 us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0000318154 amgn:FourPointOneZeroPercentNotesDue2021Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 us-gaap:ForwardContractsMember us-gaap:DesignatedAsHedgingInstrumentMember amgn:InterestRateSwapThreeMember 2020-03-31 0000318154 amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember 2020-01-01 2020-03-31 0000318154 us-gaap:InterestExpenseMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 srt:MinimumMember us-gaap:DebtSecuritiesPayableMember 2020-01-01 2020-03-31 0000318154 amgn:ThreePointFourFivePercentNotesDue2020Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 srt:MaximumMember us-gaap:DebtSecuritiesPayableMember 2020-01-01 2020-03-31 0000318154 amgn:ThreePointEightSevenFivePercentNotesDue2021Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 us-gaap:ForwardContractsMember us-gaap:DesignatedAsHedgingInstrumentMember amgn:InterestRateSwapOneMember 2020-03-31 0000318154 amgn:FourPointFiveZeroPercentNotesDue2020Member us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-03-31 0000318154 us-gaap:NotesPayableToBanksMember 2020-03-31 0000318154 us-gaap:ForwardContractsMember us-gaap:DesignatedAsHedgingInstrumentMember amgn:InterestRateSwapTwoMember 2020-03-31 0000318154 amgn:FourPointNineFivePercentNotesDue2041Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:FivePointOneFivePercentNotesDue2041Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2024Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:TwoPointTwoZeroNotesDue2020Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:ThreePointOneFivePercentNotesDue2040Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:FloatingRateNotesDue2020Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:FourPointFiveZeroPercentNotesDue2020Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:FivePointSixFivePercentNotesDue2042Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:OnePointEightFivePercentNotesDueTwoZeroTwoOneMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:TwoPointSixFiveNotesDue2022Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2022Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:ThreePointFourFivePercentNotesDue2020Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:ThreePointTwoZeroNotesDue2027Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:FourPercentPoundSterlingNotesDue2029Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:FivePointThreeSevenFivePercentNotesDue2043Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:FivePointSevenFivePercentNotesDue2040Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:SixPointFourZeroPercentNotesDue2039Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:FourPointOneZeroPercentNotesDue2021Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:ThreePointThreeSevenFivePercentNotesDue2050Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:SixPointThreeSevenFivePercentNotesDue2037Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:TwoPointFourFivePercentNotesDue2030Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:SixPointNineZeroPercentNotesDue2038Member us-gaap:NotesPayableToBanksMember 2020-01-01 2020-03-31 0000318154 amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-03-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2024Member us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-12-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2022Member us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-03-31 0000318154 amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-03-31 0000318154 amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-12-31 0000318154 amgn:ThreePointEightSevenFivePercentNotesDue2021Member us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-12-31 0000318154 amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-03-31 0000318154 amgn:FourPointOneZeroPercentNotesDue2021Member us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-03-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2024Member us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-03-31 0000318154 amgn:ThreePointEightSevenFivePercentNotesDue2021Member us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-03-31 0000318154 amgn:ThreePointFourFivePercentNotesDue2020Member us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-12-31 0000318154 amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-12-31 0000318154 amgn:ThreePointFourFivePercentNotesDue2020Member us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-03-31 0000318154 amgn:FourPointOneZeroPercentNotesDue2021Member us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-12-31 0000318154 amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-12-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2022Member us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-12-31 0000318154 2020-03-01 2020-03-31 0000318154 2019-12-01 2019-12-31 0000318154 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0000318154 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-03-31 0000318154 amgn:AccumulatedOtherAdjustmentAttributabletoParentMember 2020-03-31 0000318154 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000318154 amgn:AccumulatedOtherAdjustmentAttributabletoParentMember 2020-01-01 2020-03-31 0000318154 amgn:AccumulatedOtherAdjustmentAttributabletoParentMember 2019-12-31 0000318154 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-03-31 0000318154 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-03-31 0000318154 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-31 0000318154 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-03-31 0000318154 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0000318154 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-31 0000318154 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-03-31 0000318154 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0000318154 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0000318154 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-03-31 0000318154 us-gaap:ProductMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0000318154 us-gaap:ProductMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0000318154 srt:ScenarioForecastMember 2020-06-01 2020-06-30 0000318154 us-gaap:FairValueInputsLevel3Member 2020-03-31 0000318154 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member 2020-03-31 0000318154 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2020-03-31 0000318154 us-gaap:FairValueInputsLevel2Member 2020-03-31 0000318154 us-gaap:FairValueInputsLevel1Member amgn:CorporateDebtSecuritiesOtherMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2020-03-31 0000318154 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2020-03-31 0000318154 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member 2020-03-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:FairValueInputsLevel1Member 2020-03-31 0000318154 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel1Member 2020-03-31 0000318154 us-gaap:FairValueInputsLevel1Member amgn:OtherShortTermInterestBearingSecuritiesMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel2Member amgn:CorporateDebtSecuritiesIndustrialMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel3Member amgn:CorporateDebtSecuritiesFinancialMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel1Member amgn:CorporateDebtSecuritiesFinancialMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel2Member amgn:CorporateDebtSecuritiesFinancialMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel3Member amgn:CorporateDebtSecuritiesOtherMember 2020-03-31 0000318154 us-gaap:InterestRateSwapMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel1Member amgn:CorporateDebtSecuritiesIndustrialMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel3Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryBillSecuritiesMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel3Member amgn:CorporateDebtSecuritiesIndustrialMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryBillSecuritiesMember 2020-03-31 0000318154 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member 2020-03-31 0000318154 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member 2020-03-31 0000318154 us-gaap:FairValueInputsLevel2Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2020-03-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:FairValueInputsLevel2Member 2020-03-31 0000318154 amgn:CrossCurrencySwapContractsMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel3Member amgn:OtherShortTermInterestBearingSecuritiesMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel1Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2020-03-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:FairValueInputsLevel3Member 2020-03-31 0000318154 us-gaap:FairValueInputsLevel2Member amgn:OtherShortTermInterestBearingSecuritiesMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel2Member amgn:CorporateDebtSecuritiesOtherMember 2020-03-31 0000318154 us-gaap:ForeignExchangeContractMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBillSecuritiesMember 2020-03-31 0000318154 us-gaap:FairValueInputsLevel3Member 2019-12-31 0000318154 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000318154 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000318154 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2019-12-31 0000318154 amgn:CrossCurrencySwapContractsMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel1Member 2019-12-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000318154 us-gaap:FairValueInputsLevel2Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel3Member amgn:CorporateDebtSecuritiesIndustrialMember 2019-12-31 0000318154 us-gaap:ForeignExchangeContractMember 2019-12-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000318154 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000318154 us-gaap:FairValueInputsLevel3Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel1Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel2Member amgn:OtherShortTermInterestBearingSecuritiesMember 2019-12-31 0000318154 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000318154 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel1Member amgn:CorporateDebtSecuritiesFinancialMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel2Member amgn:CorporateDebtSecuritiesIndustrialMember 2019-12-31 0000318154 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000318154 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryBillSecuritiesMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel1Member amgn:OtherShortTermInterestBearingSecuritiesMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryBillSecuritiesMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel2Member 2019-12-31 0000318154 us-gaap:FairValueInputsLevel2Member amgn:CorporateDebtSecuritiesOtherMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBillSecuritiesMember 2019-12-31 0000318154 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000318154 us-gaap:FairValueInputsLevel3Member amgn:OtherShortTermInterestBearingSecuritiesMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel3Member amgn:CorporateDebtSecuritiesOtherMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2019-12-31 0000318154 us-gaap:InterestRateSwapMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel3Member amgn:CorporateDebtSecuritiesFinancialMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel1Member amgn:CorporateDebtSecuritiesOtherMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel1Member amgn:CorporateDebtSecuritiesIndustrialMember 2019-12-31 0000318154 us-gaap:FairValueInputsLevel2Member amgn:CorporateDebtSecuritiesFinancialMember 2019-12-31 0000318154 amgn:OtherGovernmentRelatedAndCorporateDebtSecuritiesMember 2020-01-01 2020-03-31 0000318154 amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 currency:USD amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 currency:CHF amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 currency:EUR amgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 currency:USD amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 currency:USD amgn:FourPercentPoundSterlingNotesDue2029Member amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 amgn:FourPercentPoundSterlingNotesDue2029Member amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 currency:EUR amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 currency:GBP amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 currency:USD amgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 currency:GBP amgn:FourPercentPoundSterlingNotesDue2029Member amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 amgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 currency:USD amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-03-31 0000318154 us-gaap:InterestRateSwapMember 2019-01-01 2019-03-31 0000318154 us-gaap:ProductMember us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0000318154 us-gaap:LongTermDebtMember 2019-12-31 0000318154 amgn:LongTermDebtCurrentMaturitiesMember 2019-12-31 0000318154 us-gaap:LongTermDebtMember 2020-03-31 0000318154 amgn:LongTermDebtCurrentMaturitiesMember 2020-03-31 0000318154 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000318154 us-gaap:ForwardContractsMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000318154 amgn:InterestRateSwapAtThenCurrentInterestRatesMember us-gaap:LongTermDebtMember 2020-03-31 0000318154 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember 2020-03-31 0000318154 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember 2019-12-31 0000318154 us-gaap:ForwardContractsMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000318154 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000318154 amgn:ForeignCurrencyAndCrossCurrencySwapsMember 2020-03-31 0000318154 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2020-01-01 2020-03-31 0000318154 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2019-01-01 2019-03-31 0000318154 us-gaap:CashFlowHedgingMember 2019-01-01 2019-03-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2020-01-01 2020-03-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2019-01-01 2019-03-31 0000318154 us-gaap:CashFlowHedgingMember 2020-01-01 2020-03-31 0000318154 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2020-01-01 2020-03-31 0000318154 us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000318154 amgn:OtherCurrentNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000318154 amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember amgn:CrossCurrencySwapContractsMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000318154 amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000318154 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-12-31 0000318154 amgn:OtherCurrentNoncurrentAssetsMember amgn:CrossCurrencySwapContractsMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000318154 us-gaap:NondesignatedMember 2019-12-31 0000318154 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-12-31 0000318154 amgn:OtherCurrentNoncurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000318154 amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000318154 amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000318154 amgn:OtherCurrentNoncurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000318154 amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember amgn:CrossCurrencySwapContractsMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000318154 us-gaap:NondesignatedMember 2020-03-31 0000318154 amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000318154 us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000318154 amgn:OtherCurrentNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000318154 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2020-03-31 0000318154 amgn:OtherCurrentNoncurrentAssetsMember amgn:CrossCurrencySwapContractsMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000318154 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2020-03-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0000318154 us-gaap:ProductMember us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0000318154 us-gaap:InterestRateSwapMember 2020-01-01 2020-03-31 0000318154 amgn:HospiraMember 2020-03-23 2020-03-23 0000318154 amgn:HospiraMember us-gaap:SubsequentEventMember 2020-04-17 2020-04-17 iso4217:GBP iso4217:USD amgn:segment iso4217:USD shares iso4217:CHF pure iso4217:EUR shares 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 false --12-31 Q1 2020 0000318154 1.60 1.60 1.45 1.60 0.0001 0.0001 2750000000 2750000000 591400000 588000000 475000000 700000000 1250000000 750000000 700000000 0.0550 0.0515 0.0575 0.0565 0.05375 0.0400 0.0450 0.0440 0.0495 0.041 0.0410 0.04663 0.0125 0.0640 0.0690 0.06375 0.03875 0.0345 0.03125 0.03625 0.03625 0.0320 0.0200 0.02125 0.0270 0.0265 0.026 0.0260 0.0225 0.0220 0.0041 0.017 0.000 0.020 0.011 0.009 0.016 0.014 0.003 0.017 0.026 0.020 0.011 0.018 0.027 0.032 0.018 10-Q true 2020-03-31 false 001-37702 Amgen Inc. DE 95-3540776 One Amgen Center Drive 91320-1799 Thousand Oaks CA 805 447-1000 Common stock, $0.0001 par value AMGN NASDAQ 1.250% Senior Notes Due 2022 AMGN22 NYSE 2.00% Senior Notes Due 2026 AMGN26 NYSE Yes Yes Large Accelerated Filer false false false 588247399 5894000000 5286000000 267000000 271000000 6161000000 5557000000 1513000000 1055000000 952000000 879000000 1316000000 1154000000 25000000 -3000000 3806000000 3085000000 2355000000 2472000000 346000000 343000000 11000000 185000000 2020000000 2314000000 195000000 322000000 1825000000 1992000000 3.09 3.20 3.07 3.18 590000000 622000000 594000000 626000000 1825000000 1992000000 -52000000 -13000000 -61000000 45000000 -19000000 221000000 -2000000 0 -134000000 253000000 1691000000 2245000000 7687000000 6037000000 325000000 2874000000 5009000000 4057000000 3682000000 3584000000 2110000000 1888000000 18813000000 18440000000 4879000000 4928000000 18653000000 19413000000 14683000000 14703000000 4641000000 2223000000 61669000000 59707000000 1338000000 1371000000 8649000000 8511000000 1840000000 2953000000 11827000000 12835000000 30008000000 26950000000 427000000 606000000 8111000000 8037000000 1811000000 1606000000 31525000000 31531000000 -21378000000 -21330000000 -662000000 -528000000 9485000000 9673000000 61669000000 59707000000 591400000 31531000000 -21330000000 -528000000 9673000000 -2000000 -2000000 1825000000 1825000000 -134000000 -134000000 938000000 938000000 900000 10000000 10000000 52000000 52000000 -68000000 -68000000 4300000 933000000 933000000 588000000.0 31525000000 -21378000000 -662000000 9485000000 629600000 31246000000 -17977000000 -769000000 12500000000 1992000000 1992000000 253000000 253000000 879000000 879000000 700000 6000000 6000000 64000000 64000000 -73000000 -73000000 15900000 3031000000 3031000000 614400000 31243000000 -19895000000 -516000000 10832000000 1825000000 1992000000 897000000 495000000 -84000000 -50000000 -107000000 -24000000 955000000 207000000 113000000 28000000 -319000000 249000000 -25000000 -112000000 137000000 277000000 74000000 100000000 -48000000 -397000000 2134000000 1845000000 129000000 6898000000 2574000000 125000000 113000000 10455000000 142000000 116000000 2645000000 5000000 1000000 6000000 -230000000 3555000000 4963000000 0 3250000000 1000000000 961000000 3032000000 945000000 901000000 -61000000 -54000000 -254000000 -4987000000 1650000000 413000000 6037000000 6945000000 7687000000 7358000000 Summary of significant accounting policies<div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Business</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> business segment: human therapeutics.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of presentation</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The financial information for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of consolidation</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Use of estimates</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Property, plant and equipment, net</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.5 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$8.4 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Equity method investments</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The equity method of accounting is used for equity investments that give us the ability to exert significant influence, but not control, over an investee based on such factors as our ownership percentage, voting and other shareholder rights, board of director representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of the investees’ earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Interest and other income, net, in the Condensed Consolidated Statements of Income.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors including, but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Recent accounting pronouncements</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the Financial Accounting Standards Board (FASB) issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. We adopted this standard as of January 1, 2020, using a modified-retrospective approach. Adoption of the standard did not have a material impact on our condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens of the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity may change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022, as a result of reference rate reform. We are currently evaluating the impact that this new standard will have on our condensed consolidated financial statements.</span></div> <div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Business</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> business segment: human therapeutics.</span></div> 1 <div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of presentation</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The financial information for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div> <div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of consolidation</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.</span></div> <div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Use of estimates</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.</span></div> <div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Property, plant and equipment, net</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.5 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$8.4 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div> 8500000000 8400000000 <div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Equity method investments</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The equity method of accounting is used for equity investments that give us the ability to exert significant influence, but not control, over an investee based on such factors as our ownership percentage, voting and other shareholder rights, board of director representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of the investees’ earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Interest and other income, net, in the Condensed Consolidated Statements of Income.</span></div>We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors including, but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value. <div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Recent accounting pronouncements</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the Financial Accounting Standards Board (FASB) issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. We adopted this standard as of January 1, 2020, using a modified-retrospective approach. Adoption of the standard did not have a material impact on our condensed consolidated financial statements.</span></div> Revenues<div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We operate in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. Rest-of-world (ROW) revenues relate to products that are sold primarily in Europe. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues were as follows (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">US</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">ROW</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">US</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">ROW</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Enbrel</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></span><span style="font-family:inherit;font-size:10pt;">(etanercept)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,117</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,153</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,106</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,151</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prolia</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> (denosumab)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>422</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>232</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>654</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>390</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>202</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>592</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Neulasta</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></span><span style="font-family:inherit;font-size:10pt;">(pegfilgrastim)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>534</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>609</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>893</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,021</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XGEVA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> (denosumab)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>355</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>481</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>356</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>471</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Otezla</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> (apremilast)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>377</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>479</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Aranesp</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></span><span style="font-family:inherit;font-size:10pt;">(darbepoetin alfa)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>175</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>247</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>422</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>232</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>414</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">KYPROLIS</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></span><span style="font-family:inherit;font-size:10pt;">(carfilzomib)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>187</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>280</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>154</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>245</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Repatha</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></span><span style="font-family:inherit;font-size:10pt;">(evolocumab)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>124</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>229</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other products</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>988</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>599</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,587</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>827</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>424</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,251</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total product sales</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,279</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,615</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,894</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,991</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,295</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,286</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other revenues</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>267</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>271</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,161</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,557</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:18px;text-indent:-18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">____________</sup> </span></div><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup> </span></div><span style="font-family:inherit;font-size:10pt;">Hedging gains and losses, which are included in product sales, were not material for the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span>. 1 <div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues were as follows (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">US</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">ROW</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">US</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">ROW</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Enbrel</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></span><span style="font-family:inherit;font-size:10pt;">(etanercept)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,117</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,153</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,106</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,151</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prolia</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> (denosumab)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>422</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>232</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>654</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>390</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>202</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>592</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Neulasta</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></span><span style="font-family:inherit;font-size:10pt;">(pegfilgrastim)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>534</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>609</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>893</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,021</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XGEVA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> (denosumab)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>355</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>481</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>356</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>471</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Otezla</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> (apremilast)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>377</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>479</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Aranesp</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></span><span style="font-family:inherit;font-size:10pt;">(darbepoetin alfa)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>175</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>247</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>422</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>232</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>414</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">KYPROLIS</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></span><span style="font-family:inherit;font-size:10pt;">(carfilzomib)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>187</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>280</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>154</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>245</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Repatha</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></span><span style="font-family:inherit;font-size:10pt;">(evolocumab)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>124</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>229</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other products</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>988</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>599</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,587</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>827</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>424</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,251</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total product sales</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,279</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,615</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,894</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,991</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,295</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,286</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other revenues</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>267</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>271</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,161</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,557</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:18px;text-indent:-18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">____________</sup> </span></div><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup> </span></div><span style="font-family:inherit;font-size:10pt;">Hedging gains and losses, which are included in product sales, were not material for the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span>. 1117000000 36000000 1153000000 1106000000 45000000 1151000000 422000000 232000000 654000000 390000000 202000000 592000000 534000000 75000000 609000000 893000000 128000000 1021000000 355000000 126000000 481000000 356000000 115000000 471000000 377000000 102000000 479000000 0 0 0 175000000 247000000 422000000 182000000 232000000 414000000 187000000 93000000 280000000 154000000 91000000 245000000 124000000 105000000 229000000 83000000 58000000 141000000 988000000 599000000 1587000000 827000000 424000000 1251000000 4279000000 1615000000 5894000000 3991000000 1295000000 5286000000 267000000 271000000 6161000000 5557000000 Income taxes<div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The effective tax rates for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and 2019, were </span><span style="font-family:inherit;font-size:10pt;"><span>9.7%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>13.9%</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The decrease in our effective tax rate for the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, was due primarily to amortization related to the Otezla</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> acquisition, changes in jurisdictional mix of earnings and certain favorable items in the quarter. The effective tax rates differ from the federal statutory rate primarily as a result of foreign earnings from the Company’s operations conducted in Puerto Rico, a territory of the United States that is treated as a foreign jurisdiction for U.S. tax purposes and are subject to tax incentive grants through 2035. In addition, the Company’s operations conducted in Singapore are subject to a tax incentive grant through 2034. These earnings are also subject to U.S. tax at a reduced rate of 10.5%.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The U.S. territory of Puerto Rico imposes an excise tax on the gross intercompany purchase price of goods and services from our manufacturer in Puerto Rico. The rate of 4% is effective through December 31, 2027. We account for the excise tax as a manufacturing cost that is capitalized in inventory and expensed in cost of sales when the related products are sold. For U.S. income tax purposes, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes may arise with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. As previously disclosed, we received a Revenue Agent Report (RAR) from the Internal Revenue Service (IRS) for the years 2010, 2011 and 2012. The RAR proposes to make significant adjustments that relate primarily to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. In November 2017, we received a modified RAR that revised the IRS’s calculations but continued to propose substantial adjustments. We disagree with the proposed adjustments and calculations and are pursuing resolution with the IRS administrative appeals office, which currently has jurisdiction over the matter. If we deem necessary, we will vigorously contest the proposed adjustments through the judicial process. In addition, in April, we received draft notice of proposed adjustments (NOPAs) from the IRS for the years 2013, 2014 and 2015, which are similar to the proposed adjustments for the years 2010, 2011 and 2012 that relate primarily to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagree with the proposed adjustments and calculations and intend to contest them. We are also currently under examination by a number of other state and foreign tax jurisdictions.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Final resolution of these complex matters is not likely within the next 12 months and could have a material impact on our condensed consolidated financial statements. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes, the ultimate resolution of any tax matters may result in payments substantially greater or less than amounts accrued. We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the gross amounts of our unrecognized tax benefits (UTBs) increased </span><span style="font-family:inherit;font-size:10pt;"><span>$50 million</span></span><span style="font-family:inherit;font-size:10pt;"> as a result of tax positions taken during the current year. Substantially all of the UTBs as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, if recognized, would affect our effective tax rate.</span></div> 0.097 0.139 50000000 Earnings per share<div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The computation of basic earnings per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which include primarily shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The computations for basic and diluted EPS were as follows (in millions, except per-share data):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended<br/>March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (Numerator):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income for basic and diluted EPS</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,825</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares (Denominator):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average shares for basic EPS</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>590</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>622</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average shares for diluted EPS</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>594</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>626</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic EPS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.09</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted EPS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.07</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.</span></div> <div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The computations for basic and diluted EPS were as follows (in millions, except per-share data):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended<br/>March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (Numerator):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income for basic and diluted EPS</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,825</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares (Denominator):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average shares for basic EPS</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>590</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>622</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average shares for diluted EPS</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>594</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>626</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic EPS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.09</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted EPS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.07</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1825000000 1992000000 590000000 622000000 4000000 4000000 594000000 626000000 3.09 3.20 3.07 3.18 Collaborations<div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 2, 2020, we closed our strategic collaboration with BeiGene, Ltd. (BeiGene) to expand our oncology presence in China. Under the collaboration, BeiGene will commercialize XGEVA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">, KYPROLIS</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> and BLINCYTO</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></span><span style="font-family:inherit;font-size:10pt;">(blinatumomab) in China, and Amgen will share profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we will jointly develop a portion of our oncology portfolio with BeiGene sharing in global research and development (R&amp;D) costs by providing cash and development services up to </span><span style="font-family:inherit;font-size:10pt;"><span>$1.25 billion</span></span><span style="font-family:inherit;font-size:10pt;">. Upon regulatory approval, BeiGene will assume commercialization rights in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside of China, Amgen will also pay BeiGene royalties.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, costs recovered from BeiGene for oncology product candidates were </span><span style="font-family:inherit;font-size:10pt;"><span>$57 million</span></span><span style="font-family:inherit;font-size:10pt;"> and were recorded in R&amp;D expense in the Condensed Consolidated Statements of Income. For the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, no profit share payments or product sales were recorded between Amgen and BeiGene. In connection with this collaboration, we acquired an ownership interest in BeiGene. See Note 6, Investments.</span></div> 1250000000 57000000 Investments<div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Available-for-sale investments</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Types of securities as of March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">values</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>173</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury bills</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>900</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>900</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Industrial</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Residential-mortgage-backed securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market mutual funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,762</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,762</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other short-term interest-bearing securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>432</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>432</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total interest-bearing securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,291</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,294</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Types of securities as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">values</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>359</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>360</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury bills</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,108</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,121</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Industrial</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>824</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>834</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>198</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Residential-mortgage-backed securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>181</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market mutual funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other short-term interest-bearing securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>289</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>289</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total interest-bearing securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,206</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,234</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:66%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Condensed Consolidated Balance Sheets locations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,969</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,360</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>325</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,874</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total interest-bearing securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,294</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,234</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents in the above table excludes bank account cash of </span><span style="font-family:inherit;font-size:10pt;"><span>$718 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$677 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair values of interest-bearing securities by contractual maturity, except for residential-mortgage-backed securities that do not have a single maturity date, were as follows (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:66%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual maturities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturing in one year or less</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,165</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,629</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturing after one year through three years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,304</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturing after three years through five years</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Residential mortgage-backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total interest-bearing securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,294</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,234</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, realized gains on interest-bearing securities were </span><span style="font-family:inherit;font-size:10pt;"><span>$37 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and realized losses on interest-bearing securities were </span><span style="font-family:inherit;font-size:10pt;"><span>$4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$5 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. Realized gains and losses on interest-bearing securities are recorded in Interest and other income, net, in the Condensed Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of March 31, 2020 and December 31, 2019, aggregated gross unrealized losses of available-for-sale investments were not material, and accordingly, no allowance for credit losses was recorded as of March 31, 2020.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Equity securities</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We held investments in equity securities with readily determinable fair values of </span><span style="font-family:inherit;font-size:10pt;"><span>$220 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$303 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, which are included in Other assets in the Condensed Consolidated Balance Sheets. Gains and losses recognized on equity securities with readily determinable fair values, including gains and losses recognized on sales, were not material for the three months ended March 31, 2020 and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We held investments of </span><span style="font-family:inherit;font-size:10pt;"><span>$183 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$176 million</span></span><span style="font-family:inherit;font-size:10pt;"> in equity securities without readily determinable fair values as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, which are included in Other assets in the Condensed Consolidated Balance Sheets. Adjustments to the carrying values of these securities were not material for the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Equity method investments </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Limited partnerships</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We held limited partnership investments of </span><span style="font-family:inherit;font-size:10pt;"><span>$331 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$320 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, which are included in Other assets in the Condensed Consolidated Balance Sheets. These investments, primarily investment funds of early-stage biotechnology companies, are accounted for by using the equity method of accounting and measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, unfunded additional commitments to be made for these investments during the next several years were not material. Gains and losses recognized on our limited partnership investments were not material for the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">BeiGene</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 2, 2020, we acquired a </span><span style="font-family:inherit;font-size:10pt;"><span>20.5%</span></span><span style="font-family:inherit;font-size:10pt;"> ownership interest in BeiGene for </span><span style="font-family:inherit;font-size:10pt;"><span>$2.8 billion</span></span><span style="font-family:inherit;font-size:10pt;">, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$2.6 billion</span></span><span style="font-family:inherit;font-size:10pt;"> was attributed to the fair value of equity securities upon closing, with the remainder attributed to prepaid R&amp;D. Our equity investment in BeiGene is included in Other assets in the Condensed Consolidated Balance Sheets. The fair value of equity securities acquired exceeded our proportionate share of the carrying value of the underlying net assets of BeiGene by approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$2.4 billion</span></span><span style="font-family:inherit;font-size:10pt;">. This investment is accounted for by using the equity method of accounting, which requires us to identify and allocate amounts to the items that give rise to the basis difference and to amortize these items over their useful lives. This amortization, along with our share of the results of operations of BeiGene, will be recognized in Interest and other income, net, in our Condensed Consolidated Statements of Income. Recognition will occur one quarter in arrears, beginning in the second quarter of 2020. The basis difference was allocated to finite-lived intangible assets, indefinite-lived intangible assets, equity-method goodwill and related deferred taxes. The finite-lived intangible assets will be amortized over a period ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>8</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>15 years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the carrying and fair values of our approximately </span><span style="font-family:inherit;font-size:10pt;"><span>20.5%</span></span><span style="font-family:inherit;font-size:10pt;"> ownership interest in BeiGene totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$2.6 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0 billion</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we believe the carrying value of our equity investment in BeiGene is fully recoverable. See Note 1, Summary of significant accounting policies, for factors considered in determining our conclusion. For information on a collaboration agreement we entered into with BeiGene in connection with this investment, see Note 5, Collaborations.</span></div> <div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Types of securities as of March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">values</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>173</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury bills</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>900</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>900</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Industrial</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Residential-mortgage-backed securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market mutual funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,762</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,762</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other short-term interest-bearing securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>432</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>432</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total interest-bearing securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,291</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,294</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Types of securities as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">values</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>359</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>360</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury bills</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,108</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,121</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Industrial</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>824</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>834</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>198</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Residential-mortgage-backed securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>181</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market mutual funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other short-term interest-bearing securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>289</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>289</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total interest-bearing securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,206</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,234</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 173000000 3000000 0 176000000 900000000 0 0 900000000 12000000 0 0 12000000 12000000 0 0 12000000 0 0 0 0 0 0 0 0 5762000000 0 0 5762000000 432000000 0 0 432000000 7291000000 3000000 0 7294000000 359000000 1000000 0 360000000 0 0 0 0 1108000000 13000000 0 1121000000 824000000 10000000 0 834000000 195000000 3000000 0 198000000 181000000 1000000 0 182000000 5250000000 0 0 5250000000 289000000 0 0 289000000 8206000000 28000000 0 8234000000 <div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:66%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Condensed Consolidated Balance Sheets locations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,969</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,360</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>325</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,874</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total interest-bearing securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,294</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,234</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 6969000000 5360000000 325000000 2874000000 7294000000 8234000000 718000000 677000000 <div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair values of interest-bearing securities by contractual maturity, except for residential-mortgage-backed securities that do not have a single maturity date, were as follows (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:66%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual maturities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturing in one year or less</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,165</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,629</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturing after one year through three years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,304</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturing after three years through five years</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Residential mortgage-backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total interest-bearing securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,294</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,234</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 7165000000 5629000000 129000000 2304000000 0 119000000 0 182000000 7294000000 8234000000 37000000 1000000 4000000 5000000 220000000 303000000 183000000 176000000 331000000 320000000 0.205 2800000000 2600000000 2400000000 P8Y P15Y 0.205 2600000000 2000000000.0 Inventories<div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories consisted of the following (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>446</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>358</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,192</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,227</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,044</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>999</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventories</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,682</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,584</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories consisted of the following (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>446</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>358</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,192</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,227</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,044</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>999</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventories</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,682</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,584</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 446000000 358000000 2192000000 2227000000 1044000000 999000000 3682000000 3584000000 Goodwill and other intangible assets<div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The change in the carrying amount of goodwill was as follows (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended<br/>March 31, 2020</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,703</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Currency translation adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,683</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other intangible assets</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets consisted of the following (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">amounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other intangible</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">assets, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">amounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other intangible</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">assets, net</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finite-lived intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed-product-technology rights</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,549</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,876</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,673</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,575</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,322</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,253</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing rights</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,746</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,494</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,252</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,761</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,398</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,363</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketing-related rights</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,375</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(979</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>396</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,382</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(965</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>417</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development technology rights</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,269</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(967</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>302</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,273</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(947</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>326</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total finite-lived intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,939</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13,316</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,623</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,991</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,632</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,359</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indefinite-lived intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,969</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13,316</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,653</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,045</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,632</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,413</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed-product-technology rights consists of rights related to marketed products. Licensing rights consists primarily of contractual rights to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and up-front payments associated with royalty obligations for marketed products. Marketing-related rights consists primarily of rights related to the sale and distribution of marketed products. R&amp;D technology rights pertains to technologies used in R&amp;D that have alternative future uses.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-process research and development (IPR&amp;D) consists of R&amp;D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. We review IPR&amp;D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, we recognized amortization associated with our finite-lived intangible assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$709 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$315 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. Amortization of intangible assets is included primarily in Cost of sales in the Condensed Consolidated Statements of Income. The total estimated amortization for our finite-lived intangible assets for the remaining nine months ending </span><span style="font-family:inherit;font-size:10pt;">December 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, and the years ending December 31, </span><span style="font-family:inherit;font-size:10pt;">2021</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2022</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2023</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2024</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2025</span><span style="font-family:inherit;font-size:10pt;">, are </span><span style="font-family:inherit;font-size:10pt;"><span>$2.1 billion</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$2.6 billion</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$2.5 billion</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$2.4 billion</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$2.4 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 billion</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div> <div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The change in the carrying amount of goodwill was as follows (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended<br/>March 31, 2020</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,703</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Currency translation adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,683</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 14703000000 -20000000 14683000000 <div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets consisted of the following (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">amounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other intangible</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">assets, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">amounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other intangible</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">assets, net</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finite-lived intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed-product-technology rights</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,549</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,876</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,673</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,575</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,322</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,253</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing rights</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,746</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,494</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,252</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,761</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,398</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,363</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketing-related rights</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,375</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(979</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>396</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,382</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(965</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>417</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development technology rights</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,269</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(967</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>302</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,273</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(947</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>326</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total finite-lived intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,939</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13,316</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,623</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,991</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,632</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,359</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indefinite-lived intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,969</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13,316</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,653</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,045</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,632</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,413</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 25549000000 8876000000 16673000000 25575000000 8322000000 17253000000 3746000000 2494000000 1252000000 3761000000 2398000000 1363000000 1375000000 979000000 396000000 1382000000 965000000 417000000 1269000000 967000000 302000000 1273000000 947000000 326000000 31939000000 13316000000 18623000000 31991000000 12632000000 19359000000 30000000 30000000 54000000 54000000 31969000000 13316000000 18653000000 32045000000 12632000000 19413000000 709000000 315000000 2100000000 2600000000 2500000000 2400000000 2400000000 2200000000 Financing arrangements<div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our borrowings consisted of the following (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.50% notes due 2020 (4.50% 2020 Notes)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.125% notes due 2020 (2.125% 2020 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Floating Rate Notes due 2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.20% notes due 2020 (2.20% 2020 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.45% notes due 2020 (3.45% 2020 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.10% notes due 2021 (4.10% 2021 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.85% notes due 2021 (1.85% 2021 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.875% notes due 2021 (3.875% 2021 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,450</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,379</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,402</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.70% notes due 2022 (2.70% 2022 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.65% notes due 2022 (2.65% 2022 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.625% notes due 2022 (3.625% 2022 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>728</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>725</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.25% notes due 2023 (2.25% 2023 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.625% notes due 2024 (3.625% 2024 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,400</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,400</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.90% notes due 2025 (1.90% 2025 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.125% notes due 2025 (3.125% 2025 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.00% €750 million notes due 2026 (2.00% 2026 euro Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>827</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>841</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.60% notes due 2026 (2.60% 2026 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>590</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>630</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.20% notes due 2027 (2.20% 2027 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.20% notes due 2027 (3.20% 2027 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>869</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>928</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.45% notes due 2030 (2.45% 2030 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6.375% notes due 2037 (6.375% 2037 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>552</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>552</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6.90% notes due 2038 (6.90% 2038 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>291</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>291</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6.40% notes due 2039 (6.40% 2039 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>466</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>466</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.15% notes due 2040 (3.15% 2040 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.75% notes due 2040 (5.75% 2040 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>412</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>412</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.95% notes due 2041 (4.95% 2041 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>600</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>600</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.15% notes due 2041 (5.15% 2041 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>974</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>974</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.65% notes due 2042 (5.65% 2042 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>487</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>487</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.375% notes due 2043 (5.375% 2043 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>261</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>261</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.40% notes due 2045 (4.40% 2045 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.563% notes due 2048 (4.563% 2048 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,415</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,415</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.375% notes due 2050 (3.375% 2050 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.663% notes due 2051 (4.663% 2051 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,541</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,541</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other notes due 2097</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized bond discounts, premiums and issuance costs, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(892</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(868</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>648</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total carrying value of debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,848</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,903</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less current portion</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,840</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,953</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,008</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,950</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There are no material differences between the effective interest rates and coupon rates of any of our borrowings, except for the </span><span style="font-family:inherit;font-size:10pt;"><span>4.563%</span></span><span style="font-family:inherit;font-size:10pt;"> 2048 Notes and the </span><span style="font-family:inherit;font-size:10pt;"><span>4.663%</span></span><span style="font-family:inherit;font-size:10pt;"> 2051 Notes, which have effective interest rates of </span><span style="font-family:inherit;font-size:10pt;"><span>6.3%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>5.6%</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Debt issuances and repayments</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the three months ended March 31, 2020, we issued </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of debt, consisting of the </span><span style="font-family:inherit;font-size:10pt;"><span>1.90%</span></span><span style="font-family:inherit;font-size:10pt;"> 2025 Notes, the </span><span style="font-family:inherit;font-size:10pt;"><span>2.20%</span></span><span style="font-family:inherit;font-size:10pt;"> 2027 Notes, the </span><span style="font-family:inherit;font-size:10pt;"><span>2.45%</span></span><span style="font-family:inherit;font-size:10pt;"> 2030 Notes, the </span><span style="font-family:inherit;font-size:10pt;"><span>3.15%</span></span><span style="font-family:inherit;font-size:10pt;"> 2040 Notes and the </span><span style="font-family:inherit;font-size:10pt;"><span>3.375%</span></span><span style="font-family:inherit;font-size:10pt;"> 2050 Notes. In the event of a change-in-control triggering event, as defined in the terms of the notes, we may be required to purchase all or a portion of these notes at a price equal to </span><span style="font-family:inherit;font-size:10pt;">101%</span><span style="font-family:inherit;font-size:10pt;"> of the principal amount of the notes plus accrued and unpaid interest. In addition, these notes may be redeemed at any time at our option, in whole or in part, at the principal amount of the notes being redeemed plus accrued and unpaid interest and a “make-whole” amount, which are defined by the terms of the notes. The notes may be redeemed without payment of make-whole amounts if redemption occurs during specified periods of time immediately prior to the maturity of the notes. Such time periods range from </span><span style="font-family:inherit;font-size:10pt;"><span>one month</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>six months</span></span><span style="font-family:inherit;font-size:10pt;"> prior to maturity.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A portion of the proceeds from the issuance of these notes were used to redeem the </span><span style="font-family:inherit;font-size:10pt;"><span>3.45%</span></span><span style="font-family:inherit;font-size:10pt;"> 2020 Notes, the </span><span style="font-family:inherit;font-size:10pt;"><span>4.10%</span></span><span style="font-family:inherit;font-size:10pt;"> 2021 Notes, the </span><span style="font-family:inherit;font-size:10pt;"><span>1.85%</span></span><span style="font-family:inherit;font-size:10pt;"> 2021 Notes and </span><span style="font-family:inherit;font-size:10pt;"><span>$300 million</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of our </span><span style="font-family:inherit;font-size:10pt;"><span>3.875%</span></span><span style="font-family:inherit;font-size:10pt;"> 2021 Notes. In connection with the redemption of these notes, we paid a total of </span><span style="font-family:inherit;font-size:10pt;"><span>$50 million</span></span><span style="font-family:inherit;font-size:10pt;"> in make-whole amounts plus associated accrued and unpaid interest, all of which was recognized in Interest expense, net, in the Condensed Consolidated Statements of Income during the three months ended March 31, 2020. In addition to these redemptions, the </span><span style="font-family:inherit;font-size:10pt;"><span>4.50%</span></span><span style="font-family:inherit;font-size:10pt;"> 2020 Notes matured and were repaid during the three months ended March 31, 2020.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest rate swaps</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the redemption of certain of the notes discussed above, associated interest rate swap contracts with an aggregate notional value of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 billion</span></span><span style="font-family:inherit;font-size:10pt;"> were terminated. Additionally, due to historically low interest rates, during the three months ended March 31, 2020, we terminated interest rate swaps with an aggregate notional amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.2 billion</span></span><span style="font-family:inherit;font-size:10pt;"> that hedged the </span><span style="font-family:inherit;font-size:10pt;"><span>3.625%</span></span><span style="font-family:inherit;font-size:10pt;"> 2024 Notes, </span><span style="font-family:inherit;font-size:10pt;"><span>2.60%</span></span><span style="font-family:inherit;font-size:10pt;"> 2026 Notes, </span><span style="font-family:inherit;font-size:10pt;"><span>4.663%</span></span><span style="font-family:inherit;font-size:10pt;"> 2051 Notes and portions of our </span><span style="font-family:inherit;font-size:10pt;"><span>3.625%</span></span><span style="font-family:inherit;font-size:10pt;"> 2022 Notes and </span><span style="font-family:inherit;font-size:10pt;"><span>3.125%</span></span><span style="font-family:inherit;font-size:10pt;"> 2025 Notes, which resulted in the receipt of </span><span style="font-family:inherit;font-size:10pt;"><span>$576 million</span></span><span style="font-family:inherit;font-size:10pt;"> of cash and reduced counterparty credit risk. Immediately following termination of these contracts, we entered into new interest rate swap agreements at then-current interest rates on the same </span><span style="font-family:inherit;font-size:10pt;"><span>$5.2 billion</span></span><span style="font-family:inherit;font-size:10pt;"> principal amount of notes. See Note 12, Derivative instruments.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Notional amounts</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective interest rates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Notional amounts</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective interest rates</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.45% 2020 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 1.1%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 1.1%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.10% 2021 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 1.7%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 1.7%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.875% 2021 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,450</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 2.0%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 2.0%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.625% 2022 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 2.7%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 1.6%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.625% 2024 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,400</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 3.2%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,400</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 1.4%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.125% 2025 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 1.8%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 0.9%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.60% 2026 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 1.8%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 0.3%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.663% 2051 Notes</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 2.6%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 0.0%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total notional amounts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,350</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,550</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:18px;text-indent:-18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">____________</sup> </span></div><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Excludes an additional </span><span style="font-family:inherit;font-size:10pt;"><span>1.5%</span></span><span style="font-family:inherit;font-size:10pt;"> of interest for the difference between the coupon rate paid to note holders and the fixed rate received under the interest rate swap contracts.</span></div> <div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our borrowings consisted of the following (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.50% notes due 2020 (4.50% 2020 Notes)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.125% notes due 2020 (2.125% 2020 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Floating Rate Notes due 2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.20% notes due 2020 (2.20% 2020 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.45% notes due 2020 (3.45% 2020 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.10% notes due 2021 (4.10% 2021 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.85% notes due 2021 (1.85% 2021 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.875% notes due 2021 (3.875% 2021 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,450</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,379</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,402</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.70% notes due 2022 (2.70% 2022 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.65% notes due 2022 (2.65% 2022 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.625% notes due 2022 (3.625% 2022 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>728</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>725</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.25% notes due 2023 (2.25% 2023 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.625% notes due 2024 (3.625% 2024 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,400</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,400</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.90% notes due 2025 (1.90% 2025 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.125% notes due 2025 (3.125% 2025 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.00% €750 million notes due 2026 (2.00% 2026 euro Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>827</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>841</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.60% notes due 2026 (2.60% 2026 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>590</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>630</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.20% notes due 2027 (2.20% 2027 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.20% notes due 2027 (3.20% 2027 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>869</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>928</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.45% notes due 2030 (2.45% 2030 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6.375% notes due 2037 (6.375% 2037 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>552</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>552</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6.90% notes due 2038 (6.90% 2038 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>291</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>291</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6.40% notes due 2039 (6.40% 2039 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>466</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>466</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.15% notes due 2040 (3.15% 2040 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.75% notes due 2040 (5.75% 2040 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>412</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>412</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.95% notes due 2041 (4.95% 2041 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>600</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>600</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.15% notes due 2041 (5.15% 2041 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>974</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>974</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.65% notes due 2042 (5.65% 2042 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>487</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>487</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.375% notes due 2043 (5.375% 2043 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>261</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>261</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.40% notes due 2045 (4.40% 2045 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.563% notes due 2048 (4.563% 2048 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,415</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,415</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.375% notes due 2050 (3.375% 2050 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.663% notes due 2051 (4.663% 2051 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,541</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,541</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other notes due 2097</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized bond discounts, premiums and issuance costs, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(892</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(868</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>648</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total carrying value of debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,848</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,903</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less current portion</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,840</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,953</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,008</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,950</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 300000000 750000000 750000000 300000000 300000000 700000000 700000000 900000000 1000000000 0 750000000 1450000000 1750000000 1379000000 1402000000 500000000 500000000 1500000000 1500000000 750000000 750000000 728000000 725000000 750000000 750000000 1400000000 1400000000 500000000 1000000000 1000000000 827000000 841000000 1250000000 1250000000 590000000 630000000 750000000 1000000000 1000000000 869000000 928000000 1250000000 552000000 552000000 291000000 291000000 466000000 466000000 1250000000 412000000 412000000 600000000 600000000 974000000 974000000 487000000 487000000 261000000 261000000 2250000000 2250000000 1415000000 1415000000 1250000000 3541000000 3541000000 100000000 100000000 892000000 868000000 648000000 296000000 31848000000 29903000000 1840000000 2953000000 30008000000 26950000000 0.04563 0.04663 0.063 0.056 5000000000.0 0.0190 0.0220 0.0245 0.0315 0.03375 P1M P6M 0.0345 0.0410 0.0185 300000000 0.03875 50000000 0.0450 2200000000 5200000000 0.03625 0.0260 0.04663 0.03625 0.03125 576000000 5200000000 <div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Notional amounts</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective interest rates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Notional amounts</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective interest rates</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.45% 2020 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 1.1%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 1.1%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.10% 2021 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 1.7%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 1.7%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.875% 2021 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,450</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 2.0%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 2.0%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.625% 2022 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 2.7%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 1.6%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.625% 2024 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,400</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 3.2%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,400</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 1.4%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.125% 2025 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 1.8%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 0.9%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.60% 2026 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 1.8%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 0.3%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.663% 2051 Notes</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 2.6%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIBOR + 0.0%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total notional amounts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,350</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,550</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:18px;text-indent:-18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">____________</sup> </span></div><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Excludes an additional </span><span style="font-family:inherit;font-size:10pt;"><span>1.5%</span></span><span style="font-family:inherit;font-size:10pt;"> of interest for the difference between the coupon rate paid to note holders and the fixed rate received under the interest rate swap contracts.</span></div> 0 900000000 0 1000000000 1450000000 1750000000 750000000 750000000 1400000000 1400000000 1000000000 1000000000 1250000000 1250000000 1500000000 1500000000 7350000000 9550000000 0.015 Stockholders’ equity<div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock repurchase program</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">First quarter</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>933</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,031</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, our Board of Directors increased the amount authorized under our stock repurchase program by an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 billion</span></span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$5.5 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of authorization remained available under our stock repurchase program.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Dividends</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2020, the Board of Directors declared a quarterly cash dividend of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.60</span></span><span style="font-family:inherit;font-size:10pt;"> per share, which will be paid in June 2020. In December 2019, the Board of Directors declared a quarterly cash dividend of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.60</span></span><span style="font-family:inherit;font-size:10pt;"> per share, which was paid in March 2020. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive income (loss)</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of Accumulated other comprehensive income (loss) (AOCI) were as follows (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">currency</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash flow</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Available-for-sale</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">AOCI</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(718</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>175</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(528</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(52</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(52</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized (losses) gains</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(162</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(154</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reclassification adjustments to income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(770</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(662</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reclassifications out of AOCI and into earnings were as follows (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:25%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Components of AOCI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Condensed Consolidated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Statements of Income locations</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency contract gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap contract losses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(42</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest and other income, net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(84</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(28</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before income taxes</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision for income taxes</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(66</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale securities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net realized gains (losses)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest and other income, net</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision for income taxes</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:25%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;color:#ffffff;font-weight:bold;">Three months ended March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">First quarter</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>933</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,031</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 4300000 933000000 15900000 3031000000 4000000000.0 5500000000 1.60 1.60 <div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of Accumulated other comprehensive income (loss) (AOCI) were as follows (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">currency</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash flow</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Available-for-sale</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">AOCI</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(718</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>175</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(528</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(52</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(52</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized (losses) gains</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(162</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(154</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reclassification adjustments to income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(770</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(662</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -718000000 175000000 22000000 -7000000 -528000000 -52000000 -52000000 -162000000 8000000 0 -154000000 84000000 -33000000 51000000 -2000000 -2000000 0 17000000 6000000 -23000000 -770000000 114000000 3000000 -9000000 -662000000 <div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reclassifications out of AOCI and into earnings were as follows (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:25%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Components of AOCI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Condensed Consolidated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Statements of Income locations</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency contract gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap contract losses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(42</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest and other income, net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(84</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(28</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before income taxes</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision for income taxes</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(66</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale securities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net realized gains (losses)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest and other income, net</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision for income taxes</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 49000000 14000000 -133000000 -42000000 -84000000 -28000000 -18000000 -6000000 -66000000 -22000000 33000000 -4000000 7000000 0 26000000 -4000000 Fair value measurement<div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:8%;"/><td style="width:2%;"/><td style="width:90%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuations for which all significant inputs are observable either directly or indirectly—other than Level 1 inputs</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuations based on inputs that are unobservable and significant to the overall fair value measurement</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair values of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted prices in<br/>active markets for<br/>identical assets<br/>(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">other observable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair value measurement as of March 31, 2020, using:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury bills</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>900</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>900</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Industrial</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Residential-mortgage-backed securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market mutual funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,762</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,762</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other short-term interest-bearing securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>432</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>432</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>220</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>220</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivatives:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>375</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>375</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,058</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>930</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,988</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivatives:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>657</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>657</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>685</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>745</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted prices in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">active markets for</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">identical assets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">other observable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair value measurement as of December 31, 2019, using:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>360</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>360</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury bills</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,121</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,121</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Industrial</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>834</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>834</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>198</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>198</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Residential-mortgage-backed securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market mutual funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other short-term interest-bearing securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>289</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>289</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>303</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>303</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivatives:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,913</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,173</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,086</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivatives:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>315</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>315</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>346</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>407</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest-bearing and equity securities</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair values of our U.S. Treasury securities, money market mutual funds and equity securities are based on quoted market prices in active markets, with no valuation adjustment.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of March 31, 2020, our corporate debt securities are investment grade and have maturity dates of</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;"><span>three years</span></span><span style="font-family:inherit;font-size:10pt;"> or less from the balance sheet date. Our corporate debt securities portfolio has weighted-average credit ratings of BBB or equivalent by Standard &amp; Poor’s Financial Services LLC (S&amp;P), BBB+ by Moody’s Investors Service, Inc. (Moody’s) and A– by Fitch Ratings, Inc. (Fitch). We estimate the fair values of these securities by taking into consideration valuations obtained from third-party pricing services. The pricing services use industry-standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable either directly or indirectly to estimate fair value. The inputs include reported trades of and broker-dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We value our other short-term interest-bearing securities at amortized cost, which approximates fair value given their near-term maturity dates.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All of our foreign currency forward derivative contracts have maturities of </span><span style="font-family:inherit;font-size:10pt;"><span>three years</span></span><span style="font-family:inherit;font-size:10pt;"> or less, and all are with counterparties that have minimum credit ratings of A– or equivalent by S&amp;P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts include implied volatility measures. These inputs, when applicable, are at commonly quoted intervals. See Note 12, Derivative instruments.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our cross-currency swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&amp;P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency-basis swap spreads. See Note 12, Derivative instruments.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our interest rate swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&amp;P, Moody’s or Fitch. We estimate the fair values of these contracts by using an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include LIBOR, swap rates and obligor credit default swap rates. See Note 12, Derivative instruments.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Summary of the fair values of other financial instruments</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash equivalents</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Borrowings</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimated the fair values of our borrowings by using Level 2 inputs. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the aggregate fair values of our borrowings were </span><span style="font-family:inherit;font-size:10pt;"><span>$35.8 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$33.7 billion</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and the carrying values were </span><span style="font-family:inherit;font-size:10pt;"><span>$31.8 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$29.9 billion</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div> <div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair values of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted prices in<br/>active markets for<br/>identical assets<br/>(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">other observable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair value measurement as of March 31, 2020, using:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury bills</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>900</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>900</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Industrial</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Residential-mortgage-backed securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market mutual funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,762</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,762</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other short-term interest-bearing securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>432</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>432</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>220</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>220</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivatives:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>375</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>375</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,058</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>930</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,988</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivatives:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>657</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>657</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>685</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>745</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted prices in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">active markets for</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">identical assets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">other observable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair value measurement as of December 31, 2019, using:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>360</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>360</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury bills</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,121</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,121</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Industrial</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>834</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>834</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>198</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>198</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Residential-mortgage-backed securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market mutual funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other short-term interest-bearing securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>289</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>289</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>303</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>303</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivatives:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,913</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,173</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,086</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivatives:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>315</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>315</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>346</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>407</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 176000000 0 0 176000000 900000000 0 0 900000000 0 12000000 0 12000000 0 12000000 0 12000000 0 0 0 0 0 0 0 0 5762000000 0 0 5762000000 0 432000000 0 432000000 220000000 0 0 220000000 0 375000000 0 375000000 0 10000000 0 10000000 0 89000000 0 89000000 7058000000 930000000 0 7988000000 0 5000000 0 5000000 0 657000000 0 657000000 0 23000000 0 23000000 0 0 60000000 60000000 0 685000000 60000000 745000000 360000000 0 0 360000000 0 0 0 0 0 1121000000 0 1121000000 0 834000000 0 834000000 0 198000000 0 198000000 0 182000000 0 182000000 5250000000 0 0 5250000000 0 289000000 0 289000000 303000000 0 0 303000000 0 224000000 0 224000000 0 66000000 0 66000000 0 259000000 0 259000000 5913000000 3173000000 0 9086000000 0 31000000 0 31000000 0 315000000 0 315000000 0 0 0 0 0 0 61000000 61000000 0 346000000 61000000 407000000 P3Y P3Y 35800000000 33700000000 31800000000 29900000000 Derivative instruments<div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, foreign currency option, cross-currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative trading purposes.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash flow hedges</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates associated primarily with our euro-denominated international product sales. Increases and decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are offset partially by corresponding increases and decreases in the cash flows from our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations with regard to our international product sales, we enter into foreign currency forward contracts to hedge a portion of our projected international product sales primarily </span><span style="font-family:inherit;font-size:10pt;">over a three-year time horizon</span><span style="font-family:inherit;font-size:10pt;">, with, at any given point in time, a higher percentage of nearer-term projected product sales being hedged than in successive periods.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had outstanding foreign currency forward contracts with aggregate notional amounts of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.9 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 billion</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. We have designated these foreign currency forward contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report the unrealized gains and losses on these contracts in AOCI in the Condensed Consolidated Balance Sheets, and we reclassify them to Product sales in the Condensed Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros, pounds sterling and Swiss francs and received U.S. dollars for the notional amounts at the inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the lives of the contracts by paying U.S. dollars and receiving euros, pounds sterling and Swiss francs. In addition, we will pay U.S. dollars to and receive euros, pounds sterling and Swiss francs from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros, pounds sterling and Swiss francs to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Condensed Consolidated Balance Sheets and reclassified to Interest and other income, net, in the Condensed Consolidated Statements of Income in the same periods during which the hedged debt affects earnings.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The notional amounts and interest rates of our cross-currency swaps as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, were as follows (notional amounts in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign currency</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">U.S. dollars</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Hedged notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Notional amounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Interest rates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Notional amounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Interest rates</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.25% 2022 euro Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">€</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,388</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.41% 2023 Swiss franc Bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CHF</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>704</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.00% 2026 euro Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">€</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>833</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.50% 2026 pound sterling Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">£</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>475</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>747</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.00% 2029 pound sterling Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">£</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>700</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,111</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#231f20;">In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI i</span><span style="font-family:inherit;font-size:10pt;">n the Condensed Consolidated Balance Sheets </span><span style="font-family:inherit;font-size:10pt;color:#231f20;">and are amortized into Interest expense, net, in the Condensed Consolidated Statements of Income over the lives of the associated debt issuances. Amounts recognized in connection with forward interest rate swaps during the </span><span style="font-family:inherit;font-size:10pt;color:#231f20;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;color:#231f20;">, and amounts expected to be recognized during the subsequent 12 months are not material.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:78%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended<br/>March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivatives in cash flow hedging relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>239</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(401</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(55</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total unrealized (losses) gains</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(162</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair value hedges</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate LIBOR-based coupons over the terms of the related hedge contracts. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had interest rate swap contracts with aggregate notional amounts of </span><span style="font-family:inherit;font-size:10pt;"><span>$7.4 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$9.6 billion</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, that hedge certain portions of our long-term debt issuances.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swaps with an aggregate notional value of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 billion</span></span><span style="font-family:inherit;font-size:10pt;"> were terminated during the three months ended March 31, 2020, in connection with the redemption of certain of our notes. The termination of these interest rate swaps resulted in a gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$17 million</span></span><span style="font-family:inherit;font-size:10pt;"> recognized in Interest expense, net, in the Condensed Consolidated Statements of Income. Additionally, we terminated </span><span style="font-family:inherit;font-size:10pt;"><span>$5.2 billion</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate notional amount of interest rate swaps, which resulted in the receipt of </span><span style="font-family:inherit;font-size:10pt;"><span>$576 million</span></span><span style="font-family:inherit;font-size:10pt;"> from the counterparties that was included in Net cash provided by operating activities in the Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2020. This amount will be recognized in Interest expense, net, in the Condensed Consolidated Statements of Income over the remaining life of the underlying notes. Immediately following the termination of these interest rate swap contracts, we entered into new interest rate swap agreements at then-current interest rates on the same </span><span style="font-family:inherit;font-size:10pt;"><span>$5.2 billion</span></span><span style="font-family:inherit;font-size:10pt;"> principal amount of notes. See Note 9, Financing arrangements, for information on our interest rate swaps.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Condensed Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining life of the previously hedged debt.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying amounts of hedged liabilities</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Condensed Consolidated Balance Sheets locations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of long-term debt</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>903</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,784</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,814</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>558</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>292</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:18px;text-indent:-18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">____________</sup> </span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of long-term debt includes </span><span style="font-family:inherit;font-size:10pt;"><span>$90 million</span></span><span style="font-family:inherit;font-size:10pt;"> of carrying value with discontinued hedging relationships as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">. Long-term debt includes </span><span style="font-family:inherit;font-size:10pt;"><span>$592 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$136 million</span></span><span style="font-family:inherit;font-size:10pt;"> of carrying value with discontinued hedging relationships as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of long-term debt includes </span><span style="font-family:inherit;font-size:10pt;"><span>$90 million</span></span><span style="font-family:inherit;font-size:10pt;"> of hedging adjustments on discontinued hedging relationships as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">. Long-term debt includes </span><span style="font-family:inherit;font-size:10pt;"><span>$492 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$36 million</span></span><span style="font-family:inherit;font-size:10pt;"> of hedging adjustments on discontinued hedging relationships as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:18px;text-indent:-18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Impact of hedging transactions</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Interest and other income, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Interest (expense), net</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,894</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(346</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The effects of cash flow and fair value hedging:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gains (losses) on cash flow hedging relationships reclassified out of AOCI:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gains (losses) on fair value hedging relationships—interest rate swap agreements:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hedged items</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>210</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivatives designated as hedging instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(190</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Interest and other income, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Interest (expense), net</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,286</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>185</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(343</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The effects of cash flow and fair value hedging:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gains (losses) on cash flow hedging relationships reclassified out of AOCI:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(42</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Losses) gains on fair value hedging relationships—interest rate swap agreements:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hedged items</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(130</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivatives designated as hedging instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:18px;text-indent:-18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">__________</sup> </span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gains (losses) on hedged items do not completely offset gains (losses) on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges where the corresponding hedged item was paid down in the period.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we expected to reclassify </span><span style="font-family:inherit;font-size:10pt;"><span>$162 million</span></span><span style="font-family:inherit;font-size:10pt;"> of net gains on our foreign currency and cross-currency swap contracts out of AOCI and into earnings during the next 12 months.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:18px;text-indent:-18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives not designated as hedges</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the total notional amounts of these foreign currency forward contracts were </span><span style="font-family:inherit;font-size:10pt;"><span>$0.8 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 billion</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.70731707317073%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivative assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivative liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Condensed Consolidated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance Sheets locations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair values</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Condensed Consolidated<br/>Balance Sheets locations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair values</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivatives designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets/ Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>375</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets/ Other assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>657</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets/ Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total derivatives designated as hedging instruments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>474</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>685</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivatives not designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total derivatives not designated as hedging instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total derivatives</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>474</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>685</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivative assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivative liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Condensed Consolidated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance Sheets locations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair values</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Condensed Consolidated<br/>Balance Sheets locations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair values</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivatives designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets/ Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>223</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets/ Other assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>315</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets/ Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total derivatives designated as hedging instruments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>548</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>346</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivatives not designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total derivatives not designated as hedging instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total derivatives</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>549</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>346</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our derivative contracts that were in liability positions as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, contain certain credit-risk-related contingent provisions that would be triggered if (i) we were to undergo a change in control and (ii) our or the surviving entity’s creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right but not the obligation to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The cash flow effects of our derivative contracts in the Condensed Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash used in financing activities.</span></div> 4900000000 5000000000.0 <div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The notional amounts and interest rates of our cross-currency swaps as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, were as follows (notional amounts in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign currency</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">U.S. dollars</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Hedged notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Notional amounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Interest rates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Notional amounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Interest rates</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.25% 2022 euro Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">€</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,388</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.41% 2023 Swiss franc Bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CHF</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>704</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.00% 2026 euro Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">€</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>833</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.50% 2026 pound sterling Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">£</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>475</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>747</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.00% 2029 pound sterling Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">£</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>700</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,111</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1250000000 0.013 1388000000 0.032 700000000 0.004 704000000 0.034 750000000 0.020 833000000 0.039 475000000 0.055 747000000 0.060 700000000 0.040 1111000000 0.045 <div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:78%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended<br/>March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivatives in cash flow hedging relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>239</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(401</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(55</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total unrealized (losses) gains</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(162</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 239000000 85000000 -401000000 -55000000 -162000000 30000000 7400000000 9600000000 2200000000 17000000 5200000000 576000000 5200000000 <div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying amounts of hedged liabilities</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Condensed Consolidated Balance Sheets locations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of long-term debt</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>903</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,784</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,814</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>558</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>292</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:18px;text-indent:-18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">____________</sup> </span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of long-term debt includes </span><span style="font-family:inherit;font-size:10pt;"><span>$90 million</span></span><span style="font-family:inherit;font-size:10pt;"> of carrying value with discontinued hedging relationships as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">. Long-term debt includes </span><span style="font-family:inherit;font-size:10pt;"><span>$592 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$136 million</span></span><span style="font-family:inherit;font-size:10pt;"> of carrying value with discontinued hedging relationships as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of long-term debt includes </span><span style="font-family:inherit;font-size:10pt;"><span>$90 million</span></span><span style="font-family:inherit;font-size:10pt;"> of hedging adjustments on discontinued hedging relationships as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">. Long-term debt includes </span><span style="font-family:inherit;font-size:10pt;"><span>$492 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$36 million</span></span><span style="font-family:inherit;font-size:10pt;"> of hedging adjustments on discontinued hedging relationships as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div> 90000000 903000000 90000000 4000000 7784000000 8814000000 558000000 292000000 90000000 592000000 136000000 90000000 492000000 36000000 <div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Interest and other income, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Interest (expense), net</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,894</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(346</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The effects of cash flow and fair value hedging:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gains (losses) on cash flow hedging relationships reclassified out of AOCI:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gains (losses) on fair value hedging relationships—interest rate swap agreements:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hedged items</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>210</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivatives designated as hedging instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(190</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Interest and other income, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Interest (expense), net</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,286</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>185</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(343</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The effects of cash flow and fair value hedging:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gains (losses) on cash flow hedging relationships reclassified out of AOCI:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(42</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Losses) gains on fair value hedging relationships—interest rate swap agreements:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hedged items</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(130</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivatives designated as hedging instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:18px;text-indent:-18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">__________</sup> </span></div><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gains (losses) on hedged items do not completely offset gains (losses) on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges where the corresponding hedged item was paid down in the period.</span></div> 5894000000 11000000 346000000 49000000 -133000000 210000000 -190000000 5286000000 185000000 343000000 14000000 -42000000 -130000000 133000000 -162000000 800000000 1200000000 <div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.70731707317073%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivative assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivative liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Condensed Consolidated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance Sheets locations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair values</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Condensed Consolidated<br/>Balance Sheets locations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair values</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivatives designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets/ Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>375</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets/ Other assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>657</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets/ Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total derivatives designated as hedging instruments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>474</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>685</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivatives not designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total derivatives not designated as hedging instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total derivatives</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>474</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>685</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivative assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivative liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Condensed Consolidated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance Sheets locations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair values</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Condensed Consolidated<br/>Balance Sheets locations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair values</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivatives designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets/ Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>223</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets/ Other assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>315</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets/ Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total derivatives designated as hedging instruments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>548</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>346</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivatives not designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total derivatives not designated as hedging instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total derivatives</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>549</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>346</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 375000000 5000000 10000000 657000000 89000000 23000000 474000000 685000000 0 0 0 0 474000000 685000000 223000000 31000000 66000000 315000000 259000000 0 548000000 346000000 1000000 0 1000000 0 549000000 346000000 Contingencies and commitments<div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Contingencies</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See our Annual Report on Form 10-K for the year ended December 31, 2019, Part I, Item 1A. Risk Factors—</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Our business may be affected by litigation and government investigations. </span><span style="font-family:inherit;font-size:10pt;">We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing, or in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing, or in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain recent developments concerning our legal proceedings and other matters are discussed below:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Abbreviated New Drug Application (ANDA) Patent Litigation</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">KYPROLIS</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> (carfilzomib) ANDA Patent Litigation</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Onyx Therapeutics, Inc. v. Cipla Limited, et al</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 30, 2020, the U.S. District Court for the District of Delaware (the Delaware District Court) issued an order advising the parties in the litigation that, due to the recent and current challenges, the court does not anticipate issuing its post-trial opinion until approximately on or before May 8, 2020.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Otezla</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> (apremilast) ANDA Patent Litigation</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Amgen Inc. v. Sandoz Inc., et al.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 14, 2020, the U.S. District Court for the District of New Jersey (the New Jersey District Court) granted the motion by Amgen and Celgene Corp. (Celgene) and issued an order substituting Amgen for Celgene as plaintiff in the consolidated action and all related actions, terminating Celgene as plaintiff in the consolidated action and all related actions, and amending the case caption in the consolidated action and all related actions to reflect Amgen as the sole plaintiff.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 25, 2020, based on a joint request by Amgen and Unichem Laboratories, Ltd. (Unichem), the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Unichem’s apremilast product during the term of the U.S. Patent Nos. 6,962,940 (the ’940 Patent); 7,427,638 (the ’638 Patent); 7,659,302 (the ’302 Patent); 7,893,101 (the ’101 Patent); 8,455,536 (the ’536 Patent); 9,018,243 (the ’243 Patent); 9,724,330 (the ’330 Patent); and 10,092,541 (the ’541 Patent), unless authorized pursuant to a confidential settlement agreement. On April 3, 2020, based on a joint request by Amgen and Annora Pharma Private Ltd. and Hetero USA Inc. (collectively, Hetero), the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Hetero’s apremilast product during the term of the ’940 Patent; U.S. Patent No. 7,208,516; the ’638 Patent; the ’302 Patent; the ’101 Patent; the ’536 Patent; U.S. Patent No. 8,802,717; the ’243 Patent; the ’330 Patent; U.S. Patent No. 9,872,854 and the ’541 Patent, unless authorized pursuant to a confidential settlement agreement. Trial in the consolidated action is scheduled to commence in May 2021.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Sensipar</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(cinacalcet) ANDA Patent Litigation</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Amgen Inc. v. Amneal Pharmaceuticals LLC, et al. (formerly, Amgen Inc. v. Aurobindo Pharma Ltd. et al.) Consolidated Case</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 13, 2020, Amgen petitioned the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit Court) to rehear Amgen’s appeal of the judgment of noninfringement with respect to Piramal Healthcare UK Limited, and Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York, LLC (collectively, Amneal) petitioned the Federal Circuit Court for panel rehearing of the court’s opinion vacating and remanding the judgment of noninfringement with respect to Amneal. On April 15, 2020, the Federal Circuit Court denied each of Amgen’s and Amneal’s petitions. On April 22, 2020, the Federal Circuit Court issued a mandate returning the case to the Delaware District Court.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">ENBREL (etanercept) Patent Litigation</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Immunex Corporation, et al. v. Sandoz Inc., et al.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 4, 2020, the Federal Circuit Court heard oral argument on the appeal by Sandoz Inc., Sandoz International GmbH and Sandoz GmbH from final judgment upholding the validity of U.S. Patent Nos. 8,063,182 and 8,163,522.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Repatha</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> (evolocumab) Patent Litigation</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Patent Disputes in the International Region</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A two-day hearing before the Technical Board of Appeal of the European Patent Office, which was scheduled to begin on March 24, 2020, has been rescheduled to begin on October 28, 2020.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As previously disclosed, we are also involved in and expect future involvement in additional disputes regarding our proprotein convertase subtilisin/kexin type 9 (PCSK9) patents in other jurisdictions and regions, including matters filed against us and that we have filed in the United Kingdom, Germany, France and Japan. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 24, 2020, the Supreme Court of Japan declined to hear Sanofi K.K.’s appeals making final the Japanese High Court’s decisions that PRALUENT</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> infringes Amgen’s valid patent rights in Japan.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">NEUPOGEN</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> (filgrastim)/Neulasta</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(pegfilgrastim) Patent Litigation</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Apotex PTAB Challenge</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 24, 2020, the Federal Circuit Court vacated the decision by the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office and remanded the case to the PTAB for proceeding consistent with the Federal Circuit Court’s decision in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Arthrex</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inc. v. Smith &amp; Nephew, Inc</span><span style="font-family:inherit;font-size:10pt;">., 941 F.3d 1320 (Fed. Cir. 2019).</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Amgen Inc., et al. v. Pfizer Inc. et al.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 18, 2020, the Delaware District Court entered an amended scheduling order moving the trial on the infringement of our U.S. Patent No. 9,643,997 to May 17, 2021, to enable Amgen Inc. and its wholly owned subsidiary, Amgen Manufacturing, Limited (collectively Amgen), to seek additional discovery into the defenses of Pfizer Inc. (Pfizer) and Hospira Inc. (Hospira).</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 24, 2020, Amgen filed a separate lawsuit in the Delaware District Court against Hospira and Pfizer for infringement of U.S. Patent No. 10,577,392 (the ’392 Patent) and seeks, among other remedies, damages and injunctive relief to prohibit Hospira and Pfizer from infringing the ’392 Patent by the manufacture, import and sale of Pfizer’s NIVESTYM</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></span><span style="font-family:inherit;font-size:10pt;"> biosimilar filgrastim product, which was launched in the U.S. in October 2018.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Amgen Inc., et al. v. Hospira Inc. et al.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 4, 2020, Hospira and Pfizer filed a motion requesting the Delaware District Court to dismiss the complaint by Amgen Inc. and its wholly owned subsidiary, Amgen Manufacturing, Limited, alleging non-infringement of U.S. Patent No. 8,273,707. The motion has been fully briefed.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fresenius PTAB Challenge</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 30, 2020, Amgen filed its preliminary response to a petition to institute inter partes review before the PTAB to challenge the patentability of U.S. Patent No. 9,856,287 filed by Fresenius Kabi USA, LLC and Fresenius Kabi SwissBioSim GmbH, and the PTAB will have 3 months to render a decision on whether to institute trial proceedings.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">EPOGEN</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> (epoetin alfa) Patent Litigation</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Amgen Inc., et al. v. Hospira, Inc.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Federal Circuit Court denied petition for rehearing </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">en banc</span><span style="font-family:inherit;font-size:10pt;"> by Hospira and issued the mandate on March 23, 2020 affirming the final judgment of the Delaware District Court that Amgen’s U.S. Patent No. 5,856,298 is valid and infringed by Hospira, that Amgen’s U.S. Patent No. 5,756,349 is not infringed by Hospira, and awarding Amgen </span><span style="font-family:inherit;font-size:10pt;"><span>$70 million</span></span><span style="font-family:inherit;font-size:10pt;"> in damages for Hospira’s infringement. On April 17, 2020, Amgen acknowledged satisfaction of judgment upon receipt of </span><span style="font-family:inherit;font-size:10pt;"><span>$83 million</span></span><span style="font-family:inherit;font-size:10pt;"> in damages, interest and cost.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Litigation relating to our Biosimilar Products</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">KANJINTI</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> (trastuzumab-anns) Patent Litigation</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Genentech, Inc. v. Amgen Inc.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 6, 2020, the Federal Circuit Court affirmed the District Court’s denial of Genentech Inc.’s (Genentech) motion for a preliminary injunction. On March 9, 2020, the Delaware District Court entered a </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Markman</span><span style="font-family:inherit;font-size:10pt;"> order construing a term of U.S. Patent No. 8,574,869 (the ’869 Patent). On March 16, 2020, the Delaware District Court signed a joint stipulation and order vacating the April 20, 2020 trial date. On April 17, 2020, the Delaware District Court rescheduled the jury trial to begin on February 22, 2021.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">MVASI</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(bevacizumab-awwb) Patent Litigation</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Genentech, Inc. and City of Hope v. Amgen Inc.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 19, 2020, Genentech filed its second amended complaint in the Delaware District Court, adding additional claims for legal and declaratory relief with respect to patents already in suit. On March 4, 2020, Amgen filed its second amended affirmative answer and counterclaims, adding affirmative defenses and counterclaims that the ’869 Patent is unenforceable for inequitable conduct and unclean hands.</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">On March 9, 2020, the Delaware District Court entered a </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Markman</span><span style="font-family:inherit;font-size:10pt;"> order construing a term of the ’869 Patent.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Genentech, Inc. and City of Hope v. Immunex Rhode Island Corp. and Amgen Inc.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Argument before the Federal Circuit Court on Genentech’s appeal of the Delaware District Court’s denial of Genentech’s motions for injunctive relief has been scheduled for June 3, 2020.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Breach of Contract Action</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cipla Ltd. et al. v. Amgen Inc.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 6, 2020, Amgen’s motion was transferred to the U.S. Magistrate Judge for the District of Delaware for a recommendation. A hearing on the motion was held on April 28, 2020.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Novartis Pharma AG v. Amgen Inc.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 18, 2020, Novartis Pharma AG filed in the U.S. District Court for the Southern District of New York its answer and affirmative defenses to Amgen’s second amended counterclaims.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Antitrust Class Action</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Sensipar</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Antitrust Class Actions</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 6, 2020, the motions in the class action lawsuits against Amgen and various entities affiliated with Teva Pharmaceutical Industries Limited were transferred to the U.S. Magistrate Judge for the District of Delaware for a recommendation. A hearing on the motions was held on April 28, 2020.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The multidistrict litigation panel certified its conditional transfer order on February 6, 2020 transferring the additional class action lawsuit brought in the U.S. District Court for the Southern District of Florida, captioned </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">MSP Recovery Claims v. Amgen Inc., et al.</span><span style="font-family:inherit;font-size:10pt;">,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">to the Delaware District Court.</span></div> 70000000 83000000 XML 51 R16.htm IDEA: XBRL DOCUMENT v3.20.1
Goodwill and other intangible assets
3 Months Ended
Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and other intangible assets Goodwill and other intangible assets
Goodwill
The change in the carrying amount of goodwill was as follows (in millions):
 
Three months ended
March 31, 2020
Beginning balance
$
14,703

Currency translation adjustment
(20
)
Ending balance
$
14,683


Other intangible assets
Other intangible assets consisted of the following (in millions):
 
March 31, 2020
 
December 31, 2019
 
Gross
carrying
amounts
 
Accumulated
amortization
 
Other intangible
assets, net
 
Gross
carrying
amounts
 
Accumulated
amortization
 
Other intangible
assets, net
Finite-lived intangible assets:
 
 
 
 
 
 
 
 
 
 
 
Developed-product-technology rights
$
25,549

 
$
(8,876
)
 
$
16,673

 
$
25,575

 
$
(8,322
)
 
$
17,253

Licensing rights
3,746

 
(2,494
)
 
1,252

 
3,761

 
(2,398
)
 
1,363

Marketing-related rights
1,375

 
(979
)
 
396

 
1,382

 
(965
)
 
417

Research and development technology rights
1,269

 
(967
)
 
302

 
1,273

 
(947
)
 
326

Total finite-lived intangible assets
31,939

 
(13,316
)
 
18,623

 
31,991

 
(12,632
)
 
19,359

Indefinite-lived intangible assets:
 
 
 
 
 
 
 
 
 
 
 
In-process research and development
30

 

 
30

 
54

 

 
54

Total other intangible assets
$
31,969

 
$
(13,316
)
 
$
18,653

 
$
32,045

 
$
(12,632
)
 
$
19,413


Developed-product-technology rights consists of rights related to marketed products. Licensing rights consists primarily of contractual rights to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and up-front payments associated with royalty obligations for marketed products. Marketing-related rights consists primarily of rights related to the sale and distribution of marketed products. R&D technology rights pertains to technologies used in R&D that have alternative future uses.
In-process research and development (IPR&D) consists of R&D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. We review IPR&D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval.
During the three months ended March 31, 2020 and 2019, we recognized amortization associated with our finite-lived intangible assets of $709 million and $315 million, respectively. Amortization of intangible assets is included primarily in Cost of sales in the Condensed Consolidated Statements of Income. The total estimated amortization for our finite-lived intangible assets for the remaining nine months ending December 31, 2020, and the years ending December 31, 2021, 2022, 2023, 2024 and 2025, are $2.1 billion, $2.6 billion, $2.5 billion, $2.4 billion, $2.4 billion and $2.2 billion, respectively.
XML 52 R12.htm IDEA: XBRL DOCUMENT v3.20.1
Earnings per share
3 Months Ended
Mar. 31, 2020
Earnings Per Share [Abstract]  
Earnings per share Earnings per share
The computation of basic earnings per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which include primarily shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method.
The computations for basic and diluted EPS were as follows (in millions, except per-share data):
 
Three months ended
March 31,
 
2020
 
2019
Income (Numerator):
 
 
 
Net income for basic and diluted EPS
$
1,825

 
$
1,992

 
 
 
 
Shares (Denominator):
 
 
 
Weighted-average shares for basic EPS
590

 
622

Effect of dilutive securities
4

 
4

Weighted-average shares for diluted EPS
594

 
626

 
 
 
 
Basic EPS
$
3.09

 
$
3.20

Diluted EPS
$
3.07

 
$
3.18


For the three months ended March 31, 2020 and 2019, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.
ZIP 53 0000318154-20-000031-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000318154-20-000031-xbrl.zip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

5_C".56SFT C6EX+1A$R@J9R>[Y\H[0(R)QJ*VCR)NYNP?\XN@>2RF%+EWH(0*)X M6_1> Q&GX( 'NKP%Q&NCSGG@1],W2'>%<[XY\?0!>HD\-;H(/FIV3@*&N$=: M(\LH*6?EK@E2(>F[B+DH8 (0I[A< FHXQH=MF?H:5;F-3QY,W5ON+?Q,']^AZ65 MS4@5.PK>6.\AD=)@XR "'")PQ:#9DKZJ$E*!30F M4 ,@<7D=@9*HK&+0D[=R]P-Z\U"2S5VQ>F2XO/ P>^+S@!'CJ4X(A BF3+V M2E*.E@CI6MV.Z!>IL#82NTR; 1&0$'BI+ Z&3K*710AFQ68-OK+7)O9 MK9LB.@QCNJ]UB2WWBAG%K! >2Q.744+!"@]MJF".^S%B&H'RMHH<'^VTAVE\75ZMBMBYLL?OW&9XV[#$PJPBWP%!)?#P//*:H MQ(<@+G-.W]JFU&_%ZL_E&]LL^\&]+UY6+,CYK%JD$I8J8Q73BFI$(%!.EC,A MP.;X)]2WDBXWL_LWQ9\,*(<@A7E8)90J#22\*5%!12Y@ %<)?)/,W+ M"Y$3I%3=W/F&#\%\3(?@RN_+Q54MNCPV",H8;0G"5CCL-4*>D!*IE X_Q\=[ M]#;,=OG2&-1A=/>\2N)., :HTRR5N_9.*2QT.4.ILI+ECMZNV;:NW1C6QM;M M1UO%\N9%>>?ES=;BNKF;;;[,?OQ9?)C-K__XNER\O]J1^RHV,7>I./1\89:+ M343Q\VI^>UO$;F[=M^-[4/>_-#BK% 0 B^5UM101TJC,%6(Y7A2C=[QMSDA M1R>81TKW6N/\T]5=/ ,V$)I4H22&&J-&\(YMIX M5&5Y]'$J-2ED+@FVU@M@)6561HU>>K.?FS(@*Z'#2.W:.0*N4,B\'J!]:KRY MA.(X' ?F8::#?I&H\U95NED'D].(N7,C[0,0D8MC!O$ M 8Y:/5&I+$$Y7PGASU'4O++0SQ0USP=WF$MV_=+FCFH $."(4H0 5:A$BWC MC,H*G1X?9=H\H;+!'(8B>:7-L:*>$,X4<,@XB[#4)5C&8IV5?7'L=*DGXJJE MS>LAVH)3="_%0+GF%ALL!.=4$1*W8T'+66&O20H'B1 *FZF_'ES*QU.2$] M;RDD,9-'[2/=,8=:+?TB 7)Q?S5>"&R!)%[)TJQA@6(YC]YO*=ZP0PXU0[H% M#@U:HF,[*R<=B9<2#%"\OS)YV'69R-&5WE*T82:ONL2\.=05S&\^7-5+R;& 0D/E,:7.X7*AN)1P>\HN M.ZU=Y#K%O"\#Y#]FJWDRM28OAPL6ZI>?!F:4U%[%.?BX>N*=E<2+QGY&AF5M M3:._QN79IS.A'((<%^W2KS\.!"J %!>.8BT%P03"TI+ATBRG96EL+M0S[&B$ M9(^OZ]?+Q=91ZL_9XJ_W-U$>Q74:]KM?]?N/%]],*[4//.[&0'NHL8\Z'),: M0E?./9[5$WO7R!'^ZY?WUN%]>R'TW 'G$9/$*D,C6HH>O*&\5B[GN6/T1J(V M7U&;(MI85TY$O9YO2;NX*I*KYGSODKF*?[/^/HO8WV]%LKZ;?SVE(M?K):J$ MB$==$*.H&49%S0ASN =XP4R.9CS"S29;PLN^D.YOWUG-OVVC!Z,R'X=:>C^? MW7B.-PF842\M)!PC!PG%F*O2X.49E%G5Q:;+I99AG6H&#VX- M3$O9UX1S@' M^*!<>N%-5CJSGX%<'0'=_SZE9^OY^E,4V.SZ_>*I]EAIRSK9.I"X-Z?DIL!R MHIR1C.KRV=!;9G/B1T>O-[6Y>[6%\$#A,%L5\NT'O7"C,&%.>R(LM1 +X8!! M*N6?A]!7R[[6S0S+>*/W-\\YN/X<8=;Q=_YU9K:7&P>O*$"1O9H2ZY"/RA:# MY[KA'@<^-/C[7%?VJWL>B2KU%-05'NKD+3(J1Z;R=\ZP+L[@^17Y;+Z^_S^WNUN-YZZL=9Q+-D'L>L MUNMB,]Q)\F1@+\=4ZX"IU4]P0L=+BH'&Q_LM-9;CN$=()!T50%->:?<=$(\J MVT.]CH( U&,@$(/.1<4*4XY\B8@R8&*!,!VQ9=FC"(;?,_:1UVD"#[/[GVP' MP98RX@G@6B!KJ<26J9VPF([WT4H.:MW@H79IX;;2WAY71S?Z(P"<;QBTC;<@ M![2ABL>;D2?2D?V,#38@QR7OS>\0E=FP[!#ROE38>"&=;XIW4>MY!6 M]+0?JO8OEW'R^?=XM'W^7MQ_*WY;+C9WYS;4O(X#T/'>:DB\,4ALXFH77IH2 M+>I43G3["&W)8V1QIDC&2>"T$C]_7[;&VWU_06.%F76".RP(TIP**TML),@J MSCE"R_08Z=I,$B-F:7+B;)>GJ<< F2("0Q3_3T!*XB;] 1\*?6!66IY3DKJ$8:KC)6I#40Q M8J+&;]LE:OPVI34$42'RRCG&*546Z5(QLMSKG&?I$<;#C):H]44QO!FQ_/N/ MR_M[OUQ]GZVNA\[I.(Q),>EK1#G!XD[CN-! 2+X3'%>"XTI6BV[Q>"*B"K-^ M\G40B*G(?ACO_8BQQ$>WWSVY-I!-+ -D1W(_\;S0'.>^3JERI!5(DPK1Q;T2 M.8()=UYC))DL9Z!U-<-Z6TSY6JSFR^M/F]EJTPM?&DGR!"MJ MDW%>(TB_GM M8I?"_^K'Y]5LL=ZY(?\RFR_>+=?G#&O5.PF. 8YYQ,\3(;T&4C)3HN!EEE5B MQ*;@-HG4.LACW'644-PIS*#7CA,+D08'D#PCO?KM[G8=M^BV,$TX]&(?7 M/7^]CIW.;[;.GR>>MW\R)=0C*+"7'A*%H#)2$KJ_K'!$*:ZT$+KWG+LN;DY? MCBYE**_74;#>L#AS2)TB\?YOX_#*S0UY!R86+ML16\ZXT[4N@K[.EPM#US]^ MF_W7,HRJC7Q B/%<+G-8@\9G!8ENR++LD\AC(24 MCW.HE-6V06]!:J,DL% @1(@W2D3-H<1%09&C2HV0G)VQIAX[6Y!$?PS]L%I> M%>OUQRCC^$OOMO5*OQ7WRZ_)@_]B>H)*[8-DSANIA=#2$T:)8@*6<\?6_UPL MS&/'*R:VC_](=L>GJ_5=A>0&3;H+VA-#L% 19&TY%Y@QO$;+Z#?Q2)X%HCH'WQAD@H,74(HX.*&A:MRZ:_02A)<, VT1AAQZS2SUKL0!:C&QZ@Q=$*2Z M(AZ A7/(1[7OU:(:*U+/-3D2H5TPI3J;&Q! OUE']G>PHKKS\75W6)YO[S] M\3%5([A<)NU"RV !P\9ZJJT2J>*Q%2FC\W:^E,?EWR?C^LA6T!D?7N4C:1/W MWA),SJ^*Q3IE)+E=%;M\))>32IYJ$XQE"%AGF44*2ZMLG'0Y1^)ICL/'"#6\ MOIC5%MY]<>JWV>JO8A/'^S%EHSL"SB6"5>L@*(^,3_FB!!:,.F'BG,O92P-R MTI:.,*BJ+[9U G[C%)7JZK\?YBFGZE$#9>7#L7%?P?BH!6LH%39>:VZ=9\;82A4UR3K2PXCN#A4,3I7:1Z\%QY:![!S!FF.@'>E3RF#&$S,[6W8 M^VI3U$? MU]6YQTM+S4-BB/HD&%:,VFP,D9X6LX8")?SF/&VKJ(-2%"=84VP M'@&[U-75PY>'K4+P-&"E8?31\2. M@8OB-HWO\V2)V(X01D#-WXMS+I/G&P:-L":4.^'C_P5A6LGR;9MQ:/M-S+#< MS.XGR;7Z2#>^,)QS SYU1%9K&*SW&& *J-'80Y$TS\/*H"(K\&F$]\UNWZ\Z M@;P3TE0_^9IV%:BR"H&49%T(ZI&%6I=W&RXHS#GWJM\QGY][4Z96.V+HSX?D MU5Y:SV_D&>T4B+=I)"4_V*8Y9CK'DE8_BT;GIV _+_,= #]\D,W MNS#E>Z&'?MP5/.J%ZVZ5>M B XU2\R"EIL MJ!"Y;Q^O:+/L:96^P 4--ICZI#02L4[ M)*7EY<%AB"?V M@M?[I$OONCY-=%_&/Q>?;W@.?%80RU3HJ=!!?/(:12RGL )6"&B9*) !@ MO?J ]1$;T (GECV!W9=9X8_%JKA:WB[F_RJNX^AUL2ANYIMUG,ZJF*V+%!'V M<)_<0'S$Z#*C']"2FTK MN1OU-M=J^N7I9H%KIC".UU5/,24FZE1.E[.- .2DFARI?MF"Y%_IEZT!W.NB M'5Z_;'OM*HUH/.N!(1H!H0Q,AMT=V)@8/6"^G<.H/\Z^_Q;UE-5\=I\,TN]O MD@_>ZEMQ/C+Z4N.0+C!2*.X=ME([!+Q0Y$>T,Y3'N[?"$)35M B6IA^_H*G0JS6<>^=7 MI:GU^G6P?./':8 E^F_RWD[GI,6K+9CQYOG5VLX]\ZO M\XYD3S\+4C-",:/*XJA)8:,$%N5,!,X*9:\?%=#Y@WFG?*D/9Z]JZL OWEUH MJ8J)2()4229J$$0HNR]$)UC\YX#U4I\^=>W'OS='-"JD?*Z+X#T3&,5+$3!, MP^236!I3!%<"3/!EHP5&G,G\V"+8_2SO]68;2#GHPMZ/(=6W5HMK]]\/\\V/ M3\75PVJ^B3M/Q75>K9.DVRG)(8[RU 0;%N__>_.=Y@"Z 8NU6C5!>_,J1,@,YYJ"!B&GF,H\I3HBR1 MZC7C?5_;2ML$/*(HC$!6O>Y*ZMML?I^FYY>K3[/DP?H$YE%4:NY[^U)684"M M@YP3CYA2/-Y0+18 *:(BJX;;OLQL?7=FCNFO P.*(^RL9,Q9*^,Y".!^]%3; MK,H%;WU;J"S893:N_>5N^7/S9*8OUO+'8G:?GN)^.9](J'HGP7.G$)%>8X"] ME9I0)DH4(K"]!@A/A%V=H3\N#EZHS5*]DZ -MISR10CTF*#'#JL1"-LK[%1 M/Q4'&Z#?JRHSAF>^/A65E 6#2D&H9LI[JX H4_(HXWFU; U=FU=>7M+M]@IRTMK0+?8\1W+/%U7QV_^LB M(O&0L+J!K8__U<5$GFW^FF UI49"KQ"V1@&B/"W7 MO"463KBN[4KF/G^ME=IDVR[L32-L5^75P_Q-DVY=C+YB$J%()AI*G13".; MRGX=%@P0.H=D[-\DJTRR3+FTS;)M$J%&!'O2,CBF*4:40"$SVT+/KOXJKFLH;I7["-Y*Q#B0 MQA(JM%26BL/2,B(K;9_X-RV/*F]=":8Q4CK5%_IN$1TG8GCCZHMUORT7Q8^U3U >7YL8(QN'J/@6RO":*S9;4_]3W=QM_UK\E+^ MKD)5EEK]!,T%M(@ AA U! G,T6$9QI_FY+ 8X7-']]X(7:+?FYKW8N0O7/EV M2:>+:[.,2VRV/NL$4[>K *@DF#!#>%R=@#MB7+G\O1&JWZ??SD-3.V++2XVO M6R&,A):/:=&WR?=3WJA'/V==W"Q7*3-5Z[ MMM&XR9TCH*'(_3BOY[.LP=]3702DB,> X<0%EIK05D9H0F\QCFW^Q$^1@_# MS9; [S6$XZ4K^T\:@DJD,XP:PZDWT)+X'T C2R!P%## !TS-^'+(_MOO\S-S M/O9YD-1*+.*,,'/*<\]A"J#5B<6UB-^PR".4,EQT)&H)Q1 MD$%68B0-RBG)-T+]?P F=B6*7@^EPU#7^L>V*O7\9GZU[>]GBSAD A*JD<;0 M6H,1@UB63T[42U(I]'8*$8>$)B@! &K4U@^WA/81B\K(B_4]T@E4F2..( MPWK0O\&(0TVC,LZXX@0332$C9;EF1:V'O>:I'L?-J*;*:-QLA@"A CA%O#;'D2,<-, MKSF0IG!"=XE^XRWN\<[W>EA/EL?+"^&O"[-/$(:<\!A*7F&GG>DV0TL>6VA&CEF.45E][;4J"ES)> MQG^EV]^W.,^4/7)C9JO5CWAB;<$XL\=6:A^P%IH@FDJ6:@>0,_S@Z\^MM),Y M_$?#H2.I#MN6TMC>+_>)HUMXQMSW%#"*1Q[ BFOK&-:(,U):/;AB/"=%_ZBR M(HZ5M=W*:VS\;>/]W7ALF6"066B-4E #7WK5?>6^=K33$- M]RBR7&P!>9C=_S;;I,'_^-E>1BQTWC(7;SZ$I-)9&BB<4DVY>!,7=,B7D?-D MV\MK_U0W7[Q?%/]9S%8'Z3;>;"YU'+C16AFBN8] \7CY4H*4B!D#)I:HK LJ MU=I56I9':[;#4Z-4-U$H<9"?[U;+A]N[^*]B.^#U.6JV_!L"PE!P93BF&#@( MN<%,[C$A4NM>J\&]:8X.*YA^R+H=YW[,?OZM"[:>_Q5!"X,@PT1(B:5B$'-P M0 50FK.ECC#UU*CHVJIDQG'C>#'#-*MR11:+B^1N_7<$[8!U1%JON1/>:FK) M(X9$YE1^':'/\(@4AK9%,S9Z[YW4/LT7M_?%X0(3KWUM:\'G?TE $FN$.!+LF(^\XP.[^9?YIKC^,%MM%G'SN)M__8E+D<4!, Y:21D*2R=%K"2KI*USX3C]/Y=1%E6WPLOBY748([A^QDUHL[X.UR M]:.ZWVR]+H.53!,)(BR*4,@0I=:6**6*1C^M":@R?U,$@V/M_5J\X2G M\;]>!$;*G>]$N M\T'NG!@GO0M??!$< (QBS#5T\8B,RIN@J!RW%'0B6TM#6;V4="/,NI3U;_/% M_,O#E[/2?O9-P$0[S%DDNS>*,*P09.78M9A*H9[&$ENV@UNG,I_]?5GF3[\) M'!JI&4948PLQAK6^59DGH%;7W=9_;">+XKU6EU%K6@]WPKD M? C-B18!4:D]!LHP9XQ(FA3@Y?RDR]*X8M O[D+1*?UP5Q<4PF8MM M U:<448XQP#:""43U!SF+&%. /&(CIW6)%^!23GX-G[GT\7\EV)Q6KM\_5$ M@(JH8@GOL,<:>N< .8P,TIPD.Z/R5.U 5LN60.UK"WG<5U, SH5#Z?7'01KN M&(;40H\QM+2?_/Q?6YE>3)-\N7'P@#+# M>*I1+SU@2&MSF+5"HM4]Z9F#?YV=D^O+UE*BB?-/6/PQ__8UZLXN^_^_&N M^%;<7TI<4*F#(*6'PC.G)$OO8P( IFOT?NAU(H7>.?C;MI)D M\=RA_#"-B_>S6OT$'%Q!'3'E A]; M%4'_^0PJGR+O:J4WJ-]M4)Q$F2,D.)!6:!O_HSR@&+)9-0=&Z)36^SG>HVSZ M8O'.J^&W8G.WO'[B\W"&H"=:! [B!..TJ.91$8<6((P/\XM_.:V-LA\J'$W8 MF O]L-12M[>K;9KQ5!2A-LV>M0X,*FFB)H20E$0Q[;D\6"#C4339$BN#4RY' M#+VYV]Y'D2RB7+\]B1P^YUM[[/O *76,*\4 IE'Y5@8S6LZ-(CJQ O*P- MX(?=T]Y_WQN5HN)ZE21]>\X#LW(?02D*"90$R93"2]I4HK?$(.K#.4?J-,PR M7>UO^<(8EI#_]V$9X=J5!KP4$U.QAZ"I(YP!)QA"UEI"O#O,'Q.9$Z\XC;M% M5V3,%<6P5+3SFRC88G%5Z&+SO2@697:B'7YJMTCP(;V1\$&DJ!)4I"K;ADC@ /=&.:"LI90[6&E==(/$BX)W M+T)8MV)*Q;IT_.U_G<&B3C?!1B(20*&-=R4)F=WFT-BC81";F)-M%S19]H9^ M8Q?<]M/T721C+[\W$*NL<$PSY0CD4$&N18E?%-=DDH/VP-\Q"JQ_Y]%U.;$X MC:.I%^,$*V_$.=T&'C4&RZ@@%FEH&(P;!2R14GGUZ&M;LM\XM0>01_<*W,?B M6[%X&%!OVP_ 1TF6"*9<+^9AO8E:]ZJ"TE:QAX"8!EQ+(WU$71A%K-X7R+ & M<%2I",X@&%39)*IV$8A&QD$N;;Q"<&\9TXB5*%!*)I;3LW5N+'N!O;]U/W36 ME_Z6/S2 81SW7H0]E)H8S#&*FWY*A\8!&C#][^\/R>'M_2/<[)-P-):;1C1V -MHV)$(-C-4T+JR<1\:%N7_K(;G/OW3W2+351!_CF_ MCBKWS7+U92O,)W"YO[FQ%9#D),:9(0N/EUS> PRZC3<:C?$]ZO] ,^D)CKV:2!0((40U0 J M!C0V",AR)O&$S@G^'.&..3 ;EJT*HP=:/9WKR7"7L]\'A $6U"B $#$<,IHF MN9L3$II/I&!LODA?/(@,-$EMHICCS,24,W0I?J%J3:'+S&(GV_*?YU M?T&F3[\)R7@*?1I.W$(8I_\><]] C>AB9PRI'*1ZAEVX+4*>@T-AB0X"G+#%16"@(H"9G(8_0=;0%:;<#9,8)?%>LRHOZ MI8/XU:6J P$Y(Y38&4BI7G5-1)S(120W=F^VH#V"XMZ)^B9+;)9'XIEK>KV=>[ M^=7L5.ZRL]\'[D147BS#-N6$$4 SDGV(B,M2W)==D^HM58LBYILBZN_N?M M\MO_NDH1.:L?B2F\_(]$%/Z$*/L?AS\^'6'%XU\&(Y(G&&4"&Z&IT1)0\#A] M/1'WN):$MLR$KR_UY??EXH_3"NV1KX+&&#'B)1,>:"0AP*J\:!'&^43J$[1+ M@WP<>XNAK'FJOJN0P:UQG\$;8IS5QC-GK5-,Z\.Y3 66.7;,$3XYC$.WZ5MJ M?3'[@BO9KXNK^X?K%'>_7A?Q_]>?9W\W=ZT]UEMP+%YJ9)1!LBAKYIUD^H"+ M1Y,KNM #@^KYG+<@E9[9>FY;+3^)FH51V&F?ZE]%'2->E 4L9\#B!7<:)_+@ MK*H+='^1"@/'E_<7J.#@-IFC M02HCCG41+[4!&EAHTLGZ]G^QR 48;O;_8S MJAY27J5]2$6*J-:.8>&I=M9;7\;B**FG5K"I=5:\#"3O //N%_VG31S5W?(^ M2FW]/#]4[PM_]^LKK._G'P8OH\2,L34?.NBPZ9+6/*K/"J7$ T@C(BB$48@>.0VT$DP.MZ35 MU=7#EX?[E#=A^Q24$%\5=\5BODF>&"(UP(03 1W(.4 MAVB/AA&V$AIOYYQN2H67:6^[0[BW$,/R[>#EXKY0E>ALNV P$I@C:1R#3D!F M#7#E7 5@$S&\=TN#5T=(>X#WF][N,-2+]86.?A^D$0A3HQB1GG@NE+"VG!N* MQ^_J_B2;+0IJR!YU'(%=0 BH#QC2'I6(J(X[34@ZDWSKPNXFX=E MO- _'[=AM=FLYG\^;)+FN5E>V-0:]Q60%88K)1UA0!&*;-SS#PO-9SUZCS B MJQU2]87V -O:J4M0G?WL?!]! 82)U5H9[!SE&AN+2PRT43G.?;7#Q=[T1M8J MSB/B6MJ%WU7P]*G;59!$$(^C/L&UH0QK3E6)N96,YQC*1OATW8MIHV,9],7* M.-*H$:P+6^S^_>OBM?'\X_+^WB]7WV>KZS.DK-E3D,XY%4%QS&(*&2?^<,VR M5N!>L\3UL1MV1YA7V6&[%$1_-MY3[Z^5W@)#!(Y[91CGA&GF.4P^H_M9<2(J MY5IMBUY?B]5\>?UI,UMM.DX]W)'D+[X,UH2[+Q*=6F@1@&)^NS /JU02Z,?6 M&C2[VHIY<=PV%.].[V\^S_[^L%QM_^*)IOMYK^F>X6>OXPC*$ ,IX$ZD*#Z/ MA0:^E(6#ME?7\7XR;O=#^S%+L;<5=377Q4V<\,?BZEGJ_/7NQW%2===&LQX# MDM(I2Y3 5"@)(85:'O AU9["WX[3>F\<[T4:_;GW/I]$\G%+[A^[I;KYL#V7 MFQ(WO_/ L;;*.2B@L-Q2%(55GII.:97#X1':H/KB<.^"R1S8EJ'F$&HZX)V)<=KV+YBW M8D0 CG$&L":8QWW; YPJ=4XA%6.$:%VMJB=$<$MKB?!M6RPA_ BWGL-)\?G MA]G]6_4A!@PIQB'Q''MC%2+&:R,A5XA23O2 /L2/D;E;[/?5V:H7@'C5*N6M MDIX;3(E0Q'(%4U+0_5P=S:H=.UIWJ?J"/EFM(1?07E+[?+HJ%K.X-U9)Z_/T MVZ Y)E1S8[%3!CBI'7;E7# S$POS:D6JQQ+S9&#:*3_VP_ICL?Y:7&U+Y)U/ MRG/J^\!2,)KBW##@( ">D++.474)E0\(5.FR_;1[(,AR7Y[-5N?=C(Z_7%0 M##,8+_5>6R6HM](04\Y&85JIIM<;X4:^1(_P(PO.OJX1VYUROV^^J^"?KYX?BZ\/JZN[>(_ZL$K9 MC;ZHA\W=.T4K- ]&$!UU M#^B( P80*0DJ%08I' >@E5$!8S[#3 M./YCFZP#0N_-@,F=7F*]@_JRV^PE W%6OP$CQ+F4UDII&*8,>H9*O)32$TG) MG$N6"RX874(^E#-1U3E=2$J1TVV@1%++XLW$"[:M32B(*Y$2&N38%$9(SIY8 MU1*7&PAH[%2^F PCK^, N=@FC31*6\"1=A[: UIY/IT3HG,]8K7$YD82&CN? M+P9WYG4<*#:(&N:]4\!Q)C11Y9:#/-6]QCB-E\]UJ=42HQO)J"]&VV(U_Q:G MDP8;=;&']"BW+B/U]8^4-V*^N/U8["(+UG?SKQ?4C&8=!FTUY!XZ""!5'&BD MG"_1@1SDO&^-\-%B& 6C%]'T1=PCH[VH-9QL$YAD!@"/'*$>>RLU >4IAX29 MVMM&UT18=@-[;R:_)TESXK@O'MY'OT^N_8YA+0"T$@N"O..JG!N"K-? T#XL MQBU(^:5IKP5%:,EG.5+&I9;AM1^@G MF92-;U],V@<4N[^O[F:+V\.X+QYX9]L%C3A15'H/#8[* D4$P0. 1N34+QDU MEW+$ONP.X,9!@V85M<$RV/S3]]G7,LQ("8;3G*94T<=B#YM(FW3@I%'=5@:Z'$4A\0I"C'M7Z$+^?# MJ$AM2J OMK637%L03A70VC,A.(Q_D >3'2; Y/AEC/ D:TG.E9)KUT-V@-1Y M/><^=D Z!IAEV#%"J,%.'/ S+D^F39O,OE_MJ\R>"6X\]FD@6'')H<5* M"LIT_!,J9T(0%SDVJA$F]NA7 6L)]![H\[1,\=G@QY/?!RD\A!9BAZ4C0CI] MJ/H'"5-.3T/7RA?I:VYD@]G7 ;9PFV MU=((O"EBY,ASV1Z20_G4/*8MJKJ[OJL0*MGB;PD,*(^LPYA[C8CS48<\K%5+ MLGP5JB<'FNB9-[R\^N/]T 7LK?&>.TZHBG*A'D/$2SLR< ^/:M7S7G9&@-^*S=WRR57]G!;1XRB"-) (8;A7'%/@M,!>E'+@G.7X M]+X![X\AUL1XI=OO*HLSVV\&NE@4-_-S07\G6@1"E+.$Q?]IPBBG\<_ETR:5 M(NN-M_K#7-\)-,=#XER!]*9&%)O']7).=7CZ7;"64(1]4HJ 4(99?5")J*$X M)SMK=:-C3PX$8^!4#OI#!%-O@[]?9;AXJX'4Z9E* HLIE%>1G,'^0YO1!VA ME12!KGPZGF42N;8/JWA<[O*>;V5PWK'C4N.@J'4 0TZ,M3[^@U,ERYE+9:>= M5;.RV,^G=\G'=: L0\\&_H_9_ MV$=XQ>R!2TU@'>(PV-HAW]ZNSU!Z^#'$<(ZX%@HCLC?Y(RZ9JL37BHZ>QQ-" M;7%+*:AU[.:O4\Z>5=J&J"!(CK3RACG(H/%*Z'(N&JB)A:2R6UA[V\8/ M"1GKU,<\1[26>@X("Z6(U%Q[AQB@<1,L]RHA0;\%YD=/PV% 'WL@?V6NMO,+ M0@H7U\Y')4TXK100M#03(<&MRM& 1V@$;(FR@V#?@VKS\.7+;/7C_UB M.[G%)LXJ969,2MGR?GXU'U#1>3V4"DK/Z49!:BH-DHA!)8RWE"*X,S,P(!1P M0Y:/.(=_I8.L4@>!2!=Y+JT5 "(M01[W3HB0%W6"\ HG8+;(,/+TZL+I,>R MU(JN019;'O9XST.C*TY*9^B$Y4+V_>5\^F7XJ M;B^]%9YLDS+! $J, T1:S9&$R(K=/#5 3O>:&:#[0[T-@;^T1[<$[0">_;:( M\KF:;^46_WQ?[,OWJB^IZMF_MC^/M[TXL=;;G8H?GCHAWN8L- -8@7J4ADZ A' MUABB]'X6E/A^<\0-O+ K"W39(<*-X_+U;#U?O[_Y\$06%4ERN66P%D,)B? * M8TV5AIZ*<@[0J9P:5&]M^V_$DM8A[BWI521T'.AU13Y5:18D]Q #33&R3"*. M)0:NG*G!OM<$1F^,3!W@VQ>3_EC'7=*M-_,O40,Z=T-Z_F&\A%M@+<,"(TP4 MH!9[5,Y&(M!KD?HWRI8L1'L, SNN[U;?=:IV$;SD" KO++=0>J44('R/ (-, MYSB6UPY/?:.DQ I0Y8DF=L7?SO__'_ 5!+ P04 " )IIY0 MM,;\BWXP @!:$B, % &%M9VXM,C R,#,S,7@Q,'$N:'1M[+UI=]LXMB[\ M^9Q?H>N^?5;56G%"D )IJIS%PB2*;^=V"G+Z>XZ7VK1$FRS2R9=).6A?_T+ M4 ,IB=1@2^*$[DHB">" O9\]8@/X^?\]WX]ZCRR*_3#XVPEXKYST6# (AWYP M^[>3[U?N*3[Y?Y_^^^?_DY_<]?XY9/$? MO9LHO._],XS^\!^]T]/)10\?F6>83--5I.G74%>P>:-?WS 5@^OAT-.A^>[Y MHXI458>* 0P&(+OQ,$!P8.B*R?^"0Z3/;I8]?3!]^CCF[SE]?&_>C88/+Y%_ M>Y?T5$559J\T:;]+^'CYF(/X;R=W2?+P\<.'IZ>G]T_:^S"Z_0!,T_SP+/J< M3#I]C =W;!CZIS=L&(0)FU]TX\77Z25#/_ZPU.F#J@#S5 &G&IC=YB8^]8.$ M12Q.BF^1ZU!P>7SS<.I?AZN7QLG]AVECR67QNLOBXLO\P6F<#.>7/5]'H_^%?O&S1$O1L[B<^$'!^Z5/FC06\2@"RA M?O!8]D+K:;C0I> %XVCQXHQ_49DXII 5=UP/ZFF/-<">=UNO9:8]UFB:F<+V M?:^$J?D>!4,:QZ=>-(C"$2M <]+! ^_YJSQJ(G#FY.XR(VBP>F;452R@:C@3<::&7Z=-Y>/GVT]F':(WO> M0\0&POLHO<;\,&7_AZSSH@26ONR\N4#RHA+-$!4I!B&-R M98^9#*] !0T*#,=4"0V*C,:""2^EQ7*O=3?:["T4JZ:%9W!N;?$FO%?!C;RH MA :\H: [>Q[<%3]+M!1<$ X>;DJ,>MJT9FSKQU1J)398B'+K4*ALI@V%EGWH MW_A<2'@$/SP,"A_O[2YZ%E_COWDI>1I:5N1[#^7$1!PQ1F, M_(")L#%[O;+W*L(%UZ'7)69$-!6-85BFB41+P05E 5UA#"<,R5HK4XQO[AY> M%]C1J>=X7:25[LJ&<5'@:;UC)WJ4>##EODN1Q7PH82YO*'2K)H^/Q_=WX:CD MTJ5.:QPM=;V?I199DN1NY'LEDC5M+%%A[/:^7(7QQG7CO0NC9(L1S[H5OT'I MTXO0ZM^5>=F\I5"^RZ1(M*P9V^9AE8PH&-\7Z\]A$GT0+MH'WH-%_F#N(G.- M^D=YXDJT+KO^R^'2BOM?GD:Y+C$CUT7V0^2%UL=X68>"Y)%W?QLL#(S_P(+W M@U" 2OCAB[[3^B@PWZ-(9 M4&R.2DU1D8/Z4'QSK\B;%?(<,7^-PR):BTW1?5CDB4V-D6@L\5OX'8O20IE? M59P86I&(Q>A--%][,)K MTC+THP*3D%TIVHOT8!S>W)2H0M%4$M^M5X?Y'D56ND07K,FIKAG=O+TH[<+? MRE\C0*0ZU&B(LMQ/6DL FB)TB[4V4$8;&%<>32Y9& YU./K M$DTY:2OT-.+PH41U3=H*,RTW3$@_*R7]- 2==YR_8VF87!H<3VU]J1-0DD J M"1'F36O\^(TY^N+\0<"23?3@75:D>H-0%Y%_%)0%*&E34;!8PN*DB XS[VJM MZU6L%[,,_(8T87D8Q#%32D9=(&K!QJRC7S'UA&)?J_5+1E:BU()"I<8M<;DO M,6LM,H#^S6-9P"V:BF,B+F//)8(_:RVQ*T79H!GYBK-!_-T?_RP?U^.?I:F= M@O@K2^P4Q5^IF5GO*!?SJLQ!*G:,[MB@+#@3345<"@=E;B)O*31R!09@8MT* MXQ$Q1['.>RJ>^_:#0>(]EPP];2NXZ.&A)(_$&];HR(UYCF+A]I^Y1\4&"P(^ MNS++N7U((B^(;\+H/DV;BON@4P4OO$90_-:#2?>2 &]M94#.VP,K;UVLDC:] MLGJJZCG?MC1(F+05B4"9;6:%AEE,(98,D+=\6)U,]+W;LOD/WE($%Z\DS\H; MB@E?2O "0B=^F7\P:RF*#@>LQ+T2+6OL&Q- _1;Z04G>O[A?B1LZ7(IHYQ9K MTC@W(R6*HS"''A,I$X+'*54A0,BR.923)^;= [:2\1 MQK69EN(LR_.H6 931_]?7W+IHXC=AB7F,&TJ\>L'H[+*CDECH38L22I.3NL-L-\\13A_8V/\'$RK) 158T%8RD M4&K01&J2DT___5\_WS%OR/_]KY_O6>+U1.]3,:G#XV@:!HD8PA6/B$YZ@\FW MOYTD[#GY,"F$^Y!>F/C)B'V:5>#]_&'RG=_ZP_3>/U^'PY=//P_]QUZ^4A^XB^9OY*/]V'D MO8@PCIU\^ME__B@>PJ+)1W\X9$'ZD;>[D3<0UJ(WY'[&O2?P=W;NGO3&@9]< M"C>81WC7+)H.[7GRFVN+I.*OX+IAOK=9M?)&8]UHW2 Y-F/?Q=)R=]= M_Y&EBDM\^%\6A=]8-. ]OG$C/>PGC$?/P>UYF+#8'C-^6_TK$P^EUW[P7[WK$KD++"_Z()Y>?] +OGE-"O,+'Z1.]6Q;>?(NX M&^(_>"-R+[R$\":]17+G)??>RS7[YOG#[P]A<#&89I?X)?3."VZ9'PA6<\1= M1?[M+0]Z@UOGD=_UI.=SB+J?P'L%_/QAD47'9]E%P-+/$_IE3(*@N4Q2;45U#.Q:%H0V!K>7W.G+ MN0T-5G7$0IR\!K6IZE ^$A,CHAL(N;9E$V!D4K2I8]6<".JBJR,6 M C67:T!5H8DU1Z>FHR#=<*F)4F5&#&*Z5)ES;5/'.G$M%T6U0P,BA3J.84/- M-2WB8I<;($LH-BY!*@* S+FTJ6-MN,0_%' I)U>"C\UEF 4T$^K 50S(N8"Y MUTUP*BV&2FVBZIDSL:%C71AV[K'215"B^QK,).1BD^JF8E-B<%];=8AFBER0I1BNPB/;3/=MZ%@7)G&? M8H-;P>6,<[*Y+'.YU0&FIB*#0$/3#,,@>JK47,MR(+;G+-O4L6*6<2:D'$M] MO +M-^47_Z?9[(+"WF@$6([C0,6BA(>X0G"0RQT(P\K8M:%C3=@E;%6Y<\'_ M:;9O@1'6;&0"0C634\=T#,,67.#ZS@#0R'R+31UKPJXI0Z;D<\91F!)KF.<8 M_Z^Y#",6UKB$:#K0"'>8'*00D=RS*. AK^+JN?S%^HX5,XQ;K77.NZIH#4Y? M*,! IFOI -LZTET7$M5.73Q%0::!,E]P4\>:,*E$"7(FX>8R"1(-ZQAB8M@: M )0[Y"2EO6)#1\56QJ1-'6O"I WI=,UH+JLL AP+LVM2Q8E9-_/2Y%UC.K";'6(HJTK$J<+%N.Q:/=:&KIXZ=I2/LP,Q";>I8 M&V;-4DBM2@-:V%5=ASB6P@FNZEC1W-3_)OR+R[5<)E,;.M:&3:4%% WF$@2N M"8&)B8T(I(Y)(4WG-X!J6+IM@LQ(;>A8)RXM.NEM"ZELT]6X7& ;8P?9FH)M MS@$1*=D\P'6I,6?9IHZU89G(,!6RC-^LP045IJ88!@]J-:IB0"UB<)H+^MN: M23$TLNFJ31T;P2C88$8Y-G6!8BF*HE)HJH8+U510#(7:P,AFK#9UK VC-OCJ MJ,$6"[EN>J:8@'' MU:EC8$M+JRT577=-SA8%W9-2M/;$4(I-C(<'K82EV+7V>H.R!+HFSK6AUU+\5.#W3T;F5"W-*#HT+2AJCNJFQ:& M$6":Q&+![)9ZFA3 MQXK9E?)H$D-%R8NH=ID0L/_DQS%_>C"PPF!8& (W7!M"P\ F=!13QZ[C(-6 M:9K(LDU3A8:3FZ;?T'$]!\\G>VN5,6@V]"'S/Q+.FJ%@CSOR;O/ANB96V ', M'XP1-52LN[JE6@!HQ#25W *]31U/>I-]1?YVXC\G'Z_#<,2\X(:CBIU\2O^9 M#6+ZTJ\8 TT9D;A^//!&OS$O_MJS)?V3]^80],.ARW^+\VN'-"HF4Z!I& 011"V% MFA8RH*A[P@[* H9-'4\^_;KW5Q:D7GYAI-D:]XY=I%""H*@NH;JB$^(2: +5 MR3((FSJ>?!)O\/97=H+$3UXH?^G(&YT%0_;\=_:2?V';IM 5%==!3E(QX[. M[Z,!#2+#QDKFH&SJ>/))X?_CU 8(EKSV1LTZCH<G"SJNJE2_$C#^_LPZ"?AX _; M?_2'7 7$L^=2+[X3.FZA3,_%NJ4;-G1,1\>6IG)#XG W@)BB@ CERO36=Q1: M2U=>;7?*J9-RGE/GC0-U;60Y$!!-=Q BU+9<326:XZBV8[BVG3.P&SKN/%!U MFV$*A -S >';#-1F@Q'_)S]0A^LU[$!;UXF&B*M9%E?<5(>ZJE,'N-E -W44 M X7H$ -=$N57#E2EFJ%:F)LBQT":Y9JJAKG])$@U;>JBW)X-&SH>"KKN6HIRXXS%B\4[\S(=3TS&R5T8^?]9@*J!$=(=&ZG$)DAS78R HQ,Q2Z^KR,AY M]YLZ8"@"&BV#*AR\5+TQ&DBF$YV? V=3SD M\+;BWL4X$1OSBI,:\YJ&0%=5+" F19!NF=BQ#-?5',4P*.:2EFF:#1U//B$3 MP.JX5SP\H.LZL#2;@XU[/Z9C<4G2L&T8NJJJW$ID\<"&CGQX&._,O44ER?&Z7")!S9V=:#D9@K6 M=SSY!&?B4@6]C[VSPPXDI@"K.K?RMFD@[M"KA(J:BDLHAR^QZ*:C5VH#0$CL/)AB%W[A V=&)KJJ8 E=JFI<#YVH7 /4&X,70-3@C U+6A:&)D:5;B5-'"^<&]] MQS1.0*AJ#AQI/\4WT5Q3D$@$:S;2,2*F;BF8FTB" >3A)M"R:KQ-'2=VNNX>JN"S2$1$B*Y;W%'1B>;R M/UEM[::.$_K#JNE_K)W*WJ9IB&X"!RHJMC7NA@/3H)B[*LB!$ 390L.-W6< M$-VL4KT?9N.Q"W$HTO3S7IT: T&Q?YOB( P< KG/@JAJ."I63+&I6^;4;.@X MH?R>RXMJ0/C]@UT7A&-L\+M*@ZJJ.H7!]DJM*6=]Q2O*J-.$#[JN5<.(^J6"MV0 M-4W%UB'6=>XN0E$(K)A !QI255O3E7NS;&W=7J;=R.B4,6 W$MW$#>@IF%3 MXG+-K6D4PUP9XJ:.$YJ;%=/\N+LTO4W#$)5:U*".J'K!@!!-UP!6-.&F:XJ2 M7S:RON.$\I7E#8ZPZ]*AK"RU#4>S+&@I0'$HH&HB M6X8=1]-LS0 FA"FZJ2FL;>;T;.HX(;]>;_*_>IN<0Y$?(0 Q]]\59"(5*H2K M="NEJN,B#&&VG&%3Q]J0_]#[J;R)W-"$:=X=:]! JJZ)Q5]0H:I.J$@>9$I_ M4\<)N=6*W,U:E=QLFTV#C@LMTS)=4<5DZA8TN%G%EF)#&W!;FF73-G1,2:]6 M-6-2Y48:;XMN*>3NHF;9R'20;6IB.;$HKR5F31TG]*_.SE:V,<;; MW$U'58AK$54E"H*Z:MD8 F @PW55P"UHYFYNZ#@AOU$Q_ ^]S\7;IL1=C1.* M0];2 $)4YY&3@@'659,3%^=*A3=UG-"ZJFJ$0VY;<3!OWA);@5BZ86" - UA M3<.IDZX1EQ(],[";.DY)WS[*'T"S*Z["O7)3Y?XX![%I63P^=8%CF-AQU=PZ MF4T=IS2O6+4;P-Z:ZJVJZI$QZ&BCB(N)!0QP(N#XY4S<[*S#9UG-*Z(J0WH)![2X;8 MMJJ(+:E=PS 0UR1$UQU#40P+V)RZN?7!FSI.5A_N-$>N;<$.L7RM9J4)\W[_ M\")?_"Y(O' #?O=A&*0($=/V6&X.L%65OF_J>-$6^Y2#;H-WZHNA*XK MVU2QC9%C&@KD7""&S?6?R[GAZMR9U%PK$[=-'0\3YM6^EKH63'0I=Q45W<*. MZ]K$X%;!,"?1FT)M4\U*!#9UW#VEOC$/'PX1YM2SPJP7C('<3J=BH4;<<;&"3( 6F.A'K(H^]J>.T8J*^K&M=F*?ID)LL7;$41W,<;.JV M;J<<,747&FX6+FSJ."VSJX1U'0SSN!S9.K(1!9P!AHT<:*5A %9L!]HD2TEO MZEBJ+<4/=_YPR"8\C)@81#!@\:>?1W[PQ\=X<,?N/'@R;4XXE?]V$OOW#R-VPN^^>(_)X_+/2+_&W(=)OSU?1R/_XQ0= M$RKD]MG]]-__]5_3+BS=,EO\,/M%[+.;^#<^BWKIX_A;W"7)P\GM[' M;/#^-GS\0,_^OK@)]O+%Z3,^+#]D^HR'= /T_%/CQ(L2L9%[NA7XJ0).Q7ZM MRVVY"]ADW_=I=RW=I7VQ)?<"\^?-?IA2IHQ0(EO2 $(![3[>SW0JB) MNE'K2"0_$-N:)E-PP%-A(A=;W@".V=$70^;_[J3O\L6/$S^XC9WG07HZ1*K< M&/_R^[_.?^O/U=Q\*WS]'(/ <:NQ7O MFOXT^6W(G_S\,/('_G2O^=[0YUUBKO[R^^\74>/DDR#'1T&.R5-7[K7MSMM#Y"+JL^C1 M'RQ&>]-&$@RGK6G,V S)Y(/[6#2X3%#6C:YC,K,U%%K&^V,RNWJYWY794NY; M"X5=34#+>-\A)3\[/Z>&7E&6^UG.=[TU]S,[5:?6@U[F]!X27D+#_YH[ZW4> M+CA_CL5YB^']0QCPKW&SHZZ5:*AH>)5'1-5K^3?#X2P8C,;BS"DR'/IB\L0; MB<,9SP+J/?B)-VH[7+8;?R?@-+$C0*J6JE3+@K6LA^&X9(GG!VSH>%$@%_9>'_ :81!6OEO%&# M_9;ZU!],%<6_O4#Z.K6R",NP>*/:R/&YWN[.GL>]LF./M(15SHONUN/H^9?+?7QZB M<.0WQ.W?P.;%P1R'T=6ONMQ.FB_9@Y?<>>PQ'(7 MPYT_\$9+&WD&W]N!D1(ZK /+E@\MI6+F0>3(*-70%NCL'M:ZIYA(Y 4L?MA* M'0W"<9!$+[]_[S<<&0N#/JSNF=+LX_>U>\)U3^7D?<+.6<%M'>(&F[[J]=]V M.)SLBSYI;@>X"D;4%99O9_+^=O6X9O-R0I;FKW,UJ.)BV]IZZQ^;7A?FM M43.51/=2Y: M9.L<$+>?EI-8/#@69?E&^QE=N)EZ!T+ G7==;U[L5SWZMHO]9 #0;M>K 8'H M:[1@J[!8@3J4[I>L=NA4M4-3<+=#M4-K8'>\(H?NH6X[+_";B/L[-M.='W.[ M4-< GV]G&]LJA^_8QE9Z>U+_=4C_58^Z[:RN7-/3>$/W&D9W1<$<R[6 M_A=M2!>KB2Y6]4C_Z,S%U)$U>+=3E= =^."WB:A\$&:#Y9 MP]':&H[J->#>[6[[?/P.K)"M'H>[9U$;CJIMDZ-M,G6OJ4OMG+K9OI*UP0JG M>BQN6[PHE^2WQL;L7JG0<%X?W\94S^1]KP9K0R35[GT7FF)+=B@!:)]7<[Q: M !E$R?T?Z[M#A/2X][=#KL M'>Z\(V%S@55-%4U36"PW(6G_)B358W'OZR+:A\0.)$4:X(:]LL:K?7 \>K&7 MU(XR&=*A9$AS=&'&@8Z J=NJ13*YM9(L*]?;6KE>O:)YS2FAG7.J.U'.5ST6 M7[$?2,.!5<'1%]6;O=VWN&HXEX]_7FU3F"PS-EW*V#0%E?+4G?:?NE,]%O=] MN%S[-&/[C[QHBL\MMR:2^J\!F8?6(*_-17W5ZSR!O%\Y\F86\^KE@5WGJ#DS/ M=W^KE)]-N#[GMNL'7C#PO=%9$"?1>,[O6?OW_E7$O'@N1O:?7FP363Z4E;W M4J0B4BZ+;U^]9_]^?#]-Y,YP88UC/V!Q3 9_COV84R(,&IJ($6G6^8A//HFO M"T-^8Q9W!JX2@E6>Z:DJG[NL:-H#J%IQ_(B6PO.C?WBC,;->YA]_X93THL'= MRQ?VR!:GN^=]OJ9A+QN2Y)PE)(Y9DO[\3:1!O(@MZ9VSX)'%B2"$2)S.E=0W MCMV 1?&=_S#+F30++-M1+_,W=R/?GG38*O$G^K*4^@W%-3!_A1+7$M>5XAJ8 MIT#='Z[/4SGEY\<.ZZG[0><\]?R0I:=^*$]]T2#*?&_=\KU[MA6[ ML5S.TE8_2ULI &3&]Y@9WZI8+>=V:C&W4S7[9<55RQDLZS!:REA92=5R1LLY MV0KG9"ME.GGT_)%W/6)N&/6]D:# +*/9%O&>[+NP<9P-9?7V-1>2U<=D]<$G ME_S 3]@7_Y$-SP)^YUN?CSB=[8@M[J7\.XSHR(OC!3O^Q1\(4@:WY#9BK)F, MWW;0F5DO'75+)'YG&-AB\BQ\8,,K-K@+PE%X^W+IW]YU @P;QMX&S;05"=I@?B1 &@Z0 M0VL0Z9^TPC\YPOH1&>#6/\"MHSF1 6ZE 6Z=7% 9N30F3\S!AL3UF_ 7!4H'LES"X35AT+^X\+[[/ M=F7DUWWS7D0F^BJTO."/AB%KE5Y3 .U,L'7HV>&%BLB=W\JQA-X-57G;8?Q M&WG!P J#X90O5W?A./:"X=43[_&2:B():@'J_5!1HOQ0*._[SRE[SOV I;Q: M-I8:ED 60-Z:4!*KA\*J&XZCF84L9('TA"=8W9I0$JMO#?HW1V^NVA))8/9AFG8;)4P[DC)K$ MZ$(>H91 $IN'SGM-4S0YTDMCOX#-4@*U'YM514\B]S)/CJ_-+EX$,GDU616_ M.\DD?@\?47'#5IP@ES[ :E"U!;':C]FJ_($L7"B=C)1I@.7(:B.IVH_7RG3L MTRQ7Z(PS[VQE9H;K% G:F3N["[W:C]SJ-:W,8,D,5KTCL7F"1EBZ@OF9+*S@ M_TG4+N2TMB>9Q._!9@MFTXOB0SDS1*O0,!+!"W.RNQ"M_1BN;!8A/^NXJ=Q. MHKAPLG9[LDD<'\SOG:D549=4[,_)HIA%!;R14NU':Y6>K\POR/Q"K9"[8X6, MS.3*3&[]_=O9U&5)N;+T;W<@F<3OH? K5]_L ])R]4V]43Y;5)(2N]Q< M:H:$-9!9H!E!KCI$=T&;0(U"=^%L&Y+>K4?N977.H@/.47R M+1P'PSXGUL@/;G-E?KH$\ * =R-;^W%=)'&ZTQ-JJ5"F4)G+2E8,2JHOIKUTIUWXT5[V7PBSGN)I*ES4-"_7G M&PDEL7HPK&ZUI!5*O&Z__A=*S!YKGDQZ"]);J+'ONV..0&I@J8$KQ^Q.'J[< MD4GNR%0WCS:U<>OG;DP)TKDWL!6E)%H/[LMR>[;!(>.F3NXAMNS([D:V]N.X MZAWO922Q6^#;;D.R]N.W*O]AIDA*JI^Y"I'.[H+& MW4BH]F.U^DQ7Z82/S!\LY[DVDDKB]6"9A%E):.D1&G(3D,7:V4V$:C]6*\UZ MR3R"S",T',?2GY7^; VPNMN*,>D?2/^@YK&7G!63LV*U0.M.^RS)M5]R[5<- MO8/=(C*YA^BV09C<0[3R-0M;;$ L_I' S<^$[40TB>%#8W@3+^16=D5SN=N2 M3.+W8/-C\@S>[=#:X3-XJS\G@E?G![Z25Y/TTZ!Y.,UUKJM!^555<7E!Q&H"H:E@#- M5Q=L))3$ZJ'GP-)%^&N=,%G-M30#M@/))'X/G8V5Y_'*\WAKAM_==YDIM('2 MFRW8568MI=J/ULKJNV2\)>.M^J%2G@8B3P-I)'+E2>9OS+[*D\QKD8>5.]#O M,E/;W1WHJ]]_-DW:E)L\51;++J%U2X))[!X\P^4_Y]5&;@>4V0GRG0?MUI22 M:#V81RO1*M':&+]5GDQ3/,/5U9-I*M.:AZV]2ODY_=P6C-:[ JN XFW6HT?; M%Z:-2&[*[C 58;IZG7RPG$$;T5S_S$%[='.]]OYN(YJE;JZEOR%UL]3--?/;C>/Z;1_?,>S. MX]2+DI5T,A J#.LWD4OB]EB^\4&.I6TC=NM].&UG_6")7XG?YNE?Z3=(OZ%F M>G='OT'&:C)6JPUV*R^1;25TZULHVS%O02)7(K=V.G>/>0998"L+;*OU&;J MN-HSN87!>+O6I]0W#&_#BI44JRD@SWA#Q.)$;&C3?_(>,J@NMQ1M:FWSYSYZ M"3<;&1,O_?B/!9"Z8?3D14/*WR'R!DF\=(]?V/#6#VYM%ONW ;]7&"QD_H7L>G#.7%C-K3*Q2S.7OX%GQNHK#9$V'[ M[_X[PM=P$+AKGN>?C,6@X+GUG3 M3)$XSP^<^G(GH5E;(5W:ZCC4$[UQE/Q^Z06W$]2);U_]P+\?W^\"4O%CGPW& MD9_X<[(V Z9\Q!_GXS_Y)+XN$. H:%Q#OT[@L1933ZW1KK6?=&I\I+9>?WK/ M'=>?>0)(_5D;;U1NQ];.A7O=\U]?F2E;76 M\V2'R)/M>RVVS))5G9+>.D4F MCU+8-JDFCU(XE%O^ZX(;M(6"7]9?G5/PNRG:8G)U0='6T 7JACKMD!)[[2SP MRA%;TK<]R!SPGL_EDKYM#9)X6[NWXK3,XO-:9+9DT;W=2*FVNK&'5R]5=.(Z]8'CU MQ-M>Y$D0N65"N]!+HKU.:$_SIY,:ARAY$8>#3WC9?_+CV(V\8&"%P;"0HT55 MTQV5@?U044I&G21#G@74@H6B$N'KS@\*YD1:(3E?O+9A22COFA9,2Y2OE/WM1#DI ;65 %GH*@M= MVX?PV00WUU+%3N:KM^IJ&<"W)93$=YWP/4N!I29V[?$O;SB/L5U(?P7)).;K MA/G<'(=@WSZV76P7PC<22.*Y3GC.?$O^H<"WS$52;SD K5T8?Q71).[KA/NC M'?W7+N0WY= _B?WJMI%N*^+KN(&TQ+GY)) MS-<1\U-&E;(O9;#$?$'5[C8DDYBO%>;GP=AJX;4A,;X8KY:22&*Z3IA.ITPF MFNA;. Z&?4[3D1_VHI1$>*T0/BMB2G53^>;&4),X7RCZVI)> M$NUU0GO.R5R;2Y"; Q3YY=N23&*^3IC/RE3+E96<3UJJZ-U(*HGQ6F)\::U! MF2NJ2[POX'TWLDGLUPG[??]Y756?JF@R1$W1OC6A)+[KA&]Y,K<\F;O-^,XE MA=>G%)#TTI>SZ-L13.*]3GB?F>$-S-/DG-&"U[(EN236ZX3U6?*LM#Q5DSI] M(2-'<0C2WI+X4RH8+Y79N[0$/])/2 MN,W&L'4[';#38EA5='G :E0IA0TL;95"6-M\JYS\D),?4AB/*(PR6I31HA3* MFN58#[")L!3'1NY(W&E!K"J7*@OIJA=*64C730'=T7V5EE):2BF(E;FL,K,J M,ZM2"*N>^I>SC'*648IAY6(H"\HK=TME07F[A7&RU%?MVT?#[ ZC7EXRJE6V M9-0&JE!9]2?3!!Y;DVD937M:.?YK;N5X/^$W%)!W_ASSD=#P_B$,^-=X0:^2 MP6!\/Q[QKL//GA]\">/XG"74B^_<4?CT"QO>LF]>Q"]KEH9=._A,N^PX^L/I MF1HMTMX'E*XB+XCY)\X3,OSW.$[N.X"@-8/N!'"62 M))%_/4Z$5Y"$+51!J;_WFO&W(0LG%4IM%&03^9F1K.W0V&KXTOQ( M)-4=234V/A(8]0!&[8)@Z974P2NIG;Z0N9'CYT8.X)IRW;"0&[ED@Y$7QYS$ M@W28%^/DXF8Y@A.4BMB=H.'?N1LMHF]R)3HNHG+INJ165$BHEM'4V=%E";7[](V>F M8-6L)/+2C__(IFUHQ$E'QQ&GU>"E_^0]4'[+R!LDR]6C1;>*9[2W7@3)_>#V MDDWBAOC.?UB0O#QK>+^EFTM-4A--L@XPTXFN38C9DR)X'=XR#5$(N#V]F]2W M4M^6G"@D]:W4MU+?2GW;1GU;?03:JAR1S..V141KE,>MCXS&4?+[MR@,6?L_!\SRX\X);-K.(TH7JD O%\?6Q"%^9 MA"X [(!N4N:PS7JMQ:=TV-IM#:3#MIJ0E,9 &@-I#*0QD,:@H]E26]$G>S*D MIF!.Q_Z !1Z_2ZJ;TI;I#T)H!E[<(/53.*:33VE3X:".YP/HN_D ^JFF[+&4 M?Z$"T_7\Z!_>:,RLE_G'7SCQO6AP]_*%/;+1HFV?]3D+'L9)G';0FH&)N?K? M:L0YVM?U R\8^-ZH:'=$&D8/8<3]3;%A7I\-QI&?^"Q.8[ON 6F_^_.6$'Y6 M9;"1\A+/>:=E(YYG[5_#@+U\]:(_6.*.@V'#IG6/Y.;M \:S#L4$;P-ZMW(R MT^T\69R(;3Q%M9#T+K?R+HO))MW*]@=+H(UP;DJPM(6+TPI4[U;[*U%=71VL M1/6!4@!;>\S?^U<1\^)Q])+%(Q8,Q[PSOZA[^#Z2V5Z7 MLUTFOT3V3OI;NJ$5Z&OIANYY^F&=?IY?TSTX'VDN8IUZ7J*^Q/7>IHD[C.L: M3!5+7!_*G^XPKFO@3DM<'\H/Z6A93PU\D):5];RA,*(IP#M4%4-36%P3%[/+ MJ:T:^)@RM;67FL1+%D_0Q>D81LFM=\LL;_ '&W8YTW7D,L6M>2 Q_JKTK:R[ M/7+JMKUUMY5./EC^:-1EM5S9!$01X26:7^5OR*FT"AP,.95VA!16E^/!&N2Q M9#RX9_W<=6^C,AW=5F^C)FO66KG/1^W7K'5M@X_#X[AA5>@MP;$LA'_+>AZ9 M;:Y^>4^GLLWU6HG9JN7R35N)V955\UNA6D*P40P_=HI+KEFK0:)+KED[_.2: M=$BKGV>3#FEE#FFK(7ED-4_D>="VJA@'FK[##T7O# M8F9@G@+U@ "HU];'#<-2N[8^[AJJ97&4+(ZJ.8YEJ-1^)[.Z4*E2+2P+1(Y? M(-( ==4PDRGMU9XE7A8ZMF1>^8B%C@U0:[)$O7F.6:TJ@AJ <;E\N3E5G35: MOER+7)"<7^X(PV5Q8Y><4)G2EG!N0TJ[13@^HJ,I@ZGJO4T93!V[1JC+H.[4 M&94-0+%<""<7PK4=XW+)4(,T=SV7#-4B=CQ:D5^KIN6:5N37HFFY>N7Y&E:X MT*X\7XM**"K(C\B2OR,G0]I;\G?$F%$>4%C70Y$J.*"P ;B6!]DW)T*4Y1$5 MQ8:M\J*;%AM*+UJ>D-0@%V1U%J:J5=HM0K/,4M< V=W,4E>0^9 ZN[/GS#0 MS0V;*)'3$W5,&(I\W^,Y-P=NA'-VFL+@F!K?# M=5PU,+JRCFN_=0%=#H\JJPF0X=#!JFP[&@[5H,)6AD/[F_GOLE:N;-9?:N6# M:>4NUXC70#6WL4:\)J4,'8X&:U#.T()HT)Z!XF++;'C/]Z=1>.8R\87CWQMI>^_[RD M'/>XLKWH5O%GSP^^\!M8+[^PX:T?W*;"([_R'!55.O?C.'85/TW[- O@J M7Z;8WI4Q>U*[]5ES_SI49":J$!;'L B'.MTQCI+?9V1/!6 P_<(#17NCH+N< MD-]"/TC$A_]ET0Q=W\)Q,.PGC#\VN)W!C#]1E_*^3WGGS/N89][)IQGW>,1I M[TUD2I3)*YDO=4IW=0K]Q=VH4U(DI; *H^3E(F!36/6?_#AV(^ZY66$P++1; M5W<18U+%'$G%<&8>6L7L!PM2XW17XSC?+S=J'($K ;()<%*SMH63S'^0JN9( MJH9S\="JYHT@D#JFNSIFFTA)>C4-435'")RD5R,USA%R,^$XVA"1FU*KM$>K M;,]OJ3G:KCFD;JB;;I#B*\7W2.D,.?M:._-_A/R%G-J56F0W)T"F).JD/636 M0(K]<7Q_6;-1:SF79152L'>,"CY;WZ38UUOLUP0'G'NR5$OJE)KIE&VF&&3A M1-UURQ'F'63AA-0QA_1;Y%1%?=3),5P5.0\B-<>6J0SI?]1"84@700IZE6&( MG/"LG:-PA+A#3GA*+3+?W0"8B[L;R)TZI[V.O5-G?K<"8.ZT6X'HOL_="G*P M$/;E6Q0.QX/D(NJSZ-$?L 4H3!MWL0_SC32V.B+TD@U&7AQSY@]2<;P8)Q/\0L3O!:?'(07B_^):OO%]^[]D>"GH+# M"\+Y)0QNQ3DO(@1LEORM'5\&E=4!'B/\.N*FB07,32U*?N 3'91\]9)F;B:W MGM6IKMUBN UE_$*:7DIUA5)]Z#D8*=4UE>K#3[Z]_<#(:8K19C$/]L2.)IU^Q9S0).#0Z*+"9V]O MJ-T9W+IA].1%P[* 5N)V)5%50"Z)VZ/A M-K6SR]J#)%<\ZIV:H'SC,IS;[J!MD?;8E79[PG:G7<;%C M,%R9/FU8@G.+4&G[03?1&9P>B?3K?HH&<\UBWGD^5?PE'*PJL=DMG.<'SA;6 M)N <16VMH?'J&RP0^3B3[16?TO3:OVJ^AM5^UZ@494OIZ#*D M)9!V<" .5$HI,5F'ZL4&2T?#G! I'5(ZI.V0D&X:D*I7LSLY(3+6D[%>=Z1C M>8*B.Y,+W,&#].\864['9*??3TI_S,)AL7I"0.&9;.9RO5*K= M 6$9]6>[PFPD_P$5:#6J7(KE%F))!H-HS(:S.CF?Q2E2.$2F8,FU["*FNX68 M4DRG8KH[.XXBML<,=*785BBVLG"D%?(J"UIJ(*BS#GG7JV)_M\$5LN6"..M1 M1N?..;8MK=0]3GPI'=ME=L%Y:22;&58BO%=N]B>^@= M2J3;6T?YE&ZO%$19&5)?^:RI_90)]Z.+;7M3HC7- [93#TL'J14*6#I,M=&\ M+9(%R? *0E6946IRQ"HS2-6+I2RYE"677:I0:(?]DQFA)ML_F0&JCUC*"CU9 MH2?MWYOW*94GMF9Z1)[8*D]LW6HH33ZQM3X;"\51\GO1R>ESD5PX./T0]EQJ MJ8JU%(? QR((9#*T@('6^1I2)TJ=^/K-UHKGP>HN\X>>ZVL++*:H^.I%JG:J M:JFY_,(#K]M4QKG$L,PO_R6,'_S(:P8 A-)?'(G\$C%-@;,_HS'<87\?LS[%0OH_\KZN7AT479:F]2S#9Q8(54S'3185D M/!Y&(0?'#AC-=W\%1L>!/P'H[?5#'BKWS(O'$?ODQR%4@?'QL_5M=H=94W9/ M<9.5&X[CX;H;?N_;.]YP2MZBFZ9@F;;O_IK?6-2_X]Y(_LY#_Y'#.T]V<<4Y M-U^1EX1YT&TYM/]:>(W%&^6>8+,@O/>#TF=,<2%>-][TD*5[S9KF0UM+E\'= MS3KVT5_<'0D=C)?5T>*8'OC''6_)QH7WF[VC\_UR5XBE="U_QS*Z+][T@__\ MD7<+Q]& Q9.O=\P;1EQ-3WR W9ZQT.7N^0C4)2__O3@#8=^<'MZ'29)>/]1 M>7B>_Y2$#Q^!RG\0DG_JC7B\\W' A,LU^<4/A";_J(EK;KA^.(W]_["/ #\D M/_''QP]>,'MJVGKCW?NCEX]^P.,-/UF^(OWZ-'FQZW TY+?X?GYVY=B]_A6Y M=?]!=R_MGIT8NO7\_Z_;.+\R.. M2MUY5&KQJ/[)PS'^)DD8O.O9[^G[GJH@:+YI)'5!G'MQ^?5__@)TY:?9<"9_ MI)+_"$LS1D_D<['*11C? D3GI3^WK);A9"OJ)1K1T!4$Y_G;-BX;4_ MY8?T-C+U#L;L?X]C[AJ^K.6VLC.WE>)A_,"CIS]Z%P'[<5]B.'O]6:\1NTD^ M%LMA[B$KO?.C%]_S;Q&$T;TW6B2BZ,-OF7C7(]8;L-%HVOJW$^4D_^I=AO=>L$RZ)W^8W$V&?QU&W""=#L+1R'N(VH)/*]4>][X _"(>M][9PB@I5S2] M&P&LY&\G/FP#],/RQ=^'VKGYQ>CF78.X.$'HEFH&IP0(ZIFC_D,KV_/>WJEVX MLXG=F])UPZB7W+'>GS-@]B:Q9H]'H6S8>X61*GG0SZLW>KKS$W8JE"'C&'Z* M/!Z[KI<^F$F?I5NZ"UW7T!%QB.IBVZ6 .E1#"H0VL(ND[ULZ-&<27V\G>Q^' M(E/..]X-O9<7)K+=)Y^XH1K<]33PKB7]%"+TW?4O#^WL_%KGSGNMSC76>YN\^]G8(J(U,*JC#HV;+HD15 M'613VS(MS2$4(4-W7:K1O%0X:=)M$\>33#\XSYT]*_5YXTXOF M5.]Y<2]^8 ,QYS;L^4'/3^+>X"[UOX^:^E"ZZAUI&[TC:):[1UIY$\0U\9Q6 M(7X(X[*%JD)*EHXU"5*X$E>(BE7D6 3;W.,R; 4B:")LDU55)4J?(NY*I;/* M:=$2#<=!$KU0[N;MX%[%XM*'*'P4#Q 1G,U&WI,GIJK>[&$=AXLIE#..[)QB MGURPF$Q_E?_8.H#FY@LTB%QN3X'FV! A%Q+-4J!C4D0U6\.NN@K0*^_Y;%H_ M,2GGV^CKF.A40U Q#'U[[-56E;P2AC^DHMP+HUXHJAU[_QY'?CST!X* W%:6 MVL #O(J?US#I&T6W7N#_)_W^H]0##078V?O+]_WW/>?^812^L/*O:@/ M>N?A^R(852K2(7_4S2A\^GCG#_G;_C1UZ-0]>;[KT)7+4'5GW+75W\>UM$B? M6UJ;Z"K05=MU5(BH:U@F1L#4=<.BBJM:!:X@&0XC%L?3?[[P. 2LL;(7 >M- MXE&:CKEG1_ZC]/:RT47ATRP6ZC(D]0R2"G?RJ&JXT"8FCTZ0:2'-4"P%(]-P MK"+G;XK%;R$/+T;_ZS^L#TH^F4!3E5-@F&8+/+_CLLG(?'0=NKIJ8@QTPT N MU3%WUS5JF;:I0!MIJ)1-E'^\B*["IV -CZ[NPG'L!A?='7&]UL6S,I $[ M. PQGL.0_V(3JFL<@C;BGXB%J8E,W344G:-1+X5A&OI<1-^B\)'''F]*8E!. M%-XI\#V)U.V16D5&X[5AS!0S(G_\$'&X^ _>J,>>V6 LEF+QGWF8P6(9IC:2 MN=QCZ F7H30\;-$TY _;SS?J()OV::X1*^C@LXP_[C#]JJLP1PZ-.Z3L,=[I,DWH/YP_:.PGJ+$D0R2C_M&6*-G4^^]Z-8/)J_G MC9-P]L/$"*:_3*8UL?E>T55T\$G7-3.K8$V]&@0-F'5]I9=PY2>CM'Z >8.[ M7KIU1/V\O;T--O)2G=E_N><6X8Q^Q?.#$Z4>+:_3+I@7W#M]W^=?^ZO;@M$A9Q>W/23<+"X"X@HQQ.5 M#/SWV<+^R4^<7/RW=[W_J[SGGA;H/7A1[]$;C9N3LZX8#;D4H0(L2@S%! 9V MD(LT8BN*YE+=H?QO !9R,U.5,]$X54.!?/U\+OF]);\SZ==T2].)1G1(+(05 MB"FP"=2 A2A7"#HIDOX9^]:60!Z'[2N)/G';68[OBCNNYZ1ODU][GT?AM3?B MONV(>[<]L5B2)7(F84?8X-SZ/6P;FD$A)@[D$317$R:%U+*AJR%;I*\BI<\"/XS.PX3%]ICQIZDSG9$V_[4WZ=!+>_1X%[$R296Z9$M0 M9'E]UW4P=*"A48T@#@4+(]?1"+FEI\!5A"R M"#"@@ZB-3:RJENUJU 3$AIIS:#NR-PBLM2@B'?!;&/W12^_9F[V(M"2[ B=+ M4P.N05P+.BYR".*?+4 ,5^P$@UP;8=.HB251>6BQ@AE]IC9$:[$=V:%2M=.0 M,!286Y9#%8T''SPJI1P"#L8$VYI%@444=4F75&5'UN,A-2.2]=NR/M,&)B>B MI5#7,J%8E&41TW(5A7)'@O\'<*$VJ,B,K$7 $:S(GF?%O1M_Q(8];S3B/<0R M83&+\>?8%W,82=B[9M,._,;3:8SY\E:NF!=_$FM=)Q^G MLCRN)V_QY<6;3RZ>#NW'=SU13?6#FAO_-0<0[W3];Q'&\HO2_OQ*\2K3FPG( MQNF;I&_JQ4G/5'I#[R5^O[_9QM6=I7:;*]M"*X"LO- U*>)F &!";:0"L4@3 M&BZ$2-<8]H8*$?KEDMV*K<#'MVC^]ZOT@6&7\U%,U M]?VT1W+GIPM='\1"UT.KHLD+SY4+BW]LENK0P%QU&*9B.BH@B(B]*)!E&8IN M6XB8.M1-FSA%ZR;G+!4I8ISZ:.KUJ3HK0F_OK$*10.O6OJO*8>\K!9E MS6F7O929;6'_],S^N0@"U7!=:KHV,H"&55?7Q>;*BDJP2^WB76 M=BBQGVSTGBJ(P?1J$>Q^*58RC\,G6>5T-UBZ[-:T MAZ7G16Y)I]G:+I/2G_AO$Y]K[L1-OD[=LPYP>QO#:F:%,YB'D:IEVZ;E0@20 MABFE!C:)P7_7'=M<-:PIF:UQS'W!>$TJJL+]#6N,46<:-DQ0.8D=)$)7$(J5 M#*&&KFG<]Z,46@#94"<:Y6Z@9B&"%:(ZQBI"9T3^G)*73@A;!Z2V9(%EV\?7 M]'FIFS7)%+$NJ3 #Y-\4Y8W3;#'WE8(P3?:.XTDBAK_U9'/P9+[?[2PQ*Q*V MXEFC%_'P)Y\_FC^V%_"@/A2YE4<_3GVOP L&0E-PCTSLYR8ZBP.RAUXTC'MB MB;,_+%O1H_W@_;@VG2(S>]ME]N([-AK-D-'[@?,[S;!-MJ3<(G]5HWSZ;RS> M844EUK)2<>(ZMDBGNZ;K(-TE!#K\_[HHX[&PK12D%OJ";&\V*]NC=!66>UE] MN<^M;H^(\]Z>\_C+.8RW+*_6CD<&DJ; 7\WZ]/S*GFK,SB]XY6W>K1J-5Y\8 ML>09NNGL%=?W2Z(+LS(;QZ26!A1*#-M!R-"(BRP5.#8EIF+:EELPH9Z5WJ*<=UY,#G,5 \R6)S[X>EG_(G1@3C M^V&83#N>?$(8OU.A\4[+]OV9C>Z-!=EXE%=?>WOS@L,#FCHY9:+W/%@]^#+I-5M3XS6S2:"&JZ3; MO9MIQ:.;HG F=P_/O3@<^7Y3T?\U8*5V@?[YQ:S(KZGB_(;&]>;O10R40 M5_69M[MI%WRZN5DE0DIF[F%,]RW^..::,!(Z\*>3WETD_)6_Q IR=:(8MJLB M'MI0C%6=:H2ZNJI9EDW=4[ZYWVW+-SFISU^=\ZM^5X1U/[QYA6S.S+NM%5=,<%:J4 &A@9%JN*?ZG4AOJEJDB2 \IJO2"AV7G M?<%U\=*<&[L$Q*<(P:R+,M7OA9HE'E6 NO]\NG5]XO[-_.%*>7\% 5OU?'$=ZT[LQ2Y.RVQW9-70+&L P M3)NJ2.6>F:W;.B#8X0!13*=Z6]R_NJ!__^7BB^U<]J=[ ?><7[^?7?TFI7H7 M-D(IU=V1:NS:)G&19KD*0:ZFFX#:+M$4$QHFYI%7Y5)-2?^7GOOEXI_2-N_$ M-B2EN#M2; .HFPZR^1\-N:I+5%US+8)5XK@ Z_HAI?C\XLKI]ZXN>B7B+)/6 M;^6=WI$));6;$TK -@@T=._?B?G5V?< M](H,M1!7_L.7V7(=?']JO>57/[=N>I=GO7_+D5X%PYJ1D=$ M&'92A'4% TM3%4(5&U%%-ZGC&EBWH8D-@L"A4]=7EQ=?^JGX?KN\H(XM)%;* MYR[L62^?':Y,!*Y*Q#FI*E(ALFW--#7'Q9"X#K%LVU8JJ$P4I8D75[\XE[(L M<6],U'!'[%,]ZA(+'G,) %Q_. MBA6]UJ3:86S;'/SC]+D[83K[HCTD3*=*E,JT17@,&U/48:PH:*3>#8 M0-> K3H DP,FD IE6D2./9?0JXM+*BUDN)X6V0 <)J9--X'HOJ@:R _$.O@VGK\#J/>,#7L0$M' .K(5,39#P:AKJ/:P#"( M_>8IO)U0WS_[?$ZNNC0'<"">P>))@9(-!Y=WMZGG'C$GG_PEU^SU^_]LL6M! MX_?_F6Z&D%; J#^MWQ)A^Z>9I26)>?INL9I\@;ZOI6>+MO5Y\YD3ZDEY9+:Z M-\_*GCZY_7Y:%-H5R$7=9E2.,>:UQ:K;&HFI;&^Q_/Q5LKV\TZ$*J].=>]@[ MK4+-_YI%^@T:W@]G08]?,A)G-+WKL>TC$UL"GZ?Z"O:&7>#\V7_55:]KVNY9 M=70R#K!WWIRUQKK4PB$VT2L=],&VS+OB 2J;G:R9;MZ>JHFO7C2XZVG@W:N. MAVG+)HJYK3?7C_0X&RI.GY+JQI5''!\Z^1VB.W0,A,3%1EP \]6G2JVL^/S+ M8,#8S4TSPKB33Y?LD05C%G]\*W*.28=:+(#MP, E]U_A08+Z"ONW*!R.!TDO M]D;BE.RCF,*##^K_OF$@KWGOPYP=NW),A*I B!G247:"F*$HU-!=DQ(5(<.U M@$VPJ1J6XCB 8&UV3,0X/KWUO(>/4]7N1N$]Y<\6#_BGG]S1<>'3>CK#YMXATVXZ9B)'5A^Z)E$<3%35=0UD4*B42'KYV;=; MBR\)AM/6E)][DV95-_8HRZ^&1VT]A]9&75+JUTJ]#O!E_C635KBV%OXJ3+S1L2Q\@T5:RT1: M,W430%.WB:$A1 @!%M&Q;B";0.C:QLZ&? ]"J;\#^C'%LK8V5YK6MXG;Z^9^ MCBN+R,C,*[)YX.QH2*$F AK MF;IKJ$9T#1M1.'.YG4O02Y"1W6,7\6RZLUD M';SD:;60NJ>2J.9/UAR1()(($A5[\*UKZUI?/#"Q@">X[;'G!Q;$;Y_$;X%S MT_;Q=8:73&;%6U'$VW-*BICDHA4-"RORY(>W'S.0R'<9;/BOOA:'C(:!J\X['$/CWX MVB6Q:NU^U2:^;J$L&KD\EDYU;$!,+<=&.G0L3*AJ 4P!)@I6G+?(XOZB:?!. M0:C5LMBN&K9+%K.TV-\+AIS?CVP4/MQS<_M&66RPR)F9R '35!2,3%1H M$",'JCH&NF$8.G *2L0FQ.3R9F>D=";AA/,\J_48_#GV(S8\"[Y%(1?)6$CJ M(>VCB=0V%'%T*1QIKWQAD*6#@:5KIJ4BA*B-,-5-2$T,*5452T,65@\J7_NS M>=@PVR!?30@1]S#\/AN-^"/?]6Y9P")OE%H^;WCO!WZP"- ^ M%R743R[;%2RFE6DUK(*HB2P:F8T4IZF)]400(K%+KXTM<4@JI8 :%#GF2N28 M4G8JB44S2R^*@!MJ_!8O?#!KDS]=RB/F)8*D5 !Q#9&B2V9A*+0FQ3 M""A:\4VWDKL=#5[,2YVNV)*U&63KL&3LQP-'H+4OX@U7Z@V:5+K? M@,)#,Y=I(K:MZ3IP#-4P$"#<40:*XIJJ3KEC;*RNYA$I(S%M,M4)!RT&UMYA M9:_1Z6MQ4,_*1!G:2MG?7?:US"?0@6XXBF.:KFTA;LVQ0H%F&2:@A&(3KO@$ MFV5_?Q&P]D[!Q_3%&R;[E>XUUH0RTY:-NTMC[22/N[$+6%9*[ >#\%[.)ZW: M9S,_G^1 VQ&+;'6"3!40VS(5%0 5V<#2-+ 2L\^H>Y82]TL8']0]5]]I+:]H MDAYV-X40*"#SDBU;4TU%(<0T$=()M5RD.DC7H.9"DQKT55*X/T=9?0>-?58Q MU4\*I:_;(3](\KC]X^Z&KWLFMA%F<3++8K_K!>RMU<.MM+6YV6'7-!W#U*@I M2A\- UM(=UT+4ZHH-B#*BJV=T7B:D;+9]4'KA34HBZ6DO]M&&S&&#:[QDK%U'D8A(LAZ#$* MB>6F3;)NJC72IV6;H9N:RJT@=K!J.,@V#6R(Y!"@B@4PLLC*XM(=I&^/Y<)' MG2JML6FL@Y]:Q^Q!5P@BB2!1T6Y_6EB4WC7CQH!-7>E>XCV_N42RR=8Z%[O: M!&", 75$3;.K4!-H%C&H3@#5#$U;6>F33=',#B+P@S$?YG0.)PQB*R7UI-^5 M(/17/PCYR[[,0AL2#!?OXOPYYLU?67(7\I9'WD6LQ3WP3&QZY%SS5]I*![L5 M(JF"S('6=5V!-G5MZ&C(5"S+Q89C:H9"N4@Z6D%*MT*1W.>TK 9:<:R0=+JE M>R6=;HF*[CK=WZ+PT8^%F>/Z?I].=XM3:*J1<\HI@H@8.G 104BE%D6Z!4S5 ML72-(K1RSL#R*:KF:)0 P,ZCHN42A 5%>PJ1(7JP!# M8B.(5U8S<;0<9QT3>(X9-LXY2I1Q9I2!%S:U2!TB'6%=,PT$:,DQH.18Q MH68@"%S;?:5** MQT"E%C(PM2E"CF:;V$$Z=E6%Z-1QW97%1/],;0T;$DXN[Y:=C^^O671Q,]&F M%^,D3KQ #'OK-'^J7.-7%0DAL]WIN%I[88!#> M\PM?^"OT@C!A\?N55Y^-:'DHJV]Y4M>A@B58I7_?1;-[/'!9/;V.F/?'J7?# MW^&C-WKR7F+^I ]WT90&7JHG8NH2VS4QL Q'0Y"J)J$8ZP9V380-K-CB&F\+ MXFTBSF;:[(4TZ=>GR6M__/?#&0Y\;QM>__;(.26W1WE]^WTJ]Q&+F[KC@/\VOSHTI_\A N "C M!1P,V&DU;TREC\9T/93#[7D")*_^>Q;US]M2[#.^]%0\P^SCZL#/AD'GW.W4A\4AZ;3AYA&'_]Z63%0YD^OKS) M?-55KVO:[EFU.L?L6&&"4:=M>*:J+1L)WG7HN%B17=U%W)6ZYPUW<8]Q&1VF MZN*K%PWN>AIX5[=3[S!=UE/3 ;4\Y4 MMRU?]KHP8HJPU#4Z_J9@QUXU\;K1'BG-I@'3,!E280?WAJDG/.6,KE1-4C5E MJ@EJ'=QRII[PK.6IX,OC7)TRSV=K3M-?]D"+B_0$19&OC]@="V+_D?5^&'&< M_9@_5E'4@T9L,/+BV+_A]$@![@W_/9X>>Y >QICN7RUK1%L_OL[P_X61FE#DD3^]3A-TU^%WSQ^F[=O=1_S5^*_K:^Y.8KSL"H?;\'+ MOD3H1QGK2+4P4PLZR-2"3A U')?H2#>1C34"=/7FJ(77Q1DU=A]^F/@//_9N/?__9^]-F]M(KG3AOU*AL6]T1T!R[DOK M'4?D:NN.FNH1V>,[GQPEH"C"!@$:BQ;_^C>S"D"!!"F28 $H .F8:1%;55;F M>9ZSY#DGAZ49T8482 M4T12 M;9P%6JNU(N^'J"!.MPDS[,,$_S7.[U_"O,N6"QC86,L*I)BP6AB$FK8)<2 C6NC+M J_-1?M( MD[L0[0_:[==)WU$X;UT3YU_R_B":?*^#*+R>!+G()D7P[OO3_LM/FSM&TUW4 M^.>QG2.AD@/L*?120PALP""S2#*XGJG_$/[58@W"$L05.%\N0/M\>+B3EI'' MH]63#W^H1/!C'N"@YH'HL!N,#0: !PL :^PU%\$$L($=(-T_#S1XR#1JTG@_ MQ'K5 _.]2UD[X8,K'U'G'-4PULH[;IE74%%*I9::6@N],H@ZJH#1OHC0%^)LQ'BE!)$*V0%%0!J%9QW MB9%WQ!-A]6Z!_@+E_.]B/.KEDZNX^@)!]#:=:GM$F= .\HQETPQYQ1"DG#FR=J1#C\BC;98 Q WV0'CQ>+S+$-A MOPF"*0Z0.*89HV0EF!B<#2>P=LHY1&GX%UH:Z,88A#RG>JW-7.,4TV"0@#:Z MH[^IT!Q5%C%HK9ER2P9;=MKV =8Y-'",[@$PGP"T[FUOF!1".2)X+'G0DGN! MG63<8V:9!G>9[Q[26Q#>=@NSF&PT^/G82K>3OTX@7))X*O'4@J=62D9Y')<- M=E(\B@,2&M.S@'=(.Z"YPFM.X+-XJD'KJX,:3=TX4)Y*'=Q2![<7/BIJK(,; MXT2)> *HH(QZ(24D A!KC SD 12,OTD=W/8V^ 1 . @0$PT1"Y3_31H@%M8!^+B)Y;C.?_PU'_^SJ.+ZC17)'V))S1QW*XW2EUM\6E:OYI[>5M3[;C1 M7MNMU=]'H*9/ 5 KAQI[[Y3$B%%H8RTJ% H10(BE*B@WQMXU@U1))Z"'&DL3#R>!WJX=2+*8O^\!6]OSW#I,--G0I+5J[)2T MU0'C!=<%;89["!P41&I/-<': TB=42HF?^OU;@$_QDM#2@AWJ$B.V>$X9O/N M'[>R' ZI_+XEL*0U+%'LSRD8!,9#BK"21 5T$0<8#2XC:3YH5OL>, 9EC4&@.> 26V@ IU@"P0B+BH ?: MH;6 RT[T)Q0=T>@Q,JW5@Z>D[C9*OFES3X$*3D%2ZVT^Q(GW7%BM*=6(2,MD M3%113BEG\%KODQUI,]$A9 OV:!M;!+2ND^1=-,XK35%#Y;3-%(F=R(2D24A2 M<X\KO#/!SW[J# M67S2OXQ&O:_]P6";,1W6;"/AUL5,6^UAM$4%'B,F<1T!(AA[H@D6PF&*,!4( M6(:YY$9P[?G:IL9FF&PJ,"0[9#?'=;=<>QZ(DEP(Q,E:H9+62 .",VM<,$RI MI]3[H/N8EM!R0+FG!M]%VO8U'.DPD78MCDQ?'3!8.%K9YW,(&./CL5A4$:^Q M "!Z46/AGS6M;27LY&PV[6]YZ#SJ,;.]8A$/(?$E>7,+P?1B& ,):GQ(E M&1)6>!- C(4&7D/M(=4 8;\QB!NKVD6H%6Q M1FN1'UNVUMH"1Z#R=T\=Z72DEF8R0K!27@.0TT8'!T4B2:V!"GAA //$0VNQ M>2"5<6LF#94=#AJMNC[@[+AW$6[]4$_ M_]0?E*W$7MIS_9CC8B?[X&GUCZL7SJ)A4G:3?X_MDG;D\[;2JSN<8!"4=6M6 M18&C6B+#97#7#!%<0*BDQ9IC9\5Z)\GYBO]6+?C62S<[&!]%VNVIAWX2S'<. M\V"8UDVZK),:. 85AU0Y([PF&F)()+>4D+7LIJ?"O+$&"9@WN4W-NJ5G0822UAC]+I.'D@TCK5 A,H#+5>(60H8U@1+ UCBDO-D?/J!4!L2!F* M#H6-YDRU#HC'Y00O@E\WHW$I?*/+;#"*HRS&UV']/[VX[&P+9^ZV!9@>$.!A!(XRKS$SEN+I68;X:ZQS$/9;)%G6W'7Z#;1 MH33.2][CCS"*5_*#I0O^HB:.,P6HUUH*:(SVA"OF8? DUS"Z.[<1!MV(COO\ M@N0W[AJ"AY#=AG&M0ZF4B@%$@=6<8HXD%!8;1#@SP:(EZSIT=]XD1!V!FSS& M[L&%/O ,MV/*T&G;@>AMR5<[LF<]R34^C8RJ]XU&D([1/):U>2PD5UPHA#!4 MU%&L@GGLN*2&&&$H6RN?6W5A=U $BT$'@$;[OR<3^>1-Y); D,#:"M9,4.>D M#?](:KW74CLE.&&6>@GI6K.BI\*PJ6 2ZTC::!2W=3 \JCK5515X6039Z&73 M_%N#4:-#AMV*\VD"V(0&D&DK@K)#(J@]"C'P!E..X%IJ@9W/YKMA=W1=7.3? M5KS1K;:@;31,U%I5=TH:[9 11&2=$T"U(YYC';= (/1*&JV08YY;JB5?LQ^? MC:"&-!@#[!@0=&H>7+-:ZRBM2%:#40DAG..,(F4HQD91:+@,+P$6DOAU9VX^ ML]_]:/S[L!OF+.\/ R9_&TWZ\5Z[:',D.O#(4W:2@W>JT!1UL8CE&%-CB<<8 M4N\#')T D#O+E%8 KA7QOPB:C673 7S&^OL%4#=?OJ$'9$H^JPM5KOE)3;(<,'U950 M@G, &&?,L.#K,22U9MQ(S:WV6JFU:,ESX--8-=3).'IML![;N&%[*A.2)B%) MQ3&;LR:\$6Y9#+M!=90'Z'5'U]?]:3RNZC%[=A])'=M0#D_2T&*U)0'3G*C8 M"Q=3#Y4@A'%OM=%>$,#,70UMZAE5P]ZM&7^:A?MMTO]EV!^$IQ_/B@=U]*B\ M5%#[?WY0-27]K8[ H5_[,]W M,FMY"!UKUF]2?J,_#),S_>5U^4XCSMKU]2C^)."^]-7B;:.ME ^RF[S?"S?, MNOE-?YH/WF9_ &\ #!\,,Z^Y(-9\39#'4[#N]GD*A]';V\VO1J-P_5[;[/1 M;#J9ADN&I\A*+D%OL^#SU%\.EX[.27E;*N$;[_9>63;49?C\]AK^5]%;NXH'1Q$E@ M//7(*>>!1L1;1*W68NW GX]%S-,I>BX?#\/C359FUE83^S*5. GS$=[[<;%& M; G99,W4ND2^9#6;$MJ?3]R[.FH(KB2U8@6AU1Q)8R1E"L?3_G@ *5+!.$5^ MK31J$P@^1_$]%8*XR7JIPX'@(3C%#:O,49EXUQU=WXR+JV(XZ7\ILL%HDD[G MW03Y*^VU N"YQ(H13P35EBLHM6<:88N,(/:^SLN+-2E3C\SJBE0%)^_#LIP5 MTP^7%_FW[6MBQE ;SOX\'/)(/F_BA?MY0:P42TN'+()><&(455PJ;)00 ! K M&7%BK:77BWFA:?. HD9;&AP_+VRR.=;V5GZ3!_?(4O/-!UD KS2]=09PBQ%5 M5%!LG*140&2U 5XY -:L@]4]25?.\]:BT[(3#)93Z+V9_.WMPNX0FOD)6FOF MH'UA;%?"D3'4 *2D)AYI*XV0FO.U*K>G8+*AH+3L,+[+?KB'VM+O&.K'*P6[ M4OY6[@T_5^$^8_F;.H][;_L<6SF+^U$Q.@"#@]?G0=4=EAX-&>Q5L+ 8M-OS^ M-(TG$B[?+_^[,IQ!?UB\GN<[0P3^>%>"(5BD#U9CGA\LRO]>C1?7N,D_ M%Z\_C8O\GZ_SRS"&7_+!U_S[));/7(WG8]-SN-ST\C4E"]O'WRO?OV+.\O>G9EU26C_X,V',^O.SIW- MPE_G']Z_L^HBO#B_"/_\ZLXNSK,//KSZ8/[KKQ_>6_?Q?.%-N?_^_=W%_Q[@ M$__T;IB%GPQB8YU.5GSK%C?3[":P>)E)G/7R:?[S(3[6[\-\UNM/B][FHW\" MP;29\]?OLG+-6Z;N\OM[YN*B?UU,LK/B:_9Q=)VO.0;7^?AS?U@-+Y]-1XLW*C^C?.=KOS>] M"M\.$S(W/((U,LAO)L4OBS_>WC4S7BU#0,O@)I2O'HX05?<@\(]O7ZU93XO[ M_^"SIC^2Z5X[NE>K#@ YYCC_,V*D:[PFGCL9XGYE<3:[_E2,'^3?70QA=%FM M4%6_TXJA=,N$^KT.I8Q;G_CFVZ,EPD<*2M,2\8L;*'L=15U/N-=AS&L9Y]Q0 MU=$D:)XD-%>RRO8JDC\LV$E2F*1P-_923*S?*NW5A&2A!64 MUTW/%)+,( :DDP(0HC4TP$D ;&*N$-IQ)IS"NFHT#$TPTWS0G> MG-\>:XRQQG_M;X21V"^Q7V*_G;'?@]6*%?TQ6&<-4^28(H0RKCS5SB$'245_ MV"#$=D5_=[LB/(_C]M+SH-FZQ?VB)!4[)W9,[#AG1UP;AU)+KID6#@&%")", MD;EQ")5B8)L^$J\,26B2T36QX>6SY"EI2=9'5M.P7T -I! MKM]D.PV?*WT96UV%92FZT[@IT+W*AY^KQLNQ)F)6GLR1W8S[PV[_9E!,.MFP M*+\XS;_MB.FVC^)Y3^I#.ESNE'8B#[--8A*J)%3[\$,,,,@T(R& M+S"EN!'0"2J5T_=L4BZ5@BMUPH?+L^*K6FJ"WQ:*X-WPMS#"4>_#I>J-;N(@ M;ALF\U+X?^1#V+XPUTEV]4S@;CNXD\9(0K4GC4%JC4$P-()SI+B.=;U( L*, M0$0Q3#5R: <:(Y']2\G^1%HXGP5?M%_&=O<=;FRS=DBM?0Y2GR3Y3/*9Y'.G MH7HNZW.;O'300:() 8A;2B2'L$KO]50B:N_:04$7U8VH[T3I;67;_/>%W:DS M_ .S"'9$.GPM8?C ,)QT3)+/-LOG4W2,P'4)"1.0&^^\ @92PX"02,63.P51 M0>.(M>9\3] Q_WMADWI(^[WWS,2'!\XX6MW2O=NR(VWJMDDEG!+S)Z%*0I6$ M*@E5$JHM[OO(E2.YH' *4>*LYPQB2)'6;E[.[ A!ZJXMNL$Y7!N'0?:2W UQ MDU7/A[-WE+!]'-C&-;:9DT0P'KQ,"YBD"!BOJQH-JJDC:VG'FV/[&>YGPN!A M[]_NR&VU_2_]<,7>) K2(!_'TWJ'6=74,:LZV_WT!_B&@=CM.2O[7.R]^*3- M-F/[0C$I$GI\D= DGTD^VRR?3S.AQ$I:'"4 "::D]LX)0[17;Y?-)Z@D"5.LGB(SUUG%% M'>;,$J:TK?03,=:8M28US]-/S>PJ)]5R\IO0[R:36=F#--8:K_KP_>C3#X=% M)>A?^].K;'I59*8ZEFU^/-5D?MIOEG_-Q[WL9CSZ/,ZOCV?/^BGY(Q"0NC65 M\L9 QC5VUEDDE6:&5:AGX3UP?_.5N 9%S\[&X?FJFHRJ'VGY7YU/BEZ<]6(X MR=>K-#8W6+?4G12\:?*8W-8J\5/2U8>,32KKTEL&@26<*R$$9UY3IT2%320% MEFNEMP]@\W_RP:S8&31WUE@3-MEG+L$VP38E5R2A2D*5A.I@A>I)!@:$=?9X ML":( @9S0BWTP;R 8F[\8RR-7,L>;\K :"C%_"@,@$/8J&_@\4O1>?TIRD>9 M0;X0D*SX%O].Y=5A> MI=1 A^S,TB:[C"2^2'R1]%F2SR2?23Z3?+95/I]D;R%0;P<0C;P2VBG!C;+2 M:&KF]I:CPJNUOFK[L;>:\>V/W!XZO6W[B_Q;UK^^"6N9C8NR#BN;CK+B^F8P M^EX4U19^L^&!=J(^!7X/6L>T4ZB>ENR%"*[3/HA 1EBND""(>X@H4O.M9<*Q MX _KD@=5257@%7!>=?'TX]'U_3'ALV+:>E?]*:5EK,EJIQDN&* Z)\X;P(A"BDL%/7!>Z'E.''?*2+$7PZ7AFO43-2Q. M9"?\8W$S&W>O@G!-[N:P;Q+;J,Y"FS_2^G%H!QD4>Y004.W)4$N,)%@PJACE M4",I%Z>'0FW=6I?=TEFHUZ"GAKV/Q;0_OB^?O>69Z^1-H\?MO522VL\P*8S^ ME##Z<3'*"[:!-IV(UAJ\2;Z/3[Z?J#%IG?6)E14860D0<< Y&M1GI3&)882M MG\_S-(W9: K.%GL3))695&:BE*0RDWR?K'P_467*6F52IXAQV *B),1.:\O] M//4"$>'7MLM>K#*;:I>0M-VVVRFT-]"D\T'9*"$OXTR_YD$6,PP[692P%R\_ M#LO?&\T^#8KE^F\R+?.+QF^L"U1+PZU5L&F MII*NGX9<1WZJD-*'V70RS8=Q'NX@?WY\93M"2U2(-TV65STJ/)L)PKZM@R,P M @X%\TTM]1^V.0V'SG2K)PM)*1AT2G-+J))20T&UQMY!Z($R]YL\5Z-!>,A) MQ5A-\]O.BG&"DJ3-'EZ4V"^Q7V*_?;/?8QX?H:RF/X*L1,YCRC0%7"AM-.9& M<(DU$,CMB/Y>%@A]TO'FL(-YHUWUGBHNSW(']PN;$\V#3.R8V+%F1[X:#^-$ M600P8X ";Y6P3 (D+4 08+S6RWI+[+B74WT8:[0V*;%E8LO$E@?'EH^1Y.0#PIF39Q 9!AXCDZ%9A_S]-\S#2Y?OE?U>& M,PAF^.NKHJ0:B, ?[TIFN,6\=/*'8UZYXBW$+W\]+[R,KU=O.8R+.+@%C_*. MX9+EN+-N,1C,/_W/5^!5^3H\:'?Q^IYYNNA?%Y/LK/B:?1Q=YVO\^+7?FUZ% M/\.SSI>M.QH,\IM)\H>!/[Q[:LU$5O<_P>? M-?V13/?:T;T>WVD['L.@L7WV+6\\=@/Q%..59Q//G8SX@_+5UXJU/@4M%JYP M-HM&^.W)V?$01I?5"E5[8JT82I7YO]>A;%IU<$R@Q"<*2M,2\L( MNJMQY;V.9#":[.JPHF.'XR:YIUM;UXO1_=J^R9KH0\E4M46WW+29)ZM"L>^T M_4,(.#-6YRY ;;2BW'%D&348*RFX-<8[K 7TCKPL216*_R;M2%)E2+YAN^@3 MV,ZH]2F7KC2N[5JZ]AOML3VV[H=.=:(^OI )+Q$TV& IJ6%*,8LXP9 (*ZS' M&^VMO8S@=IFEBDBBOT1_B?Z.B_X>2\3BH#ZTV5N@H=.2$:>H0TP"*CW%%! ? MZ)#J'?'?]M-4(>](SEM[^//A)5PE>DST>)STB&KS$#'"L87> Z0HUC XPL8; M3213C%F_UBUP2_2XESQ5SIH\USK19:++1)<'2)>/L26IV5*@8#,B2!3EBGKD M-80,.Z:5(8JKS1)5(ULV<=8GZE#0:$%Z.T7T X,:> ISXIIUB_57CK7H[T! ME"/0; ?>'CL)51*J/9D%$J\X4<);%%0Y4IHZXX2!G$O&E>)6$KU6"AW8O?)I MWH\F][10AK)5'2%A1\HF"_H2\A+R$ITGH6H5G0M M7E.CN*3> KD!G3?3K?!HF/@0#K)8O\E6CGTLPYW9K?S)N>?7R8;!"QQ=9M/\ MV]V"G-U'Y-I,_JEI[D&JBR2?23Z3?";Y3/)Y$O+Y)#L\V-GU;HLDD",E /.8 M*F"EL]1:X"@D&E.^EKKST,YQ-,N#C?[A\B+_UE2TI?$-ZQ\UH*.--BE/8$]@ M;PG849VGAZEU,,!:,X.H8$X8H QC5 @J@\^]UDUW<[ WXXL?.RA;M)^Z(T_< M]K_TPQ5[DR@.@WQ<]+(@LJNG3V8__0&^(32["1Y[696SJSYN;38>6ZLV3DD[ M)*%*0G4B0O6T'%>YTHN5, LY!I8!9Z@E6$HFA#.8>P2MW:@5O,J%UH[S55J:F)M#N&[1)$R2AVH\F""1=:P(E" !<4(R%HLPB:;BQ M'$/NI15:KW7E?IXF:,:Q/%423WO"RU^\FTQF9;N/T>5M_[,?_='AL*@$_6M_ M>I5-KXHLVAGY\'M)LOSM)"M*ZR/+O^;C7G8S'GT>Y]1CMSE"^LRX9.VF0D0@@$4 +G,DDGTD^DWPF^3QM^7R2 04AJ,,FCGBJ MA=0>"^HQTY0HCIBAP4B._H\+*]2*H># M]J/),51F)9"W'>1)M?WX2US,9%61B434=9<7TS&'TO MBFH#OUG/]L#"3BDLFL*B;9;/IZ63(5P?(X,PT10KIX FU!@MC(-,$BNQ)TS; MM;AHK:\>5%=5$5/@$G=Y672G?CRZOC]B>E9,6^\M/ZD)[T[*J XG#2XQR_$Q M2])\23Z3?";Y3/*Y5R$?RQN9N/N51"NR=TR@$V6=PLG,+<%]QC6'IE0VGDG 2<\H!]) M1:VVB@L$",'GGNJ>&O8^%M/^^+X$_Y:G\D/ZIM'C3)XH,>WGA;11 M<.@\\ +[])'G;:V9FH2R[4+Y1.5$ZS1*IS%Q2@@*C*#(.$4%*PM/A5 *DOO+ MS1Y53HTFSFRM-0'N R3>DI,<(1,D-13$LK6">43U9.LU9,L.^(@Z SEU#(N MH&5. ,@L]U[P^P\W>XEZ:B:1(FF67714:&^@1.>#LE="7L9)?LV#-&88=K(H M8R]>?AR6OS>:?1H4R_5O=+X.X #$\ >L.R:P8+EJXQT(!JOVTAN/G 00,NZ$ M(6L=E" M;\02[12.C4Z+?3&]'CJ;XMKBT@X[;Q1V F+)&? >F(I-%:(8K34X?])QLB_B MT)U5RP0-':8B,6QBV,2PB6&;=6H)D4N*]11*XK704$JMD:3!G2TIEAK#E+N_ M=+UYBGU97/4IV0!0=H2DK2#4C3SD_0(M96(F!DX,W!P#\]K(I4@C9"QC'C"! M+=0J5G-%(U M7Q4E;4$$_GA79L,MYB6PU9B[05<6XUM%L3A^93N/T[51_M,(1L M.)H6DS>-#3UFE_M?W%GV[LQL+K/[&[SY<&;=V;FS M6?CK_,/[=U9=A!?G%^&?7]W9Q7GVP6=&G?\U\^\__.W\ )_PIW?#+/QD$+39 MY.=#'/_OPWS6ZP?G:?/1WV6.4E \0#/F,F=B:="" P(GGP9[N MTM^;*'@:V9/Q-+,L2MLDNQR/KK/133'.I]$#CK&7+_UIOYC\\E+!.=FP[!$_ M>%K]XZHW/RNF6;__0J2SANW7X M%G67?N 8EH [$L!-O;3:\/":&L4E]1:LG5_W"+Z;*[V"'2F;W*W;[[9:R]O8 M-O#XMK@9A[4KNQ1ULOQZ%![QWU47VGS8RT8Q+^84.TL] D59IY-"*+ E$C$H M"978:N*PLTY:)(A%< V*JS,>_AX4\0\U[*F5N=^F!A8RG>]ZE,['B6.2P?H4 M9R@DUH1[P0"G3 %%H/ 68H"Q%ST MYLYQ-LV_%0^D !B_3.80HAM1QKIF1WF+J***64KX. MO&HJEYT4BTF 7?C7A#?[TY>[HD])R15-EO5NE%?;RM394]*'APP_6L//:$@9 MT))3 *FU(':7+&$:.M01P1RM;:VSP#D5O0I:C1 M#C6M ^1Q^9'F*A]^+B;!C5S-L9A,BNFD#+X.^OFG_J#,MRA59VQFE7>K4^K" MRKXT!^,(2.K8G^]DUK+1S"K16L1?C/->D8V+;M'_$E.[3]9F&M0&8J3A-R)>*75%DT5>#I%*_81P)*ZU[F VGB*'2#$!6^4*>>% MTQ![ I$V8.TLN77 EG/]81'M4^6<[V2O!L-&CX)K76@X.9G'"L_'%"JK%2HW M0GL$2;E9$PQ%C33D7#NI"=!"TJ;PV:!F)3N!Y;'IW$-1K8N817:3?X\1BQ.V M>P6JF]P3KB4'AEI#J-!4(P"4-5Q!9B&7]NFQH-^J:=V)!FVT;NUP )G\SJ/ MGP0U_I@DS",?=(_3U#*B',- .>(=<4KI9\1B'\3?%G(;(&RRL.QP '@B7F@0 MJ?'L3E+]R6Z//H)EA)=85@A@C 64GBLJI%742P.Q$)!![M/$)ID1![/Y_;N[W.&]6+O,D$WM9JOU-2<@<,)%'O M?"C@A03 0XH(1=RIH-Q 4&.>400( PT!J<%&)*#)LK*6*ZN#=_ZJ+%#7Q=0EIK)<2&I+&N,KL9C[[T>T4O^_3]WO;$6^:)-M/!8VRP M$I\2VEBKN8*(>6JD4Y19)KP/MH)TSIA[F@C&WM"_S2=??_]]$F-3=;;$$ S%>W'_.!I M]8^KN<5OLW'W*KB,D]BUXCH?_[.H#C.;%-W9^-@WJ![SR2%"*PUFG%+2*Z.P MH<$SET#%")W1"#D!-+JKUG_+O\>3S2<7(Q5[@8R+7Y>3>[Z;/P\1_N%1?\OX@3KH?C>,[-<9M\6FZW2@7;305I'UI6,G9 M.56(KE8",2JAXOZ]\40;3"RU6A!4/L >F3^Z"V] M&M9T+B6GZ)X^ E"T4BID):4X[A0+9BGS5B,K$2-:4:*TH.Y' /UU.6LACV3#P:3'R'W<-K'M%9[GI*2/&2HK21G "DEQ)IY@1%B,7F_9([J*T# MT*NUY(PM0:W)%,P.:;078LM5X>'[GJLQVYMQS*R8?N]D-X-\."T[$A?_FO5O MHFR=HEG[6%P)K32*0<83;;V+@25**9#8 DI]<$(!,9:O'4"U%E?Z;3[[O\6Y M#T!VBYG?JFXD35;8'D'Z5/)13Q;,*XD72FO% 2<(>TJ9HUIBR8@WQ!,@ LZ; M!'.#VA>R!.8C]F=7=774R]/OV74QO1KUYCD7I0@>L67]*()7PDR (@TB*, M2%U!0"5"BE+IE:#:6\&-9\8A9I31#CV8/N%'X]7H5;D6[Q:9HKLI(X"ID"AY MPJF^L $^(#4?:,R]D\0R21E5SBOG*/$\,1\TF%B5^" 5%F8_ MS29E"[J?;Y48WE?$T,*"IM8P J,KC. @]9P8X0D50FJH/>88&0 9DWC-\WZ@ M:&D;QL&3>K[B)KN(/'71VP__Y**GVD0L:IA+%12]9HXP:JB&0(G@#3!IN:'. M [B6)O(2F#>G\W&'-GM67ZI-/*3:Q,O^,!]V^ZDV,=4FIMK$4ZI-C.;^S:U\ MT/YD,@M<4,3-M%[QZ:7Y+6VVWA_1ZH2P.HM%T.#%.\4ABUK=."2T$5A9C(DA MZ\>IK/KP[^8S^N$R=BB]*,;7VRZ9(!W)4F[G 9#)J2!IQ0T62 +NL9?7@M3+"9[L3I?A#J*-1IX./^*< M')!3!2\%-7B-,EAQBIR%@ ;%J1G@2#/*'<=&0; Y>)ML>04:;3Y]!. ]+O\Q M"-5J]F5W='T]BE<8=?]YQ.;NHS!%M><(O23:$B?B4=8$6>$HLT0'%4D-X_Y' MB2'UY'ZX-.7,GL>)W::VE:S);)##065R-(\$>2LQ&R:A4]@KRUVPLQF ^0UN0,#<#K5[XB]4]N/&WS#7CP!M]]+UNT]X&6\5IN&*40M M8=1K2C$0@H6O46$M0I7Q_J4 ;D[S2M!H!O3A _BX7-1=E#<<,F@9$'5,B0LJ ML;7":D$]5RJXJ!I(8@G10JH?;LZLF,_EE/M%3LF.$Q4;]6!3GN)1*M]CAC-: MA;.7DFE-C':4(J2YM1 :I)CQ0*JU$/&+X;R%@X[H+D\X.1PX-^DT'T(YPKP: MX=Y,Q52KM %-$%EWMG, ($6Q%IQ2SIAB0%L)@<)!]VO"GIBRO"^%CW9*$4=@ MWR<'O6VLT(HBATT.$KS([;\*_^(_86^!%%[04>A M%TQ%2_(YF01U.Q,D/1#4(RLPU<0IXPS$R!O" :1X[="62 /Q_UT]D1^+R73< M[TZ+7OQ #7NWWUCYYF]AT+'IR=VS6+N#69PJ]ZU[E0\_%Q_S:>$N+XON=GL$ M=EBCF6DIRWJ?:O_P4M8\I%NS?)I]*C[WA\/HZL<>O*6,'9)-WQ960'(E%\UXA806 MSE/JG1 42RR4U2I8[\"LQ0-?Q IW0/ZN!#EIY. G@%MAO+=682<'_E3!3NK@ M/Z'&0.4,P!Y01IET7$DHD):>$R?67/2FP2X: GO#^34'!_8G-R4X!IU?A/Q:[M:;($5@J<_#)0R_07'KVSG,=HYT/.BR/)N M=W0=?O@]!EV&HVDQ>;,V],43W7V4]5&^:NNCTCMB5?[W:KRXQDW^N7C]:5SD M_WR=7X8Q_)(/ON;?)^%.?[H:S^<@+REE8B$)?E6P4QS%U".O$,->*X&4\U P M%G^3/V'R'INFD:DI7WZMAO%I-.B%2ZA?_^+.LG=G9ET2VC_XLP\7[CR[ M^)"9#V?6G9T[&_\Z__#^G547X85_=Z;.S#OU/CN_"&_\ZLXNS@_P,7_-Q]VK M#,-.%@W8Q0.\_+K9 <[%3[\/\UFO'U3OS_=0UQRV1#OC/+ <4$H53$H2O/BM3$0,@HYB$>Z 0_* M$BT@K;>:B4"-K^M=8@LETXK%O%-"!96!*(-#!RP44%NH<648]8>SHJ>FS[Y/ ML*"*8";=1#4TGA5!F31T*L_/V]9\^L@>&?Q$,SBP^6'FV)Q%8P/OK=E!19IX+5+ &T B/L/;5WUZ.]("J_ M_DM_&N[5#=?0LTD8WF32F,5VW^B;LF/4]>=BF+T;=M]D/_47NZU9?SK))K-/ MDWZOGX^#A'>R<7%9C,=%+YN.LGR2Q<96"+PM?]TI7\"WBS>G5T5F*AOP[D=? MB[OOC&;CQ3NC\>+-V63^WL]9?Y+EV>?!Z%,^R#[U@SG9O1J.!J//W[.;(&]% M,C2AY'VBB_%8'03_KK.A[/+(&I!C"=EM+!7#/KQ2UE_.!Q] M"4+]I=R: I9$%P?3P> MH]PZ2+6$G%! 3- GCG)'O;.,*+E&O0'2GXKQ$J;#S^?%YR>?IC6IOKOJ+KX[ M\TM_$=SR%U]/BF[T&;\&OVY2#%_].<8\)-^QPR2[.7'7 ;3UW!\%\%X&FYI4 @5OZPTK2 M(SC#7U'<-L?\]&I<%)M#X#J\^3",6?1A-),Z-?QV#4QO_N!/9 M?[:PQ0,S3+-*144Z'PRRO!?EHR2[[*< \R")TWFJQV@X^)X-XXH.HN[JSL;C MLMYCY1>SX2#2S"@2R]=^F:?9"R9>M/H[V=>K?IB\2CF65^Y%M3$LNN$GT2B, M(I)GEWE_?$OPXZVC[@P_";(:RTWBC^/F8+QN&,AD-IB6Z.2_*[R M0'7!J;CECO?#265"5V04_)W8I7A2/?6G(LQ:<%ZNPUQ/BP71 MU3*T#9C_'AM7N2!2<<23^X#-"\X M^/:>2"@H)EHCQQT)+K\(+A!T_F"!'6:I/#)Z,4\'@^9@MMSDXZ75\CQPQR]% M>SD>DUUJV=_?G+_) K2#43,(MDF ?'$3?[\:+:LI\*>_*/7;ST%GEV?11@(8 MYI_+B\?PPG7^SZ*>T!(-^60RN[ZIT%'Z^WF9 U[1RW7%+N-2*5?@F#Z3KLI[ MK&]<9:H[C?I^85Q=Y]^S7C_<>ER=1@\;F8OTYV,RC# MMV&EB\4<=H)!/3T(Q/[P,:*;%'RBPEP5\$/"@HUFO[=T:1ZRHCQ(.&S MZ]F@A$&O" 008%#BOQ3_ZX">_K^7A/#"@-&_DX0*H/H M,6 A=\S"8"Q"LY8]H>K'L"M/$?X>%/&/@!*U\C /(NC9F5MB&1B3/TRD$&_6 MLTVS3_W!8-7:VXL[_L2U6:D!,B@PB,.8@:#AM162!C:0C%*H ,!X=VOS2.+_ MT]=FO="_N;69O @YK8C8-.=[QL#+Y";JHB_%X/LVE.,#I]A7JO$^C0BT%P8: M:X"2 MG8_IPJZZT,CJA"%*YN3SDN'-&8.6ND")XHL21\U1&D@B:EZ(=; M9VVW\6 4:C7GV74YZ?.S7*_72YE;JD>CY5O<>H)*+RZ,U!APC"9CC.;,O[?R MB)7M^3F&W&:3RO@,U!&_%,S6XEM@LCN^Z>5@5@0OKE/&+J,/&V5F/!ITLKA9 M%8 ZOWH17+P\WCL$K'N2?1N-YE'%<;\Z,BT$5O0QC"G;R8].ZM/3CM(UB\'84(ZWE M?2N#NKSQIV+Z-7JZ90 SQE:_Y&$"RQWX&,(MO>APV?):O>JY9S$ .XJ6?QA- MO&0Y!_$GI0^0C\>E/;^\4'QW%F1J/"C?#XY%$:/'\>U/Y59&/9R?XU"C.S^: MQ3A%<3U9-92*:J'JKT^J-0U7"@,/0G0Y&V1QNS%,SX?9^/:X%JM>[G-"_C8K M\G&L4IS$21Z,)I-B(87W[ES'LT2E#Q$LC<#0LLG_-\N .CS-)Y,JO.TWGM,H71O"M_^ BQMY0(GI"6 M\002__/?%I.>]8/OV!^7YOA\ 4=5S+AXB##CTGT-\E\4UY50U%<(@O>IJ);G M=>"LPZT'&\_'W*B 6?Q+)XRF_J)EE(A#;_G5Q%YA!%C\5@]'7>[ 6V2E21,F.#?,_N\LL&RPD%D%%;\, M+-52$@ESV L*>)+I4@__Y-6Y_KD\(#-JL,"Y7UH\7_SP+ M#!Q59)3[ZR*?S,8+U5_Q3WS5#5JQOTH_=:QKKN>J7U91@H4>ZY5!@NS3]V@8 M#/*R+UZ%NKAK6O1>Q^MEUZ->,:AB?6&FBF_1KK_UV9ORLMH9O0GY90MYRDX?Z/:NBAG[?8L ME(;*/&WI2]X?Q-#\ZS")KR?!62P/>%NU+3ZMZ- \JN"*;WSWJB, MI4[CT]=/7JK@_YL'A@O\-_<9.UDTT,)MX\^#&1I6*/#H>+1PP[+\)F M[UZ% MU8I7G9L5)3DO+MSK]U:V6U;V*\+8NM.%5GM&=/41 V&-JX^D0H"]O$)@90X: MR")%S>N(!MFT"GY40ES2:2#*)_!D\+MBCZWIK62>:BL@?O'3;!S%="'D2VJY MSL?_##@NM]WZ5=)/%= OLO=!LD=S0_E3/OQG]J&TMGM9[#V3_?3^G?[P\>=; MYO/BBZ/Y%\?EOD5IJH2/AI7W5"90EEY.^7%G?L[5X/O=U,K;7XPO1^/KRL6Z M17TW51^\<*.EI5?[FU47R+VS'5[LEH04%9W(2I%,5 M>73S>CORJNA]+E96X$UV'F:R_-(@TGU^ZS?Q+BM3&Y]K^(/)B';D-"!ANF3= MXDMI[)69G:/PB)&/YBQ?CW)\4 MO_(F^W4T+J+]V*G,R:":IM]OJBWZ^,"5Y[KBZ';*L<7MW._E7E#5DZB4FCM/ M%!7E:%:2:'G/45 U8:T"CA9N[WTWJ%9YN<)A6NHMM:+<\8J3MQCK \MUG?>* MY9JM/4*8VF B5RIQKM#N1/P0ZI2K,-_UJI*+[A7)J)O&2Y46QUA=>VE!5!JC M7,;IFNHN38%2R32B4NY1(?-*#0,TH809Y3V@W!F-N"4P'KGMJ)=('F*E!MJT M4N-CA-:LB-VYS5Q^_A9DU82Q!XMF_$/G12MKA (4$ZRI5$)A[#ERUD %XE&O M*\X+EP0@"SPG$,3, $6XDPAJI)WRA/ ?1D\?O<]:]'3^5"^NQ'C*G5\R\"VH MX*;,E=VDNP=GEQ?AWY3N_IQT]Z@62M(M.K=R2&-DN,XCK2* \R2(&-B]S:-5 M[# JCYO9^&8T/VUS?MO:9.ID\TS:^&[I[Y4&3K0J5M(TEE]_DRVP%SW(8),$ M+ZB*Y827GXO1Y_ 45X&>PN#R3AV*ZL[Y9AD +0/"\3&J2&;M'Y8!IGB7R?3U MZ/)U6(U!<*,_?OA;S!^9W[ER\J*6G0]@D242KA0F(-I*8;GG6;.9F\5=QS=- MA(1L?Y)__CPN/I=C_W YGXN+Z&7^.#4#0VH!4H003;7C4DIC@_DNK5+26[!" MI1 YRH!V)+ GM0()9#D--CY0GCOGZ0\9Z='[;'TCJBE^6HK9UP"%:*!6COUX=4Y6L?JL!1CFD<,FR M44'6+0:#^:]"G^&R9CW M:B@W?&XFQ2^+/]9FY-6RCU3=1(V^>KC-5'4/3/[X=O&ENY_!C3X235\PW>O$ M[K77GFAM:C]T!,]7TZL67R4-O:_R51 MWXZH0W@2HKZ:"I=6^KA7NDXV3.1UE,^W%.E]J.EG]*G=FHS_?IX6_B07_N.' MOZ65/\F5OQA-\T%:^Y-<^T3W)[KPB>Y/=>4?HOLGNS$[/7BE 6EPPT_C8O"" M#>/9S0,3$D^G6MNVJ2_ ;Z:E+'+R-N[ES6XVWX;]J9CFPUA9 MG*S]'DFZ43O[Q]:][0T91YRS!&ZIEY M1LN#_529L5?T+O)O#V9P_'TRGO[]MVIG_\/XO!A_Z7<+]:T_^7MLWO?WBH!^ M+7/8RJ\NJY3^LLP_R ?E]\LDP/'WO_]^WLC9G1 V>D!'.X&1#A#;)RD>'>^U MA-I$G6!CM'9<.\2HT!1(+QQ2$&L*A36$ 788U#8?W=_/1L/?)]4O&N XS'9! M<(G#$H>,*V*QIU@#:04'$"CL)/(0R99P6#-6%VWR=.9$ M2HF4$BDU1TJP;AZ%+*5< A&6VU')F11&6<8]-0BXP$Y;(:7Y*?#M]1E!,JD2 M>R7V:B=[X?KL:X<\589Y )VD'!@!B3?"!.M*> \\/ SVVHY;V.QQVHG#$H; // M%41AT,_WNT_\PFWBBC=_"BP\FLRN\T^;[!4?@8JHJVT>R?%H-.]\MR0J4+T_ MP F)'71D^(AZK:046BJ+K7 "&2GV&%NK,+5[-Y8@U"#7MM;.2U@]!*Q" .H\ M!4R,M7:8R7P/O,4G@'6[7AM""?4)M2V!K5H90L>>DN1 M,[''.K0 8($@M)@9K+SQZT= [ FU#6"0T?7S!Q(&$P;WA$&RB W1J&.. M ZD4"C8NQ&X[9N[38@7[,G.Q! FL":QM 2NMMU:A91 I#Q&7F&H9 M+%XII#>0*@N=8-LQ(?$&7R!<88,@DA%X!&E2W M#(@W!CCLA0Q:?CM) EM _G:,>8A$HH!$ <=' 0C4%."!U\1:%N /*#1."H$E M=@923X)UO\^*TL:M>=@!*%4TM+FBX?_]Q?V/2@4-)\2OATRCF-3IEI0@A0T$ M&AOJA)*$*&JIZ4UE)1B#@2!"!I)N7;2 M8;[/:H:]V[@P.:8)M*T!+:Y!Z[U4G!/MC7*4!_1Z!"6'2A*$'.';:3G[;- V M8>/RH[!QC[:6X<.T^/?@*!H+Y3?C(GPQGZ13:-(.Z KKLKI*FVG C":$ 1HC M@T9Q8*$-_SHDE.;[S&>L<+@'OX;OY!26UMI."??'BON5TE&MN8U)C@1@YH'2 MD@ 0<6\,,IR([:0]-H[[+?E(C19\)P)(!- 6 I!U$2/WP! $"1" (T&@\T)$ M G#,*L#I=MI1/Y\ &O&W4AE#@O,1PIG &LX:$82)),9RK0SE2 L4X>R=MDZ# M?7:7WYD=_^\BC"&?7$61"4^/WB;8)]@?(>QQ79!,'+82*X(D8U1BK+!3 ?86 M*J&0E]MI1= X[!LRXQ/^$_Y/ ?^TQK_5TAG*)"94<(^=<4!&_&/"*5%^GQV@ M7FK%GQ::#[UV08WS83&Y.?#^3[U\_*FX&173_C#+!Y=YJE\XVJUG(NH:<&,= MQI)2[;"ADGIM)&&6,F< IMO*%WE:+&2.JSV<+-AH-Y?66DD)K0>!5KI2M&D] MD48J+0"("=!&4BN9@)@9:XTC^VSN_ART;JE9+6ER\S+!-L'V1;!%=9&@5)@8 M;PT#GE#"28"OCZ77TBGC,=CGCN,MV*;CC!((CPN$I 8AL8 J**!7T%+!K!0 M06N$1X *S?=9Q; _2UFUDN/@M0K$;7N4;!.6+CR*X\>. MMI;AO_[WMX\?WK\[/_"X?#Y??'0\,=J&3S0&U&&B&&;* M8^N5T<&8WTY9\M-"*'LTYAL]ZSTA/R&_+<@7=6$R)0X#YZR$0E*JG,1(6><= M4MIKN:7LGBT@?TO&_'%W<$\,<*(,P(%G7HQUH77X(T=-.!#$>] \WQ2C6X1)![A047 MT@HCJ% $64RPH=P9OYUS;9X6#YDCJA;)/?A1Z"@VK1-NCP.W*^6<'"FC-!/. M"6.?9/O26DTV$X_AAM[<5M80(^3,,'V4TE*9.T&;GA9N1HW"O&BR>!-]^RR6C0[V7_ 5FI6 KN<<&6Q;;K7G#J:%<0FT% \98RYS;4M_5I[91#@\Y_W@/V4I2-&F> M;"QGK;5K$GV<*GV(.L]14&J9(,!ZA:C35#/-N&,&(>:4)?L,^#^?/K;DYW5/!$KT MD>@CT<D$:3"1./)!XY M%AZA-8]$!C$*!.*PB')"%"?06ZXYX!@KO<\\C&VY)X@V6JIU<+QPZ)4?%Z-I M/EAL#V63L.;+/:)=5X'\!'^^70%R6KOGSP &#L#HC6:?!L42&9M,P/RB\1OK M4-LZHOZPS6EH_*EWK%1D'3LW&%D##')46FH," ZM@AI:R:@R#.XIYK6P,N&A/\00"6D$EBO@YT= M?'D*H=Q3/[1-B'%+Y4,=!ALMNTX,V5*&/('$RX"\NO,TYP 8SKPT"E'*?;"& ME)"(:^ <5&)/Z03W(K^)S(".D*F2]S"0F&R59*LL&8O4D4'GN<"$84\$HI : M:3#UP&/BC8."[>D Z[T[<;@CFVWUE$R41(R)&-M.C*QN!6& 9TQQXVS,#(5> M6Z&EL9ICIY"@>^J"U28G#LGDQ)T"0YZ$$R?J@RPX1AQC#Z 3DA*BI 4*6JVM MM]I[N)WPS6;(;\2)0X(=@Q-W8H5SXTKJ4N'< V2%=]G%LV63<+(/GE8_K7Y* M![O7PH&D]FV<-!Y:H; CFGKBI0).*(2\YY0;\E![RLG+8\]JV)M_6FJQYEI@ ML91-?O*P3Z1_@@^>5C^M?E+Y]ZI\!.I]'L")=19A#)6G&G AB(DIX40S:SEZ MJ*77/2K_N9&*K:E\GA*\GY_@#=L;UZ@ROE\0US@F/GM,FQW!LQ[[\Z6U/)'G M2[O$)[5+C'B=ZHLEDY!(9A7'E*I8 *&88)Q:18BW#Q76/1Q):< P8AW(4N[* M*;!2TC#'\WQI+4_D^9*U<%+6 L:UM0"H=4(Z3(&1%&(H+-;,<\R)C"64Y-E! MF$;R/RC=WM[)P5@+933E3],\C'3Y?OG?E>&LU8G?$5V^TX@XOJC*_>\K_ZO*W>^EN$I0SF;781#=ZG44SOYP MEE>24\YAUBT&@_ES_^C_.^&5Q]V(O^=3')SHJOVT0V-=^;WI53?*KI<0^.6(6YNE5">C51RH1?1%6[+P8%"4\7@L,J04H MV/@D'I'*I93&0D:E54IZ"U[#"K+A$D5/39_]<_2D46AEC5" QO-4J%1"8>PY M&12[L'_^D,V(&$_7MM'?XZ;D3#\,@DCFXC(7XO>YR!GV>>\/YQD^;"7#48Q MM;*3?;WJ=Z^R?%QD_3+ILNB%/V[W$ E?*L+GP]$T"QHQW" ?1.V83:^*;./^ M(M.K<5%DU^'MJTE6#.-]?\W'82@8=K+HVF]\Y?+Q-OYUM!.6$'B"\#\?K0T( M,GM,^9=OY^40)MQP@8Q%#"H=S"2KPXPZHCV S'OLX]#_E#=H M*:S:!: )JZ!\^;4:R*?1H!C+K_?'7/DDG/(8,^++S5I0AP1JB1&%IB 1'P]4H;;@$=)(I11#%U MBBGJL)?0:,2PHI+]D&4>O4]0QD6PA6^B13F>%:_^7#U)-LV_Q7VFNQ;-JG@\ M+IA/N?M+!H\>T3<;2!9N1+1>_?DB<&9Q>1F?Y$LYF]DX4.JD(3[=G#-O$?'& MEVF2P2,1SS7/"YI8_=#;1!B1@J#Z$" EC9.08BV$H1H P7G &,<.*\DE7FL] MZQ8KN<3YQ[":IA+=(&$?;HIQ"8(G!:^#EUEN\]<>*5XZI-%V^='!%6_6_=$_ MWG%(=ZQ(GS;WM:,OD.:< *EUH"]+G#!6TJ P8/@V4((U.??KH8 7S#W$;]9[ M%[UX\CO9N)C<5$\X^/[F-L6VF-S"M(R+?!+-R6PT&]]#=FVV'0/AY).L-RN" M!1Q6=QR^G$U'67X]"C[-ORM]-BX&X2EZ\?WX%!^FQ;\'^;[Z[ 6?C9.WMUOM M;0#T[K]F_4D_/EXGZU[EP\]!)84%_,=LW)_T^J5(!Z/_NO\M&UUF13X>!@FK M_(AN&'-P*K++_,MH7(8Q^M/BNOQUG)U_S?)Q9 \IOEX_O#G.+L>CZ_(' MET4OX'80QI]/9]/1^'LE,_5RA/7)(S9F@VD<3!"F,#O#>E#+*YG1=9B([__G M/P2"_.TD&RT)(?)!=&\J7^>W67B$4?:QWQUUPJ7#:,,DQ1N'J\?K_!XX(GRS M+!:=A'?R:=8/_P8ICV^7PUD,8G6^2C'__O[IH$1(8ILBU5RJK/OIYR1 $A I%;6 %$BB M%Q4W()&9Y_S.DF!\RV#Y,#KCW^T/=A63J>Y_A38Z_9O%#G:R/R_Z MDX**1P6=7XW!GH;EA*LOBJU)6PZL-,EI]R)?CJO1J%=0P*2([IM3:\+)F^YP M=@G" RR$\0I5%LRS6%/V72*_"BO-M\QG%WF8X ($Y5GG[[!?%WF-AR7F5IX\ MI]QRV.0>N!A-IDL*!^V_/X6%_Y^"DOK#+[#>:5W2!+(_;[/AI/@FOPJ>+'<6 M=+Y>9\62+'!RT:ZNH$ PJ,XZ<<$:_:55L>20D]7G+'@]1Y0%GZ6/0
XML 55 R31.htm IDEA: XBRL DOCUMENT v3.20.1
Derivative instruments (Tables)
3 Months Ended
Mar. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of notional amounts and interest rates for cross-currency swaps
The notional amounts and interest rates of our cross-currency swaps as of March 31, 2020, were as follows (notional amounts in millions):
 
 
Foreign currency
 
U.S. dollars
Hedged notes
 
Notional amounts
 
Interest rates
 
Notional amounts
 
Interest rates
1.25% 2022 euro Notes
 
1,250

 
1.3
%
 
$
1,388

 
3.2
%
0.41% 2023 Swiss franc Bonds
 
CHF
700

 
0.4
%
 
$
704

 
3.4
%
2.00% 2026 euro Notes
 
750

 
2.0
%
 
$
833

 
3.9
%
5.50% 2026 pound sterling Notes
 
£
475

 
5.5
%
 
$
747

 
6.0
%
4.00% 2029 pound sterling Notes
 
£
700

 
4.0
%
 
$
1,111

 
4.5
%

Unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges
The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):
 
 
Three months ended
March 31,
Derivatives in cash flow hedging relationships
 
2020
 
2019
Foreign currency contracts
 
$
239

 
$
85

Cross-currency swap contracts
 
(401
)
 
(55
)
Total unrealized (losses) gains
 
$
(162
)
 
$
30


Derivatives in fair value hedging relationships
The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions):
 
 
Carrying amounts of hedged liabilities(1)
 
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities(2)
Condensed Consolidated Balance Sheets locations
 
March 31, 2020
 
December 31, 2019
 
March 31, 2020
 
December 31, 2019
Current portion of long-term debt
 
$
90

 
$
903

 
$
90

 
$
4

Long-term debt
 
$
7,784

 
$
8,814

 
$
558

 
$
292

____________ 
(1)
Current portion of long-term debt includes $90 million of carrying value with discontinued hedging relationships as of March 31, 2020. Long-term debt includes $592 million and $136 million of carrying value with discontinued hedging relationships as of March 31, 2020 and December 31, 2019, respectively.
(2) 
Current portion of long-term debt includes $90 million of hedging adjustments on discontinued hedging relationships as of March 31, 2020. Long-term debt includes $492 million and $36 million of hedging adjustments on discontinued hedging relationships as of March 31, 2020 and December 31, 2019, respectively.
Summary of amounts of income and expense line items
The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):
 
 
Three months ended March 31, 2020
 
 
Product sales
 
Interest and other income, net
 
Interest (expense), net
Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income
 
$
5,894

 
$
11

 
$
(346
)
The effects of cash flow and fair value hedging:
 
 
 
 
 
 
Gains (losses) on cash flow hedging relationships reclassified out of AOCI:
 
 
 
 
 
 
Foreign currency contracts
 
$
49

 
$

 
$

Cross-currency swap contracts
 
$

 
$
(133
)
 
$

Gains (losses) on fair value hedging relationships—interest rate swap agreements:
 
 
 
 
 
 
Hedged items(1)
 
$

 
$

 
$
210

Derivatives designated as hedging instruments
 
$

 
$

 
$
(190
)
 
 
Three months ended March 31, 2019
 
 
Product sales
 
Interest and other income, net
 
Interest (expense), net
Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income
 
$
5,286

 
$
185

 
$
(343
)
The effects of cash flow and fair value hedging:
 
 
 
 
 
 
Gains (losses) on cash flow hedging relationships reclassified out of AOCI:
 
 
 
 
 
 
Foreign currency contracts
 
$
14

 
$

 
$

Cross-currency swap contracts
 
$

 
$
(42
)
 
$

(Losses) gains on fair value hedging relationships—interest rate swap agreements:
 
 
 
 
 
 
Hedged items(1)
 
$

 
$

 
$
(130
)
Derivatives designated as hedging instruments
 
$

 
$

 
$
133

__________ 
(1) 
Gains (losses) on hedged items do not completely offset gains (losses) on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges where the corresponding hedged item was paid down in the period.
Fair values of derivatives included in the Condensed Consolidated Balance Sheets
The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions):
 
 
Derivative assets
 
Derivative liabilities
March 31, 2020
 
Condensed Consolidated
Balance Sheets locations
 
Fair values
 
Condensed Consolidated
Balance Sheets locations
 
Fair values
Derivatives designated as hedging instruments:
 
 
 
 
 
 
 
 
Foreign currency contracts
 
Other current assets/ Other assets
 
$
375

 
Accrued liabilities/ Other noncurrent liabilities
 
$
5

Cross-currency swap contracts
 
Other current assets/ Other assets
 
10

 
Accrued liabilities/ Other noncurrent liabilities
 
657

Interest rate swap contracts
 
Other current assets/ Other assets
 
89

 
Accrued liabilities/ Other noncurrent liabilities
 
23

Total derivatives designated as hedging instruments
 
 
 
474

 
 
 
685

Derivatives not designated as hedging instruments:
 
 
 
 
 
 
 
 
Foreign currency contracts
 
Other current assets
 

 
Accrued liabilities
 

Total derivatives not designated as hedging instruments
 
 
 

 
 
 

Total derivatives
 
 
 
$
474

 
 
 
$
685

 
 
Derivative assets
 
Derivative liabilities
December 31, 2019
 
Condensed Consolidated
Balance Sheets locations
 
Fair values
 
Condensed Consolidated
Balance Sheets locations
 
Fair values
Derivatives designated as hedging instruments:
 
 
 
 
 
 
 
 
Foreign currency contracts
 
Other current assets/ Other assets
 
$
223

 
Accrued liabilities/ Other noncurrent liabilities
 
$
31

Cross-currency swap contracts
 
Other current assets/ Other assets
 
66

 
Accrued liabilities/ Other noncurrent liabilities
 
315

Interest rate swap contracts
 
Other current assets/ Other assets
 
259

 
Accrued liabilities/ Other noncurrent liabilities
 

Total derivatives designated as hedging instruments
 
 
 
548

 
 
 
346

Derivatives not designated as hedging instruments:
 
 
 
 
 
 
 
 
Foreign currency contracts
 
Other current assets
 
1

 
Accrued liabilities
 

Total derivatives not designated as hedging instruments
 
 
 
1

 
 
 

Total derivatives
 
 
 
$
549

 
 
 
$
346


XML 56 R35.htm IDEA: XBRL DOCUMENT v3.20.1
Earnings per share (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Income (Numerator):    
Net income for basic and diluted EPS $ 1,825 $ 1,992
Shares (Denominator):    
Weighted-average shares for basic EPS (in shares) 590 622
Effect of dilutive securities (in shares) 4 4
Weighted-average shares for diluted EPS (in shares) 594 626
Basic EPS (in usd per share) $ 3.09 $ 3.20
Diluted EPS (in usd per share) $ 3.07 $ 3.18
EXCEL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 58 R24.htm IDEA: XBRL DOCUMENT v3.20.1
Earnings per share (Tables)
3 Months Ended
Mar. 31, 2020
Earnings Per Share [Abstract]  
Computation for basic and diluted earnings per share
The computations for basic and diluted EPS were as follows (in millions, except per-share data):
 
Three months ended
March 31,
 
2020
 
2019
Income (Numerator):
 
 
 
Net income for basic and diluted EPS
$
1,825

 
$
1,992

 
 
 
 
Shares (Denominator):
 
 
 
Weighted-average shares for basic EPS
590

 
622

Effect of dilutive securities
4

 
4

Weighted-average shares for diluted EPS
594

 
626

 
 
 
 
Basic EPS
$
3.09

 
$
3.20

Diluted EPS
$
3.07

 
$
3.18


XML 59 R20.htm IDEA: XBRL DOCUMENT v3.20.1
Derivative instruments
3 Months Ended
Mar. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative instruments Derivative instruments
The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, foreign currency option, cross-currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative trading purposes.
Cash flow hedges
We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates associated primarily with our euro-denominated international product sales. Increases and decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are offset partially by corresponding increases and decreases in the cash flows from our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations with regard to our international product sales, we enter into foreign currency forward contracts to hedge a portion of our projected international product sales primarily over a three-year time horizon, with, at any given point in time, a higher percentage of nearer-term projected product sales being hedged than in successive periods.
As of March 31, 2020 and December 31, 2019, we had outstanding foreign currency forward contracts with aggregate notional amounts of $4.9 billion and $5.0 billion, respectively. We have designated these foreign currency forward contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report the unrealized gains and losses on these contracts in AOCI in the Condensed Consolidated Balance Sheets, and we reclassify them to Product sales in the Condensed Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings.
To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros, pounds sterling and Swiss francs and received U.S. dollars for the notional amounts at the inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the lives of the contracts by paying U.S. dollars and receiving euros, pounds sterling and Swiss francs. In addition, we will pay U.S. dollars to and receive euros, pounds sterling and Swiss francs from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros, pounds sterling and Swiss francs to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Condensed Consolidated Balance Sheets and reclassified to Interest and other income, net, in the Condensed Consolidated Statements of Income in the same periods during which the hedged debt affects earnings.
The notional amounts and interest rates of our cross-currency swaps as of March 31, 2020, were as follows (notional amounts in millions):
 
 
Foreign currency
 
U.S. dollars
Hedged notes
 
Notional amounts
 
Interest rates
 
Notional amounts
 
Interest rates
1.25% 2022 euro Notes
 
1,250

 
1.3
%
 
$
1,388

 
3.2
%
0.41% 2023 Swiss franc Bonds
 
CHF
700

 
0.4
%
 
$
704

 
3.4
%
2.00% 2026 euro Notes
 
750

 
2.0
%
 
$
833

 
3.9
%
5.50% 2026 pound sterling Notes
 
£
475

 
5.5
%
 
$
747

 
6.0
%
4.00% 2029 pound sterling Notes
 
£
700

 
4.0
%
 
$
1,111

 
4.5
%

In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI in the Condensed Consolidated Balance Sheets and are amortized into Interest expense, net, in the Condensed Consolidated Statements of Income over the lives of the associated debt issuances. Amounts recognized in connection with forward interest rate swaps during the three months ended March 31, 2020, and amounts expected to be recognized during the subsequent 12 months are not material.
The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):
 
 
Three months ended
March 31,
Derivatives in cash flow hedging relationships
 
2020
 
2019
Foreign currency contracts
 
$
239

 
$
85

Cross-currency swap contracts
 
(401
)
 
(55
)
Total unrealized (losses) gains
 
$
(162
)
 
$
30


Fair value hedges
To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate LIBOR-based coupons over the terms of the related hedge contracts. As of March 31, 2020 and December 31, 2019, we had interest rate swap contracts with aggregate notional amounts of $7.4 billion and $9.6 billion, respectively, that hedge certain portions of our long-term debt issuances.
Interest rate swaps with an aggregate notional value of $2.2 billion were terminated during the three months ended March 31, 2020, in connection with the redemption of certain of our notes. The termination of these interest rate swaps resulted in a gain of $17 million recognized in Interest expense, net, in the Condensed Consolidated Statements of Income. Additionally, we terminated $5.2 billion aggregate notional amount of interest rate swaps, which resulted in the receipt of $576 million from the counterparties that was included in Net cash provided by operating activities in the Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2020. This amount will be recognized in Interest expense, net, in the Condensed Consolidated Statements of Income over the remaining life of the underlying notes. Immediately following the termination of these interest rate swap contracts, we entered into new interest rate swap agreements at then-current interest rates on the same $5.2 billion principal amount of notes. See Note 9, Financing arrangements, for information on our interest rate swaps.
For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Condensed Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining life of the previously hedged debt.
The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions):
 
 
Carrying amounts of hedged liabilities(1)
 
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities(2)
Condensed Consolidated Balance Sheets locations
 
March 31, 2020
 
December 31, 2019
 
March 31, 2020
 
December 31, 2019
Current portion of long-term debt
 
$
90

 
$
903

 
$
90

 
$
4

Long-term debt
 
$
7,784

 
$
8,814

 
$
558

 
$
292

____________ 
(1)
Current portion of long-term debt includes $90 million of carrying value with discontinued hedging relationships as of March 31, 2020. Long-term debt includes $592 million and $136 million of carrying value with discontinued hedging relationships as of March 31, 2020 and December 31, 2019, respectively.
(2) 
Current portion of long-term debt includes $90 million of hedging adjustments on discontinued hedging relationships as of March 31, 2020. Long-term debt includes $492 million and $36 million of hedging adjustments on discontinued hedging relationships as of March 31, 2020 and December 31, 2019, respectively.
Impact of hedging transactions
The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):
 
 
Three months ended March 31, 2020
 
 
Product sales
 
Interest and other income, net
 
Interest (expense), net
Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income
 
$
5,894

 
$
11

 
$
(346
)
The effects of cash flow and fair value hedging:
 
 
 
 
 
 
Gains (losses) on cash flow hedging relationships reclassified out of AOCI:
 
 
 
 
 
 
Foreign currency contracts
 
$
49

 
$

 
$

Cross-currency swap contracts
 
$

 
$
(133
)
 
$

Gains (losses) on fair value hedging relationships—interest rate swap agreements:
 
 
 
 
 
 
Hedged items(1)
 
$

 
$

 
$
210

Derivatives designated as hedging instruments
 
$

 
$

 
$
(190
)
 
 
Three months ended March 31, 2019
 
 
Product sales
 
Interest and other income, net
 
Interest (expense), net
Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income
 
$
5,286

 
$
185

 
$
(343
)
The effects of cash flow and fair value hedging:
 
 
 
 
 
 
Gains (losses) on cash flow hedging relationships reclassified out of AOCI:
 
 
 
 
 
 
Foreign currency contracts
 
$
14

 
$

 
$

Cross-currency swap contracts
 
$

 
$
(42
)
 
$

(Losses) gains on fair value hedging relationships—interest rate swap agreements:
 
 
 
 
 
 
Hedged items(1)
 
$

 
$

 
$
(130
)
Derivatives designated as hedging instruments
 
$

 
$

 
$
133

__________ 
(1) 
Gains (losses) on hedged items do not completely offset gains (losses) on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges where the corresponding hedged item was paid down in the period.
No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of March 31, 2020, we expected to reclassify $162 million of net gains on our foreign currency and cross-currency swap contracts out of AOCI and into earnings during the next 12 months.
Derivatives not designated as hedges
To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of March 31, 2020 and December 31, 2019, the total notional amounts of these foreign currency forward contracts were $0.8 billion and $1.2 billion, respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the three months ended March 31, 2020 and 2019.
The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions):
 
 
Derivative assets
 
Derivative liabilities
March 31, 2020
 
Condensed Consolidated
Balance Sheets locations
 
Fair values
 
Condensed Consolidated
Balance Sheets locations
 
Fair values
Derivatives designated as hedging instruments:
 
 
 
 
 
 
 
 
Foreign currency contracts
 
Other current assets/ Other assets
 
$
375

 
Accrued liabilities/ Other noncurrent liabilities
 
$
5

Cross-currency swap contracts
 
Other current assets/ Other assets
 
10

 
Accrued liabilities/ Other noncurrent liabilities
 
657

Interest rate swap contracts
 
Other current assets/ Other assets
 
89

 
Accrued liabilities/ Other noncurrent liabilities
 
23

Total derivatives designated as hedging instruments
 
 
 
474

 
 
 
685

Derivatives not designated as hedging instruments:
 
 
 
 
 
 
 
 
Foreign currency contracts
 
Other current assets
 

 
Accrued liabilities
 

Total derivatives not designated as hedging instruments
 
 
 

 
 
 

Total derivatives
 
 
 
$
474

 
 
 
$
685

 
 
Derivative assets
 
Derivative liabilities
December 31, 2019
 
Condensed Consolidated
Balance Sheets locations
 
Fair values
 
Condensed Consolidated
Balance Sheets locations
 
Fair values
Derivatives designated as hedging instruments:
 
 
 
 
 
 
 
 
Foreign currency contracts
 
Other current assets/ Other assets
 
$
223

 
Accrued liabilities/ Other noncurrent liabilities
 
$
31

Cross-currency swap contracts
 
Other current assets/ Other assets
 
66

 
Accrued liabilities/ Other noncurrent liabilities
 
315

Interest rate swap contracts
 
Other current assets/ Other assets
 
259

 
Accrued liabilities/ Other noncurrent liabilities
 

Total derivatives designated as hedging instruments
 
 
 
548

 
 
 
346

Derivatives not designated as hedging instruments:
 
 
 
 
 
 
 
 
Foreign currency contracts
 
Other current assets
 
1

 
Accrued liabilities
 

Total derivatives not designated as hedging instruments
 
 
 
1

 
 
 

Total derivatives
 
 
 
$
549

 
 
 
$
346


Our derivative contracts that were in liability positions as of March 31, 2020, contain certain credit-risk-related contingent provisions that would be triggered if (i) we were to undergo a change in control and (ii) our or the surviving entity’s creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right but not the obligation to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur.
The cash flow effects of our derivative contracts in the Condensed Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash used in financing activities.
XML 60 R28.htm IDEA: XBRL DOCUMENT v3.20.1
Financing arrangements (Tables)
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Debt Disclosure [Abstract]    
Schedule of borrowings
Our borrowings consisted of the following (in millions):
 
March 31,
2020
 
December 31,
2019
4.50% notes due 2020 (4.50% 2020 Notes)
$

 
$
300

2.125% notes due 2020 (2.125% 2020 Notes)
750

 
750

Floating Rate Notes due 2020
300

 
300

2.20% notes due 2020 (2.20% 2020 Notes)
700

 
700

3.45% notes due 2020 (3.45% 2020 Notes)

 
900

4.10% notes due 2021 (4.10% 2021 Notes)

 
1,000

1.85% notes due 2021 (1.85% 2021 Notes)

 
750

3.875% notes due 2021 (3.875% 2021 Notes)
1,450

 
1,750

1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes)
1,379

 
1,402

2.70% notes due 2022 (2.70% 2022 Notes)
500

 
500

2.65% notes due 2022 (2.65% 2022 Notes)
1,500

 
1,500

3.625% notes due 2022 (3.625% 2022 Notes)
750

 
750

0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)
728

 
725

2.25% notes due 2023 (2.25% 2023 Notes)
750

 
750

3.625% notes due 2024 (3.625% 2024 Notes)
1,400

 
1,400

1.90% notes due 2025 (1.90% 2025 Notes)
500

 

3.125% notes due 2025 (3.125% 2025 Notes)
1,000

 
1,000

2.00% €750 million notes due 2026 (2.00% 2026 euro Notes)
827

 
841

2.60% notes due 2026 (2.60% 2026 Notes)
1,250

 
1,250

5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes)
590

 
630

2.20% notes due 2027 (2.20% 2027 Notes)
750

 

3.20% notes due 2027 (3.20% 2027 Notes)
1,000

 
1,000

4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes)
869

 
928

2.45% notes due 2030 (2.45% 2030 Notes)
1,250

 

6.375% notes due 2037 (6.375% 2037 Notes)
552

 
552

6.90% notes due 2038 (6.90% 2038 Notes)
291

 
291

6.40% notes due 2039 (6.40% 2039 Notes)
466

 
466

3.15% notes due 2040 (3.15% 2040 Notes)
1,250

 

5.75% notes due 2040 (5.75% 2040 Notes)
412

 
412

4.95% notes due 2041 (4.95% 2041 Notes)
600

 
600

5.15% notes due 2041 (5.15% 2041 Notes)
974

 
974

5.65% notes due 2042 (5.65% 2042 Notes)
487

 
487

5.375% notes due 2043 (5.375% 2043 Notes)
261

 
261

4.40% notes due 2045 (4.40% 2045 Notes)
2,250

 
2,250

4.563% notes due 2048 (4.563% 2048 Notes)
1,415

 
1,415

3.375% notes due 2050 (3.375% 2050 Notes)
1,250

 

4.663% notes due 2051 (4.663% 2051 Notes)
3,541

 
3,541

Other notes due 2097
100

 
100

Unamortized bond discounts, premiums and issuance costs, net
(892
)
 
(868
)
Fair value adjustments
648

 
296

Total carrying value of debt
31,848

 
29,903

Less current portion
(1,840
)
 
(2,953
)
Total long-term debt
$
30,008

 
$
26,950


 
Schedule of interest rate swaps  
The effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions):
 
 
March 31, 2020
 
December 31, 2019
Notes
 
Notional amounts
Effective interest rates
 
Notional amounts
Effective interest rates
3.45% 2020 Notes
 
$

LIBOR + 1.1%
 
$
900

LIBOR + 1.1%
4.10% 2021 Notes
 

LIBOR + 1.7%
 
1,000

LIBOR + 1.7%
3.875% 2021 Notes
 
1,450

LIBOR + 2.0%
 
1,750

LIBOR + 2.0%
3.625% 2022 Notes
 
750

LIBOR + 2.7%
 
750

LIBOR + 1.6%
3.625% 2024 Notes
 
1,400

LIBOR + 3.2%
 
1,400

LIBOR + 1.4%
3.125% 2025 Notes
 
1,000

LIBOR + 1.8%
 
1,000

LIBOR + 0.9%
2.60% 2026 Notes
 
1,250

LIBOR + 1.8%
 
1,250

LIBOR + 0.3%
4.663% 2051 Notes(1)
 
1,500

LIBOR + 2.6%
 
1,500

LIBOR + 0.0%
Total notional amounts
 
$
7,350

 
 
$
9,550

 
____________ 
(1)
Excludes an additional 1.5% of interest for the difference between the coupon rate paid to note holders and the fixed rate received under the interest rate swap contracts.
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.20.1
Financing arrangements (Schedule Interest Rate Swaps) (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2020
Dec. 31, 2019
4.663% notes due 2051 (4.663% 2051 Notes) [Member]    
Debt Instrument [Line Items]    
Rate difference in an interest rate swap relationship 1.50%  
Notes Payable, Other Payables [Member]    
Debt Instrument [Line Items]    
Notional amounts $ 7,350 $ 9,550
Notes Payable, Other Payables [Member] | 3.45% notes due 2020 (3.45% 2020 Notes) [Member]    
Debt Instrument [Line Items]    
Notional amounts $ 0 $ 900
Interest rate, stated percentage 3.45%  
Notes Payable, Other Payables [Member] | 3.45% notes due 2020 (3.45% 2020 Notes) [Member] | London Interbank Offered Rate (LIBOR) [Member]    
Debt Instrument [Line Items]    
Derivative, Basis Spread on Variable Rate 1.10% 1.10%
Notes Payable, Other Payables [Member] | 4.10% notes due 2021 (4.10% 2021 Notes) [Member]    
Debt Instrument [Line Items]    
Notional amounts $ 0 $ 1,000
Interest rate, stated percentage 4.10%  
Notes Payable, Other Payables [Member] | 4.10% notes due 2021 (4.10% 2021 Notes) [Member] | London Interbank Offered Rate (LIBOR) [Member]    
Debt Instrument [Line Items]    
Derivative, Basis Spread on Variable Rate 1.70% 1.70%
Notes Payable, Other Payables [Member] | 3.875% notes due 2021 (3.875% 2021 Notes) [Member]    
Debt Instrument [Line Items]    
Notional amounts $ 1,450 $ 1,750
Interest rate, stated percentage 3.875%  
Notes Payable, Other Payables [Member] | 3.875% notes due 2021 (3.875% 2021 Notes) [Member] | London Interbank Offered Rate (LIBOR) [Member]    
Debt Instrument [Line Items]    
Derivative, Basis Spread on Variable Rate 2.00% 2.00%
Notes Payable, Other Payables [Member] | 3.625% notes due 2022 (3.625% 2022 Notes) [Member]    
Debt Instrument [Line Items]    
Notional amounts $ 750 $ 750
Interest rate, stated percentage 3.625%  
Notes Payable, Other Payables [Member] | 3.625% notes due 2022 (3.625% 2022 Notes) [Member] | London Interbank Offered Rate (LIBOR) [Member]    
Debt Instrument [Line Items]    
Derivative, Basis Spread on Variable Rate 2.70% 1.60%
Notes Payable, Other Payables [Member] | 3.625% notes due 2024 (3.625% 2024 Notes) [Member]    
Debt Instrument [Line Items]    
Notional amounts $ 1,400 $ 1,400
Interest rate, stated percentage 3.625%  
Notes Payable, Other Payables [Member] | 3.625% notes due 2024 (3.625% 2024 Notes) [Member] | London Interbank Offered Rate (LIBOR) [Member]    
Debt Instrument [Line Items]    
Derivative, Basis Spread on Variable Rate 3.20% 1.40%
Notes Payable, Other Payables [Member] | 3.125% notes due 2025 (3.125% 2025 Notes) [Member]    
Debt Instrument [Line Items]    
Notional amounts $ 1,000 $ 1,000
Interest rate, stated percentage 3.125%  
Notes Payable, Other Payables [Member] | 3.125% notes due 2025 (3.125% 2025 Notes) [Member] | London Interbank Offered Rate (LIBOR) [Member]    
Debt Instrument [Line Items]    
Derivative, Basis Spread on Variable Rate 1.80% 0.90%
Notes Payable, Other Payables [Member] | 2.60% notes due 2026 (2.60% 2026 notes) [Member]    
Debt Instrument [Line Items]    
Notional amounts $ 1,250 $ 1,250
Interest rate, stated percentage 2.60%  
Notes Payable, Other Payables [Member] | 2.60% notes due 2026 (2.60% 2026 notes) [Member] | London Interbank Offered Rate (LIBOR) [Member]    
Debt Instrument [Line Items]    
Derivative, Basis Spread on Variable Rate 1.80% 0.30%
Notes Payable, Other Payables [Member] | 4.663% notes due 2051 (4.663% 2051 Notes) [Member]    
Debt Instrument [Line Items]    
Notional amounts $ 1,500 $ 1,500
Interest rate, stated percentage 4.663%  
Notes Payable, Other Payables [Member] | 4.663% notes due 2051 (4.663% 2051 Notes) [Member] | London Interbank Offered Rate (LIBOR) [Member]    
Debt Instrument [Line Items]    
Derivative, Basis Spread on Variable Rate 2.60% 0.00%
XML 62 R41.htm IDEA: XBRL DOCUMENT v3.20.1
Investments (Equity Securities) (Details Textual) - USD ($)
$ in Millions
Mar. 31, 2020
Dec. 31, 2019
Investments, Debt and Equity Securities [Abstract]    
Equity securities $ 220 $ 303
Equity securities without readily determinable fair value $ 183 $ 176
XML 63 R45.htm IDEA: XBRL DOCUMENT v3.20.1
Goodwill and other intangible assets (Identifiable Intangible Assets) (Details) - USD ($)
$ in Millions
Mar. 31, 2020
Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amounts $ 31,939 $ 31,991
Accumulated amortization (13,316) (12,632)
Other intangible assets, net 18,623 19,359
Gross carrying amount 31,969 32,045
Accumulated amortization (13,316) (12,632)
Intangible assets, net 18,653 19,413
In-process Research and Development [Member]    
Indefinite-lived Intangible Assets [Line Items]    
Indefinite-lived intangible assets 30 54
Developed-Product-Technology Rights [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amounts 25,549 25,575
Accumulated amortization (8,876) (8,322)
Other intangible assets, net 16,673 17,253
Licensing Rights [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amounts 3,746 3,761
Accumulated amortization (2,494) (2,398)
Other intangible assets, net 1,252 1,363
Marketing-Related Rights [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amounts 1,375 1,382
Accumulated amortization (979) (965)
Other intangible assets, net 396 417
Research and Development Technology Rights [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amounts 1,269 1,273
Accumulated amortization (967) (947)
Other intangible assets, net $ 302 $ 326
XML 64 R4.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 7,687 $ 6,037
Marketable securities 325 2,874
Trade receivables, net 5,009 4,057
Inventories 3,682 3,584
Other current assets 2,110 1,888
Total current assets 18,813 18,440
Property, plant and equipment, net 4,879 4,928
Intangible assets, net 18,653 19,413
Goodwill 14,683 14,703
Other assets 4,641 2,223
Total assets 61,669 59,707
Current liabilities:    
Accounts payable 1,338 1,371
Accrued liabilities 8,649 8,511
Current portion of long-term debt 1,840 2,953
Total current liabilities 11,827 12,835
Long-term debt 30,008 26,950
Long-term deferred tax liabilities 427 606
Long-term tax liabilities 8,111 8,037
Other noncurrent liabilities 1,811 1,606
Contingencies and commitments
Stockholders’ equity:    
Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding — 588.0 shares in 2020 and 591.4 shares in 2019 31,525 31,531
Accumulated deficit (21,378) (21,330)
Accumulated other comprehensive loss (662) (528)
Total stockholders’ equity 9,485 9,673
Total liabilities and stockholders’ equity $ 61,669 $ 59,707
XML 65 R8.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Cash flows from operating activities:    
Net income $ 1,825 $ 1,992
Depreciation, amortization and other 897 495
Deferred income taxes (84) (50)
Other items, net 107 24
Changes in operating assets and liabilities, net of acquisition:    
Trade receivables, net (955) (207)
Inventories (113) (28)
Other assets 319 (249)
Accounts payable (25) (112)
Accrued income taxes, net 137 277
Long-term tax liabilities 74 100
Other liabilities (48) (397)
Net cash provided by operating activities 2,134 1,845
Cash flows from investing activities:    
Purchases of marketable securities (129) (6,898)
Proceeds from sales of marketable securities 2,574 125
Proceeds from maturities of marketable securities 113 10,455
Purchases of property, plant and equipment (142) (116)
Purchases of equity method investments (2,645) (5)
Other (1) (6)
Net cash (used in) provided by investing activities (230) 3,555
Cash flows from financing activities:    
Proceeds from Issuance of Long-term Debt 4,963 0
Repayment of debt (3,250) (1,000)
Repurchases of common stock (961) (3,032)
Dividends paid (945) (901)
Other (61) (54)
Net cash used in financing activities (254) (4,987)
Increase in cash and cash equivalents 1,650 413
Cash and cash equivalents at beginning of period 6,037 6,945
Cash and cash equivalents at end of period $ 7,687 $ 7,358
XML 66 R62.htm IDEA: XBRL DOCUMENT v3.20.1
Derivative instruments (Fair Value of Derivatives) (Details) - USD ($)
$ in Millions
Mar. 31, 2020
Dec. 31, 2019
Assets    
Total derivative assets, fair value $ 474 $ 549
Liabilities    
Total derivative liabilities, fair value 685 346
Derivatives designated as hedging instrument [Member]    
Assets    
Total derivative assets, fair value 474 548
Liabilities    
Total derivative liabilities, fair value 685 346
Derivatives designated as hedging instrument [Member] | Foreign currency contracts [Member] | Other current assets/Other assets [Member]    
Assets    
Total derivative assets, fair value 375 223
Derivatives designated as hedging instrument [Member] | Foreign currency contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]    
Liabilities    
Total derivative liabilities, fair value 5 31
Derivatives designated as hedging instrument [Member] | Cross-currency swap contracts [Member] | Other current assets/Other assets [Member]    
Assets    
Total derivative assets, fair value 10 66
Derivatives designated as hedging instrument [Member] | Cross-currency swap contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]    
Liabilities    
Total derivative liabilities, fair value 657 315
Derivatives designated as hedging instrument [Member] | Interest rate swap contracts [Member] | Other current assets/Other assets [Member]    
Assets    
Total derivative assets, fair value 89 259
Derivatives designated as hedging instrument [Member] | Interest rate swap contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]    
Liabilities    
Total derivative liabilities, fair value 23 0
Derivatives not designated as hedging instrument [Member]    
Assets    
Total derivative assets, fair value 0 1
Liabilities    
Total derivative liabilities, fair value 0 0
Derivatives not designated as hedging instrument [Member] | Foreign currency contracts [Member] | Other current assets [Member]    
Assets    
Total derivative assets, fair value 0 1
Derivatives not designated as hedging instrument [Member] | Foreign currency contracts [Member] | Accrued liabilities [Member]    
Liabilities    
Total derivative liabilities, fair value $ 0 $ 0
XML 67 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 450 313 1 false 121 0 false 8 false false R1.htm 0001000 - Document - Cover Page Sheet http://www.amgen.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.amgen.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 2 false false R3.htm 1001000 - Statement - Condensed Consolidated Statements of Income Sheet http://www.amgen.com/role/CondensedConsolidatedStatementsOfIncome Condensed Consolidated Statements of Income Statements 3 false false R4.htm 1002000 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.amgen.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 4 false false R5.htm 1002501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.amgen.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 1003000 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 6 false false R7.htm 1003501 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) Sheet http://www.amgen.com/role/CondensedConsolidatedStatementsOfStockholdersEquityParenthetical Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) Statements 7 false false R8.htm 1004000 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.amgen.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 8 false false R9.htm 2101100 - Disclosure - Summary of significant accounting policies Sheet http://www.amgen.com/role/SummaryOfSignificantAccountingPolicies Summary of significant accounting policies Notes 9 false false R10.htm 2104100 - Disclosure - Revenues Sheet http://www.amgen.com/role/Revenues Revenues Notes 10 false false R11.htm 2105100 - Disclosure - Income taxes Sheet http://www.amgen.com/role/IncomeTaxes Income taxes Notes 11 false false R12.htm 2106100 - Disclosure - Earnings per share Sheet http://www.amgen.com/role/EarningsPerShare Earnings per share Notes 12 false false R13.htm 2107100 - Disclosure - Collaborations Sheet http://www.amgen.com/role/Collaborations Collaborations Notes 13 false false R14.htm 2108100 - Disclosure - Investments Sheet http://www.amgen.com/role/Investments Investments Notes 14 false false R15.htm 2109100 - Disclosure - Inventories Sheet http://www.amgen.com/role/Inventories Inventories Notes 15 false false R16.htm 2110100 - Disclosure - Goodwill and other intangible assets Sheet http://www.amgen.com/role/GoodwillAndOtherIntangibleAssets Goodwill and other intangible assets Notes 16 false false R17.htm 2112100 - Disclosure - Financing arrangements Sheet http://www.amgen.com/role/FinancingArrangements Financing arrangements Notes 17 false false R18.htm 2113100 - Disclosure - Stockholders' equity Sheet http://www.amgen.com/role/StockholdersEquity Stockholders' equity Notes 18 false false R19.htm 2114100 - Disclosure - Fair value measurement Sheet http://www.amgen.com/role/FairValueMeasurement Fair value measurement Notes 19 false false R20.htm 2115100 - Disclosure - Derivative instruments Sheet http://www.amgen.com/role/DerivativeInstruments Derivative instruments Notes 20 false false R21.htm 2116100 - Disclosure - Contingencies and commitments Sheet http://www.amgen.com/role/ContingenciesAndCommitments Contingencies and commitments Notes 21 false false R22.htm 2201201 - Disclosure - Summary of significant accounting policies (Policies) Sheet http://www.amgen.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of significant accounting policies (Policies) Policies 22 false false R23.htm 2304301 - Disclosure - Revenues (Tables) Sheet http://www.amgen.com/role/RevenuesTables Revenues (Tables) Tables http://www.amgen.com/role/Revenues 23 false false R24.htm 2306301 - Disclosure - Earnings per share (Tables) Sheet http://www.amgen.com/role/EarningsPerShareTables Earnings per share (Tables) Tables http://www.amgen.com/role/EarningsPerShare 24 false false R25.htm 2308301 - Disclosure - Investments (Tables) Sheet http://www.amgen.com/role/InvestmentsTables Investments (Tables) Tables http://www.amgen.com/role/Investments 25 false false R26.htm 2309301 - Disclosure - Inventories (Tables) Sheet http://www.amgen.com/role/InventoriesTables Inventories (Tables) Tables http://www.amgen.com/role/Inventories 26 false false R27.htm 2310301 - Disclosure - Goodwill and other intangible assets (Tables) Sheet http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsTables Goodwill and other intangible assets (Tables) Tables http://www.amgen.com/role/GoodwillAndOtherIntangibleAssets 27 false false R28.htm 2312301 - Disclosure - Financing arrangements (Tables) Sheet http://www.amgen.com/role/FinancingArrangementsTables Financing arrangements (Tables) Tables http://www.amgen.com/role/FinancingArrangements 28 false false R29.htm 2313301 - Disclosure - Stockholders' equity (Tables) Sheet http://www.amgen.com/role/StockholdersEquityTables Stockholders' equity (Tables) Tables http://www.amgen.com/role/StockholdersEquity 29 false false R30.htm 2314301 - Disclosure - Fair value measurement (Tables) Sheet http://www.amgen.com/role/FairValueMeasurementTables Fair value measurement (Tables) Tables http://www.amgen.com/role/FairValueMeasurement 30 false false R31.htm 2315301 - Disclosure - Derivative instruments (Tables) Sheet http://www.amgen.com/role/DerivativeInstrumentsTables Derivative instruments (Tables) Tables http://www.amgen.com/role/DerivativeInstruments 31 false false R32.htm 2401402 - Disclosure - Summary of significant accounting policies (Details) Sheet http://www.amgen.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of significant accounting policies (Details) Details http://www.amgen.com/role/SummaryOfSignificantAccountingPoliciesPolicies 32 false false R33.htm 2404402 - Disclosure - Revenues (Details) Sheet http://www.amgen.com/role/RevenuesDetails Revenues (Details) Details http://www.amgen.com/role/RevenuesTables 33 false false R34.htm 2405401 - Disclosure - Income taxes (Details) Sheet http://www.amgen.com/role/IncomeTaxesDetails Income taxes (Details) Details http://www.amgen.com/role/IncomeTaxes 34 false false R35.htm 2406402 - Disclosure - Earnings per share (Details) Sheet http://www.amgen.com/role/EarningsPerShareDetails Earnings per share (Details) Details http://www.amgen.com/role/EarningsPerShareTables 35 false false R36.htm 2407401 - Disclosure - Collaborations (Details) Sheet http://www.amgen.com/role/CollaborationsDetails Collaborations (Details) Details http://www.amgen.com/role/Collaborations 36 false false R37.htm 2408402 - Disclosure - Investments (Details) Sheet http://www.amgen.com/role/InvestmentsDetails Investments (Details) Details http://www.amgen.com/role/InvestmentsTables 37 false false R38.htm 2408403 - Disclosure - Investments (Fair Values by Classification) (Details) Sheet http://www.amgen.com/role/InvestmentsFairValuesByClassificationDetails Investments (Fair Values by Classification) (Details) Details http://www.amgen.com/role/InvestmentsTables 38 false false R39.htm 2408404 - Disclosure - Investments (Available-for-sale Investments) (Details Textual) Sheet http://www.amgen.com/role/InvestmentsAvailableForSaleInvestmentsDetailsTextual Investments (Available-for-sale Investments) (Details Textual) Details http://www.amgen.com/role/InvestmentsTables 39 false false R40.htm 2408405 - Disclosure - Investments (Fair Values by Contractual Maturity) (Details) Sheet http://www.amgen.com/role/InvestmentsFairValuesByContractualMaturityDetails Investments (Fair Values by Contractual Maturity) (Details) Details http://www.amgen.com/role/InvestmentsTables 40 false false R41.htm 2408407 - Disclosure - Investments (Equity Securities) (Details Textual) Sheet http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual Investments (Equity Securities) (Details Textual) Details http://www.amgen.com/role/InvestmentsTables 41 false false R42.htm 2408408 - Disclosure - Investments Investments (Limited Partnership Investments) (Details) Sheet http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails Investments Investments (Limited Partnership Investments) (Details) Details 42 false false R43.htm 2409402 - Disclosure - Inventories (Details) Sheet http://www.amgen.com/role/InventoriesDetails Inventories (Details) Details http://www.amgen.com/role/InventoriesTables 43 false false R44.htm 2410402 - Disclosure - Goodwill and other intangible assets (Goodwill Roll Forward) (Details) Sheet http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsGoodwillRollForwardDetails Goodwill and other intangible assets (Goodwill Roll Forward) (Details) Details http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsTables 44 false false R45.htm 2410403 - Disclosure - Goodwill and other intangible assets (Identifiable Intangible Assets) (Details) Sheet http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsIdentifiableIntangibleAssetsDetails Goodwill and other intangible assets (Identifiable Intangible Assets) (Details) Details http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsTables 45 false false R46.htm 2410404 - Disclosure - Goodwill and other intangible assets (Details Textual) Sheet http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsDetailsTextual Goodwill and other intangible assets (Details Textual) Details http://www.amgen.com/role/GoodwillAndOtherIntangibleAssetsTables 46 false false R47.htm 2412402 - Disclosure - Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details) Sheet http://www.amgen.com/role/FinancingArrangementsPrincipalAmountsAndCarryingValueOfLongTermBorrowingsDetails Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details) Details http://www.amgen.com/role/FinancingArrangementsTables 47 false false R48.htm 2412403 - Disclosure - Financing arrangements (Details Textual) Sheet http://www.amgen.com/role/FinancingArrangementsDetailsTextual Financing arrangements (Details Textual) Details http://www.amgen.com/role/FinancingArrangementsTables 48 false false R49.htm 2412404 - Disclosure - Financing arrangements (Schedule Interest Rate Swaps) (Details) Sheet http://www.amgen.com/role/FinancingArrangementsScheduleInterestRateSwapsDetails Financing arrangements (Schedule Interest Rate Swaps) (Details) Details http://www.amgen.com/role/FinancingArrangementsTables 49 false false R50.htm 2412405 - Disclosure - Financing arrangements (Interest Rate Swaps Textual) (Details) Sheet http://www.amgen.com/role/FinancingArrangementsInterestRateSwapsTextualDetails Financing arrangements (Interest Rate Swaps Textual) (Details) Details http://www.amgen.com/role/FinancingArrangementsTables 50 false false R51.htm 2413402 - Disclosure - Stockholders' equity (Share Repurchase Program) (Details) Sheet http://www.amgen.com/role/StockholdersEquityShareRepurchaseProgramDetails Stockholders' equity (Share Repurchase Program) (Details) Details http://www.amgen.com/role/StockholdersEquityTables 51 false false R52.htm 2413403 - Disclosure - Stockholders' equity (Details Textual) (Details) Sheet http://www.amgen.com/role/StockholdersEquityDetailsTextualDetails Stockholders' equity (Details Textual) (Details) Details http://www.amgen.com/role/StockholdersEquityTables 52 false false R53.htm 2413404 - Disclosure - Stockholders' equity (Components of AOCI) (Details) Sheet http://www.amgen.com/role/StockholdersEquityComponentsOfAociDetails Stockholders' equity (Components of AOCI) (Details) Details http://www.amgen.com/role/StockholdersEquityTables 53 false false R54.htm 2413405 - Disclosure - Stockholders' equity (Reclassifications out of AOCI) (Details) Sheet http://www.amgen.com/role/StockholdersEquityReclassificationsOutOfAociDetails Stockholders' equity (Reclassifications out of AOCI) (Details) Details http://www.amgen.com/role/StockholdersEquityTables 54 false false R55.htm 2414402 - Disclosure - Fair value measurement (Details) Sheet http://www.amgen.com/role/FairValueMeasurementDetails Fair value measurement (Details) Details http://www.amgen.com/role/FairValueMeasurementTables 55 false false R56.htm 2414403 - Disclosure - Fair value measurement (Details Textual) Sheet http://www.amgen.com/role/FairValueMeasurementDetailsTextual Fair value measurement (Details Textual) Details http://www.amgen.com/role/FairValueMeasurementTables 56 false false R57.htm 2415402 - Disclosure - Derivative instruments (Details Textual) Sheet http://www.amgen.com/role/DerivativeInstrumentsDetailsTextual Derivative instruments (Details Textual) Details http://www.amgen.com/role/DerivativeInstrumentsTables 57 false false R58.htm 2415403 - Disclosure - Derivative instruments (Cross-currency Swaps) (Details) Sheet http://www.amgen.com/role/DerivativeInstrumentsCrossCurrencySwapsDetails Derivative instruments (Cross-currency Swaps) (Details) Details http://www.amgen.com/role/DerivativeInstrumentsTables 58 false false R59.htm 2415404 - Disclosure - Derivative instruments (Effective Portion of Unrealized Gain (Loss)) (Details) Sheet http://www.amgen.com/role/DerivativeInstrumentsEffectivePortionOfUnrealizedGainLossDetails Derivative instruments (Effective Portion of Unrealized Gain (Loss)) (Details) Details http://www.amgen.com/role/DerivativeInstrumentsTables 59 false false R60.htm 2415405 - Disclosure - Derivative instruments (Hedged Liabilities and Cumulative Amount) (Details) Sheet http://www.amgen.com/role/DerivativeInstrumentsHedgedLiabilitiesAndCumulativeAmountDetails Derivative instruments (Hedged Liabilities and Cumulative Amount) (Details) Details http://www.amgen.com/role/DerivativeInstrumentsTables 60 false false R61.htm 2415406 - Disclosure - Derivative instruments (Summary of Income and Expense Line Items) (Details) Sheet http://www.amgen.com/role/DerivativeInstrumentsSummaryOfIncomeAndExpenseLineItemsDetails Derivative instruments (Summary of Income and Expense Line Items) (Details) Details http://www.amgen.com/role/DerivativeInstrumentsTables 61 false false R62.htm 2415407 - Disclosure - Derivative instruments (Fair Value of Derivatives) (Details) Sheet http://www.amgen.com/role/DerivativeInstrumentsFairValueOfDerivativesDetails Derivative instruments (Fair Value of Derivatives) (Details) Details http://www.amgen.com/role/DerivativeInstrumentsTables 62 false false R63.htm 2416401 - Disclosure - Contingencies and commitments (Details) Sheet http://www.amgen.com/role/ContingenciesAndCommitmentsDetails Contingencies and commitments (Details) Details http://www.amgen.com/role/ContingenciesAndCommitments 63 false false R9999.htm Uncategorized Items - amgn-2020331x10q.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - amgn-2020331x10q.htm Cover 64 false false All Reports Book All Reports amgn-2020331x10q.htm amendmentno2tosharepur.htm amgn-20200331.xsd amgn-20200331_cal.xml amgn-20200331_def.xml amgn-20200331_lab.xml amgn-20200331_pre.xml amgn-ex312020331xq1.htm amgn-ex322020331xq1.htm petergriffith-signedof.htm sideletterregardingcol.htm http://xbrl.sec.gov/currency/2019-01-31 http://xbrl.sec.gov/exch/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/srt/2019-01-31 true true XML 68 R29.htm IDEA: XBRL DOCUMENT v3.20.1
Stockholders' equity (Tables)
3 Months Ended
Mar. 31, 2020
Equity [Abstract]  
Summary of activity under our stock repurchase program
Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):
 
2020
 
2019
 
Shares
 
Dollars 
 
Shares
 
Dollars
First quarter
4.3

 
$
933

 
15.9

 
$
3,031


Components of accumulated other comprehensive income
The components of Accumulated other comprehensive income (loss) (AOCI) were as follows (in millions):
 
Foreign
currency
translation
 
Cash flow
hedges
 
Available-for-sale
securities
 
Other
 
AOCI
Balance as of December 31, 2019
$
(718
)
 
$
175

 
$
22

 
$
(7
)
 
$
(528
)
Foreign currency translation adjustments
(52
)
 

 

 

 
(52
)
Unrealized (losses) gains

 
(162
)
 
8

 

 
(154
)
Reclassification adjustments to income

 
84

 
(33
)
 

 
51

Other

 

 

 
(2
)
 
(2
)
Income taxes

 
17

 
6

 

 
23

Balance as of March 31, 2020
$
(770
)
 
$
114

 
$
3

 
$
(9
)
 
$
(662
)

Reclassifications out of accumulated other comprehensive income
Reclassifications out of AOCI and into earnings were as follows (in millions):
 
 
Three months ended March 31,
 
 
Components of AOCI
 
2020
 
2019
 
Condensed Consolidated
Statements of Income locations
Cash flow hedges:
 
 
 
 
 
 
Foreign currency contract gains
 
$
49

 
$
14

 
Product sales
Cross-currency swap contract losses
 
(133
)
 
(42
)
 
Interest and other income, net
 
 
(84
)
 
(28
)
 
Income before income taxes
 
 
18

 
6

 
Provision for income taxes
 
 
$
(66
)
 
$
(22
)
 
Net income
Available-for-sale securities:
 
 
 
 
 
 
Net realized gains (losses)
 
$
33

 
$
(4
)
 
Interest and other income, net
 
 
(7
)
 

 
Provision for income taxes
 
 
$
26

 
$
(4
)
 
Net income

XML 69 R25.htm IDEA: XBRL DOCUMENT v3.20.1
Investments (Tables)
3 Months Ended
Mar. 31, 2020
Investments, Debt and Equity Securities [Abstract]  
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions):
Types of securities as of March 31, 2020
 
Amortized
cost
 
Gross
unrealized
gains
 
Gross
unrealized
losses
 
Fair
values
U.S. Treasury notes
 
$
173

 
$
3

 
$

 
$
176

U.S. Treasury bills
 
900

 

 

 
900

Corporate debt securities:
 
 
 
 
 
 
 
 
Financial
 
12

 

 

 
12

Industrial
 
12

 

 

 
12

Other
 

 

 

 

Residential-mortgage-backed securities
 

 

 

 

Money market mutual funds
 
5,762

 

 

 
5,762

Other short-term interest-bearing securities
 
432

 

 

 
432

Total interest-bearing securities
 
$
7,291

 
$
3

 
$

 
$
7,294

Types of securities as of December 31, 2019
 
Amortized
cost
 
Gross
unrealized
gains
 
Gross
unrealized
losses
 
Fair
values
U.S. Treasury notes
 
$
359

 
$
1

 
$

 
$
360

U.S. Treasury bills
 

 

 

 

Corporate debt securities:
 
 
 
 
 
 
 
 
Financial
 
1,108

 
13

 

 
1,121

Industrial
 
824

 
10

 

 
834

Other
 
195

 
3

 

 
198

Residential-mortgage-backed securities
 
181

 
1

 

 
182

Money market mutual funds
 
5,250

 

 

 
5,250

Other short-term interest-bearing securities
 
289

 

 

 
289

Total interest-bearing securities
 
$
8,206

 
$
28

 
$

 
$
8,234


Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets
The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions):
Condensed Consolidated Balance Sheets locations
 
March 31,
2020
 
December 31,
2019
Cash and cash equivalents
 
$
6,969

 
$
5,360

Marketable securities
 
325

 
2,874

Total interest-bearing securities
 
$
7,294

 
$
8,234


Fair values of available-for-sale interest-bearing security investments by contractual maturity
The fair values of interest-bearing securities by contractual maturity, except for residential-mortgage-backed securities that do not have a single maturity date, were as follows (in millions):
Contractual maturities
 
March 31,
2020
 
December 31,
2019
Maturing in one year or less
 
$
7,165

 
$
5,629

Maturing after one year through three years
 
129

 
2,304

Maturing after three years through five years
 

 
119

Residential mortgage-backed securities
 

 
182

Total interest-bearing securities
 
$
7,294

 
$
8,234


XML 70 R21.htm IDEA: XBRL DOCUMENT v3.20.1
Contingencies and commitments
3 Months Ended
Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]  
Contingencies and commitments Contingencies and commitments
Contingencies
In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See our Annual Report on Form 10-K for the year ended December 31, 2019, Part I, Item 1A. Risk Factors—Our business may be affected by litigation and government investigations. We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote.
We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.
Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing, or in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing, or in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.
Certain recent developments concerning our legal proceedings and other matters are discussed below:
Abbreviated New Drug Application (ANDA) Patent Litigation
KYPROLIS® (carfilzomib) ANDA Patent Litigation
Onyx Therapeutics, Inc. v. Cipla Limited, et al.
On March 30, 2020, the U.S. District Court for the District of Delaware (the Delaware District Court) issued an order advising the parties in the litigation that, due to the recent and current challenges, the court does not anticipate issuing its post-trial opinion until approximately on or before May 8, 2020.
Otezla® (apremilast) ANDA Patent Litigation
Amgen Inc. v. Sandoz Inc., et al.
On February 14, 2020, the U.S. District Court for the District of New Jersey (the New Jersey District Court) granted the motion by Amgen and Celgene Corp. (Celgene) and issued an order substituting Amgen for Celgene as plaintiff in the consolidated action and all related actions, terminating Celgene as plaintiff in the consolidated action and all related actions, and amending the case caption in the consolidated action and all related actions to reflect Amgen as the sole plaintiff.
On March 25, 2020, based on a joint request by Amgen and Unichem Laboratories, Ltd. (Unichem), the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Unichem’s apremilast product during the term of the U.S. Patent Nos. 6,962,940 (the ’940 Patent); 7,427,638 (the ’638 Patent); 7,659,302 (the ’302 Patent); 7,893,101 (the ’101 Patent); 8,455,536 (the ’536 Patent); 9,018,243 (the ’243 Patent); 9,724,330 (the ’330 Patent); and 10,092,541 (the ’541 Patent), unless authorized pursuant to a confidential settlement agreement. On April 3, 2020, based on a joint request by Amgen and Annora Pharma Private Ltd. and Hetero USA Inc. (collectively, Hetero), the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Hetero’s apremilast product during the term of the ’940 Patent; U.S. Patent No. 7,208,516; the ’638 Patent; the ’302 Patent; the ’101 Patent; the ’536 Patent; U.S. Patent No. 8,802,717; the ’243 Patent; the ’330 Patent; U.S. Patent No. 9,872,854 and the ’541 Patent, unless authorized pursuant to a confidential settlement agreement. Trial in the consolidated action is scheduled to commence in May 2021.
Sensipar® (cinacalcet) ANDA Patent Litigation
Amgen Inc. v. Amneal Pharmaceuticals LLC, et al. (formerly, Amgen Inc. v. Aurobindo Pharma Ltd. et al.) Consolidated Case
On February 13, 2020, Amgen petitioned the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit Court) to rehear Amgen’s appeal of the judgment of noninfringement with respect to Piramal Healthcare UK Limited, and Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York, LLC (collectively, Amneal) petitioned the Federal Circuit Court for panel rehearing of the court’s opinion vacating and remanding the judgment of noninfringement with respect to Amneal. On April 15, 2020, the Federal Circuit Court denied each of Amgen’s and Amneal’s petitions. On April 22, 2020, the Federal Circuit Court issued a mandate returning the case to the Delaware District Court.
ENBREL (etanercept) Patent Litigation
Immunex Corporation, et al. v. Sandoz Inc., et al.
On March 4, 2020, the Federal Circuit Court heard oral argument on the appeal by Sandoz Inc., Sandoz International GmbH and Sandoz GmbH from final judgment upholding the validity of U.S. Patent Nos. 8,063,182 and 8,163,522.
Repatha® (evolocumab) Patent Litigation
Patent Disputes in the International Region
A two-day hearing before the Technical Board of Appeal of the European Patent Office, which was scheduled to begin on March 24, 2020, has been rescheduled to begin on October 28, 2020.
As previously disclosed, we are also involved in and expect future involvement in additional disputes regarding our proprotein convertase subtilisin/kexin type 9 (PCSK9) patents in other jurisdictions and regions, including matters filed against us and that we have filed in the United Kingdom, Germany, France and Japan.
On April 24, 2020, the Supreme Court of Japan declined to hear Sanofi K.K.’s appeals making final the Japanese High Court’s decisions that PRALUENT® infringes Amgen’s valid patent rights in Japan.
NEUPOGEN® (filgrastim)/Neulasta® (pegfilgrastim) Patent Litigation
Apotex PTAB Challenge
On March 24, 2020, the Federal Circuit Court vacated the decision by the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office and remanded the case to the PTAB for proceeding consistent with the Federal Circuit Court’s decision in Arthrex Inc. v. Smith & Nephew, Inc., 941 F.3d 1320 (Fed. Cir. 2019).
Amgen Inc., et al. v. Pfizer Inc. et al.
On February 18, 2020, the Delaware District Court entered an amended scheduling order moving the trial on the infringement of our U.S. Patent No. 9,643,997 to May 17, 2021, to enable Amgen Inc. and its wholly owned subsidiary, Amgen Manufacturing, Limited (collectively Amgen), to seek additional discovery into the defenses of Pfizer Inc. (Pfizer) and Hospira Inc. (Hospira).
On April 24, 2020, Amgen filed a separate lawsuit in the Delaware District Court against Hospira and Pfizer for infringement of U.S. Patent No. 10,577,392 (the ’392 Patent) and seeks, among other remedies, damages and injunctive relief to prohibit Hospira and Pfizer from infringing the ’392 Patent by the manufacture, import and sale of Pfizer’s NIVESTYMTM biosimilar filgrastim product, which was launched in the U.S. in October 2018.
Amgen Inc., et al. v. Hospira Inc. et al.
On March 4, 2020, Hospira and Pfizer filed a motion requesting the Delaware District Court to dismiss the complaint by Amgen Inc. and its wholly owned subsidiary, Amgen Manufacturing, Limited, alleging non-infringement of U.S. Patent No. 8,273,707. The motion has been fully briefed.
Fresenius PTAB Challenge
On March 30, 2020, Amgen filed its preliminary response to a petition to institute inter partes review before the PTAB to challenge the patentability of U.S. Patent No. 9,856,287 filed by Fresenius Kabi USA, LLC and Fresenius Kabi SwissBioSim GmbH, and the PTAB will have 3 months to render a decision on whether to institute trial proceedings.
EPOGEN® (epoetin alfa) Patent Litigation
Amgen Inc., et al. v. Hospira, Inc.
The Federal Circuit Court denied petition for rehearing en banc by Hospira and issued the mandate on March 23, 2020 affirming the final judgment of the Delaware District Court that Amgen’s U.S. Patent No. 5,856,298 is valid and infringed by Hospira, that Amgen’s U.S. Patent No. 5,756,349 is not infringed by Hospira, and awarding Amgen $70 million in damages for Hospira’s infringement. On April 17, 2020, Amgen acknowledged satisfaction of judgment upon receipt of $83 million in damages, interest and cost.
Litigation relating to our Biosimilar Products
KANJINTI® (trastuzumab-anns) Patent Litigation
Genentech, Inc. v. Amgen Inc.
On March 6, 2020, the Federal Circuit Court affirmed the District Court’s denial of Genentech Inc.’s (Genentech) motion for a preliminary injunction. On March 9, 2020, the Delaware District Court entered a Markman order construing a term of U.S. Patent No. 8,574,869 (the ’869 Patent). On March 16, 2020, the Delaware District Court signed a joint stipulation and order vacating the April 20, 2020 trial date. On April 17, 2020, the Delaware District Court rescheduled the jury trial to begin on February 22, 2021.
MVASI® (bevacizumab-awwb) Patent Litigation
Genentech, Inc. and City of Hope v. Amgen Inc.
On February 19, 2020, Genentech filed its second amended complaint in the Delaware District Court, adding additional claims for legal and declaratory relief with respect to patents already in suit. On March 4, 2020, Amgen filed its second amended affirmative answer and counterclaims, adding affirmative defenses and counterclaims that the ’869 Patent is unenforceable for inequitable conduct and unclean hands. On March 9, 2020, the Delaware District Court entered a Markman order construing a term of the ’869 Patent.
Genentech, Inc. and City of Hope v. Immunex Rhode Island Corp. and Amgen Inc.
Argument before the Federal Circuit Court on Genentech’s appeal of the Delaware District Court’s denial of Genentech’s motions for injunctive relief has been scheduled for June 3, 2020.
Breach of Contract Action
Cipla Ltd. et al. v. Amgen Inc.
On February 6, 2020, Amgen’s motion was transferred to the U.S. Magistrate Judge for the District of Delaware for a recommendation. A hearing on the motion was held on April 28, 2020.
Novartis Pharma AG v. Amgen Inc.
On February 18, 2020, Novartis Pharma AG filed in the U.S. District Court for the Southern District of New York its answer and affirmative defenses to Amgen’s second amended counterclaims.
Antitrust Class Action
Sensipar® Antitrust Class Actions
On February 6, 2020, the motions in the class action lawsuits against Amgen and various entities affiliated with Teva Pharmaceutical Industries Limited were transferred to the U.S. Magistrate Judge for the District of Delaware for a recommendation. A hearing on the motions was held on April 28, 2020.
The multidistrict litigation panel certified its conditional transfer order on February 6, 2020 transferring the additional class action lawsuit brought in the U.S. District Court for the Southern District of Florida, captioned MSP Recovery Claims v. Amgen Inc., et al., to the Delaware District Court.
XML 71 R40.htm IDEA: XBRL DOCUMENT v3.20.1
Investments (Fair Values by Contractual Maturity) (Details) - USD ($)
$ in Millions
Mar. 31, 2020
Dec. 31, 2019
Investments, Debt and Equity Securities [Abstract]    
Maturing in one year or less $ 7,165 $ 5,629
Maturing after one year through three years 129 2,304
Maturing after three years through five years 0 119
Residential mortgage-backed securities 0 182
Total interest-bearing securities $ 7,294 $ 8,234
XML 72 R44.htm IDEA: XBRL DOCUMENT v3.20.1
Goodwill and other intangible assets (Goodwill Roll Forward) (Details)
$ in Millions
3 Months Ended
Mar. 31, 2020
USD ($)
Goodwill [Roll Forward]  
Beginning balance $ 14,703
Currency translation adjustment (20)
Ending balance $ 14,683
XML 73 R48.htm IDEA: XBRL DOCUMENT v3.20.1
Financing arrangements (Details Textual) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Debt Instrument [Line Items]    
Repayments of Long-term Debt $ 3,250 $ 1,000
Notes [Member]    
Debt Instrument [Line Items]    
Face amount $ 5,000  
Notes [Member] | 4.563% notes due 2048 (4.563% 2048 Notes) [Member]    
Debt Instrument [Line Items]    
Interest rate, stated percentage 4.563%  
Effective interest rate 6.30%  
Notes [Member] | 4.663% notes due 2051 (4.663% 2051 Notes) [Member]    
Debt Instrument [Line Items]    
Interest rate, stated percentage 4.663%  
Effective interest rate 5.60%  
Notes [Member] | Interest Expense [Member]    
Debt Instrument [Line Items]    
MakeWholePayments $ 50  
Notes [Member] | 1.90% notes due 2025 (1.90% 2025 Notes) [Member]    
Debt Instrument [Line Items]    
Interest rate, stated percentage 1.90%  
Notes [Member] | 2.20% notes due 2027 (2.20% 2027 Notes) [Member]    
Debt Instrument [Line Items]    
Interest rate, stated percentage 2.20%  
Notes [Member] | 2.45% notes due 2030 (2.45% 2030 Notes) [Member]    
Debt Instrument [Line Items]    
Interest rate, stated percentage 2.45%  
Notes [Member] | 3.15% notes due 2040 (3.15% 2040 Notes) [Member]    
Debt Instrument [Line Items]    
Interest rate, stated percentage 3.15%  
Notes [Member] | 3.375% notes due 2050 (3.375% 2050 Notes) [Member]    
Debt Instrument [Line Items]    
Interest rate, stated percentage 3.375%  
Notes [Member] | 3.45% notes due 2020 (3.45% 2020 Notes) [Member]    
Debt Instrument [Line Items]    
Interest rate, stated percentage 3.45%  
Notes [Member] | 4.10% notes due 2021 (4.10% 2021 Notes) [Member]    
Debt Instrument [Line Items]    
Interest rate, stated percentage 4.10%  
Notes [Member] | 1.85% notes due 2021 (1.85% 2021 Notes) [Member]    
Debt Instrument [Line Items]    
Interest rate, stated percentage 1.85%  
Notes [Member] | 3.875% notes due 2021 (3.875% 2021 Notes) [Member]    
Debt Instrument [Line Items]    
Interest rate, stated percentage 3.875%  
Repayments of Long-term Debt $ 300  
Notes [Member] | 4.50% notes due 2020 (4.50% 2020 Notes) [Member]    
Debt Instrument [Line Items]    
Interest rate, stated percentage 4.50%  
Minimum [Member] | Debt Securities Payable [Member]    
Debt Instrument [Line Items]    
Debt Instrument, Redemption Period without Payment of Make Whole Amount 1 month  
Maximum [Member] | Debt Securities Payable [Member]    
Debt Instrument [Line Items]    
Debt Instrument, Redemption Period without Payment of Make Whole Amount 6 months  
XML 74 R9.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of significant accounting policies
3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Summary of significant accounting policies Summary of significant accounting policies
Business
Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.
Basis of presentation
The financial information for the three months ended March 31, 2020 and 2019, is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year.
The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2019.
Principles of consolidation
The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.
Use of estimates
The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
Property, plant and equipment, net
Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization of $8.5 billion and $8.4 billion as of March 31, 2020 and December 31, 2019, respectively.
Equity method investments
The equity method of accounting is used for equity investments that give us the ability to exert significant influence, but not control, over an investee based on such factors as our ownership percentage, voting and other shareholder rights, board of director representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of the investees’ earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Interest and other income, net, in the Condensed Consolidated Statements of Income.
We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors including, but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value.
Recent accounting pronouncements
In June 2016, the Financial Accounting Standards Board (FASB) issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. We adopted this standard as of January 1, 2020, using a modified-retrospective approach. Adoption of the standard did not have a material impact on our condensed consolidated financial statements.
In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens of the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity may change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022, as a result of reference rate reform. We are currently evaluating the impact that this new standard will have on our condensed consolidated financial statements.
XML 75 R63.htm IDEA: XBRL DOCUMENT v3.20.1
Contingencies and commitments (Details) - Hospira, Inc. [Member] - USD ($)
$ in Millions
Apr. 17, 2020
Mar. 23, 2020
Loss Contingencies [Line Items]    
Amount awarded from settlement   $ 70
Subsequent Event [Member]    
Loss Contingencies [Line Items]    
Amount received from settlement $ 83  
XML 76 R5.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
shares in Millions
Mar. 31, 2020
Dec. 31, 2019
Statement of Financial Position [Abstract]    
Common stock and additional paid-in capital, par value (in usd per share) $ 0.0001 $ 0.0001
Common stock and additional paid-in capital, shares authorized 2,750.0 2,750.0
Common stock and additional paid-in capital, shares outstanding 588.0 591.4
XML 77 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Cover Page - shares
3 Months Ended
Mar. 31, 2020
Apr. 27, 2020
Entity Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2020  
Document Transition Report false  
Entity File Number 001-37702  
Entity Registrant Name Amgen Inc.  
Entity Central Index Key 0000318154  
Amendment Flag false  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q1  
Current Fiscal Year End Date --12-31  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 95-3540776  
Entity Address, Address Line One One Amgen Center Drive  
Entity Address, City or Town Thousand Oaks  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 91320-1799  
City Area Code 805  
Local Phone Number 447-1000  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   588,247,399
The NASDAQ Global Select Market [Member] | Common Stock [Member]    
Entity Information [Line Items]    
Title of 12(b) Security Common stock, $0.0001 par value  
Trading Symbol AMGN  
Security Exchange Name NASDAQ  
New York Stock Exchange [Member] | 1.250% Senior Notes Due 2022 [Member]    
Entity Information [Line Items]    
Title of 12(b) Security 1.250% Senior Notes Due 2022  
Trading Symbol AMGN22  
Security Exchange Name NYSE  
New York Stock Exchange [Member] | 2.00% Senior Notes Due 2026 [Member]    
Entity Information [Line Items]    
Title of 12(b) Security 2.00% Senior Notes Due 2026  
Trading Symbol AMGN26  
Security Exchange Name NYSE  
XML 78 R59.htm IDEA: XBRL DOCUMENT v3.20.1
Derivative instruments (Effective Portion of Unrealized Gain (Loss)) (Details) - Cash flow hedge [Member] - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]    
Total unrealized (losses) gains $ (162) $ 30
Foreign currency contracts [Member]    
Derivative Instruments, Gain (Loss) [Line Items]    
Total unrealized (losses) gains 239 85
Cross-currency swap contracts [Member]    
Derivative Instruments, Gain (Loss) [Line Items]    
Total unrealized (losses) gains $ (401) $ (55)
XML 79 R55.htm IDEA: XBRL DOCUMENT v3.20.1
Fair value measurement (Details) - USD ($)
$ in Millions
Mar. 31, 2020
Dec. 31, 2019
Assets:    
Interest-bearing securities $ 7,294 $ 8,234
Equity securities 220 303
Derivatives:    
Total assets 7,988 9,086
Derivatives:    
Contingent consideration obligations 60 61
Total liabilities 745 407
Foreign currency contracts [Member]    
Derivatives:    
Foreign currency and cross-currency swap contracts 375 224
Derivatives:    
Foreign currency and cross-currency swap contracts 5 31
Cross-currency swap contracts [Member]    
Derivatives:    
Foreign currency and cross-currency swap contracts 10 66
Derivatives:    
Foreign currency and cross-currency swap contracts 657 315
Interest rate swap contracts [Member]    
Derivatives:    
Interest rate swap contracts 89 259
Derivatives:    
Interest rate swap contracts 23 0
Quoted prices in active markets for identical assets (Level 1) [Member]    
Assets:    
Equity securities 220 303
Derivatives:    
Total assets 7,058 5,913
Derivatives:    
Contingent consideration obligations 0 0
Total liabilities 0 0
Quoted prices in active markets for identical assets (Level 1) [Member] | Foreign currency contracts [Member]    
Derivatives:    
Foreign currency and cross-currency swap contracts 0 0
Derivatives:    
Foreign currency and cross-currency swap contracts 0 0
Quoted prices in active markets for identical assets (Level 1) [Member] | Cross-currency swap contracts [Member]    
Derivatives:    
Foreign currency and cross-currency swap contracts 0 0
Derivatives:    
Foreign currency and cross-currency swap contracts 0 0
Quoted prices in active markets for identical assets (Level 1) [Member] | Interest rate swap contracts [Member]    
Derivatives:    
Interest rate swap contracts 0 0
Derivatives:    
Interest rate swap contracts 0 0
Significant other observable inputs (Level 2) [Member]    
Assets:    
Equity securities 0 0
Derivatives:    
Total assets 930 3,173
Derivatives:    
Contingent consideration obligations 0 0
Total liabilities 685 346
Significant other observable inputs (Level 2) [Member] | Foreign currency contracts [Member]    
Derivatives:    
Foreign currency and cross-currency swap contracts 375 224
Derivatives:    
Foreign currency and cross-currency swap contracts 5 31
Significant other observable inputs (Level 2) [Member] | Cross-currency swap contracts [Member]    
Derivatives:    
Foreign currency and cross-currency swap contracts 10 66
Derivatives:    
Foreign currency and cross-currency swap contracts 657 315
Significant other observable inputs (Level 2) [Member] | Interest rate swap contracts [Member]    
Derivatives:    
Interest rate swap contracts 89 259
Derivatives:    
Interest rate swap contracts 23 0
Significant unobservable inputs (Level 3) [Member]    
Assets:    
Equity securities 0 0
Derivatives:    
Total assets 0 0
Derivatives:    
Contingent consideration obligations 60 61
Total liabilities 60 61
Significant unobservable inputs (Level 3) [Member] | Foreign currency contracts [Member]    
Derivatives:    
Foreign currency and cross-currency swap contracts 0 0
Derivatives:    
Foreign currency and cross-currency swap contracts 0 0
Significant unobservable inputs (Level 3) [Member] | Cross-currency swap contracts [Member]    
Derivatives:    
Foreign currency and cross-currency swap contracts 0 0
Derivatives:    
Foreign currency and cross-currency swap contracts 0 0
Significant unobservable inputs (Level 3) [Member] | Interest rate swap contracts [Member]    
Derivatives:    
Interest rate swap contracts 0 0
Derivatives:    
Interest rate swap contracts 0 0
U.S. Treasury notes [Member]    
Assets:    
Interest-bearing securities 176 360
U.S. Treasury notes [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]    
Assets:    
Interest-bearing securities 176 360
U.S. Treasury notes [Member] | Significant other observable inputs (Level 2) [Member]    
Assets:    
Interest-bearing securities 0 0
U.S. Treasury notes [Member] | Significant unobservable inputs (Level 3) [Member]    
Assets:    
Interest-bearing securities 0 0
U.S. Treasury bills [Member]    
Assets:    
Interest-bearing securities 900 0
U.S. Treasury bills [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]    
Assets:    
Interest-bearing securities 900 0
U.S. Treasury bills [Member] | Significant other observable inputs (Level 2) [Member]    
Assets:    
Interest-bearing securities 0 0
U.S. Treasury bills [Member] | Significant unobservable inputs (Level 3) [Member]    
Assets:    
Interest-bearing securities 0 0
Corporate debt securities - Financial [Member]    
Assets:    
Interest-bearing securities 12 1,121
Corporate debt securities - Financial [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]    
Assets:    
Interest-bearing securities 0 0
Corporate debt securities - Financial [Member] | Significant other observable inputs (Level 2) [Member]    
Assets:    
Interest-bearing securities 12 1,121
Corporate debt securities - Financial [Member] | Significant unobservable inputs (Level 3) [Member]    
Assets:    
Interest-bearing securities 0 0
Corporate debt securities - Industrial [Member]    
Assets:    
Interest-bearing securities 12 834
Corporate debt securities - Industrial [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]    
Assets:    
Interest-bearing securities 0 0
Corporate debt securities - Industrial [Member] | Significant other observable inputs (Level 2) [Member]    
Assets:    
Interest-bearing securities 12 834
Corporate debt securities - Industrial [Member] | Significant unobservable inputs (Level 3) [Member]    
Assets:    
Interest-bearing securities 0 0
Corporate debt securities - Other [Member]    
Assets:    
Interest-bearing securities 0 198
Corporate debt securities - Other [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]    
Assets:    
Interest-bearing securities 0 0
Corporate debt securities - Other [Member] | Significant other observable inputs (Level 2) [Member]    
Assets:    
Interest-bearing securities 0 198
Corporate debt securities - Other [Member] | Significant unobservable inputs (Level 3) [Member]    
Assets:    
Interest-bearing securities 0 0
Residential mortgage-backed securities [Member]    
Assets:    
Interest-bearing securities 0 182
Residential mortgage-backed securities [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]    
Assets:    
Interest-bearing securities 0 0
Residential mortgage-backed securities [Member] | Significant other observable inputs (Level 2) [Member]    
Assets:    
Interest-bearing securities 0 182
Residential mortgage-backed securities [Member] | Significant unobservable inputs (Level 3) [Member]    
Assets:    
Interest-bearing securities 0 0
Money market mutual funds [Member]    
Assets:    
Interest-bearing securities 5,762 5,250
Money market mutual funds [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]    
Assets:    
Interest-bearing securities 5,762 5,250
Money market mutual funds [Member] | Significant other observable inputs (Level 2) [Member]    
Assets:    
Interest-bearing securities 0 0
Money market mutual funds [Member] | Significant unobservable inputs (Level 3) [Member]    
Assets:    
Interest-bearing securities 0 0
Other short-term interest-bearing securities [Member]    
Assets:    
Interest-bearing securities 432 289
Other short-term interest-bearing securities [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]    
Assets:    
Interest-bearing securities 0 0
Other short-term interest-bearing securities [Member] | Significant other observable inputs (Level 2) [Member]    
Assets:    
Interest-bearing securities 432 289
Other short-term interest-bearing securities [Member] | Significant unobservable inputs (Level 3) [Member]    
Assets:    
Interest-bearing securities $ 0 $ 0
XML 80 R51.htm IDEA: XBRL DOCUMENT v3.20.1
Stockholders' equity (Share Repurchase Program) (Details) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Equity [Abstract]    
Stock repurchased, Shares 4.3 15.9
Stock repurchased $ 933 $ 3,031
XML 81 R17.htm IDEA: XBRL DOCUMENT v3.20.1
Financing arrangements
3 Months Ended
Mar. 31, 2020
Debt Disclosure [Abstract]  
Financing arrangements Financing arrangements
Our borrowings consisted of the following (in millions):
 
March 31,
2020
 
December 31,
2019
4.50% notes due 2020 (4.50% 2020 Notes)
$

 
$
300

2.125% notes due 2020 (2.125% 2020 Notes)
750

 
750

Floating Rate Notes due 2020
300

 
300

2.20% notes due 2020 (2.20% 2020 Notes)
700

 
700

3.45% notes due 2020 (3.45% 2020 Notes)

 
900

4.10% notes due 2021 (4.10% 2021 Notes)

 
1,000

1.85% notes due 2021 (1.85% 2021 Notes)

 
750

3.875% notes due 2021 (3.875% 2021 Notes)
1,450

 
1,750

1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes)
1,379

 
1,402

2.70% notes due 2022 (2.70% 2022 Notes)
500

 
500

2.65% notes due 2022 (2.65% 2022 Notes)
1,500

 
1,500

3.625% notes due 2022 (3.625% 2022 Notes)
750

 
750

0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)
728

 
725

2.25% notes due 2023 (2.25% 2023 Notes)
750

 
750

3.625% notes due 2024 (3.625% 2024 Notes)
1,400

 
1,400

1.90% notes due 2025 (1.90% 2025 Notes)
500

 

3.125% notes due 2025 (3.125% 2025 Notes)
1,000

 
1,000

2.00% €750 million notes due 2026 (2.00% 2026 euro Notes)
827

 
841

2.60% notes due 2026 (2.60% 2026 Notes)
1,250

 
1,250

5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes)
590

 
630

2.20% notes due 2027 (2.20% 2027 Notes)
750

 

3.20% notes due 2027 (3.20% 2027 Notes)
1,000

 
1,000

4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes)
869

 
928

2.45% notes due 2030 (2.45% 2030 Notes)
1,250

 

6.375% notes due 2037 (6.375% 2037 Notes)
552

 
552

6.90% notes due 2038 (6.90% 2038 Notes)
291

 
291

6.40% notes due 2039 (6.40% 2039 Notes)
466

 
466

3.15% notes due 2040 (3.15% 2040 Notes)
1,250

 

5.75% notes due 2040 (5.75% 2040 Notes)
412

 
412

4.95% notes due 2041 (4.95% 2041 Notes)
600

 
600

5.15% notes due 2041 (5.15% 2041 Notes)
974

 
974

5.65% notes due 2042 (5.65% 2042 Notes)
487

 
487

5.375% notes due 2043 (5.375% 2043 Notes)
261

 
261

4.40% notes due 2045 (4.40% 2045 Notes)
2,250

 
2,250

4.563% notes due 2048 (4.563% 2048 Notes)
1,415

 
1,415

3.375% notes due 2050 (3.375% 2050 Notes)
1,250

 

4.663% notes due 2051 (4.663% 2051 Notes)
3,541

 
3,541

Other notes due 2097
100

 
100

Unamortized bond discounts, premiums and issuance costs, net
(892
)
 
(868
)
Fair value adjustments
648

 
296

Total carrying value of debt
31,848

 
29,903

Less current portion
(1,840
)
 
(2,953
)
Total long-term debt
$
30,008

 
$
26,950


There are no material differences between the effective interest rates and coupon rates of any of our borrowings, except for the 4.563% 2048 Notes and the 4.663% 2051 Notes, which have effective interest rates of 6.3% and 5.6%, respectively.
Debt issuances and repayments
During the three months ended March 31, 2020, we issued $5.0 billion of debt, consisting of the 1.90% 2025 Notes, the 2.20% 2027 Notes, the 2.45% 2030 Notes, the 3.15% 2040 Notes and the 3.375% 2050 Notes. In the event of a change-in-control triggering event, as defined in the terms of the notes, we may be required to purchase all or a portion of these notes at a price equal to 101% of the principal amount of the notes plus accrued and unpaid interest. In addition, these notes may be redeemed at any time at our option, in whole or in part, at the principal amount of the notes being redeemed plus accrued and unpaid interest and a “make-whole” amount, which are defined by the terms of the notes. The notes may be redeemed without payment of make-whole amounts if redemption occurs during specified periods of time immediately prior to the maturity of the notes. Such time periods range from one month to six months prior to maturity.
A portion of the proceeds from the issuance of these notes were used to redeem the 3.45% 2020 Notes, the 4.10% 2021 Notes, the 1.85% 2021 Notes and $300 million aggregate principal amount of our 3.875% 2021 Notes. In connection with the redemption of these notes, we paid a total of $50 million in make-whole amounts plus associated accrued and unpaid interest, all of which was recognized in Interest expense, net, in the Condensed Consolidated Statements of Income during the three months ended March 31, 2020. In addition to these redemptions, the 4.50% 2020 Notes matured and were repaid during the three months ended March 31, 2020.
Interest rate swaps
In connection with the redemption of certain of the notes discussed above, associated interest rate swap contracts with an aggregate notional value of $2.2 billion were terminated. Additionally, due to historically low interest rates, during the three months ended March 31, 2020, we terminated interest rate swaps with an aggregate notional amount of $5.2 billion that hedged the 3.625% 2024 Notes, 2.60% 2026 Notes, 4.663% 2051 Notes and portions of our 3.625% 2022 Notes and 3.125% 2025 Notes, which resulted in the receipt of $576 million of cash and reduced counterparty credit risk. Immediately following termination of these contracts, we entered into new interest rate swap agreements at then-current interest rates on the same $5.2 billion principal amount of notes. See Note 12, Derivative instruments.
The effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions):
 
 
March 31, 2020
 
December 31, 2019
Notes
 
Notional amounts
Effective interest rates
 
Notional amounts
Effective interest rates
3.45% 2020 Notes
 
$

LIBOR + 1.1%
 
$
900

LIBOR + 1.1%
4.10% 2021 Notes
 

LIBOR + 1.7%
 
1,000

LIBOR + 1.7%
3.875% 2021 Notes
 
1,450

LIBOR + 2.0%
 
1,750

LIBOR + 2.0%
3.625% 2022 Notes
 
750

LIBOR + 2.7%
 
750

LIBOR + 1.6%
3.625% 2024 Notes
 
1,400

LIBOR + 3.2%
 
1,400

LIBOR + 1.4%
3.125% 2025 Notes
 
1,000

LIBOR + 1.8%
 
1,000

LIBOR + 0.9%
2.60% 2026 Notes
 
1,250

LIBOR + 1.8%
 
1,250

LIBOR + 0.3%
4.663% 2051 Notes(1)
 
1,500

LIBOR + 2.6%
 
1,500

LIBOR + 0.0%
Total notional amounts
 
$
7,350

 
 
$
9,550

 
____________ 
(1)
Excludes an additional 1.5% of interest for the difference between the coupon rate paid to note holders and the fixed rate received under the interest rate swap contracts.
XML 82 R13.htm IDEA: XBRL DOCUMENT v3.20.1
Collaborations
3 Months Ended
Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Collaborations Collaborations
On January 2, 2020, we closed our strategic collaboration with BeiGene, Ltd. (BeiGene) to expand our oncology presence in China. Under the collaboration, BeiGene will commercialize XGEVA®, KYPROLIS® and BLINCYTO® (blinatumomab) in China, and Amgen will share profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China.
In addition, we will jointly develop a portion of our oncology portfolio with BeiGene sharing in global research and development (R&D) costs by providing cash and development services up to $1.25 billion. Upon regulatory approval, BeiGene will assume commercialization rights in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside of China, Amgen will also pay BeiGene royalties.
For the three months ended March 31, 2020, costs recovered from BeiGene for oncology product candidates were $57 million and were recorded in R&D expense in the Condensed Consolidated Statements of Income. For the three months ended March 31, 2020, no profit share payments or product sales were recorded between Amgen and BeiGene. In connection with this collaboration, we acquired an ownership interest in BeiGene. See Note 6, Investments.
XML 83 R30.htm IDEA: XBRL DOCUMENT v3.20.1
Fair value measurement (Tables)
3 Months Ended
Mar. 31, 2020
Fair Value Disclosures [Abstract]  
Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis
The fair values of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):
 
 
Quoted prices in
active markets for
identical assets
(Level 1)
 
Significant
other observable
inputs
(Level 2)
 
Significant
unobservable
inputs
(Level 3)
 
 
 
 
 
 
 
 
Fair value measurement as of March 31, 2020, using:
 
 
 
 
Total
Assets:
 
 
 
 
 
 
 
 
Available-for-sale securities:
 
 
 
 
 
 
 
 
U.S. Treasury notes
 
$
176

 
$

 
$

 
$
176

U.S. Treasury bills
 
900

 

 

 
900

Corporate debt securities:
 
 
 
 
 
 
 
 
Financial
 

 
12

 

 
12

Industrial
 

 
12

 

 
12

Other
 

 

 

 

Residential-mortgage-backed securities
 

 

 

 

Money market mutual funds
 
5,762

 

 

 
5,762

Other short-term interest-bearing securities
 

 
432

 

 
432

Equity securities
 
220

 

 

 
220

Derivatives:
 
 
 
 
 
 
 
 
Foreign currency contracts
 

 
375

 

 
375

Cross-currency swap contracts
 

 
10

 

 
10

Interest rate swap contracts
 

 
89

 

 
89

Total assets
 
$
7,058

 
$
930

 
$

 
$
7,988

 
 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
 
Derivatives:
 
 
 
 
 
 
 
 
Foreign currency contracts
 
$

 
$
5

 
$

 
$
5

Cross-currency swap contracts
 

 
657

 

 
657

Interest rate swap contracts
 

 
23

 

 
23

Contingent consideration obligations
 

 

 
60

 
60

Total liabilities
 
$

 
$
685

 
$
60

 
$
745


 
 
Quoted prices in
active markets for
identical assets
(Level 1)
 
Significant
other observable
inputs
(Level 2)
 
Significant
unobservable
inputs
(Level 3)
 
 
 
 
 
 
 
 
Fair value measurement as of December 31, 2019, using:
 
 
 
 
Total
Assets:
 
 
 
 
 
 
 
 
Available-for-sale securities:
 
 
 
 
 
 
 
 
U.S. Treasury notes
 
$
360

 
$

 
$

 
$
360

U.S. Treasury bills
 

 

 

 

Corporate debt securities:
 
 
 
 
 
 
 
 
Financial
 

 
1,121

 

 
1,121

Industrial
 

 
834

 

 
834

Other
 

 
198

 

 
198

Residential-mortgage-backed securities
 

 
182

 

 
182

Money market mutual funds
 
5,250

 

 

 
5,250

Other short-term interest-bearing securities
 

 
289

 

 
289

Equity securities
 
303

 

 

 
303

Derivatives:
 
 
 
 
 
 
 
 
Foreign currency contracts
 

 
224

 

 
224

Cross-currency swap contracts
 

 
66

 

 
66

Interest rate swap contracts
 

 
259

 

 
259

Total assets
 
$
5,913

 
$
3,173

 
$

 
$
9,086

 
 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
 
Derivatives:
 
 
 
 
 
 
 
 
Foreign currency contracts
 
$

 
$
31

 
$

 
$
31

Cross-currency swap contracts
 

 
315

 

 
315

Interest rate swap contracts
 

 

 

 

Contingent consideration obligations
 

 

 
61

 
61

Total liabilities
 
$

 
$
346

 
$
61

 
$
407


XML 84 R34.htm IDEA: XBRL DOCUMENT v3.20.1
Income taxes (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Income Tax Disclosure [Abstract]    
Effective income tax rate 9.70% 13.90%
Increase in unrecognized tax benefits resulting from tax positions taken during the current period $ 50  
XML 85 R38.htm IDEA: XBRL DOCUMENT v3.20.1
Investments (Fair Values by Classification) (Details) - USD ($)
$ in Millions
Mar. 31, 2020
Dec. 31, 2019
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets    
Cash and cash equivalents $ 7,687 $ 6,037
Marketable securities 325 2,874
Total interest-bearing securities 7,294 8,234
Available-for-sale investments [Member]    
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets    
Cash and cash equivalents 6,969 5,360
Marketable securities 325 2,874
Total interest-bearing securities $ 7,294 $ 8,234

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htm IDEA: XBRL DOCUMENT v3.20.1
Investments (Available-for-sale Investments) (Details Textual) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Investments, Debt and Equity Securities [Abstract]      
Cash and cash equivalents $ 718   $ 677
Total realized gains 37 $ 1  
Total realized losses $ 4 $ 5  

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